-DOCSTART-	412

We	O
report	O
a	O
case	O
of	O
fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
associated	O
with	O
didanosine	B-Drug
and	O
masquerading	O
as	O
a	O
surgical	O
abdomen	O
and	O
compare	O
the	O
clinical	O
,	O
biologic	O
,	O
histologic	O
,	O
and	O
ultrastructural	O
findings	O
with	O
reports	O
described	O
previously	O
.	O

-DOCSTART-	284

Depressive	B-ADE
symptoms	I-ADE
disappeared	O
after	O
interferon	B-Drug
therapy	O
was	O
stopped	O
.	O

-DOCSTART-	1972

Pathogenesis	O
of	O
methotrexate	B-Drug
-	O
induced	O
papular	B-ADE
eruption	I-ADE
in	O
psoriasis	O
may	O
involve	O
immune	O
mechanisms	O
other	O
than	O
those	O
of	O
methotrexate	B-Drug
-	O
induced	O
cutaneous	B-ADE
vasculitis	I-ADE
in	O
collagen	O
vascular	O
disease	O
.	O

-DOCSTART-	1458

In	O
this	O
case	O
senna	B-Drug
was	O
likely	O
the	O
cause	O
of	O
a	O
subacute	B-ADE
cholestatic	I-ADE
hepatitis	I-ADE
exemplifying	O
again	O
the	O
potential	O
role	O
of	O
herbal	O
related	O
liver	B-ADE
injury	I-ADE
.	O

-DOCSTART-	1874

We	O
assume	O
that	O
rIFN	B-Drug
-	I-Drug
gamma	I-Drug
induced	O
the	O
de	O
novo	O
development	O
of	O
SLE	B-ADE
in	O
our	O
patient	O
.	O

-DOCSTART-	79

We	O
present	O
a	O
case	O
of	O
an	O
elderly	O
woman	O
with	O
a	O
pre	O
-	O
existing	O
history	O
of	O
ischaemic	O
heart	O
disease	O
,	O
who	O
was	O
treated	O
with	O
venlafaxine	B-Drug
,	O
and	O
developed	O
acute	B-ADE
myocardial	I-ADE
ischaemia	I-ADE
within	O
the	O
first	O
week	O
of	O
treatment	O
.	O

-DOCSTART-	1030

Hypernatraemia	B-ADE
induced	O
by	O
sodium	B-Drug
polystyrene	I-Drug
sulphonate	I-Drug
(	O
Kayexalate	B-Drug
)	O
in	O
two	O
extremely	O
low	O
birth	O
weight	O
newborns	O
.	O

-DOCSTART-	2774

Rifampicin	B-Drug
-	O
induced	O
adrenal	B-ADE
insufficiency	I-ADE
in	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
:	O
difficulties	O
in	O
diagnosis	O
and	O
treatment	O
.	O

-DOCSTART-	4245

Physicians	O
should	O
be	O
aware	O
of	O
the	O
possible	O
association	O
between	O
the	O
use	O
of	O
alteplase	B-Drug
and	O
the	O
development	O
of	O
subfascial	B-ADE
hemorrhage	I-ADE
.	O

-DOCSTART-	2689

The	O
authors	O
caution	O
that	O
treatment	O
with	O
alprazolam	B-Drug
may	O
be	O
complicated	O
by	O
the	O
induction	O
of	O
mania	B-ADE
.	O

-DOCSTART-	2173

Oxcarbazepine	B-Drug
-	O
induced	O
Drug	B-ADE
Reaction	I-ADE
with	I-ADE
Eosinophilia	I-ADE
and	I-ADE
Systemic	I-ADE
Symptoms	I-ADE
(	O
DRESS	B-ADE
)	O
.	O

-DOCSTART-	1296

Intraventricular	O
vancomycin	B-Drug
-	O
induced	O
cerebrospinal	B-ADE
fluid	I-ADE
eosinophilia	I-ADE
:	O
report	O
of	O
two	O
patients	O
.	O

-DOCSTART-	2353

Acute	B-ADE
ocular	I-ADE
ischemic	I-ADE
change	I-ADE
may	O
be	O
associated	O
with	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
in	O
patients	O
with	O
vascular	O
compromised	O
diabetic	O
retinopathy	O
and/or	O
underlying	O
stenosis	O
of	O
the	O
carotid	O
artery	O
.	O

-DOCSTART-	4213

Progressive	B-ADE
hypokalemia	I-ADE
developed	O
during	O
phosphate	B-Drug
treatment	O
.	O

-DOCSTART-	704

We	O
report	O
a	O
patient	O
with	O
recurrent	O
,	O
increasingly	O
severe	O
episodes	O
of	O
PPE	B-ADE
,	O
ultimately	O
complicated	O
by	O
a	O
severe	O
bullous	B-ADE
eruption	I-ADE
,	O
following	O
successive	O
cycles	O
of	O
high	O
-	O
dose	O
cytarabine	B-Drug
for	O
the	O
treatment	O
of	O
acute	O
lymphoblastic	O
leukaemia	O
.	O

-DOCSTART-	2485

Thrombocytosis	B-ADE
induced	O
by	O
enoxaparin	B-Drug
has	O
been	O
reported	O
as	O
a	O
rare	O
adverse	O
effect	O
of	O
this	O
medication	O
in	O
adults	O
.	O

-DOCSTART-	1438

Sirolimus	B-Drug
-	O
associated	O
hepatotoxicity	B-ADE
in	O
the	O
kidney	O
graft	O
recipient	O
.	O

-DOCSTART-	3388

Development	O
of	O
an	O
extensive	B-ADE
skin	I-ADE
rash	I-ADE
following	O
a	O
single	O
dose	O
of	O
MTX	B-Drug
may	O
be	O
an	O
early	O
warning	O
sign	O
for	O
life	O
-	O
threatening	O
bone	O
marrow	O
aplasia	O
.	O

-DOCSTART-	1666

Localized	B-ADE
purpura	I-ADE
associated	O
with	O
lamotrigine	B-Drug
.	O

-DOCSTART-	2962

Our	O
findings	O
suggest	O
that	O
hyperkalemia	B-ADE
can	O
develop	O
with	O
the	O
use	O
of	O
low	O
-	O
dose	O
heparin	B-Drug
,	O
within	O
seven	O
days	O
of	O
initiating	O
heparin	B-Drug
therapy	O
,	O
and	O
that	O
patients	O
with	O
diabetes	O
mellitus	O
or	O
chronic	O
renal	O
insufficiency	O
are	O
especially	O
predisposed	O
to	O
this	O
complication	O
.	O

-DOCSTART-	3052

Neurotoxicity	B-ADE
of	O
intrathecal	O
administration	O
of	O
amphotericin	B-Drug
B	I-Drug
.	O

-DOCSTART-	1941

Sustained	B-ADE
monomorphic	I-ADE
ventricular	I-ADE
tachycardia	I-ADE
after	O
adenosine	B-Drug
infusion	O
.	O

-DOCSTART-	3256

Dural	B-ADE
sinus	I-ADE
thrombosis	I-ADE
developed	O
in	O
two	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
during	O
induction	O
treatment	O
with	O
vincristine	B-Drug
sulfate	I-Drug
,	O
prednisone	B-Drug
,	O
and	O
asparaginase	B-Drug
.	O

-DOCSTART-	1997

Rituximab	B-Drug
-	I-Drug
CHOP	I-Drug
induced	O
interstitial	B-ADE
pneumonitis	I-ADE
in	O
patients	O
with	O
disseminated	O
extranodal	O
marginal	O
zone	O
B	O
cell	O
lymphoma	O
.	O

-DOCSTART-	2117

The	O
patient	O
expired	O
after	O
seven	O
cycles	O
of	O
treatment	O
had	O
been	O
completed	O
because	O
of	O
pulmonary	B-ADE
fibrosis	I-ADE
and	O
the	O
drug	O
toxicity	O
of	O
bleomycin	B-Drug
.	O

-DOCSTART-	1474

Progressive	B-ADE
hypoxemia	I-ADE
mandated	O
endotracheal	O
intubation	O
1	O
week	O
after	O
rituximab	B-Drug
administration	O
and	O
led	O
to	O
death	O
4	O
weeks	O
after	O
admission	O
.	O

-DOCSTART-	3904

We	O
report	O
a	O
case	O
of	O
amiodarone	B-Drug
-	O
induced	O
thyrotoxicosis	B-ADE
of	O
protracted	O
duration	O
,	O
unresponsive	O
to	O
conventional	O
thionamide	O
therapy	O
,	O
with	O
therapy	O
limited	O
by	O
severe	O
adverse	O
drug	O
reactions	O
.	O

-DOCSTART-	220

HUS	B-ADE
has	O
been	O
reported	O
after	O
several	O
anticancer	O
chemotherapies	O
and	O
most	O
often	O
after	O
mitomycin	B-Drug
C	I-Drug
-	O
based	O
chemotherapy	O
regimens	O
.	O

-DOCSTART-	547

To	O
treat	O
hepatitis	O
B	O
,	O
interferon	B-Drug
alpha	I-Drug
was	O
administered	O
until	O
the	O
proximal	O
muscle	B-ADE
weakness	I-ADE
developed	O
.	O

-DOCSTART-	1987

Severe	B-ADE
hepatocellular	I-ADE
dysfunction	I-ADE
following	O
cyproterone	B-Drug
acetate	I-Drug
therapy	O
.	O

-DOCSTART-	4165

We	O
present	O
the	O
first	O
case	O
(	O
to	O
our	O
knowledge	O
)	O
of	O
a	O
potentially	O
serious	O
drug	B-ADE
-	I-ADE
drug	I-ADE
interaction	I-ADE
between	O
zafirlukast	B-Drug
and	O
theophylline	B-Drug
.	O

-DOCSTART-	924

However	O
,	O
follow	O
-	O
up	O
revealed	O
that	O
gestational	B-ADE
diabetes	I-ADE
when	O
associated	O
with	O
norethisterone	B-Drug
had	O
a	O
lesser	O
risk	O
of	O
emerging	O
diabetes	B-ADE
mellitus	I-ADE
and	O
impaired	B-ADE
glucose	I-ADE
tolerance	I-ADE
.	O

-DOCSTART-	550

Aggressive	B-ADE
endometrial	I-ADE
carcinoma	I-ADE
in	O
a	O
breast	O
cancer	O
patient	O
treated	O
with	O
tamoxifen	B-Drug
with	O
normal	O
transvaginal	O
ultrasonography	O
.	O

-DOCSTART-	3467

Mefloquine	B-Drug
-	O
associated	O
hypoglycaemia	B-ADE
in	O
a	O
cachectic	O
AIDS	O
patient	O
.	O

-DOCSTART-	2887

She	O
was	O
receiving	O
phenytoin	B-Drug
sodium	I-Drug
300	O
mg	O
/	O
day	O
;	O
carbamazepine	B-Drug
200	O
mg	O
four	O
times	O
daily	O
had	O
been	O
discontinued	O
four	O
days	O
before	O
admission	O
because	O
of	O
leukopenia	B-ADE
.	O

-DOCSTART-	1705

This	O
eruption	B-ADE
appears	O
to	O
be	O
a	O
distinct	O
cutaneous	O
toxicity	O
of	O
PLD	B-Drug
.	O

-DOCSTART-	1110

Deepening	B-ADE
of	I-ADE
lid	I-ADE
sulcus	I-ADE
from	O
topical	O
bimatoprost	B-Drug
therapy	O
.	O

-DOCSTART-	1327

Although	O
various	O
manifestations	O
of	O
pentamidine	B-Drug
-	O
induced	O
cardiotoxicity	B-ADE
have	O
been	O
reported	O
,	O
to	O
our	O
knowledge	O
,	O
second	B-ADE
-	I-ADE
degree	I-ADE
heart	I-ADE
block	I-ADE
associated	O
with	O
this	O
agent	O
has	O
not	O
been	O
described	O
.	O

-DOCSTART-	2772

A	O
dapsone	B-Drug
hypersensitivity	B-ADE
syndrome	I-ADE
,	O
consisting	O
of	O
fever	B-ADE
,	O
headache	B-ADE
,	O
nausea	B-ADE
,	O
vomiting	B-ADE
,	O
lymphadenopathy	B-ADE
,	O
hepatitis	B-ADE
,	O
hemolysis	B-ADE
,	O
leukopenia	B-ADE
,	O
and	O
mononucleosis	B-ADE
,	O
has	O
been	O
described	O
in	O
patients	O
treated	O
with	O
the	O
drug	O
for	O
leprosy	O
.	O

-DOCSTART-	2868

Progressive	B-ADE
pulmonary	I-ADE
fibrosis	I-ADE
complicating	O
cyclophosphamide	B-Drug
therapy	O
.	O

-DOCSTART-	3960

The	O
evidence	O
of	O
high	O
plasmatic	O
levels	O
of	O
CBZ	B-Drug
and	O
the	O
absence	O
of	O
other	O
aetiologic	O
factors	O
lead	O
the	O
authors	O
to	O
conclude	O
that	O
the	O
overdose	O
of	O
CBZ	B-Drug
could	O
have	O
represented	O
the	O
precipitating	O
of	O
the	O
episode	O
of	O
acute	B-ADE
pancreatitis	I-ADE
.	O

-DOCSTART-	3733

We	O
report	O
an	O
unusual	O
pattern	O
of	O
supravenous	B-ADE
hyperpigmentation	I-ADE
occurring	O
after	O
CHOP	B-Drug
chemotherapy	O
.	O

-DOCSTART-	1205

We	O
hypothesize	O
that	O
decreased	O
renal	O
elimination	O
of	O
MTX	B-Drug
induced	O
by	O
the	O
COX-2	O
inhibitor	O
resulted	O
in	O
enhanced	O
hematopoietic	B-ADE
toxicity	I-ADE
and	O
immunosuppression	B-ADE
causing	O
the	O
EBV	B-ADE
-	I-ADE
associated	I-ADE
lymphoproliferative	I-ADE
disease	I-ADE
.	O

-DOCSTART-	23

Hydroxyurea	B-Drug
-	O
induced	O
acute	B-ADE
interstitial	I-ADE
pneumonitis	I-ADE
in	O
a	O
patient	O
with	O
essential	O
thrombocythemia	O
.	O

-DOCSTART-	1636

Rapid	O
resolution	O
of	O
topiramate	B-Drug
-	O
induced	O
angle	B-ADE
-	I-ADE
closure	I-ADE
glaucoma	I-ADE
with	O
methylprednisolone	B-Drug
and	O
mannitol	B-Drug
.	O

-DOCSTART-	2465

Case	O
report	O
:	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
after	O
administering	O
intravenous	O
immunoglobulin	B-Drug
.	O

-DOCSTART-	3285

L	B-Drug
-	I-Drug
asparaginase	I-Drug
-	O
induced	O
pancreatitis	B-ADE
has	O
been	O
reported	O
during	O
or	O
closely	O
following	O
administration	O
of	O
the	O
drug	O
.	O

-DOCSTART-	4037

We	O
diagnosed	O
this	O
case	O
as	O
danazol	B-Drug
induced	O
thrombocytopenia	B-ADE
.	O

-DOCSTART-	2763

Although	O
differential	O
diagnostic	O
alternatives	O
can	O
be	O
considered	O
in	O
all	O
described	O
cases	O
it	O
is	O
very	O
likely	O
that	O
vincristine	B-Drug
does	O
cause	O
severe	B-ADE
visual	I-ADE
loss	I-ADE
in	O
a	O
small	O
number	O
of	O
patients	O
.	O

-DOCSTART-	3901

His	O
impaired	B-ADE
memory	I-ADE
was	O
found	O
to	O
be	O
due	O
to	O
the	O
atenolol	B-Drug
he	O
was	O
on	O
and	O
he	O
made	O
a	O
complete	O
recovery	O
on	O
withdrawing	O
the	O
beta	O
-	O
blocker	O
.	O

-DOCSTART-	1411

She	O
died	O
within	O
six	O
weeks	O
of	O
developing	O
congestive	B-ADE
heart	I-ADE
failure	I-ADE
coupled	O
with	O
liver	B-ADE
failure	I-ADE
due	O
to	O
haemosiderosis	B-ADE
despite	O
regular	O
use	O
of	O
desferrioxamine	B-Drug
.	O

-DOCSTART-	1842

Bleomycin	B-Drug
induced	O
hyperpigmentation	B-ADE
with	O
yolk	O
sac	O
tumor	O
.	O

-DOCSTART-	2260

Aliskiren	B-Drug
-	O
associated	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
with	O
hyperkalemia	O
.	O

-DOCSTART-	2810

Dyspnea	B-ADE
possibly	O
associated	O
with	O
controlled	O
-	O
release	O
morphine	B-Drug
sulfate	I-Drug
tablets	O
.	O

-DOCSTART-	590

Atypical	O
neuroleptic	B-ADE
malignant	I-ADE
syndrome	I-ADE
associated	O
with	O
olanzapine	B-Drug
.	O

-DOCSTART-	3107

We	O
report	O
5	O
cases	O
of	O
acute	B-ADE
reversible	I-ADE
renal	I-ADE
failure	I-ADE
coinciding	O
with	O
the	O
onset	O
of	O
treatment	O
with	O
captopril	B-Drug
in	O
patients	O
with	O
severe	O
drug	O
-	O
resistant	O
hypertension	O
.	O

-DOCSTART-	958

Colchicine	B-Drug
-	O
induced	O
myopathy	B-ADE
in	O
a	O
teenager	O
with	O
familial	O
Mediterranean	O
fever	O
.	O

-DOCSTART-	267

We	O
describe	O
the	O
clinical	O
and	O
liver	O
biopsy	O
morphologic	O
features	O
for	O
4	O
patients	O
with	O
minocycline	B-Drug
-	O
induced	O
autoimmune	B-ADE
hepatitis	I-ADE
(	O
group	O
1	O
)	O
.	O

-DOCSTART-	1067

The	O
majority	O
of	O
radiation	B-ADE
recall	I-ADE
reactions	I-ADE
attributed	O
to	O
gemcitabine	B-Drug
are	O
reported	O
to	O
affect	O
internal	O
tissue	O
or	O
organs	O
.	O

-DOCSTART-	1152

Ciprofloxacin	B-Drug
-	O
induced	O
renal	B-ADE
insufficiency	I-ADE
in	O
cystic	O
fibrosis	O
.	O

-DOCSTART-	766

Minimal	B-ADE
change	I-ADE
disease	I-ADE
in	O
a	O
patient	O
receiving	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
therapy	O
for	O
chronic	O
hepatitis	O
C	O
virus	O
infection	O
.	O

-DOCSTART-	1654

Factors	O
that	O
suggested	O
an	O
association	O
between	O
the	O
severe	B-ADE
angioedematous	I-ADE
reaction	I-ADE
and	O
BP	B-Drug
topical	O
application	O
include	O
the	O
strong	O
reaction	O
to	O
BP	O
in	O
the	O
patch	O
-	O
test	O
,	O
the	O
temporal	O
relationship	O
,	O
the	O
complete	O
resolution	O
of	O
symptoms	O
after	O
the	O
drug	O
was	O
withdrawn	O
and	O
the	O
absence	O
of	O
other	O
identified	O
explanations	O
.	O

-DOCSTART-	1352

Lansoprazole	B-Drug
-	O
associated	O
collagenous	B-ADE
colitis	I-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	2460

Acute	B-ADE
kidney	I-ADE
injury	I-ADE
caused	O
by	O
zonisamide	B-Drug
-	O
induced	O
hypersensitivity	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1934

Myoclonus	B-ADE
associated	O
with	O
continuous	O
dobutamine	B-Drug
infusion	O
in	O
a	O
patient	O
with	O
end	O
-	O
stage	O
renal	O
disease	O
.	O

-DOCSTART-	3836

We	O
report	O
the	O
case	O
histories	O
of	O
identical	O
twin	O
brothers	O
who	O
developed	O
concordant	O
acute	O
lymphoblastic	O
leukemia	O
at	O
the	O
age	O
of	O
4	O
years	O
and	O
who	O
later	O
developed	O
leukoencephalopathy	B-ADE
and	O
hydrocephalus	B-ADE
related	O
to	O
central	O
nervous	O
system	O
prophylaxis	O
by	O
,	O
in	O
the	O
first	O
case	O
intrathecally	O
administered	O
methotrexate	B-Drug
and	O
,	O
in	O
the	O
second	O
by	O
intrathecally	O
administered	O
methotrexate	B-Drug
and	O
cranial	O
irradiation	O
.	O

-DOCSTART-	446

The	O
renal	O
consequences	O
of	O
indinavir	B-Drug
-	O
associated	O
nephrotoxicity	B-ADE
are	O
uncertain	O
.	O

-DOCSTART-	1481

Radiation	B-ADE
recall	I-ADE
related	O
to	O
gemcitabine	B-Drug
has	O
been	O
reported	O
in	O
lung	O
and	O
breast	O
cancer	O
.	O

-DOCSTART-	153

Caution	O
is	O
,	O
therefore	O
,	O
needed	O
to	O
prevent	O
undesired	O
accumulation	O
of	O
TCA	B-Drug
that	O
may	O
lead	O
to	O
protracted	O
Cushing	B-ADE
's	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1684

Neutropenia	B-ADE
and	O
agranulocytosis	B-ADE
are	O
risks	O
known	O
to	O
occur	O
with	O
phenothiazines	B-Drug
and	O
clozapine	B-Drug
.	O

-DOCSTART-	1282

Enalapril	B-Drug
-	O
induced	O
anemia	B-ADE
in	O
two	O
kidney	O
transplant	O
recipients	O
.	O

-DOCSTART-	3769

Milk	B-ADE
-	I-ADE
alkali	I-ADE
syndrome	I-ADE
induced	O
by	O
1,25(OH)2D	B-Drug
in	O
a	O
patient	O
with	O
hypoparathyroidism	O
.	O

-DOCSTART-	1876

Clozapine	B-Drug
-	O
induced	O
eosinophilia	B-ADE
and	O
switch	O
to	O
quetiapine	O
in	O
a	O
patient	O
with	O
chronic	O
schizophrenia	O
with	O
suicidal	O
tendencies	O
.	O

-DOCSTART-	1756

This	O
experience	O
supports	O
the	O
hypothesis	O
that	O
heparin	O
can	O
be	O
readministered	O
early	O
to	O
patients	O
with	O
heparin	B-Drug
-	O
associated	O
thrombocytopenia	B-ADE
and	O
thrombosis	B-ADE
,	O
provided	O
antiplatelet	O
therapy	O
is	O
given	O
.	O

-DOCSTART-	2420

Retinopathy	B-ADE
in	O
hepatitis	O
C	O
patients	O
due	O
to	O
combination	O
therapy	O
with	O
pegylated	B-Drug
interferon	I-Drug
and	O
ribavirin	B-Drug
.	O

-DOCSTART-	3374

The	O
frequency	O
and	O
relationship	O
of	O
granulocytopenia	B-ADE
caused	O
by	O
sustained	O
-	O
release	O
procainamide	B-Drug
in	O
patients	O
with	O
tachyarrhythmias	O
are	O
briefly	O
discussed	O
,	O
and	O
prior	O
reported	O
cases	O
are	O
reviewed	O
.	O

-DOCSTART-	3576

Ibopamine	B-Drug
-	O
induced	O
reversible	O
leukopenia	B-ADE
during	O
treatment	O
for	O
congestive	O
heart	O
failure	O
.	O

-DOCSTART-	2806

Cardiopulmonary	B-ADE
arrest	I-ADE
following	O
intravenous	O
phenytoin	B-Drug
loading	O
.	O

-DOCSTART-	1872

Induction	O
of	O
systemic	B-ADE
lupus	I-ADE
erythematosus	I-ADE
by	O
interferon	B-Drug
-	I-Drug
gamma	I-Drug
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	2792

We	O
also	O
describe	O
a	O
case	O
of	O
timolol	B-Drug
-	O
induced	O
ocular	B-ADE
pemphigoid	I-ADE
.	O

-DOCSTART-	2390

Ciprofloxacin	B-Drug
-	O
induced	O
hemorrhagic	B-ADE
vasculitis	I-ADE
.	O

-DOCSTART-	92

Heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
is	O
a	O
rare	O
and	O
serious	O
complication	O
of	O
anticoagulation	O
therapy	O
.	O

-DOCSTART-	91

We	O
report	O
the	O
case	O
of	O
a	O
female	O
acromegalic	O
patient	O
in	O
whom	O
multiple	O
hepatic	B-ADE
adenomas	I-ADE
appeared	O
soon	O
after	O
danazol	B-Drug
treatment	O
for	O
uterine	O
fibromatosis	O
.	O

-DOCSTART-	3216

Focal	B-ADE
renal	I-ADE
cortical	I-ADE
necrosis	I-ADE
associated	O
with	O
zomepirac	B-Drug
.	O

-DOCSTART-	1026

RESULTS	O
:	O
Evidence	O
of	O
neurological	O
improvement	O
and	O
rehabilitation	O
potential	O
after	O
severe	B-ADE
myelopathy	I-ADE
due	O
to	O
intrathecal	O
injection	O
of	O
doxorubicin	B-Drug
.	O

-DOCSTART-	2756

Isotretinoin	B-Drug
teratogenicity	B-ADE
.	O

-DOCSTART-	313

Type	O
II	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
(	O
HIT	O
)	O
is	O
an	O
immunological	O
disorder	O
characterized	O
by	O
antibodies	O
to	O
heparin	O
-	O
platelet	O
factor	O
4	O
complexes	O
and	O
a	O
high	O
risk	O
of	O
thrombotic	O
complications	O
.	O

-DOCSTART-	57

OBJECTIVE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
desensitization	O
to	O
NPH	B-Drug
insulin	I-Drug
,	O
as	O
well	O
as	O
standard	O
insulin	B-Drug
desensitization	O
,	O
could	O
control	O
allergic	B-ADE
symptoms	I-ADE
in	O
a	O
patient	O
allergic	O
to	O
both	O
NPH	O
and	O
regular	O
insulin	O
.	O

-DOCSTART-	3445

CONCLUSIONS	O
:	O
We	O
have	O
seen	O
an	O
increased	O
incidence	O
of	O
acute	O
INH	B-Drug
neurotoxicity	B-ADE
because	O
of	O
the	O
resurgence	O
of	O
TB	O
in	O
New	O
York	O
City	O
.	O

-DOCSTART-	1632

Amphotericin	B-Drug
B	I-Drug
(	O
AmB	B-Drug
)	O
is	O
effective	O
,	O
but	O
its	O
use	O
is	O
limited	O
by	O
toxicity	O
:	O
renal	B-ADE
impairment	I-ADE
,	O
anaemia	B-ADE
,	O
fever	B-ADE
,	O
malaise	B-ADE
,	O
and	O
hypokalaemia	B-ADE
are	O
common	O
.	O

-DOCSTART-	2840

Transient	O
leucopenia	B-ADE
and	O
thrombocytopenia	B-ADE
associated	O
with	O
sodium	B-Drug
nitroprusside	I-Drug
infusion	O
.	O

-DOCSTART-	3371

The	O
patient	O
's	O
clinical	O
presentation	O
,	O
histologic	O
features	O
on	O
liver	O
biopsy	O
and	O
favorable	O
course	O
after	O
stopping	O
the	O
drug	O
suggest	O
that	O
barbiturates	B-Drug
can	O
be	O
added	O
to	O
the	O
list	O
of	O
agents	O
which	O
can	O
cause	O
submassive	B-ADE
hepatic	I-ADE
necrosis	I-ADE
.	O

-DOCSTART-	1866

A	O
case	O
of	O
colchicine	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
is	O
reported	O
.	O

-DOCSTART-	1920

The	O
concomitant	O
use	O
,	O
however	O
,	O
of	O
colchicine	B-Drug
and	O
statin	B-Drug
has	O
been	O
associated	O
with	O
the	O
rapid	O
onset	O
of	O
muscle	B-ADE
weakness	I-ADE
.	O

-DOCSTART-	1

Immobilization	O
,	O
while	O
Paget	O
's	O
bone	O
disease	O
was	O
present	O
,	O
and	O
perhaps	O
enhanced	O
activation	O
of	O
dihydrotachysterol	B-Drug
by	O
rifampicin	O
,	O
could	O
have	O
led	O
to	O
increased	B-ADE
calcium	I-ADE
-	I-ADE
release	I-ADE
into	O
the	O
circulation	O
.	O

-DOCSTART-	2826

We	O
describe	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
gold	B-Drug
salts	O
,	O
who	O
developed	O
bilateral	B-ADE
interstitial	I-ADE
pulmonary	I-ADE
abnormalities	I-ADE
and	O
showed	O
a	O
dramatic	O
response	O
on	O
corticosteroid	O
therapy	O
.	O

-DOCSTART-	1999

A	O
diagnosis	O
of	O
trastuzumab	B-Drug
-	O
induced	O
pneumonitis	B-ADE
was	O
made	O
.	O

-DOCSTART-	3554

Occurrence	O
of	O
IDDM	B-ADE
during	O
interferon	B-Drug
therapy	O
for	O
chronic	O
viral	O
hepatitis	O
.	O

-DOCSTART-	3492

However	O
,	O
EO	B-Drug
-	O
induced	O
noncardiogenic	B-ADE
pulmonary	I-ADE
edema	I-ADE
has	O
not	O
been	O
reported	O
in	O
human	O
.	O

-DOCSTART-	4234

MTX	B-Drug
-	O
induced	O
hepatic	B-ADE
injury	I-ADE
and	O
liver	B-ADE
enzyme	I-ADE
elevations	I-ADE
have	O
been	O
demonstrated	O
after	O
treatment	O
of	O
leukemia	O
,	O
gestational	O
disease	O
and	O
during	O
treatment	O
of	O
psoriasis	O
and	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	3765

The	O
possibility	O
can	O
be	O
raised	O
that	O
M	B-Drug
-	I-Drug
CSF	I-Drug
accelerated	O
the	O
underlying	O
renal	B-ADE
disease	I-ADE
in	O
this	O
case	O
through	O
enhancing	O
macrophage	O
accumulation	O
into	O
the	O
glomerulus	O
,	O
leading	O
to	O
the	O
development	O
of	O
nephrotic	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1155

Sensory	B-ADE
neuropathy	I-ADE
revealing	O
necrotizing	B-ADE
vasculitis	I-ADE
during	O
infliximab	B-Drug
therapy	O
for	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	1855

Paralytic	B-ADE
ileus	I-ADE
in	O
patients	O
undergoing	O
bortezomib	B-Drug
treatment	O
has	O
been	O
reported	O
,	O
although	O
a	O
definite	O
attribution	O
to	O
bortezomib	O
administration	O
has	O
not	O
been	O
established	O
.	O

-DOCSTART-	2048

Pregabalin	B-Drug
-	O
induced	O
cortical	B-ADE
negative	I-ADE
myoclonus	I-ADE
in	O
a	O
patient	O
with	O
neuropathic	O
pain	O
.	O

-DOCSTART-	1087

Restless	B-ADE
legs	I-ADE
syndrome	I-ADE
may	O
thus	O
be	O
an	O
adverse	O
effect	O
of	O
IFN	B-Drug
alpha	I-Drug
treatment	O
.	O

-DOCSTART-	3535

Acyclovir	B-Drug
produces	O
neurologic	B-ADE
symptoms	I-ADE
that	O
resemble	O
extension	O
of	O
viral	O
infection	O
into	O
the	O
central	O
nervous	O
system	O
.	O

-DOCSTART-	1189

We	O
present	O
two	O
cases	O
of	O
anaphylaxis	B-ADE
under	O
anaesthesia	O
where	O
return	O
of	O
spontaneous	O
circulation	O
was	O
refractory	O
to	O
epinephrine	O
,	O
but	O
occurred	O
following	O
the	O
administration	O
of	O
the	O
alpha	O
-	O
agonist	O
metaraminol	B-Drug
.	O

-DOCSTART-	397

A	O
patient	O
that	O
received	O
methadone	B-Drug
for	O
cancer	O
-	O
associated	O
pain	O
developed	O
myoclonus	B-ADE
as	O
a	O
side	O
effect	O
.	O

-DOCSTART-	2241

In	O
this	O
case	O
,	O
discontinuing	O
piroxicam	B-Drug
,	O
a	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
and	O
starting	O
a	O
palliative	O
treatment	O
plan	O
helped	O
resolve	O
a	O
patient	O
's	O
ulcers	B-ADE
.	O

-DOCSTART-	3161

The	O
responsibility	O
of	O
CCNU	B-Drug
in	O
the	O
pathogenesis	O
of	O
pulmonary	B-ADE
fibrosis	I-ADE
seems	O
very	O
likely	O
.	O

-DOCSTART-	104

Cessation	O
of	O
D	B-Drug
-	I-Drug
Pen	I-Drug
and	O
the	O
start	O
of	O
corticosteroid	O
therapy	O
were	O
followed	O
by	O
recovery	O
from	O
bicytopenia	B-ADE
.	O

-DOCSTART-	3378

CONCLUSION	O
:	O
Atovaquone	B-Drug
should	O
be	O
added	O
to	O
the	O
list	O
of	O
agents	O
causing	O
vortex	B-ADE
keratopathy	I-ADE
involving	O
the	O
corneal	O
epithelium	O
.	O

-DOCSTART-	1810

After	O
having	O
received	O
gemcitabine	B-Drug
on	O
day	O
1	O
of	O
the	O
second	O
course	O
,	O
the	O
patient	O
developed	O
dry	B-ADE
cough	I-ADE
,	O
subfebrile	B-ADE
temperatures	I-ADE
and	O
dyspnea	B-ADE
within	O
48	O
h	O
.	O

-DOCSTART-	3157

A	O
further	O
case	O
of	O
anaphylactoid	B-ADE
reaction	I-ADE
to	O
methylprednisolone	B-Drug
is	O
reported	O
.	O

-DOCSTART-	3932

Fever	B-ADE
,	O
lymphadenopathy	B-ADE
,	O
eosinophilia	B-ADE
,	O
lymphocytosis	B-ADE
,	O
hepatitis	B-ADE
,	O
and	O
dermatitis	B-ADE
:	O
a	O
severe	O
adverse	O
reaction	O
to	O
minocycline	B-Drug
.	O

-DOCSTART-	365

Indolent	O
aspergillus	B-ADE
arthritis	I-ADE
complicating	O
fludarabine	B-Drug
-	O
based	O
non	O
-	O
myeloablative	O
stem	O
cell	O
transplantation	O
.	O

-DOCSTART-	2692

Alprazolam	B-Drug
withdrawal	O
delirium	B-ADE
unresponsive	O
to	O
diazepam	O
:	O
case	O
report	O
.	O

-DOCSTART-	3601

Electrical	B-ADE
proarrhythmia	I-ADE
with	O
procainamide	B-Drug
:	O
a	O
new	O
ICD	O
-	O
drug	O
interaction	O
.	O

-DOCSTART-	1032

Bull's	B-ADE
-	I-ADE
eye	I-ADE
maculopathy	I-ADE
associated	O
with	O
quinacrine	B-Drug
therapy	O
for	O
malaria	O
.	O

-DOCSTART-	3770

This	O
article	O
presents	O
a	O
patient	O
with	O
hypoparathyroidism	O
who	O
was	O
treated	O
with	O
calcium	B-Drug
carbonate	I-Drug
and	O
calcitriol	B-Drug
resulting	O
in	O
two	O
admissions	O
to	O
the	O
hospital	O
for	O
milk	B-ADE
-	I-ADE
alkali	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	530

After	O
a	O
second	O
dose	O
of	O
metoclopramide	B-Drug
,	O
these	O
symptoms	O
recurred	O
and	O
were	O
associated	O
with	O
confusion	B-ADE
,	O
agitation	B-ADE
,	O
fever	B-ADE
,	O
diaphoresis	B-ADE
,	O
tachypnea	B-ADE
,	O
tachycardia	B-ADE
,	O
and	O
hypertension	B-ADE
.	O

-DOCSTART-	2269

Posterior	B-ADE
reversible	I-ADE
encephalopathy	I-ADE
syndrome	I-ADE
associated	O
with	O
methotrexate	B-Drug
neurotoxicity	O
:	O
conventional	O
magnetic	O
resonance	O
and	O
diffusion	O
-	O
weighted	O
imaging	O
findings	O
.	O

-DOCSTART-	2386

Recovery	O
of	O
the	O
tubular	B-ADE
dysfunction	I-ADE
took	O
15	O
days	O
following	O
cessation	O
of	O
the	O
offending	O
drug	O
,	O
Amikacin	B-Drug
.	O

-DOCSTART-	406

We	O
observed	O
ventricular	B-ADE
fibrillation	I-ADE
in	O
2	O
patients	O
who	O
presented	O
to	O
the	O
emergency	O
department	O
with	O
pre	O
-	O
excited	O
atrial	O
fibrillation	O
and	O
were	O
given	O
12	O
mg	O
of	O
adenosine	B-Drug
.	O

-DOCSTART-	3911

Focal	B-ADE
glomerulonephritis	I-ADE
and	O
interstitial	B-ADE
nephritis	I-ADE
in	O
methicillin	B-Drug
-	O
treated	O
,	O
heroin	O
-	O
related	O
infective	O
endocarditis	O
.	O

-DOCSTART-	2688

Alprazolam	B-Drug
-	O
induced	O
mania	B-ADE
:	O
two	O
clinical	O
cases	O
.	O

-DOCSTART-	3586

In	O
two	O
patients	O
,	O
apomorphine	B-Drug
remained	O
effective	O
in	O
the	O
morning	O
,	O
but	O
increased	O
the	O
intensity	O
of	O
the	O
dyskinesias	B-ADE
in	O
the	O
afternoon	O
.	O

-DOCSTART-	3524

Basilar	B-ADE
invagination	I-ADE
and	O
mid	B-ADE
-	I-ADE
line	I-ADE
skeletal	I-ADE
abnormalities	I-ADE
due	O
to	O
in	O
utero	O
exposure	O
to	O
phenytoin	B-Drug
.	O

-DOCSTART-	754

Fulminant	B-ADE
hepatitis	I-ADE
and	O
lymphocyte	O
sensitization	O
due	O
to	O
propylthiouracil	B-Drug
.	O

-DOCSTART-	2098

A	O
37-year	O
-	O
old	O
woman	O
with	O
relapsing	O
invasive	O
vertebral	O
aspergillosis	O
received	O
intravenous	O
VRC	B-Drug
and	O
developed	O
angio	B-ADE
-	I-ADE
oedema	I-ADE
10	O
days	O
after	O
starting	O
therapy	O
.	O

-DOCSTART-	2466

The	O
hospital	O
course	O
of	O
the	O
acute	O
renal	O
failure	O
is	O
presented	O
with	O
a	O
review	O
of	O
the	O
literature	O
on	O
cases	O
of	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
after	O
IVIG	B-Drug
.	O

-DOCSTART-	1959

Quetiapine	B-Drug
-	O
induced	O
leucopenia	B-ADE
and	O
thrombocytopenia	B-ADE
.	O

-DOCSTART-	959

CONCLUSIONS	O
:	O
Colchicine	B-Drug
-	O
induced	O
myopathy	B-ADE
should	O
be	O
excluded	O
in	O
patients	O
with	O
FMF	O
who	O
present	O
with	O
generalized	O
muscle	O
weakness	O
.	O

-DOCSTART-	2545

Because	O
of	O
a	O
hypersensitivity	B-ADE
reaction	I-ADE
,	O
initial	O
therapy	O
with	O
penicillin	B-Drug
G	I-Drug
and	O
gentamicin	B-Drug
was	O
stopped	O
and	O
substituted	O
with	O
cefazolin	O
.	O

-DOCSTART-	1867

Colchicine	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
is	O
a	O
rare	O
complication	O
,	O
and	O
the	O
postulated	O
mechanisms	O
and	O
risk	O
factors	O
for	O
this	O
severe	O
complication	O
are	O
discussed	O
.	O

-DOCSTART-	3433

This	O
report	O
suggests	O
that	O
bleomycin	B-Drug
lung	B-ADE
toxicity	I-ADE
may	O
be	O
reversible	O
if	O
treated	O
aggressively	O
.	O

-DOCSTART-	3418

The	O
authors	O
describe	O
a	O
case	O
of	O
neuroleptic	B-ADE
malignant	I-ADE
syndrome	I-ADE
that	O
occurred	O
in	O
a	O
patient	O
on	O
amitriptyline	B-Drug
and	O
lithium	B-Drug
carbonate	I-Drug
.	O

-DOCSTART-	3001

The	O
following	O
is	O
a	O
report	O
of	O
2	O
cases	O
of	O
rifampicin	B-Drug
-	O
induced	O
renal	B-ADE
insufficiency	I-ADE
.	O

-DOCSTART-	2270

The	O
addition	O
of	O
intrathecal	O
methotrexate	B-Drug
to	O
treatment	O
protocols	O
has	O
increased	O
survival	O
rates	O
in	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
but	O
is	O
also	O
associated	O
with	O
varying	O
degrees	O
of	O
neurotoxicity	B-ADE
.	O

-DOCSTART-	2715

Abnormal	B-ADE
retinal	I-ADE
function	I-ADE
associated	O
with	O
isotretinoin	B-Drug
therapy	O
for	O
acne	O
.	O

-DOCSTART-	3352

Although	O
useful	O
in	O
the	O
management	O
of	O
chronic	O
alcoholism	O
,	O
disulfiram	B-Drug
is	O
being	O
increasingly	O
associated	O
with	O
a	O
wide	O
spectrum	O
of	O
side	O
effects	O
and	O
untoward	O
medical	O
sequelae	O
,	O
which	O
now	O
include	O
catatonia	B-ADE
.	O

-DOCSTART-	4095

Because	O
the	O
combination	O
of	O
bleomycin	B-Drug
and	O
vinca	O
alkaloids	O
is	O
commonly	O
used	O
for	O
the	O
treatment	O
of	O
AIDS	O
-	O
related	O
Kaposi	O
's	O
sarcoma	O
,	O
clinicians	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
provoking	O
acral	B-ADE
necrosis	I-ADE
in	O
patients	O
who	O
develop	O
Raynaud	B-ADE
's	I-ADE
phenomenon	I-ADE
under	O
chemotherapy	O
.	O

-DOCSTART-	2357

Three	O
days	O
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
,	O
acute	B-ADE
ocular	I-ADE
ischemic	I-ADE
syndrome	I-ADE
occurred	O
.	O

-DOCSTART-	3050

Telescoped	B-ADE
digits	I-ADE
of	I-ADE
the	I-ADE
hands	I-ADE
and	I-ADE
feet	I-ADE
developed	O
in	O
a	O
69-year	O
-	O
old	O
male	O
with	O
severe	O
chronic	O
tophaceous	O
gout	O
during	O
allopurinol	B-Drug
treatment	O
.	O

-DOCSTART-	3060

Sulindac	B-Drug
(	O
Clinoril	B-Drug
)	O
,	O
a	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
agent	O
,	O
has	O
few	O
reported	O
neurologic	B-ADE
toxic	I-ADE
effects	I-ADE
,	O
all	O
of	O
which	O
have	O
been	O
associated	O
with	O
systemic	O
disease	O
.	O

-DOCSTART-	498

CONCLUSIONS	O
:	O
There	O
is	O
very	O
little	O
published	O
information	O
regarding	O
ofloxacin	B-Drug
-	O
induced	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
.	O

-DOCSTART-	1310

Mycophenolate	B-Drug
mofetil	I-Drug
-	O
induced	O
neutropenia	B-ADE
in	O
liver	O
transplantation	O
.	O

-DOCSTART-	461

CONCLUSIONS	O
:	O
Amphotericin	B-Drug
B	I-Drug
seems	O
to	O
be	O
the	O
probable	O
cause	O
of	O
the	O
seizures	B-ADE
.	O

-DOCSTART-	3084

Allergic	B-ADE
contact	I-ADE
dermatitis	I-ADE
to	O
compound	O
tincture	O
of	O
benzoin	B-Drug
.	O

-DOCSTART-	1575

The	O
visual	B-ADE
loss	I-ADE
in	O
this	O
patient	O
seems	O
to	O
result	O
from	O
phenol	B-Drug
neurotoxicity	B-ADE
rather	O
than	O
mechanical	O
compression	O
of	O
the	O
intraorbital	O
optic	O
nerve	O
.	O

-DOCSTART-	4243

We	O
describe	O
a	O
case	O
of	O
disseminated	O
muscular	O
cysticercosis	O
followed	O
by	O
myositis	B-ADE
(	O
fever	B-ADE
,	O
diffuse	B-ADE
myalgia	I-ADE
,	O
weakness	B-ADE
of	I-ADE
the	I-ADE
lower	I-ADE
limbs	I-ADE
,	O
and	O
inflammatory	B-ADE
reaction	I-ADE
around	I-ADE
dying	I-ADE
cysticerci	I-ADE
)	O
induced	O
by	O
praziquantel	B-Drug
therapy	O
,	O
an	O
event	O
not	O
described	O
previously	O
.	O

-DOCSTART-	722

A	O
paradoxical	B-ADE
ocular	I-ADE
effect	I-ADE
of	O
brimonidine	B-Drug
.	O

-DOCSTART-	2684

Administration	O
of	O
intrathecal	O
Ara	B-Drug
-	I-Drug
C	I-Drug
in	O
the	O
same	O
dose	O
over	O
longer	O
intervals	O
within	O
3	O
-	O
5	O
days	O
between	O
consecutive	O
doses	O
resulted	O
in	O
mild	O
,	O
transient	O
neurological	O
symptoms	O
(	O
paresthesias	B-ADE
)	O
in	O
only	O
one	O
of	O
30	O
patients	O
so	O
treated	O
.	O

-DOCSTART-	3779

While	O
undergoing	O
treatment	O
with	O
albendazole	B-Drug
,	O
he	O
developed	O
worsening	B-ADE
diarrhea	I-ADE
with	O
abdominal	B-ADE
pain	I-ADE
and	O
fever	B-ADE
.	O

-DOCSTART-	2876

Rupture	B-ADE
of	I-ADE
a	I-ADE
cerebral	I-ADE
aneurysm	I-ADE
associated	O
with	O
nifedipine	B-Drug
treatment	O
.	O

-DOCSTART-	3702

Hepatotoxicity	B-ADE
of	O
paracetamol	B-Drug
enhanced	O
by	O
ingestion	O
of	O
alcohol	O
:	O
report	O
of	O
two	O
cases	O
.	O

-DOCSTART-	2850

An	O
8-year	O
-	O
old	O
girl	O
,	O
who	O
had	O
been	O
vaccinated	O
with	O
BCG	B-Drug
without	O
subsequent	O
regional	O
reactions	O
,	O
developed	O
osteomyelitis	B-ADE
in	I-ADE
the	I-ADE
left	I-ADE
calcaneus	I-ADE
7	O
months	O
later	O
.	O

-DOCSTART-	2572

In	O
a	O
female	O
with	O
acute	O
lymphoblastic	O
leukemia	O
,	O
inadvertent	O
doxorubicin	B-Drug
administration	O
intrathecally	O
caused	O
severe	O
,	O
life	O
-	O
threatening	O
,	O
acute	B-ADE
encephalopathy	I-ADE
with	O
high	B-ADE
-	I-ADE
pressure	I-ADE
hydrocephalus	I-ADE
.	O

-DOCSTART-	1254

Livedo	B-ADE
reticularis	I-ADE
associated	O
with	O
interferon	B-Drug
alpha	I-Drug
therapy	O
in	O
two	O
melanoma	O
patients	O
.	O

-DOCSTART-	236

Phantom	B-ADE
limb	I-ADE
pain	I-ADE
as	O
a	O
manifestation	O
of	O
paclitaxel	B-Drug
neurotoxicity	B-ADE
.	O

-DOCSTART-	793

We	O
conjectured	O
that	O
the	O
side	O
effects	O
of	O
insulin	B-Drug
,	O
such	O
as	O
anti	B-ADE
-	I-ADE
natriuresis	I-ADE
and	O
increased	B-ADE
vascular	I-ADE
permeability	I-ADE
,	O
might	O
be	O
pronounced	O
in	O
the	O
presence	O
of	O
the	O
hepatic	O
dysfunction	O
that	O
accompanies	O
insulin	B-ADE
insensitivity	I-ADE
,	O
hyperinsulinaemia	B-ADE
and	O
hypoalbuminaemia	B-ADE
.	O

-DOCSTART-	1253

Typically	O
,	O
drug	O
-	O
induced	O
neutropenia	B-ADE
occurs	O
in	O
a	O
patient	O
receiving	O
a	O
semisynthetic	O
penicillin	B-Drug
for	O
two	O
weeks	O
or	O
more	O
.	O

-DOCSTART-	150

In	O
conclusion	O
,	O
this	O
case	O
strongly	O
suggests	O
that	O
gliclazide	B-Drug
can	O
induce	O
acute	B-ADE
icteric	I-ADE
liver	I-ADE
necro	I-ADE
-	I-ADE
inflammation	I-ADE
which	O
may	O
be	O
misdiagnosed	O
clinically	O
as	O
acute	O
viral	O
hepatitis	O
.	O

-DOCSTART-	2328

The	O
patient	O
's	O
other	O
comorbidities	O
and	O
medications	O
have	O
not	O
been	O
suggested	O
as	O
possible	O
interactions	O
with	O
sertraline	B-Drug
that	O
can	O
cause	O
rhabdomyolysis	B-ADE
.	O

-DOCSTART-	1010

To	O
the	O
best	O
of	O
the	O
authors	O
'	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
Propecia	B-Drug
-	O
associated	O
cataract	B-ADE
.	O

-DOCSTART-	1366

We	O
report	O
a	O
case	O
of	O
reversible	O
DKA	B-ADE
and	O
new	O
-	O
onset	O
DM	B-ADE
that	O
developed	O
in	O
a	O
demented	O
patient	O
who	O
was	O
treated	O
with	O
quetiapine	B-Drug
for	O
14	O
days	O
.	O

-DOCSTART-	3585

The	O
association	O
of	O
phenothiazine	B-Drug
overdose	O
and	O
respiratory	B-ADE
distress	I-ADE
syndrome	I-ADE
merits	O
consideration	O
.	O

-DOCSTART-	1910

Interstitial	B-ADE
lung	I-ADE
disease	I-ADE
(	O
ILD	B-ADE
)	O
related	O
to	O
therapy	O
with	O
the	O
drug	O
gefitinib	B-Drug
has	O
been	O
well	O
reported	O
.	O

-DOCSTART-	1659

Severe	O
dapsone	B-Drug
hypersensitivity	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1847

Capecitabine	B-Drug
-	O
induced	O
headache	B-ADE
responding	O
to	O
diltiazem	O
.	O

-DOCSTART-	4192

Methimazole	B-Drug
-	O
induced	O
aplastic	B-ADE
anemia	I-ADE
in	O
third	O
exposure	O
:	O
successful	O
treatment	O
with	O
recombinant	O
human	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
.	O

-DOCSTART-	2305

The	O
more	O
common	O
grade	O
3	O
or	O
4	O
adverse	O
effects	O
of	O
sunitinib	B-Drug
include	O
hypertension	B-ADE
,	O
fatigue	B-ADE
,	O
hand	B-ADE
-	I-ADE
foot	I-ADE
syndrome	I-ADE
,	O
elevated	B-ADE
lipase	I-ADE
and	O
lymphopenia	B-ADE
.	O

-DOCSTART-	390

We	O
report	O
the	O
case	O
histories	O
of	O
two	O
patients	O
with	O
histologically	O
confirmed	O
adenocarcinoma	O
of	O
the	O
prostate	O
,	O
both	O
of	O
whom	O
had	O
been	O
treated	O
with	O
steroidal	O
anti	O
-	O
androgen	O
therapy	O
in	O
the	O
form	O
of	O
cyproterone	B-Drug
acetate	I-Drug
prior	O
to	O
radical	O
or	O
palliative	O
pelvic	O
irradiation	O
,	O
and	O
who	O
subsequently	O
developed	O
femoral	B-ADE
head	I-ADE
avascular	I-ADE
necrosis	I-ADE
.	O

-DOCSTART-	3784

Assessment	O
of	O
cortisol	O
response	O
was	O
by	O
insulin	B-Drug
-	O
induced	O
hypoglycaemia	B-ADE
in	O
three	O
cases	O
,	O
by	O
short	O
tetracosactrin	O
test	O
in	O
two	O
,	O
and	O
by	O
low	O
-	O
dose	O
tetracosactrin	O
and	O
24-hour	O
urinary	O
cortisol	O
/	O
creatinine	O
ratio	O
in	O
one	O
.	O

-DOCSTART-	443

Papillary	B-ADE
necrosis	I-ADE
associated	O
with	O
the	O
HIV	O
protease	O
inhibitor	O
indinavir	B-Drug
.	O

-DOCSTART-	2569

Renal	B-ADE
toxicities	I-ADE
have	O
been	O
reported	O
in	O
less	O
than	O
one	O
percent	O
of	O
the	O
patients	O
receiving	O
ciprofloxacin	B-Drug
therapy	O
.	O

-DOCSTART-	1720

Use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicated	O
a	O
highly	O
probable	O
relationship	O
between	O
the	O
observed	O
cardiac	B-ADE
toxicity	I-ADE
and	O
amphotericin	B-Drug
B	I-Drug
deoxycholate	I-Drug
therapy	O
in	O
this	O
patient	O
.	O

-DOCSTART-	1889

Here	O
we	O
describe	O
another	O
case	O
of	O
VOD	B-ADE
occurring	O
after	O
LT	O
,	O
but	O
in	O
which	O
the	O
causative	O
role	O
was	O
played	O
by	O
azathioprine	B-Drug
.	O

-DOCSTART-	2469

Severe	O
vancomycin	B-Drug
-	O
induced	O
anaphylactic	B-ADE
reaction	I-ADE
.	O

-DOCSTART-	2708

Ampicillin	B-Drug
-	O
induced	O
interstitial	B-ADE
nephritis	I-ADE
with	O
generalised	B-ADE
exfoliative	I-ADE
dermatitis	I-ADE
.	O

-DOCSTART-	3865

CONCLUSIONS	O
:	O
This	O
study	O
confirmed	O
that	O
in	O
most	O
patients	O
MTX	B-Drug
-	O
induced	O
liver	B-ADE
cirrhosis	I-ADE
is	O
not	O
aggressive	O
.	O

-DOCSTART-	880

The	O
newborn	O
manifested	O
a	O
four	O
day	O
course	O
of	O
lethargy	B-ADE
with	O
unexplained	O
high	O
lithium	B-Drug
levels	O
in	O
the	O
adult	O
toxic	O
range	O
.	O

-DOCSTART-	1122

OBJECTIVE	O
:	O
To	O
study	O
therapy	O
with	O
indapamide	B-Drug
impairing	B-ADE
carbohydrate	I-ADE
metabolism	I-ADE
in	O
essential	O
hypertension	O
patients	O
and	O
achieve	O
earlier	O
prevention	O
,	O
diagnoses	O
and	O
treatment	O
of	O
diabetes	B-ADE
induced	O
by	O
indapamide	B-Drug
.	O

-DOCSTART-	1463

Thus	O
,	O
the	O
possible	O
in	O
vivo	O
effects	O
of	O
insulin	O
on	O
adipocytes	O
were	O
clearly	O
observed	O
in	O
this	O
case	O
of	O
insulin	B-Drug
-	O
induced	O
lipohypertrophy	B-ADE
.	O

-DOCSTART-	2768

Niacin	B-Drug
maculopathy	B-ADE
.	O

-DOCSTART-	1505

Arthritis	B-ADE
and	O
bursitis	B-ADE
in	O
multiple	O
sclerosis	O
patients	O
treated	O
with	O
interferon	B-Drug
-	I-Drug
beta	I-Drug
.	O

-DOCSTART-	3173

Myoglobinuria	B-ADE
and	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
were	O
observed	O
in	O
two	O
patients	O
with	O
vasopressin	B-Drug
-	O
treated	O
gastrointestinal	O
hemorrhage	O
.	O

-DOCSTART-	4047

Acute	B-ADE
pancreatitis	I-ADE
is	O
a	O
known	O
,	O
although	O
rare	O
,	O
complication	O
of	O
mesalamine	B-Drug
treatment	O
.	O

-DOCSTART-	3930

Fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
associated	O
with	O
bicalutamide	B-Drug
.	O

-DOCSTART-	593

DISCUSSION	O
:	O
The	O
occurrence	O
of	O
priapism	B-ADE
in	O
our	O
patient	O
was	O
related	O
to	O
zuclopenthixol	B-Drug
.	O

-DOCSTART-	1275

Risperidone	B-Drug
is	O
a	O
frequently	O
used	O
member	O
of	O
a	O
new	O
class	O
of	O
atypical	O
antipsychotics	O
-	O
the	O
serotonin	O
-	O
dopamine	O
antagonists	O
(	O
SDAs	O
)	O
-	O
due	O
to	O
its	O
comparatively	O
high	O
efficacy	O
and	O
low	O
D2/5HT2	O
binding	O
ratio	O
,	O
which	O
results	O
in	O
a	O
low	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
including	O
tardive	B-ADE
dyskinesia	I-ADE
(	O
TD	B-ADE
)	O
.	O

-DOCSTART-	3615

Clonidine	B-Drug
-	O
induced	O
bradycardia	B-ADE
in	O
patients	O
with	O
spinal	O
cord	O
injury	O
.	O

-DOCSTART-	551

Since	O
tamoxifen	B-Drug
therapy	O
can	O
induce	O
endometrial	B-ADE
disorders	I-ADE
,	O
surveillance	O
schemes	O
of	O
women	O
taking	O
tamoxifen	B-Drug
have	O
been	O
recommended	O
.	O

-DOCSTART-	2614

Although	O
this	O
type	O
of	O
hyperpigmentation	B-ADE
has	O
been	O
previously	O
seen	O
in	O
patients	O
with	O
cancer	O
who	O
are	O
receiving	O
bleomycin	B-Drug
,	O
this	O
is	O
,	O
to	O
our	O
knowledge	O
,	O
the	O
first	O
reported	O
case	O
of	O
bleomycin	B-Drug
-	O
induced	O
hyperpigmentation	B-ADE
in	O
an	O
AIDS	O
patient	O
and	O
should	O
be	O
added	O
to	O
the	O
growing	O
list	O
of	O
cutaneous	O
eruptions	O
seen	O
in	O
these	O
patients	O
.	O

-DOCSTART-	482

Anisocoria	B-ADE
from	O
transdermal	O
scopolamine	B-Drug
.	O

-DOCSTART-	33

CONCLUSION	O
:	O
Fixed	O
drug	O
eruption	B-ADE
is	O
associated	O
with	O
many	O
drugs	O
but	O
this	O
is	O
the	O
first	O
such	O
report	O
with	O
omeprazole	B-Drug
.	O

-DOCSTART-	1602

The	O
patient	O
was	O
enrolled	O
in	O
a	O
weight	O
-	O
loss	O
clinic	O
,	O
and	O
his	O
diabetes	O
medications	O
were	O
adjusted	O
.	O
Subsequently	O
,	O
olanzapine	B-Drug
was	O
discontinued	O
because	O
of	O
weight	B-ADE
gain	I-ADE
and	O
uncontrolled	B-ADE
diabetes	I-ADE
.	O

-DOCSTART-	666

Mean	O
time	O
between	O
initiation	O
of	O
gemcitabine	B-Drug
therapy	O
and	O
onset	O
of	O
HUS	B-ADE
was	O
7.4	O
+	O
/-	O
3.5	O
months	O
,	O
or	O
21.9	O
+	O
/-	O
10.9	O
doses	O
of	O
gemcitabine	B-Drug
.	O

-DOCSTART-	1625

Acute	B-ADE
coronary	I-ADE
syndrome	I-ADE
induced	O
by	O
capecitabine	B-Drug
therapy	O
.	O

-DOCSTART-	1841

Neurointensive	O
care	O
management	O
of	O
raised	B-ADE
intracranial	I-ADE
pressure	I-ADE
caused	O
by	O
severe	O
valproic	B-Drug
acid	I-Drug
intoxication	O
.	O

-DOCSTART-	1794

Tuberculous	B-ADE
uveitis	I-ADE
after	O
treatment	O
with	O
etanercept	B-Drug
.	O

-DOCSTART-	913

Valproic	B-Drug
acid	I-Drug
induced	O
coma	B-ADE
is	O
presented	O
in	O
an	O
adult	O
patient	O
without	O
a	O
history	O
of	O
metabolic	O
disease	O
.	O

-DOCSTART-	898

Pulmonary	B-ADE
infiltrates	I-ADE
and	O
skin	B-ADE
pigmentation	I-ADE
associated	O
with	O
sulfasalazine	B-Drug
.	O

-DOCSTART-	3699

Lymphoma	B-ADE
developing	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
taking	O
methotrexate	B-Drug
.	O

-DOCSTART-	3647

Amphotericin	B-Drug
B	I-Drug
overdose	O
in	O
pediatric	O
patients	O
with	O
associated	O
cardiac	B-ADE
arrest	I-ADE
.	O

-DOCSTART-	2331

Priapism	B-ADE
associated	O
with	O
olanzapine	B-Drug
.	O

-DOCSTART-	4205

Naproxen	B-Drug
is	O
a	O
commonly	O
used	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
(	O
NSAID	O
)	O
whose	O
side	O
effects	O
include	O
tinnitus	B-ADE
and	O
transient	B-ADE
hearing	I-ADE
loss	I-ADE
.	O

-DOCSTART-	1068

Cystoid	B-ADE
macular	I-ADE
edema	I-ADE
in	O
a	O
low	O
-	O
risk	O
patient	O
after	O
switching	O
from	O
latanoprost	B-Drug
to	O
bimatoprost	B-Drug
.	O

-DOCSTART-	4194

FSGS	B-ADE
induced	O
by	O
Adriamycin	B-Drug
(	O
Pharmacia	O
&	O
Upjohn	O
,	O
Columbus	O
,	O
OH	O
)	O
has	O
been	O
observed	O
experimentally	O
in	O
rats	O
.	O

-DOCSTART-	1800

CASE	O
SUMMARY	O
:	O
A	O
65-year	O
-	O
old	O
patient	O
chronically	O
treated	O
with	O
the	O
selective	O
serotonin	O
reuptake	O
inhibitor	O
(	O
SSRI	O
)	O
citalopram	B-Drug
developed	O
confusion	B-ADE
,	O
agitation	B-ADE
,	O
tachycardia	B-ADE
,	O
tremors	B-ADE
,	O
myoclonic	B-ADE
jerks	I-ADE
and	O
unsteady	B-ADE
gait	I-ADE
,	O
consistent	O
with	O
serotonin	B-ADE
syndrome	I-ADE
,	O
following	O
initiation	O
of	O
fentanyl	B-Drug
,	O
and	O
all	O
symptoms	O
and	O
signs	O
resolved	O
following	O
discontinuation	O
of	O
fentanyl	B-Drug
.	O

-DOCSTART-	2291

Isoniazid	B-Drug
causing	O
breast	B-ADE
tissue	I-ADE
enlargement	I-ADE
has	O
been	O
very	O
rarely	O
reported	O
.	O

-DOCSTART-	2747

Accordingly	O
,	O
camptocormia	B-ADE
is	O
a	O
dose	O
-	O
dependent	O
side	O
effect	O
of	O
valproate	B-Drug
.	O

-DOCSTART-	2453

We	O
describe	O
a	O
patient	O
who	O
experienced	O
chronic	B-ADE
nausea	I-ADE
and	O
an	O
episode	O
of	O
confusion	B-ADE
while	O
treated	O
with	O
a	O
small	O
,	O
stable	O
dose	O
of	O
oral	O
morphine	B-Drug
in	O
the	O
setting	O
of	O
mild	O
renal	O
insufficiency	O
.	O

-DOCSTART-	1367

Pulmonary	B-ADE
leukostasis	I-ADE
secondary	O
to	O
all	B-Drug
-	I-Drug
trans	I-Drug
retinoic	I-Drug
acid	I-Drug
in	O
the	O
treatment	O
of	O
acute	O
promyelocytic	O
leukemia	O
in	O
first	O
relapse	O
.	O

-DOCSTART-	2472

Four	O
patients	O
in	O
whom	O
pulmonary	B-ADE
oedema	I-ADE
developed	O
during	O
tocolysis	O
with	O
hexoprenaline	B-Drug
are	O
described	O
and	O
the	O
aetiological	O
factors	O
and	O
pathogenesis	O
of	O
this	O
potentially	O
lethal	O
complication	O
discussed	O
.	O

-DOCSTART-	3017

Inappropriate	B-ADE
antidiuretic	I-ADE
hormone	I-ADE
following	O
adenine	B-Drug
arabinoside	I-Drug
administration	O
.	O

-DOCSTART-	1134

We	O
present	O
a	O
case	O
of	O
a	O
diabetic	O
patient	O
taking	O
glyburide	B-Drug
who	O
was	O
prescribed	O
ciprofloxacin	B-Drug
and	O
developed	O
prolonged	B-ADE
hypoglycemia	I-ADE
,	O
which	O
persisted	O
for	O
over	O
24	O
hours	O
.	O

-DOCSTART-	2580

These	O
cases	O
indicate	O
that	O
sulpiride	B-Drug
can	O
cause	O
tardive	B-ADE
dyskinesia	I-ADE
and	O
that	O
this	O
drug	O
should	O
be	O
administered	O
with	O
caution	O
.	O

-DOCSTART-	529

We	O
report	O
a	O
patient	O
who	O
experienced	O
LABD	B-ADE
shortly	O
after	O
starting	O
carbamazepine	B-Drug
therapy	O
.	O

-DOCSTART-	1416

Rhabdomyolysis	B-ADE
has	O
been	O
recognized	O
as	O
a	O
complication	O
of	O
tocolytic	O
therapy	O
with	O
ritodrine	B-Drug
hydrochloride	I-Drug
.	O

-DOCSTART-	2670

Intravenous	O
cytarabine	B-Drug
and	O
methotrexate	B-Drug
appear	O
to	O
act	O
synergistically	O
to	O
enhance	O
the	O
potential	O
for	O
central	B-ADE
nervous	I-ADE
system	I-ADE
toxicity	I-ADE
.	O

-DOCSTART-	3471

Cardiac	B-ADE
arrest	I-ADE
following	O
use	O
of	O
sumatriptan	B-Drug
.	O

-DOCSTART-	2638

Ibuprofen	B-Drug
-	O
induced	O
meningitis	B-ADE
:	O
detection	O
of	O
intrathecal	O
IgG	O
synthesis	O
and	O
immune	O
complexes	O
.	O

-DOCSTART-	1604

Traumatic	B-ADE
late	I-ADE
flap	I-ADE
dehiscence	I-ADE
and	O
Enterobacter	B-ADE
keratitis	I-ADE
following	O
LASIK	B-Drug
.	O

-DOCSTART-	2383

One	O
week	O
after	O
the	O
initial	O
-	O
dose	O
of	O
adalimumab	B-Drug
(	O
160	O
mg	O
)	O
,	O
which	O
was	O
initiated	O
due	O
to	O
an	O
acute	O
exacerbation	O
of	O
Crohn	O
's	O
disease	O
,	O
the	O
patient	O
developed	O
a	O
fulminant	B-ADE
cardiomyopathy	I-ADE
.	O

-DOCSTART-	1188

PATIENT	O
AND	O
METHOD	O
:	O
A	O
34-year	O
-	O
old	O
woman	O
with	O
chronic	O
hepatitis	O
C	O
,	O
genotype	O
3	O
,	O
receiving	O
pegylated	B-Drug
interferon	I-Drug
alpha-2a	I-Drug
and	O
ribavirin	B-Drug
for	O
6	O
months	O
,	O
developed	O
progressive	B-ADE
malaise	I-ADE
and	O
anemia	B-ADE
6	O
months	O
after	O
the	O
end	O
of	O
treatment	O
.	O

-DOCSTART-	502

Ofloxacin	B-Drug
:	O
a	O
probable	O
cause	O
of	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
.	O

-DOCSTART-	934

Skin	B-ADE
rash	I-ADE
and	O
splinter	B-ADE
hemorrhages	I-ADE
from	O
ganciclovir	B-Drug
.	O

-DOCSTART-	2176

Rosaceiform	B-ADE
eruption	I-ADE
induced	O
by	O
erlotinib	B-Drug
.	O

-DOCSTART-	3913

over	O
the	O
past	O
3	O
years	O
there	O
have	O
been	O
several	O
reports	O
of	O
uveitis	B-ADE
associated	O
with	O
rifabutin	B-Drug
therapy	O
.	O

-DOCSTART-	3866

However	O
,	O
continued	O
low	O
-	O
dose	O
MTX	B-Drug
led	O
,	O
in	O
spite	O
of	O
normal	O
liver	O
tests	O
,	O
8	O
years	O
after	O
the	O
last	O
biopsy	O
to	O
liver	B-ADE
failure	I-ADE
and	O
death	B-ADE
in	O
1	O
of	O
our	O
patients	O
.	O

-DOCSTART-	1711

Premature	B-ADE
closure	I-ADE
of	I-ADE
the	I-ADE
ductus	I-ADE
arteriosus	I-ADE
:	O
variable	O
response	O
among	O
monozygotic	O
twins	O
after	O
in	O
utero	O
exposure	O
to	O
indomethacin	B-Drug
.	O

-DOCSTART-	1217

Ziprasidone	B-Drug
is	O
an	O
atypical	O
antipsychotic	O
drug	O
that	O
is	O
believed	O
to	O
have	O
a	O
low	O
propensity	O
for	O
inducing	O
extrapyramidal	B-ADE
symptoms	I-ADE
,	O
including	O
tardive	B-ADE
dyskinesia	I-ADE
(	O
TD	B-ADE
)	O
.	O

-DOCSTART-	2996

Spindle	B-ADE
coma	I-ADE
in	O
benzodiazepine	B-Drug
toxicity	O
:	O
case	O
report	O
.	O

-DOCSTART-	47

Priapism	B-ADE
as	O
a	O
complication	O
of	O
heparin	B-Drug
therapy	O
.	O

-DOCSTART-	1875

Bisphosphonate	B-Drug
induced	O
osteochemonecrosis	B-ADE
of	I-ADE
the	I-ADE
jaw	I-ADE
mimicking	O
a	O
tumour	O
.	O

-DOCSTART-	604

Posterior	B-ADE
leukoencephalopathy	I-ADE
following	O
cisplatin	B-Drug
,	O
bleomycin	B-Drug
and	O
vinblastine	B-Drug
therapy	O
for	O
germ	O
cell	O
tumor	O
of	O
the	O
ovary	O
.	O

-DOCSTART-	2798

Methemoglobinemia	B-ADE
associated	O
with	O
dermal	O
application	O
of	O
benzocaine	B-Drug
cream	O
in	O
a	O
cat	O
.	O

-DOCSTART-	3436

Arrhythmias	B-ADE
and	O
cardiac	B-ADE
arrest	I-ADE
have	O
been	O
reported	O
during	O
amphotericin	B-Drug
B	I-Drug
administration	O
but	O
no	O
effective	O
technique	O
has	O
been	O
described	O
to	O
prevent	O
them	O
.	O

-DOCSTART-	2083

Thus	O
,	O
tardive	B-ADE
seizures	I-ADE
in	O
our	O
cases	O
are	O
thought	O
to	O
be	O
related	O
to	O
piperacillin	B-Drug
and	O
cefotiam	B-Drug
.	O

-DOCSTART-	2941

Paradoxical	B-ADE
pulmonary	I-ADE
vasoconstriction	I-ADE
induced	O
by	O
nitroglycerin	B-Drug
in	O
idiopathic	O
pulmonary	O
hypertension	O
.	O

-DOCSTART-	4151

Although	O
this	O
G	B-Drug
-	I-Drug
CSF	I-Drug
-	O
driven	O
leucocytosis	B-ADE
was	O
alarming	O
it	O
did	O
not	O
appear	O
to	O
have	O
adversely	O
affected	O
the	O
patient	O
's	O
prognosis	O
.	O

-DOCSTART-	3921

A	O
49-year	O
-	O
old	O
man	O
with	O
Crohn	O
's	O
disease	O
treated	O
with	O
prednisone	B-Drug
and	O
mesalamine	B-Drug
(	O
5-ASA	B-Drug
)	O
developed	O
worsening	B-ADE
respiratory	I-ADE
distress	I-ADE
and	O
fever	B-ADE
.	O

-DOCSTART-	2904

Noncardiogenic	B-ADE
pulmonary	I-ADE
edema	I-ADE
during	O
intrabiliary	O
infusion	O
of	O
mono	B-Drug
-	I-Drug
octanoin	I-Drug
.	O

-DOCSTART-	121

Sodium	B-Drug
phenylbutyrate	I-Drug
was	O
added	O
to	O
treatment	O
with	O
HU	B-Drug
in	O
two	O
patients	O
,	O
but	O
failed	O
to	O
produce	O
an	O
increase	O
in	O
total	O
Hb	O
despite	O
increasing	B-ADE
Hb	I-ADE
F	I-ADE
levels	O
.	O

-DOCSTART-	845

Massive	B-ADE
pulmonary	I-ADE
embolism	I-ADE
due	O
to	O
late	O
-	O
onset	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
following	O
coronary	O
artery	O
bypass	O
graft	O
surgery	O
:	O
successful	O
treatment	O
with	O
lepirudin	O
.	O

-DOCSTART-	2834

This	O
case	O
report	O
illustrates	O
the	O
neurotoxicity	B-ADE
unique	O
to	O
HDARAC	B-Drug
.	O

-DOCSTART-	3470

Because	O
sumatriptan	B-Drug
can	O
cause	O
coronary	B-ADE
artery	I-ADE
vasospasm	I-ADE
,	O
patients	O
with	O
significant	O
risk	O
factors	O
for	O
coronary	O
artery	O
disease	O
should	O
be	O
carefully	O
evaluated	O
for	O
cardiovascular	O
disease	O
prior	O
to	O
the	O
use	O
of	O
sumatriptan	O
.	O

-DOCSTART-	1774

The	O
patient	O
's	O
arthritis	B-ADE
flared	O
after	O
the	O
second	O
infusion	O
of	O
infliximab	B-Drug
,	O
which	O
was	O
discontinued	O
.	O

-DOCSTART-	3831

Methemoglobinemia	B-ADE
is	O
another	O
common	O
finding	O
among	O
patients	O
receiving	O
dapsone	B-Drug
therapy	O
,	O
but	O
rarely	O
does	O
it	O
result	O
in	O
prominent	O
symptoms	O
other	O
than	O
transient	O
pallor	O
.	O

-DOCSTART-	1629

Drug	O
-	O
induced	O
hepatitis	B-ADE
in	O
an	O
acromegalic	O
patient	O
during	O
combined	O
treatment	O
with	O
pegvisomant	B-Drug
and	O
octreotide	B-Drug
long	O
-	O
acting	O
repeatable	O
attributed	O
to	O
the	O
use	O
of	O
pegvisomant	B-Drug
.	O

-DOCSTART-	4053

Early	O
ritonavir	B-Drug
-	O
induced	O
maculopapular	B-ADE
eruption	I-ADE
.	O

-DOCSTART-	224

BACKGROUND	O
:	O
Reproductive	B-ADE
endocrine	I-ADE
disorders	I-ADE
characterized	O
by	O
menstrual	B-ADE
disorders	I-ADE
,	O
polycystic	B-ADE
ovaries	I-ADE
,	O
and	O
hyperandrogenism	B-ADE
seem	O
to	O
be	O
common	O
among	O
women	O
treated	O
with	O
sodium	B-Drug
valproate	I-Drug
for	O
epilepsy	O
.	O

-DOCSTART-	657

Ticlopidine	B-Drug
-	O
induced	O
aplastic	B-ADE
anemia	I-ADE
(	O
TIAA	B-ADE
)	O
is	O
considered	O
very	O
uncommon	O
.	O

-DOCSTART-	909

Carbamazepine	B-Drug
-	O
induced	O
systemic	B-ADE
lupus	I-ADE
erythematosus	I-ADE
.	O

-DOCSTART-	1950

Sustained	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
in	O
a	O
thalidomide	B-Drug
-	O
treated	O
patient	O
with	O
primary	O
plasma	O
-	O
cell	O
leukemia	O
.	O

-DOCSTART-	164

The	O
present	O
report	O
illustrates	O
a	O
rare	O
case	O
of	O
refractory	O
akathisia	B-ADE
after	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
treatment	O
and	O
also	O
that	O
levodopa	O
treatment	O
would	O
be	O
theoretically	O
and	O
practically	O
useful	O
in	O
reducing	O
the	O
neurotoxicity	B-ADE
associated	O
with	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
.	O

-DOCSTART-	4233

Methotrexate	B-Drug
-	O
induced	O
hepatic	B-ADE
necrosis	I-ADE
requiring	O
liver	O
transplantation	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	4236

CONCLUSIONS	O
:	O
Because	O
of	O
its	O
structural	O
similarity	O
to	O
the	O
other	O
vinca	O
alkaloids	O
,	O
vinorelbine	B-Drug
is	O
believed	O
to	O
be	O
responsible	O
for	O
SIADH	B-ADE
in	O
our	O
patient	O
.	O

-DOCSTART-	2984

Propranolol	B-Drug
-	O
induced	O
hypertension	B-ADE
in	O
treatment	O
of	O
cocaine	O
intoxication	O
.	O

-DOCSTART-	3685

A	O
patient	O
with	O
acute	O
esophageal	O
variceal	O
bleeding	O
developed	O
fatal	B-ADE
rhabdomyolysis	I-ADE
during	O
treatment	O
with	O
a	O
continuous	O
intravenous	O
infusion	O
of	O
vasopressin	B-Drug
.	O

-DOCSTART-	2994

When	O
the	O
trazodone	B-Drug
was	O
reduced	O
,	O
the	O
involuntary	B-ADE
movements	I-ADE
promptly	O
ceased	O
.	O

-DOCSTART-	2276

Neuroleptic	B-ADE
malignant	I-ADE
syndrome	I-ADE
due	O
to	O
risperidone	B-Drug
treatment	O
in	O
a	O
child	O
with	O
Joubert	O
syndrome	O
.	O

-DOCSTART-	3650

INTERVENTIONS	O
AND	O
RESULTS	O
:	O
Cardiac	B-ADE
complications	I-ADE
were	O
observed	O
in	O
five	O
pediatric	O
patients	O
who	O
received	O
between	O
4.6	O
and	O
40.8	O
mg	O
/	O
kg	O
/	O
d	O
of	O
amphotericin	B-Drug
B	I-Drug
.	O

-DOCSTART-	2625

Akathisia	B-ADE
appeared	O
to	O
be	O
a	O
common	O
side	O
effect	O
of	O
fluoxetine	B-Drug
and	O
generally	O
responded	O
well	O
to	O
treatment	O
with	O
the	O
beta	O
-	O
adrenergic	O
antagonist	O
propranolol	O
,	O
dose	O
reduction	O
,	O
or	O
both	O
.	O

-DOCSTART-	3019

Dystonia	B-ADE
associated	O
with	O
carbamazepine	B-Drug
administration	O
:	O
experience	O
in	O
brain	O
-	O
damaged	O
children	O
.	O

-DOCSTART-	2787

Salicylate	B-Drug
-	O
induced	O
hepatotoxicity	B-ADE
is	O
reviewed	O
.	O

-DOCSTART-	625

Ticlopidine	B-Drug
-	O
induced	O
marrow	B-ADE
aplasia	I-ADE
treated	O
with	O
cyclosporine	O
.	O

-DOCSTART-	2438

Interferon	B-Drug
-	O
based	O
treatments	O
have	O
the	O
potential	O
to	O
decrease	O
the	O
burden	O
of	O
disease	O
,	O
but	O
are	O
complicated	O
by	O
side	O
effects	O
,	O
including	O
neuropsychiatric	B-ADE
symptoms	I-ADE
.	O

-DOCSTART-	2552

Despite	O
a	O
response	O
of	O
the	O
meningeal	O
tumor	O
the	O
patient	O
developed	O
in	O
the	O
third	O
week	O
of	O
MTX	B-Drug
treatment	O
a	O
progressive	B-ADE
visual	I-ADE
loss	I-ADE
and	O
loss	B-ADE
of	I-ADE
consciousness	I-ADE
which	O
worsened	O
during	O
subsequent	O
Ara	B-Drug
-	I-Drug
C	I-Drug
treatment	O
and	O
led	O
to	O
death	B-ADE
within	O
3	O
weeks	O
.	O

-DOCSTART-	1689

In	O
this	O
case	O
,	O
unlike	O
those	O
previously	O
reported	O
,	O
hyponatremia	B-ADE
recurred	O
5	O
months	O
after	O
switching	O
from	O
citalopram	B-Drug
to	O
mirtazapine	B-Drug
,	O
which	O
is	O
believed	O
to	O
be	O
a	O
safe	O
antidepressant	O
.	O

-DOCSTART-	1197

Vogt	B-ADE
-	I-ADE
Koyanagi	I-ADE
-	I-ADE
Harada	I-ADE
disease	I-ADE
occurring	O
during	O
interferon	B-Drug
alpha	I-Drug
therapy	O
for	O
chronic	O
hepatitis	O
C	O
.	O

-DOCSTART-	2055

Anastrozole	B-Drug
-	O
associated	O
sclerosing	B-ADE
glomerulonephritis	I-ADE
in	O
a	O
patient	O
with	O
breast	O
cancer	O
.	O

-DOCSTART-	3213

Priapism	B-ADE
associated	O
with	O
trazodone	B-Drug
therapy	O
:	O
case	O
report	O
.	O

-DOCSTART-	4071

Methyldopa	B-Drug
-	O
induced	O
liver	B-ADE
injury	I-ADE
.	O

-DOCSTART-	3845

We	O
also	O
describe	O
a	O
new	O
,	O
noninvasive	O
method	O
to	O
assess	O
magnesium	B-Drug
-	O
induced	O
neuromuscular	B-ADE
block	I-ADE
when	O
curariform	O
muscle	O
relaxant	O
was	O
given	O
simultaneously	O
.	O

-DOCSTART-	2184

To	O
our	O
knowledge	O
,	O
drug	O
-	O
induced	O
fever	B-ADE
has	O
not	O
been	O
reported	O
with	O
the	O
use	O
of	O
diltiazem	B-Drug
hydrochloride	I-Drug
,	O
a	O
commonly	O
prescribed	O
calcium	O
channel	O
blocker	O
.	O

-DOCSTART-	43

Diclofenac	B-Drug
-	O
associated	O
hepatitis	B-ADE
.	O

-DOCSTART-	1151

Acute	B-ADE
renal	I-ADE
insufficiency	I-ADE
is	O
known	O
to	O
occur	O
in	O
patients	O
who	O
are	O
taking	O
ciprofloxacin	B-Drug
,	O
particularly	O
the	O
elderly	O
.	O

-DOCSTART-	3832

Acetazolamide	B-Drug
-	O
accelerated	O
anticonvulsant	O
osteomalacia	B-ADE
.	O

-DOCSTART-	3864

BACKGROUND	O
:	O
Methotrexate	B-Drug
(	O
MTX	B-Drug
)	O
may	O
induce	O
liver	B-ADE
damage	I-ADE
,	O
which	O
in	O
some	O
psoriatics	O
will	O
lead	O
to	O
fibrosis	B-ADE
or	O
cirrhosis	B-ADE
.	O

-DOCSTART-	3954

Cephalexin	B-ADE
rash	I-ADE
in	O
infectious	O
mononucleosis	O
.	O

-DOCSTART-	1698

Scleritis	B-ADE
complicating	O
zoledronic	B-Drug
acid	I-Drug
infusion	O
.	O

-DOCSTART-	3366

In	O
a	O
phase	O
II	O
study	O
of	O
hycanthone	B-Drug
in	O
patients	O
with	O
breast	O
cancer	O
we	O
have	O
recently	O
observed	O
severe	B-ADE
hepatotoxicity	I-ADE
,	O
even	O
at	O
lower	O
doses	O
,	O
which	O
resulted	O
in	O
two	O
drug	O
-	O
related	O
deaths	O
.	O

-DOCSTART-	3189

Moxalactam	B-Drug
is	O
more	O
likely	O
to	O
be	O
associated	O
with	O
platelet	B-ADE
dysfunction	I-ADE
.	O

-DOCSTART-	876

Thrombocytosis	B-ADE
under	O
ciprofloxacin	B-Drug
and	O
tazobactam	B-Drug
/	O
piperacillin	B-Drug
.	O

-DOCSTART-	1787

Inhaled	O
tobramycin	B-Drug
solution	O
-	O
associated	O
recurrent	B-ADE
eosinophilia	I-ADE
and	O
severe	B-ADE
persistent	I-ADE
bronchospasm	I-ADE
in	O
a	O
patient	O
with	O
cystic	O
fibrosis	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	2091

RESULTS	O
:	O
Our	O
patient	O
developed	O
Crohn	B-ADE
's	I-ADE
disease	I-ADE
while	O
on	O
Copaxone	B-Drug
treatment	O
as	O
a	O
consequence	O
of	O
long	B-ADE
-	I-ADE
term	I-ADE
immunosuppression	I-ADE
.	O

-DOCSTART-	2698

Soon	O
after	O
its	O
introduction	O
in	O
1952	O
,	O
chlorpromazine	B-Drug
was	O
noted	O
to	O
induce	O
symptoms	B-ADE
resembling	I-ADE
Parkinson	I-ADE
's	I-ADE
disease	I-ADE
.	O

-DOCSTART-	2620

MR	O
findings	O
in	O
methotrexate	B-Drug
-	O
induced	O
CNS	B-ADE
abnormalities	I-ADE
.	O

-DOCSTART-	903

Scleroderma	B-ADE
in	O
association	O
with	O
the	O
use	O
of	O
bleomycin	B-Drug
:	O
a	O
report	O
of	O
3	O
cases	O
.	O

-DOCSTART-	3705

We	O
report	O
a	O
case	O
of	O
drug	O
-	O
induced	O
Kaposi	B-ADE
's	I-ADE
sarcoma	I-ADE
(	O
KS	O
)	O
on	O
the	O
sole	O
of	O
the	O
right	O
foot	O
in	O
a	O
71-year	O
-	O
old	O
man	O
,	O
treated	O
for	O
6	O
months	O
with	O
corticosteroid	O
therapy	O
(	O
prednisolone	B-Drug
25	O
mg	O
/	O
day	O
)	O
for	O
pericardial	O
effusion	O
.	O

-DOCSTART-	2742

A	O
young	O
woman	O
with	O
epilepsy	O
had	O
tonic	B-ADE
-	I-ADE
clonic	I-ADE
seizures	I-ADE
during	O
antineoplastic	O
therapy	O
with	O
adriamycin	B-Drug
and	O
cisplatin	B-Drug
.	O

-DOCSTART-	306

Acute	B-ADE
myeloid	I-ADE
leukemia	I-ADE
and	O
lung	B-ADE
cancer	I-ADE
occurring	O
in	O
a	O
chronic	O
lymphocytic	O
leukemia	O
patient	O
treated	O
with	O
fludarabine	B-Drug
and	O
autologous	O
peripheral	O
blood	O
stem	O
-	O
cell	O
transplantation	O
.	O

-DOCSTART-	2581

We	O
describe	O
six	O
patients	O
who	O
developed	O
tardive	B-ADE
dyskinesia	I-ADE
after	O
treatment	O
with	O
sulpiride	B-Drug
for	O
depression	O
or	O
gastrointestinal	O
symptoms	O
.	O

-DOCSTART-	4040

Skin	B-ADE
necrosis	I-ADE
secondary	O
to	O
low	B-Drug
-	I-Drug
molecular	I-Drug
weight	I-Drug
heparin	I-Drug
in	O
a	O
patient	O
with	O
antiphospholipid	O
antibody	O
syndrome	O
.	O

-DOCSTART-	3321

Acute	B-ADE
non	I-ADE
-	I-ADE
lymphocytic	I-ADE
leukemia	I-ADE
occurred	O
in	O
eight	O
women	O
following	O
long	O
-	O
term	O
treatment	O
with	O
Treosulfan	B-Drug
(=	O
dihydroxybusulfan	B-Drug
)	O
for	O
ovarian	O
carcinoma	O
.	O

-DOCSTART-	1407

CD20-negative	B-ADE
T	I-ADE
-	I-ADE
cell	I-ADE
-	I-ADE
rich	I-ADE
B	I-ADE
-	I-ADE
cell	I-ADE
lymphoma	I-ADE
as	O
a	O
progression	O
of	O
a	O
nodular	O
lymphocyte	O
-	O
predominant	O
Hodgkin	O
's	O
lymphoma	O
treated	O
with	O
rituximab	B-Drug
:	O
a	O
molecular	O
analysis	O
using	O
laser	O
capture	O
microdissection	O
.	O

-DOCSTART-	3606

We	O
present	O
the	O
case	O
of	O
a	O
postictal	O
patient	O
with	O
lethargy	B-ADE
,	O
hyperammonemia	B-ADE
,	O
otherwise	O
normal	O
liver	O
function	O
tests	O
,	O
and	O
a	O
therapeutic	O
valproic	B-Drug
acid	I-Drug
level	O
.	O

-DOCSTART-	3104

Nonoliguric	B-ADE
acute	I-ADE
renal	I-ADE
failure	I-ADE
after	O
captopril	B-Drug
therapy	O
.	O

-DOCSTART-	1634

Listeria	B-ADE
brain	I-ADE
abscess	I-ADE
,	O
Pneumocystis	B-ADE
pneumonia	I-ADE
and	O
Kaposi	B-ADE
's	I-ADE
sarcoma	I-ADE
after	O
temozolomide	B-Drug
.	O

-DOCSTART-	1124

RESULTS	O
:	O
After	O
4-	O
to	O
14-month	O
period	O
of	O
therapy	O
with	O
the	O
combination	O
of	O
indapamide	B-Drug
(	O
2.5	O
mg	O
/	O
day	O
)	O
and	O
fosinopril	B-Drug
(	O
10	O
mg	O
/	O
day	O
)	O
in	O
three	O
patients	O
and	O
6-month	O
period	O
of	O
monotherapy	O
with	O
indapamide	B-Drug
(	O
2.5	O
mg	O
/	O
day	O
)	O
in	O
one	O
patient	O
,	O
glucose	O
levels	O
of	O
all	O
patients	O
increased	O
and	O
achieve	O
criteria	O
of	O
diabetes	B-ADE
diagnoses	O
.	O

-DOCSTART-	2287

In	O
these	O
patients	O
,	O
long	O
-	O
acting	O
octreotide	B-Drug
may	O
trigger	O
serious	B-ADE
hypoglycemia	I-ADE
.	O

-DOCSTART-	1412

Transfusion	B-ADE
haemosiderosis	I-ADE
inspite	O
of	O
regular	O
use	O
of	O
desferrioxamine	B-Drug
:	O
case	O
report	O
.	O

-DOCSTART-	1768

CONCLUSIONS	O
:	O
Infectious	B-ADE
endophthalmitis	I-ADE
is	O
a	O
potential	O
complication	O
of	O
intravitreal	O
bevacizumab	B-Drug
injection	O
.	O

-DOCSTART-	1903

Discontinuation	O
of	O
simvastatin	B-Drug
and	O
cyclosporine	B-Drug
resulted	O
in	O
resolution	O
of	O
rhabdomyolysis	B-ADE
and	O
normalization	O
of	O
renal	O
function	O
.	O

-DOCSTART-	3105

Captopril	B-Drug
-	O
induced	O
acute	B-ADE
reversible	I-ADE
renal	I-ADE
failure	I-ADE
.	O

-DOCSTART-	2723

Gastro	B-ADE
-	I-ADE
oesophageal	I-ADE
reflux	I-ADE
associated	O
with	O
nifedipine	B-Drug
.	O

-DOCSTART-	4239

Pirmenol	B-Drug
hydrochloride	I-Drug
-	O
induced	O
QT	B-ADE
prolongation	I-ADE
and	O
T	B-ADE
wave	I-ADE
inversion	I-ADE
on	O
electrocardiogram	O
during	O
treatment	O
for	O
symptomatic	O
atrial	O
fibrillation	O
.	O

-DOCSTART-	886

Isoniazid	B-Drug
associated	O
,	O
painful	O
,	O
bilateral	B-ADE
gynaecomastia	I-ADE
.	O

-DOCSTART-	2102

Voriconazole	B-Drug
(	O
VRC	B-Drug
)	O
has	O
not	O
previously	O
been	O
reported	O
to	O
cause	O
angio	B-ADE
-	I-ADE
oedema	I-ADE
.	O

-DOCSTART-	3243

Within	O
3	O
weeks	O
of	O
beginning	O
continuous	O
daily	O
isoniazid	B-Drug
and	O
rifampin	B-Drug
therapy	O
for	O
pulmonary	O
tuberculosis	O
,	O
a	O
patient	O
developed	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
.	O

-DOCSTART-	4049

These	O
case	O
reports	O
provide	O
evidence	O
that	O
5-aminosalicylic	B-Drug
acid	I-Drug
may	O
induce	O
acute	B-ADE
pancreatitis	I-ADE
after	O
long	O
term	O
treatment	O
.	O

-DOCSTART-	4264

Sunburn	B-ADE
may	O
sometimes	O
be	O
a	O
major	O
injury	O
in	O
psoralen	B-Drug
users	O
because	O
high	O
doses	O
or	O
inappropriate	O
use	O
of	O
the	O
drug	O
may	O
render	O
the	O
skin	B-ADE
extremely	I-ADE
sensitive	I-ADE
.	O

-DOCSTART-	2400

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
fatal	O
gemcitabine	B-Drug
-	O
induced	O
pulmonary	B-ADE
toxicity	I-ADE
in	O
a	O
patient	O
with	O
gallbladder	O
metastatic	O
adenocarcinoma	O
.	O

-DOCSTART-	972

Severe	B-ADE
Raynaud	I-ADE
's	I-ADE
phenomenon	I-ADE
with	O
yohimbine	B-Drug
therapy	O
for	O
erectile	O
dysfunction	O
.	O

-DOCSTART-	354

We	O
suggest	O
that	O
meloxicam	B-Drug
might	O
have	O
intestinal	B-ADE
toxic	I-ADE
effects	I-ADE
when	O
taken	O
in	O
high	O
doses	O
,	O
because	O
of	O
reduced	O
COX-2	O
selectivity	O
.	O

-DOCSTART-	1556

Destructive	O
thyrotoxicosis	B-ADE
appeared	O
4	O
-	O
6	O
months	O
after	O
starting	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
,	O
followed	O
by	O
Graves	B-ADE
'	I-ADE
hyperthyroidism	I-ADE
within	O
8	O
to	O
11	O
months	O
.	O

-DOCSTART-	1646

Five	O
days	O
after	O
the	O
fourth	O
dose	O
of	O
vincristine	B-Drug
,	O
she	O
presented	O
with	O
bilateral	B-ADE
ptosis	I-ADE
.	O

-DOCSTART-	4167

Clozapine	B-Drug
is	O
speculated	O
to	O
cause	O
rhabdomyolysis	B-ADE
in	O
patients	O
with	O
defective	O
calcium	O
-	O
activated	O
K+	O
channels	O
.	O

-DOCSTART-	2856

Severe	B-ADE
systemic	I-ADE
hypersensitivity	I-ADE
reaction	I-ADE
to	O
ibuprofen	B-Drug
occurring	O
after	O
prolonged	O
therapy	O
.	O

-DOCSTART-	2672

Dexamethasone	O
treatment	O
of	O
amiodarone	B-Drug
-	O
induced	O
thyrotoxicosis	B-ADE
(	O
AIT	O
)	O
with	O
or	O
without	O
persistent	O
administration	O
of	O
the	O
drug	O
.	O

-DOCSTART-	2073

The	O
fifth	O
patient	O
exhibited	O
paraesthesia	B-ADE
and	O
agitation	B-ADE
caused	O
by	O
olanzapine	B-Drug
that	O
was	O
misdiagnosed	O
as	O
psychotic	O
agitation	O
.	O

-DOCSTART-	518

Gallstones	B-ADE
and	O
bile	B-ADE
sludge	I-ADE
are	O
common	O
side	O
effects	O
of	O
octreotide	B-Drug
therapy	O
but	O
rarely	O
become	O
symptomatic	O
or	O
require	O
treatment	O
.	O

-DOCSTART-	853

Proliferation	B-ADE
of	I-ADE
abnormal	I-ADE
bone	I-ADE
marrow	I-ADE
histiocytes	I-ADE
,	O
an	O
undesired	O
effect	O
of	O
granulocyte	B-Drug
macrophage	I-Drug
-	I-Drug
colony	I-Drug
-	I-Drug
stimulating	I-Drug
factor	I-Drug
therapy	O
in	O
a	O
patient	O
with	O
Hurler	O
's	O
syndrome	O
undergoing	O
bone	O
marrow	O
transplantation	O
.	O

-DOCSTART-	653

Generalised	B-ADE
pustular	I-ADE
psoriasis	I-ADE
induced	O
by	O
cyclosporin	B-Drug
a	I-Drug
withdrawal	O
responding	O
to	O
the	O
tumour	O
necrosis	O
factor	O
alpha	O
inhibitor	O
etanercept	O
.	O

-DOCSTART-	3571

In	O
a	O
series	O
of	O
104	O
cases	O
of	O
intentional	O
or	O
inadvertent	O
use	O
of	O
zidovudine	B-Drug
at	O
differing	O
gestations	O
in	O
pregnancy	O
,	O
there	O
were	O
eight	O
spontaneous	O
first	B-ADE
trimester	I-ADE
abortions	I-ADE
,	O
eight	O
therapeutic	O
terminations	O
,	O
and	O
eight	O
cases	O
of	O
fetal	B-ADE
abnormality	I-ADE
occurring	O
among	O
a	O
total	O
of	O
88	O
cases	O
where	O
the	O
pregnancy	O
progressed	O
.	O

-DOCSTART-	2412

Clozapine	B-Drug
-	O
induced	O
tardive	B-ADE
dyskinesia	I-ADE
in	O
schizophrenic	O
patients	O
taking	O
clozapine	O
as	O
a	O
first	O
-	O
line	O
antipsychotic	O
drug	O
.	O

-DOCSTART-	1937

We	O
concluded	O
that	O
the	O
colonic	B-ADE
ulcer	I-ADE
and	O
the	O
sigmoidovesical	B-ADE
fistula	I-ADE
had	O
been	O
caused	O
by	O
the	O
administration	O
of	O
calcium	B-Drug
polystyrene	I-Drug
sulfonate	I-Drug
and	O
sorbitol	B-Drug
.	O

-DOCSTART-	1859

Interstitial	B-ADE
pneumonitis	I-ADE
and	O
alveolar	B-ADE
hemorrhage	I-ADE
complicating	O
use	O
of	O
rituximab	B-Drug
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	4189

However	O
,	O
repeated	O
intracameral	O
tPA	B-Drug
injections	O
may	O
cause	O
unwanted	O
complications	O
such	O
as	O
vitreous	B-ADE
hemorrhage	I-ADE
.	O

-DOCSTART-	2339

Carbamazepine	B-Drug
-	O
induced	O
hyperammonemia	B-ADE
.	O

-DOCSTART-	1656

Reversible	O
findings	O
of	O
restricted	O
diffusion	O
in	O
5-fluorouracil	B-Drug
neurotoxicity	B-ADE
.	O

-DOCSTART-	4104

CONCLUSIONS	O
:	O
This	O
report	O
indicates	O
clindamycin	B-Drug
phosphate	I-Drug
vaginal	O
cream	O
as	O
the	O
most	O
probable	O
cause	O
of	O
CDIC	B-ADE
due	O
to	O
the	O
temporal	O
relationship	O
between	O
the	O
occurrence	O
of	O
diarrhea	B-ADE
and	O
clindamycin	B-Drug
administration	O
,	O
lack	O
of	O
concomitant	O
medications	O
,	O
and	O
documentation	O
of	O
C.	B-ADE
difficile	I-ADE
toxin	I-ADE
.	O

-DOCSTART-	3781

Oculomotor	B-ADE
disturbances	I-ADE
associated	O
with	O
5-fluorouracil	B-Drug
chemotherapy	O
.	O

-DOCSTART-	937

Renal	B-ADE
tubular	I-ADE
acidosis	I-ADE
secondary	O
to	O
FK506	B-Drug
in	O
living	O
donor	O
liver	O
transplantation	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	2084

Acute	B-ADE
delirium	I-ADE
resulting	O
from	O
levofloxacin	B-Drug
therapy	O
is	O
an	O
exceedingly	O
rare	O
complication	O
that	O
has	O
been	O
thought	O
to	O
occur	O
more	O
commonly	O
in	O
elderly	O
patients	O
.	O

-DOCSTART-	3594

Seizures	B-ADE
associated	O
with	O
fluoxetine	B-Drug
therapy	O
.	O

-DOCSTART-	640

Skin	B-ADE
necrosis	I-ADE
after	O
extravasation	O
of	O
low	O
-	O
dose	O
vasopressin	B-Drug
administered	O
for	O
septic	O
shock	O
.	O

-DOCSTART-	1843

The	O
hyperpigmentation	O
was	O
diffuse	O
scattered	O
,	O
flagellate	O
like	O
and	O
linear	O
streaking	O
which	O
was	O
thought	O
to	O
be	O
mainly	O
related	O
to	O
the	O
skin	B-ADE
toxicity	I-ADE
of	O
bleomycin	B-Drug
.	O

-DOCSTART-	3450

Arterial	B-ADE
hypertension	I-ADE
associated	O
with	O
topical	O
ocular	O
use	O
of	O
phenylephrine	B-Drug
in	O
dogs	O
.	O

-DOCSTART-	2731

Histological	O
examination	O
of	O
the	O
dacryolith	B-ADE
suggested	O
its	O
derivation	O
from	O
breakdown	O
products	O
of	O
adrenaline	B-Drug
.	O

-DOCSTART-	3654

The	O
administration	O
of	O
"	O
sweet	B-Drug
spirits	I-Drug
of	I-Drug
nitre	I-Drug
"	O
(	O
4	B-Drug
%	I-Drug
ethyl	I-Drug
nitrite	I-Drug
CH3CH2ONO	I-Drug
in	I-Drug
70	I-Drug
%	I-Drug
ethyl	I-Drug
alcohol	I-Drug
)	O
was	O
followed	O
by	O
acute	B-ADE
methemoglobinemia	I-ADE
and	O
severe	B-ADE
anoxic	I-ADE
metabolic	I-ADE
acidosis	I-ADE
in	O
infant	O
twins	O
,	O
Methylene	O
blue	O
administration	O
reversed	O
methemoglobinemia	O
in	O
both	O
,	O
but	O
one	O
twin	O
died	B-ADE
from	O
the	O
consequences	O
of	O
hypoxemia	B-ADE
.	O

-DOCSTART-	4148

Severe	B-ADE
respiratory	I-ADE
syncytial	I-ADE
virus	I-ADE
pulmonary	I-ADE
infection	I-ADE
in	O
a	O
patient	O
treated	O
with	O
fludarabine	B-Drug
for	O
chronic	O
lymphocytic	O
leukemia	O
.	O

-DOCSTART-	623

A	O
50-year	O
-	O
old	O
diabetic	O
and	O
hypertensive	O
male	O
patient	O
is	O
reported	O
who	O
had	O
ticlopidine	B-Drug
-	O
induced	O
marrow	B-ADE
aplasia	I-ADE
partially	O
responsive	O
to	O
colony	O
-	O
stimulating	O
factors	O
and	O
corticosteroids	O
,	O
but	O
experienced	O
complete	O
recovery	O
with	O
cyclosporine	O
.	O

-DOCSTART-	2318

Tigecycline	B-Drug
-	O
induced	O
acute	B-ADE
pancreatitis	I-ADE
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

-DOCSTART-	2974

Isoniazid	B-Drug
inhibits	O
the	O
conversion	O
of	O
tryptophan	O
to	O
niacin	O
and	O
may	O
induce	O
pellagra	B-ADE
,	O
particularly	O
in	O
poorly	O
nourished	O
patients	O
.	O

-DOCSTART-	4073

Acute	B-ADE
respiratory	I-ADE
depression	I-ADE
as	O
a	O
complication	O
of	O
nebulised	O
morphine	B-Drug
.	O

-DOCSTART-	1148

Sideroblastic	B-ADE
anemia	I-ADE
due	O
to	O
linezolid	B-Drug
in	O
a	O
patient	O
with	O
a	O
left	O
ventricular	O
assist	O
device	O
.	O

-DOCSTART-	2111

Use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
determined	O
the	O
association	O
between	O
cephalosporin	B-Drug
use	O
and	O
leukopenia	B-ADE
to	O
be	O
probable	O
.	O

-DOCSTART-	1673

Moreover	O
,	O
these	O
findings	O
suggest	O
that	O
the	O
incidence	O
of	O
BOOP	B-ADE
following	O
rituximab	B-Drug
therapy	O
may	O
be	O
higher	O
than	O
has	O
been	O
previously	O
appreciated	O
.	O

-DOCSTART-	3549

RESULTS	O
:	O
Budesonide	B-Drug
use	O
can	O
cause	O
contact	B-ADE
dermatitis	I-ADE
.	O

-DOCSTART-	311

Case	O
studies	O
in	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
.	O

-DOCSTART-	3797

Does	O
acyclovir	B-Drug
increase	B-ADE
serum	I-ADE
lithium	I-ADE
levels	I-ADE
?	O

-DOCSTART-	300

Even	O
after	O
a	O
strict	O
warning	O
,	O
he	O
took	O
another	O
quinine	B-Drug
tablet	O
that	O
evening	O
,	O
which	O
triggered	O
his	O
fifth	O
episode	O
of	O
severe	O
thrombocytopenia	B-ADE
,	O
and	O
confirmed	O
the	O
etiology	O
of	O
quinine	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
.	O

-DOCSTART-	2207

CONCLUSIONS	O
:	O
Amantadine	B-Drug
can	O
cause	O
reversible	B-ADE
corneal	I-ADE
edema	I-ADE
but	O
can	O
irreversibly	O
reduce	O
the	O
density	O
of	O
endothelial	O
cells	O
.	O

-DOCSTART-	419

The	O
bleeding	B-ADE
resolved	O
on	O
discontinuation	O
of	O
APV	B-Drug
.	O

-DOCSTART-	561

Thrombotic	B-ADE
stroke	I-ADE
associated	O
with	O
the	O
use	O
of	O
porcine	B-Drug
factor	I-Drug
VIII	I-Drug
in	O
a	O
patient	O
with	O
acquired	O
haemophilia	O
.	O

-DOCSTART-	1901

Pulmonary	B-ADE
fibrosis	I-ADE
associated	O
with	O
nabumetone	B-Drug
.	O

-DOCSTART-	1063

Heat	B-ADE
stroke	I-ADE
in	O
schizophrenia	O
during	O
clozapine	B-Drug
treatment	O
:	O
rapid	O
recognition	O
and	O
management	O
.	O

-DOCSTART-	401

We	O
believe	O
that	O
mucositis	O
was	O
a	O
contributing	O
factor	O
to	O
this	O
case	O
of	O
fatal	B-ADE
hyperkalemia	I-ADE
after	O
administration	O
of	O
succinylcholine	B-Drug
,	O
with	O
a	O
mechanism	O
similar	O
to	O
that	O
reported	O
with	O
thermal	O
injury	O
.	O

-DOCSTART-	2138

Ceftriaxone	B-Drug
-	O
induced	O
fixed	B-ADE
drug	I-ADE
eruption	I-ADE
:	O
first	O
report	O
.	O

-DOCSTART-	1775

A	O
32-year	O
-	O
old	O
man	O
with	O
a	O
family	O
history	O
of	O
type	O
2	O
diabetes	O
mellitus	O
presented	O
with	O
circulatory	B-ADE
collapse	I-ADE
and	O
deep	B-ADE
coma	I-ADE
after	O
9	O
days	O
of	O
treatment	O
with	O
perospirone	B-Drug
hydrochloride	I-Drug
,	O
a	O
recently	O
developed	O
atypical	O
antipsychotic	O
agent	O
available	O
only	O
in	O
Japan	O
.	O

-DOCSTART-	1289

Our	O
report	O
suggested	O
that	O
CBDCA	B-Drug
hypersensitivity	B-ADE
was	O
correlated	O
with	O
the	O
total	O
dose	O
of	O
previously	O
administered	O
platinum	O
agents	O
and	O
that	O
CBDCA	O
should	O
be	O
excluded	O
in	O
patients	O
who	O
have	O
received	O
multiple	O
platinum	O
-	O
based	O
chemotherapy	O
,	O
even	O
in	O
platinum	O
-	O
sensitive	O
cases	O
,	O
because	O
CBDCA	B-Drug
hypersensitivity	B-ADE
can	O
occur	O
even	O
with	O
low	O
-	O
dose	O
CBDCA	B-Drug
administration	O
.	O

-DOCSTART-	1086

Restless	B-ADE
legs	I-ADE
syndrome	I-ADE
due	O
to	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
.	O

-DOCSTART-	568

DISCUSSION	O
:	O
A	O
review	O
of	O
the	O
cases	O
of	O
SS	B-ADE
with	O
implication	O
of	O
mirtazapine	B-Drug
as	O
the	O
cause	O
was	O
performed	O
.	O

-DOCSTART-	4157

Antineutrophil	B-ADE
cytoplasmic	I-ADE
antibody	I-ADE
-	I-ADE
positive	I-ADE
crescentic	I-ADE
glomerulonephritis	I-ADE
associated	O
with	O
propylthiouracil	B-Drug
therapy	O
.	O

-DOCSTART-	3238

Since	O
early	O
symptoms	O
of	O
the	O
toxic	O
effects	O
of	O
theophylline	B-Drug
can	O
mimic	O
peptic	B-ADE
ulcer	I-ADE
disease	I-ADE
,	O
cimetidine	O
might	O
be	O
prescribed	O
for	O
the	O
gastrointestinal	O
symptoms	O
with	O
subsequent	O
worsening	O
of	O
theophylline	O
poisoning	O
.	O

-DOCSTART-	3997

Cutaneous	B-ADE
reactions	I-ADE
to	O
propylthiouracil	B-Drug
and	O
methimazole	B-Drug
occur	O
in	O
3%-5	O
%	O
of	O
adults	O
.	O

-DOCSTART-	746

Both	O
6-MP	B-Drug
and	O
AZA	B-Drug
are	O
widely	O
used	O
and	O
are	O
known	O
to	O
cause	O
hepatotoxicity	B-ADE
in	O
a	O
proportion	O
of	O
patients	O
.	O

-DOCSTART-	2999

Renal	B-ADE
failure	I-ADE
is	O
a	O
rare	O
complication	O
associated	O
with	O
the	O
use	O
of	O
rifampicin	B-Drug
for	O
the	O
treatment	O
of	O
tuberculosis	O
,	O
usually	O
occurring	O
well	O
into	O
the	O
course	O
of	O
therapy	O
.	O

-DOCSTART-	1074

Clinicians	O
should	O
be	O
aware	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
neurotoxicity	B-ADE
during	O
treatment	O
,	O
as	O
well	O
as	O
predisposing	O
factors	O
that	O
put	O
patients	O
receiving	O
methotrexate	B-Drug
at	O
risk	O
for	O
neurotoxic	O
effects	O
.	O

-DOCSTART-	177

Sagittal	B-ADE
sinus	I-ADE
thrombosis	I-ADE
associated	O
with	O
transient	B-ADE
free	I-ADE
protein	I-ADE
S	I-ADE
deficiency	I-ADE
after	O
L	B-Drug
-	I-Drug
asparaginase	I-Drug
treatment	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	1572

In	O
this	O
case	O
report	O
,	O
we	O
have	O
described	O
a	O
patient	O
with	O
Crohn	O
's	O
disease	O
who	O
developed	O
subfulminant	B-ADE
hepatitis	I-ADE
B	I-ADE
after	O
the	O
fourth	O
infusion	O
of	O
infliximab	B-Drug
due	O
to	O
an	O
unrecognized	O
HBs	O
-	O
antigen	O
carrier	O
state	O
.	O

-DOCSTART-	1754

Hepatotoxicity	B-ADE
resolved	O
once	O
erlotinib	B-Drug
was	O
discontinued	O
and	O
serum	O
transaminases	O
returned	O
to	O
baseline	O
normal	O
values	O
.	O

-DOCSTART-	2296

The	O
risk	O
of	O
developing	O
sAML	B-ADE
is	O
estimated	O
to	O
be	O
between	O
1	O
%	O
and	O
5	O
%	O
,	O
2	O
-	O
20	O
years	O
after	O
exposure	O
to	O
etoposide	B-Drug
but	O
may	O
also	O
be	O
related	O
to	O
cumulative	O
drug	O
doses	O
,	O
treatment	O
schedules	O
,	O
host	O
factors	O
and	O
co	O
-	O
administration	O
of	O
other	O
antineoplastic	O
agents	O
.	O

-DOCSTART-	1729

In	O
this	O
report	O
,	O
a	O
patient	O
who	O
had	O
undergone	O
a	O
renal	O
transplantation	O
as	O
a	O
result	O
of	O
malignant	O
hypertension	O
,	O
and	O
who	O
was	O
on	O
immunosuppressive	O
therapy	O
consisting	O
of	O
cyclosporin	B-Drug
,	O
prednisone	B-Drug
and	O
azathioprine	B-Drug
,	O
developed	O
thrombosis	B-ADE
of	O
the	O
central	O
retinal	O
vein	O
5	O
years	O
following	O
the	O
transplantation	O
.	O

-DOCSTART-	1718

DISCUSSION	O
:	O
Amphotericin	B-Drug
B	I-Drug
deoxycholate	I-Drug
has	O
been	O
reported	O
to	O
produce	O
significant	O
cardiac	B-ADE
toxicity	I-ADE
,	O
with	O
ventricular	B-ADE
arrhythmias	I-ADE
and	O
bradycardia	B-ADE
reported	O
in	O
overdoses	O
in	O
children	O
and	O
in	O
adults	O
with	O
preexisting	O
cardiac	O
disease	O
,	O
even	O
when	O
administered	O
in	O
conventional	O
dosages	O
and	O
infusion	O
rates	O
.	O

-DOCSTART-	776

Comeoscleral	B-ADE
perforation	I-ADE
after	O
pterygium	O
excision	O
and	O
intraoperative	O
mitomycin	B-Drug
C	I-Drug
.	O

-DOCSTART-	1456

DIAGNOSIS	O
:	O
Interferon	B-Drug
alpha-2b	I-Drug
-	O
induced	O
cardiomyopathy	B-ADE
.	O

-DOCSTART-	1062

A	O
case	O
of	O
heatstroke	B-ADE
is	O
reported	O
in	O
a	O
32-year	O
-	O
old	O
man	O
diagnosed	O
with	O
schizophrenia	O
and	O
on	O
clozapine	B-Drug
monotherapy	O
.	O

-DOCSTART-	2934

A	O
lethal	B-ADE
complication	I-ADE
of	O
peripheral	O
vein	O
vasopressin	B-Drug
infusion	O
.	O

-DOCSTART-	195

The	O
temporal	O
relationship	O
suggests	O
that	O
the	O
spinal	B-ADE
cord	I-ADE
infarction	I-ADE
may	O
be	O
related	O
to	O
the	O
use	O
of	O
zolmitriptan	B-Drug
.	O

-DOCSTART-	786

FK506	B-Drug
,	O
which	O
began	O
to	O
be	O
administered	O
12	O
days	O
earlier	O
,	O
rose	O
to	O
a	O
level	O
of	O
44	O
ng	O
/	O
mL	O
(	O
normal	O
range	O
,	O
10	O
-	O
20	O
ng	O
/	O
mL	O
)	O
1	O
day	O
before	O
neurologic	B-ADE
abnormalities	I-ADE
began	O
.	O

-DOCSTART-	742

Rapamycin	B-Drug
/	O
sirolimus	B-Drug
(	O
SR	B-Drug
)	O
,	O
trade	O
named	O
Rapammune	B-Drug
(	O
Wyeth	O
-	O
Ayerst	O
,	O
Sydney	O
,	O
Australia	O
)	O
,	O
is	O
a	O
potent	O
immunosuppressive	O
drug	O
associated	O
with	O
myelosuppression	B-ADE
,	O
hypertension	B-ADE
,	O
hyperlipidemia	B-ADE
,	O
and	O
infection	B-ADE
.	O

-DOCSTART-	3908

Ketanserin	O
in	O
the	O
treatment	O
of	O
protamine	B-Drug
-	O
induced	O
pulmonary	B-ADE
hypertension	I-ADE
.	O

-DOCSTART-	192

This	O
is	O
the	O
first	O
report	O
of	O
a	O
fluoxetine	B-Drug
-	O
related	O
death	B-ADE
in	O
a	O
child	O
with	O
a	O
confirmed	O
genetic	O
polymorphism	O
of	O
the	O
CYP2D6	O
gene	O
that	O
results	O
in	O
impaired	O
drug	O
metabolism	O
.	O

-DOCSTART-	119

Of	O
the	O
four	O
patients	O
who	O
responded	O
to	O
HU	B-Drug
with	O
an	O
increase	B-ADE
in	I-ADE
total	I-ADE
Hb	I-ADE
,	O
all	O
reported	O
symptomatic	O
improvement	O
and	O
three	O
have	O
not	O
required	O
further	O
transfusions	O
.	O

-DOCSTART-	3578

Diphenylhydantoin	B-Drug
apparently	O
adversely	O
affected	O
both	O
the	O
clinical	O
and	O
biochemical	O
parameters	O
of	O
the	O
acute	B-ADE
intermittent	I-ADE
porphyria	I-ADE
.	O

-DOCSTART-	2565

Ifosfamide	B-Drug
is	O
a	O
known	O
nephrotoxic	O
drug	O
with	O
demonstrated	O
tubulopathies	B-ADE
.	O

-DOCSTART-	1608

Due	O
to	O
discomfort	B-ADE
,	O
diplopia	B-ADE
and	O
lagophthalmos	B-ADE
,	O
the	O
haematoma	B-ADE
necessitated	O
suspension	O
of	O
warfarin	B-Drug
therapy	O
and	O
a	O
surgical	O
evacuation	O
.	O

-DOCSTART-	2697

Exacerbation	O
of	O
schizophrenia	B-ADE
associated	O
with	O
amantadine	B-Drug
.	O

-DOCSTART-	2925

The	O
main	O
clinical	O
features	O
of	O
this	O
58-year	O
-	O
old	O
female	O
patient	O
were	O
laboratory	O
evidence	O
of	O
leucopenia	B-ADE
and	O
cholestasis	B-ADE
,	O
and	O
biopsy	O
features	O
of	O
fatty	B-ADE
liver	I-ADE
parenchyma	I-ADE
degeneration	I-ADE
with	O
granulocytic	B-ADE
portal	I-ADE
infiltration	I-ADE
and	O
bile	B-ADE
stasis	I-ADE
,	O
demonstrated	O
20	O
days	O
after	O
the	O
initiation	O
of	O
antithyroid	O
therapy	O
with	O
20	O
mg	O
methimazole	B-Drug
daily	O
.	O

-DOCSTART-	1426

This	O
report	O
describes	O
a	O
probable	O
case	O
of	O
infliximab	B-Drug
-	O
induced	O
membranous	B-ADE
nephropathy	I-ADE
.	O

-DOCSTART-	386

It	O
is	O
increasingly	O
recognized	O
that	O
dose	O
adjustment	O
of	O
oral	O
valacyclovir	B-Drug
in	O
renal	O
failure	O
is	O
necessary	O
to	O
avoid	O
neurotoxicity	B-ADE
.	O

-DOCSTART-	747

Hepatotoxicity	B-ADE
associated	O
with	O
6-thioguanine	B-Drug
therapy	O
for	O
Crohn	O
's	O
disease	O
.	O

-DOCSTART-	3312

Bradycardia	B-ADE
and	O
congestive	B-ADE
heart	I-ADE
failure	I-ADE
associated	O
with	O
ocular	O
timolol	B-Drug
maleate	I-Drug
.	O

-DOCSTART-	2312

The	O
case	O
of	O
a	O
4-year	O
-	O
old	O
girl	O
with	O
valproate	B-Drug
-	O
induced	O
stupor	B-ADE
and	O
electroencephalographic	O
pattern	O
of	O
increased	O
fast	O
activity	O
is	O
reported	O
.	O

-DOCSTART-	2457

We	O
report	O
here	O
a	O
rare	O
case	O
of	O
pleuropericarditis	B-ADE
due	O
to	O
methotrexate	B-Drug
.	O

-DOCSTART-	2204

Although	O
moderate	O
myelosuppression	O
is	O
not	O
uncommonly	O
seen	O
in	O
patients	O
treated	O
with	O
lenalidomide	B-Drug
,	O
aplastic	B-ADE
anemia	I-ADE
has	O
not	O
previously	O
been	O
reported	O
to	O
be	O
associated	O
with	O
this	O
agent	O
.	O

-DOCSTART-	241

Allergic	O
reaction	O
to	O
gemfibrozil	B-Drug
manifesting	O
as	O
eosinophilic	B-ADE
gastroenteritis	I-ADE
.	O

-DOCSTART-	1974

Metabolic	B-ADE
acidosis	I-ADE
induced	O
by	O
acetazolamide	B-Drug
.	O

-DOCSTART-	3270

Atypical	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
(	O
torsade	B-ADE
de	I-ADE
pointes	I-ADE
)	O
induced	O
by	O
amiodarone	B-Drug
:	O
arrhythmia	B-ADE
previously	O
induced	O
by	O
quinidine	B-Drug
and	O
disopyramide	B-Drug
.	O

-DOCSTART-	4108

Administration	O
of	O
lamotrigine	B-Drug
,	O
especially	O
in	O
combination	O
with	O
valproic	B-Drug
acid	I-Drug
,	O
may	O
lead	O
to	O
the	O
development	O
of	O
TEN	B-ADE
.	O

-DOCSTART-	3332

Progressive	B-ADE
interstitial	I-ADE
lung	I-ADE
disease	I-ADE
from	O
prolonged	O
methotrexate	B-Drug
therapy	O
.	O

-DOCSTART-	2326

OBJECTIVE	O
:	O
To	O
describe	O
a	O
case	O
of	O
sertraline	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
in	O
an	O
elderly	O
patient	O
with	O
dementia	O
and	O
comorbidities	O
.	O

-DOCSTART-	331

We	O
report	O
a	O
fatal	O
case	O
of	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
(	O
TEN	B-ADE
)	O
resulting	O
from	O
a	O
high	O
dose	O
of	O
cytosine	B-Drug
arabinoside	I-Drug
(	O
ARA	B-Drug
-	I-Drug
C	I-Drug
)	O
.	O

-DOCSTART-	3345

Para	B-Drug
-	I-Drug
aminosalicylic	I-Drug
acid	I-Drug
-	O
induced	O
hypoglycaemia	B-ADE
in	O
a	O
patient	O
with	O
diabetic	O
nephropathy	O
.	O

-DOCSTART-	2668

Ulcerative	B-ADE
proctitis	I-ADE
in	O
juvenile	O
systemic	O
lupus	O
erythematosus	O
after	O
ibuprofen	B-Drug
treatment	O
.	O

-DOCSTART-	3632

Imidazoline	B-ADE
intoxication	I-ADE
in	O
children	O
.	O

-DOCSTART-	684

The	O
disease	O
-	O
modifying	O
drugs	O
he	O
was	O
taking	O
,	O
cyclosporin	B-Drug
and	O
methotrexate	B-Drug
,	O
were	O
stopped	O
,	O
and	O
the	O
lymphoma	B-ADE
resolved	O
spontaneously	O
without	O
the	O
use	O
of	O
chemotherapy	O
.	O

-DOCSTART-	3539

We	O
report	O
the	O
first	O
case	O
of	O
a	O
patient	O
in	O
a	O
promethazine	B-Drug
-	O
induced	O
coma	B-ADE
responding	O
to	O
treatment	O
with	O
flumazenil	O
.	O

-DOCSTART-	1052

A	O
patient	O
developed	O
cholestatic	B-ADE
hepatitis	I-ADE
while	O
being	O
treated	O
with	O
nitrofurantoin	B-Drug
.	O

-DOCSTART-	2824

Gold	B-Drug
-	O
induced	O
pneumonitis	B-ADE
.	O

-DOCSTART-	1107

Dorzolamide	B-Drug
-	O
induced	O
choroidal	B-ADE
detachment	I-ADE
in	O
a	O
surgically	O
untreated	O
eye	O
.	O

-DOCSTART-	1707

Herein	O
is	O
reported	O
an	O
unusual	O
case	O
of	O
coexistent	O
warfarin	B-Drug
-	O
induced	O
skin	B-ADE
necrosis	I-ADE
and	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
following	O
mitral	O
valve	O
replacement	O
for	O
thromboembolic	O
phenomena	O
associated	O
with	O
marantic	O
endocarditis	O
and	O
bronchial	O
adenocarcinoma	O
.	O

-DOCSTART-	3674

Carbamazepine	B-Drug
-	O
induced	O
tics	B-ADE
.	O

-DOCSTART-	4257

Mineral	B-Drug
oil	I-Drug
,	O
a	O
hydrocarbon	O
,	O
may	O
not	O
elicit	O
a	O
normal	O
protective	O
cough	O
reflex	O
and	O
may	O
impair	B-ADE
mucociliary	I-ADE
transport	I-ADE
.	O

-DOCSTART-	595

Priapism	B-ADE
associated	O
with	O
zuclopenthixol	B-Drug
.	O

-DOCSTART-	1116

Extensive	B-ADE
forearm	I-ADE
deep	I-ADE
venous	I-ADE
thrombosis	I-ADE
following	O
a	O
severe	O
infliximab	B-Drug
infusion	O
reaction	O
.	O

-DOCSTART-	1993

Temozolomide	B-Drug
-	O
induced	O
desquamative	B-ADE
skin	I-ADE
rash	I-ADE
in	O
a	O
patient	O
with	O
metastatic	O
melanoma	O
.	O

-DOCSTART-	4145

Mitomycin	B-Drug
C	I-Drug
-	O
related	O
hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
in	O
cancer	O
patients	O
.	O

-DOCSTART-	4154

Case	O
2	O
demonstrated	O
after	O
40	O
months	O
on	O
chlorambucil	B-Drug
the	O
presence	O
of	O
a	O
balanced	B-ADE
translocation	I-ADE
,	O
t	O
(	O
1;5	O
)	O
(	O
p36;q31	O
)	O
in	O
90	O
%	O
of	O
the	O
cells	O
.	O

-DOCSTART-	3672

The	O
results	O
clearly	O
demonstrate	O
that	O
CPH82	B-Drug
was	O
associated	O
with	O
suppression	B-ADE
of	I-ADE
the	I-ADE
endogeneous	I-ADE
production	I-ADE
of	I-ADE
ACTH	I-ADE
and	I-ADE
cortisol	I-ADE
with	O
a	O
concomitant	O
paradoxical	O
picture	O
of	O
clinical	O
hypercortisolism	B-ADE
.	O

-DOCSTART-	3477

We	O
believe	O
that	O
this	O
is	O
the	O
first	O
report	O
of	O
secretory	B-ADE
carcinoma	I-ADE
of	I-ADE
the	I-ADE
endometrium	I-ADE
associated	O
with	O
tamoxifen	B-Drug
use	O
.	O

-DOCSTART-	1078

We	O
report	O
a	O
third	O
case	O
of	O
a	O
6-week	O
-	O
old	O
infant	O
with	O
Escherichia	O
coli	O
sepsis	O
who	O
received	O
ampicillin	B-Drug
and	O
other	O
antibiotics	O
and	O
subsequently	O
developed	O
TEN	B-ADE
.	O

-DOCSTART-	2167

Syncope	B-ADE
induced	O
by	O
propranolol	B-Drug
in	O
hypertrophic	O
cardiomyopathy	O
.	O

-DOCSTART-	2321

We	O
report	O
a	O
case	O
of	O
biopsy	O
proven	O
myositis	B-ADE
whose	O
symptoms	O
began	O
within	O
10	O
days	O
of	O
receiving	O
leuprolide	B-Drug
acetate	I-Drug
therapy	O
for	O
prostate	O
cancer	O
.	O

-DOCSTART-	1884

This	O
report	O
suggests	O
that	O
anemia	B-ADE
can	O
occur	O
due	O
to	O
MMF	B-Drug
,	O
in	O
particular	O
when	O
it	O
is	O
given	O
with	O
prednisone	B-Drug
,	O
a	O
side	O
effect	O
well	O
documented	O
in	O
the	O
transplantation	O
literature	O
when	O
the	O
triple	O
combination	O
of	O
MMF	B-Drug
,	O
cyclosporine	B-Drug
and	O
prednisone	B-Drug
is	O
used	O
.	O

-DOCSTART-	2609

This	O
paper	O
reports	O
an	O
autopsy	O
case	O
of	O
a	O
78-year	O
-	O
old	O
male	O
with	O
multiple	B-ADE
nodules	I-ADE
in	I-ADE
the	I-ADE
liver	I-ADE
developed	O
after	O
long	O
-	O
termed	O
administration	O
of	O
phosphate	B-Drug
diethylstilbestrol	I-Drug
(	O
PDES	B-Drug
)	O
for	O
prostatic	O
cancer	O
.	O

-DOCSTART-	1048

Osteonecrosis	B-ADE
is	O
a	O
serious	O
side	O
effect	O
of	O
antiemetic	O
treatment	O
with	O
dexamethasone	B-Drug
and	O
this	O
serious	O
complication	O
should	O
be	O
incorporated	O
in	O
the	O
current	O
guidelines	O
.	O

-DOCSTART-	2139

FDE	B-ADE
from	O
cephalosporins	B-Drug
has	O
been	O
rarely	O
reported	O
,	O
and	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
there	O
is	O
no	O
published	O
report	O
of	O
ceftriaxone	B-Drug
-	O
induced	O
FDE	B-ADE
in	O
the	O
literature	O
.	O

-DOCSTART-	3577

Reversible	B-ADE
leukopenia	I-ADE
was	O
documented	O
in	O
an	O
81-year	O
-	O
old	O
woman	O
treated	O
with	O
adjunctive	O
ibopamine	B-Drug
100	O
mg	O
t.i.d	O
.	O
for	O
chronic	O
congestive	O
heart	O
failure	O
.	O

-DOCSTART-	2707

L	B-Drug
-	I-Drug
Thyroxine	I-Drug
-	O
induced	O
leukopenia	B-ADE
in	O
a	O
patient	O
with	O
Hashimoto	O
's	O
disease	O
:	O
involvement	O
of	O
suppressor	O
-	O
cytotoxic	O
T	O
cells	O
.	O

-DOCSTART-	2971

Prolonged	O
severe	B-ADE
cholestasis	I-ADE
induced	O
by	O
oxacillin	B-Drug
derivatives	O
.	O

-DOCSTART-	1746

Cardiomyopathy	B-ADE
after	O
widely	O
separated	O
courses	O
of	O
adriamycin	B-Drug
exacerbated	O
by	O
actinomycin	B-Drug
-	I-Drug
D	I-Drug
and	O
mithramycin	B-Drug
.	O

-DOCSTART-	3474

We	O
present	O
a	O
case	O
of	O
sotalol	B-Drug
-	O
induced	O
bradycardia	B-ADE
reversed	O
by	O
glucagon	O
.	O

-DOCSTART-	1610

Angioedema	B-ADE
and	O
maculopapular	B-ADE
eruptions	I-ADE
associated	O
with	O
carbamazepine	B-Drug
administration	O
.	O

-DOCSTART-	3365

Hepatotoxicity	B-ADE
of	O
hycanthone	B-Drug
in	O
patients	O
with	O
metastatic	O
breast	O
cancer	O
.	O

-DOCSTART-	3048

It	O
should	O
be	O
recognized	O
that	O
ibuprofen	B-Drug
may	O
be	O
associated	O
with	O
salt	B-ADE
and	I-ADE
water	I-ADE
retention	I-ADE
in	O
the	O
same	O
fashion	O
as	O
previously	O
described	O
with	O
phenylbutazone	B-Drug
and	O
indomethacin	B-Drug
.	O

-DOCSTART-	3604

Hyperammonemia	B-ADE
has	O
been	O
described	O
as	O
a	O
complication	O
of	O
valproic	B-Drug
acid	I-Drug
therapy	O
but	O
may	O
often	O
be	O
overlooked	O
as	O
a	O
cause	O
of	O
lethargy	B-ADE
in	O
the	O
postictal	O
patient	O
who	O
presents	O
to	O
the	O
emergency	O
department	O
.	O

-DOCSTART-	936

CASE	O
REPORT	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
58	O
year	O
old	O
patient	O
who	O
,	O
after	O
2	O
days	O
of	O
treatment	O
with	O
roxithromycin	B-Drug
and	O
betamethasone	B-Drug
,	O
manifested	O
acute	B-ADE
pancreatitis	I-ADE
.	O

-DOCSTART-	1345

Cutaneous	B-ADE
necrosis	I-ADE
as	O
a	O
result	O
of	O
interferon	B-Drug
alfa	I-Drug
is	O
an	O
infrequent	O
complication	O
with	O
unknown	O
pathogenesis	O
,	O
in	O
which	O
a	O
cutaneous	O
local	O
immune	O
-	O
mediated	O
inflammatory	O
process	O
might	O
be	O
involved	O
.	O

-DOCSTART-	1321

However	O
,	O
peripheral	B-ADE
neuropathy	I-ADE
and	O
bone	B-ADE
marrow	I-ADE
depression	I-ADE
led	O
to	O
linezolid	B-Drug
withdrawal	O
in	O
seven	O
patients	O
,	O
and	O
neuropathy	B-ADE
may	O
not	O
be	O
fully	O
reversible	O
in	O
all	O
patients	O
.	O

-DOCSTART-	462

Despite	O
administration	O
of	O
phenytoin	O
and	O
lorazepam	O
,	O
the	O
seizures	B-ADE
persisted	O
and	O
occurred	O
only	O
during	O
amphotercin	B-Drug
B	I-Drug
administration	O
.	O

-DOCSTART-	3353

Disulfiram	B-Drug
encephalopathy	B-ADE
as	O
a	O
cause	O
of	O
the	O
catatonia	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	138

In	O
both	O
patients	O
the	O
rippling	B-ADE
phenomena	I-ADE
worsened	I-ADE
with	O
pyridostigmine	B-Drug
treatment	O
but	O
markedly	O
improved	O
after	O
immunosuppression	O
with	O
azathioprine	O
.	O

-DOCSTART-	3665

Although	O
retinoic	B-Drug
acid	I-Drug
is	O
well	O
tolerated	O
by	O
the	O
majority	O
of	O
patients	O
with	O
this	O
disease	O
,	O
a	O
potentially	O
fatal	B-ADE
complication	I-ADE
of	O
this	O
kind	O
of	O
treatment	O
has	O
been	O
reported	O
:	O
"	O
the	O
retinoic	B-ADE
acid	I-ADE
syndrome	I-ADE
"	O
.	O

-DOCSTART-	3061

To	O
our	O
knowledge	O
,	O
we	O
describe	O
the	O
first	O
reported	O
case	O
of	O
isolated	B-ADE
paresthesia	I-ADE
and	O
peripheral	B-ADE
neuropathy	I-ADE
,	O
without	O
systemic	O
involvement	O
,	O
secondary	O
to	O
sulindac	B-Drug
administration	O
.	O

-DOCSTART-	2918

Two	O
patients	O
who	O
were	O
receiving	O
Tolazoline	B-Drug
by	O
infusion	O
developed	O
duodenal	B-ADE
ulceration	I-ADE
and	O
subsequent	O
intestinal	B-ADE
perforation	I-ADE
.	O

-DOCSTART-	1897

Here	O
,	O
we	O
report	O
a	O
case	O
of	O
RFP	B-Drug
-	O
induced	O
hypothyroidism	B-ADE
without	O
underlying	O
thyroid	O
disease	O
.	O

-DOCSTART-	1692

Because	O
nephrotic	B-ADE
syndrome	I-ADE
may	O
be	O
induced	O
by	O
IFN	B-Drug
therapy	O
,	O
the	O
IFN	B-Drug
was	O
stopped	O
.	O

-DOCSTART-	1795

We	O
report	O
the	O
first	O
case	O
of	O
tuberculous	B-ADE
uveitis	I-ADE
due	O
to	O
etanercept	B-Drug
.	O

-DOCSTART-	3069

Preliminary	O
results	O
suggest	O
that	O
the	O
higher	O
concentrations	O
of	O
dextrose	B-Drug
induce	O
increased	B-ADE
histamine	I-ADE
release	I-ADE
from	O
blood	O
cells	O
,	O
and	O
that	O
this	O
phenomenon	O
is	O
more	O
marked	O
in	O
diabetic	O
,	O
and	O
particularly	O
diabetic	O
-	O
allergic	O
,	O
individuals	O
.	O

-DOCSTART-	1085

A	O
patient	O
developed	O
restless	B-ADE
legs	I-ADE
symptoms	I-ADE
paralleling	O
the	O
course	O
of	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
(	O
IFN	B-Drug
alpha	I-Drug
)	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
.	O

-DOCSTART-	3031

Erythema	B-ADE
multiforme	I-ADE
bullosum	I-ADE
due	O
to	O
rifampicin	B-Drug
.	O

-DOCSTART-	4

Naproxen	B-Drug
,	O
the	O
most	O
common	O
offender	O
,	O
has	O
been	O
associated	O
with	O
a	O
dimorphic	O
clinical	O
pattern	O
:	O
a	O
PCT	O
-	O
like	O
presentation	O
and	O
one	O
simulating	O
erythropoietic	B-ADE
protoporphyria	I-ADE
in	O
the	O
pediatric	O
population	O
.	O

-DOCSTART-	3493

We	O
report	O
a	O
case	O
of	O
noncardiogenic	B-ADE
pulmonary	I-ADE
edema	I-ADE
developed	O
after	O
therapeutic	O
trial	O
of	O
EO	B-Drug
as	O
sclerosing	O
agent	O
for	O
esophageal	O
varix	O
.	O

-DOCSTART-	2470

Vancomycin	B-Drug
is	O
widely	O
used	O
against	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
infections	O
,	O
but	O
it	O
is	O
associated	O
with	O
many	O
adverse	O
effects	O
such	O
as	O
nephrotoxicity	B-ADE
,	O
ototoxicity	B-ADE
,	O
gastrointestinal	B-ADE
disturbances	I-ADE
,	O
blood	B-ADE
disorders	I-ADE
,	O
and	O
two	O
types	O
of	O
hypersensitivity	B-ADE
reactions	I-ADE
-	O
an	O
anaphylactoid	B-ADE
reaction	O
known	O
as	O
"	O
red	B-ADE
man	I-ADE
syndrome	I-ADE
"	O
and	O
anaphylaxis	B-ADE
.	O

-DOCSTART-	1806

Docetaxel	B-Drug
induced	O
Meibomian	B-ADE
duct	I-ADE
inflammation	I-ADE
and	I-ADE
blockage	I-ADE
is	O
the	O
likely	O
cause	O
of	O
this	O
presentation	O
in	O
a	O
patient	O
with	O
no	O
history	O
of	O
eyelid	O
masses	O
in	O
the	O
past	O
.	O

-DOCSTART-	1688

Five	O
months	O
after	O
initiating	O
mirtazapine	B-Drug
therapy	O
,	O
she	O
developed	O
symptomatic	B-ADE
hyponatremia	I-ADE
.	O

-DOCSTART-	3935

Eye	B-ADE
movement	I-ADE
disorders	I-ADE
in	O
bone	O
marrow	O
transplant	O
patients	O
on	O
cyclosporin	B-Drug
and	O
ganciclovir	B-Drug
.	O

-DOCSTART-	276

We	O
report	O
two	O
adults	O
who	O
received	O
gabapentin	B-Drug
(	O
GBP	B-Drug
)	O
and	O
subsequently	O
developed	O
behavioural	B-ADE
side	I-ADE
effects	I-ADE
.	O

-DOCSTART-	3998

Generalized	B-ADE
maculopapular	I-ADE
and	I-ADE
papular	I-ADE
purpuric	I-ADE
eruptions	I-ADE
are	O
perhaps	O
the	O
most	O
common	O
thionamide	B-Drug
-	O
induced	O
reactions	O
.	O

-DOCSTART-	565

There	O
have	O
been	O
more	O
than	O
20	O
observations	O
of	O
the	O
appearance	O
or	O
aggravation	O
of	O
this	O
granulomatosis	B-ADE
with	O
interferon	B-Drug
alfa	I-Drug
and	O
more	O
recently	O
with	O
the	O
combination	O
of	O
interferon	B-Drug
alfa	I-Drug
plus	O
ribavirin	B-Drug
.	O

-DOCSTART-	4109

Fatal	B-ADE
toxic	I-ADE
epidermal	I-ADE
necrolysis	I-ADE
related	O
to	O
lamotrigine	B-Drug
administration	O
.	O

-DOCSTART-	2342

PURPOSE	O
:	O
A	O
case	O
of	O
carbamazepine	B-Drug
-	O
induced	O
hyperammonemia	B-ADE
is	O
presented	O
.	O

-DOCSTART-	1025

Neurological	O
improvement	O
and	O
rehabilitation	O
potential	O
following	O
toxic	B-ADE
myelopathy	I-ADE
due	O
to	O
intrathecal	O
injection	O
of	O
doxorubicin	B-Drug
.	O

-DOCSTART-	3448

Parenteral	O
pyridoxine	O
,	O
the	O
specific	O
antidote	O
for	O
INH	B-Drug
-	O
induced	O
refractory	B-ADE
seizures	I-ADE
,	O
should	O
be	O
readily	O
available	O
in	O
every	O
emergency	O
department	O
in	O
the	O
areas	O
similarly	O
experiencing	O
increasing	O
trends	O
of	O
TB	O
.	O

-DOCSTART-	1977

From	O
1996	O
to	O
2002	O
several	O
medications	O
were	O
changed	O
due	O
to	O
their	O
adverse	O
effects	O
:	O
indinavir	B-Drug
(	O
renal	B-ADE
colic	I-ADE
and	O
fever	B-ADE
)	O
,	O
nelfinavir	B-Drug
(	O
cutaneous	B-ADE
rash	I-ADE
)	O
,	O
and	O
efavirenz	B-Drug
(	O
nausea	B-ADE
and	O
temporary	B-ADE
memory	I-ADE
loss	I-ADE
)	O
.	O

-DOCSTART-	2248

Persistent	B-ADE
hypoglycemia	I-ADE
in	O
a	O
patient	O
with	O
diabetes	O
taking	O
etanercept	B-Drug
for	O
the	O
treatment	O
of	O
psoriasis	O
.	O

-DOCSTART-	2640

Metoclopramide	B-Drug
-	O
induced	O
parkinsonism	B-ADE
is	O
not	O
rare	O
,	O
and	O
appropriate	O
dose	O
reduction	O
in	O
patients	O
with	O
renal	O
failure	O
will	O
help	O
reduce	O
the	O
incidence	O
of	O
this	O
morbidity	O
.	O

-DOCSTART-	215

Although	O
the	O
literature	O
on	O
the	O
use	O
of	O
risperidone	B-Drug
in	O
elderly	O
patients	O
with	O
dementia	O
consists	O
largely	O
of	O
uncontrolled	O
trials	O
,	O
case	O
reports	O
,	O
and	O
chart	O
reviews	O
,	O
it	O
appears	O
that	O
this	O
agent	O
is	O
effective	O
for	O
managing	O
agitation	O
in	O
this	O
population	O
and	O
does	O
so	O
with	O
a	O
low	O
frequency	O
of	O
extrapyramidal	B-ADE
symptoms	I-ADE
(	O
EPS	B-ADE
)	O
.	O

-DOCSTART-	1890

One	O
case	O
of	O
tacrolimus	B-Drug
-	O
induced	O
hepatic	B-ADE
VOD	I-ADE
developing	O
after	O
lung	O
transplantation	O
(	O
LT	O
)	O
has	O
been	O
recently	O
reported	O
.	O

-DOCSTART-	3197

Amiodarone	B-Drug
hydrochloride	I-Drug
,	O
a	O
new	O
antiarrhythmic	O
agent	O
,	O
has	O
been	O
associated	O
with	O
pulmonary	B-ADE
toxicity	I-ADE
characterized	O
by	O
cough	B-ADE
,	O
dyspnea	B-ADE
and	O
diffuse	B-ADE
pulmonary	I-ADE
infiltrates	I-ADE
.	O

-DOCSTART-	4261

An	O
unusual	O
cause	O
of	O
burn	B-Drug
injury	I-Drug
:	O
unsupervised	O
use	O
of	O
drugs	O
that	O
contain	O
psoralens	B-ADE
.	O

-DOCSTART-	3518

Fracture	B-ADE
of	I-ADE
the	I-ADE
femoral	I-ADE
neck	I-ADE
occurred	O
in	O
one	O
patient	O
during	O
PSL	B-Drug
therapy	O
,	O
although	O
the	O
relationship	O
between	O
the	O
fracture	O
and	O
PSL	O
therapy	O
was	O
uncertain	O
.	O

-DOCSTART-	1542

We	O
describe	O
a	O
case	O
of	O
intraoperative	O
gelatine	B-Drug
-	O
induced	O
anaphylaxis	B-ADE
whose	O
diagnosis	O
was	O
delayed	O
as	O
the	O
use	O
of	O
gelatine	B-Drug
during	O
surgical	O
procedures	O
was	O
omitted	O
for	O
two	O
times	O
in	O
patient	O
's	O
medical	O
records	O
.	O

-DOCSTART-	2784

A	O
new	O
case	O
of	O
Creutzfeldt	B-ADE
-	I-ADE
Jakob	I-ADE
disease	I-ADE
associated	O
with	O
human	B-Drug
growth	I-Drug
hormone	I-Drug
therapy	O
in	O
New	O
Zealand	O
.	O

-DOCSTART-	1203

Methotrexate	B-Drug
(	O
MTX	B-Drug
)	O
is	O
a	O
commonly	O
used	O
second	O
line	O
agent	O
for	O
RA	O
,	O
and	O
there	O
have	O
been	O
several	O
recent	O
reports	O
of	O
Epstein	B-ADE
-	I-ADE
Barr	I-ADE
virus	I-ADE
(	I-ADE
EBV	I-ADE
)	I-ADE
-	I-ADE
associated	I-ADE
polyclonal	I-ADE
B	I-ADE
cell	I-ADE
lymphoproliferative	I-ADE
disorder	I-ADE
in	O
MTX	B-Drug
-	O
treated	O
RA	O
patients	O
.	O

-DOCSTART-	2509

The	O
photosensitivity	B-ADE
is	O
still	O
present	O
3	O
years	O
after	O
the	O
withdrawal	O
of	O
quinine	B-Drug
.	O

-DOCSTART-	1431

Prominent	B-ADE
eye	I-ADE
movements	I-ADE
during	I-ADE
NREM	I-ADE
sleep	I-ADE
and	O
REM	B-ADE
sleep	I-ADE
behavior	I-ADE
disorder	I-ADE
associated	O
with	O
fluoxetine	B-Drug
treatment	O
of	O
depression	O
and	O
obsessive	O
-	O
compulsive	O
disorder	O
.	O

-DOCSTART-	2696

Despite	O
a	O
postulated	O
dopaminergic	O
mechanism	O
,	O
there	O
seems	O
to	O
have	O
been	O
only	O
one	O
previous	O
report	O
of	O
amantadine	B-Drug
's	O
precipitating	B-ADE
psychosis	I-ADE
in	O
a	O
schizophrenic	O
patient	O
.	O

-DOCSTART-	3711

Intravenous	O
haloperidol	B-Drug
is	O
generally	O
well	O
tolerated	O
,	O
but	O
multiform	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
has	O
been	O
reported	O
.	O

-DOCSTART-	805

Sensorimotor	B-ADE
polyneuropathy	I-ADE
with	O
5-aminosalicylic	B-Drug
acid	I-Drug
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	1175

Severe	B-ADE
leukopenia	I-ADE
associated	O
with	O
mild	B-ADE
hepatotoxicity	I-ADE
in	O
an	O
HIV	O
carrier	O
treated	O
with	O
nevirapine	B-Drug
.	O

-DOCSTART-	2530

Methotrexate	B-Drug
-	O
induced	O
leukoencephalopathy	B-ADE
is	O
treatable	O
with	O
high	O
-	O
dose	O
folinic	O
acid	O
:	O
a	O
case	O
report	O
and	O
analysis	O
of	O
the	O
literature	O
.	O

-DOCSTART-	2863

We	O
describe	O
a	O
patient	O
with	O
Wilson	O
's	O
disease	O
who	O
presented	O
with	O
neurologic	O
disease	O
,	O
was	O
treated	O
with	O
D	B-Drug
-	I-Drug
penicillamine	I-Drug
,	O
and	O
suffered	O
sudden	O
neurologic	B-ADE
deterioration	I-ADE
coincident	O
with	O
therapy	O
.	O

-DOCSTART-	2802

Based	O
upon	O
the	O
observed	O
fall	B-ADE
of	I-ADE
the	I-ADE
filtration	I-ADE
fraction	I-ADE
,	O
the	O
rise	B-ADE
in	I-ADE
the	I-ADE
relative	I-ADE
clearance	I-ADE
of	I-ADE
99Tc	I-ADE
-	I-ADE
dimercaptosuccinic	I-ADE
acid	I-ADE
and	O
the	O
increase	B-ADE
in	I-ADE
proteinuria	I-ADE
,	O
we	O
suggest	O
that	O
in	O
this	O
case	O
the	O
tubules	O
and/or	O
interstitium	O
are	O
the	O
main	O
targets	O
for	O
cyclosporine	B-Drug
A	I-Drug
nephrotoxicity	B-ADE
.	O

-DOCSTART-	2468

However	O
,	O
the	O
use	O
of	O
lithium	B-Drug
should	O
be	O
avoided	O
with	O
any	O
patient	O
who	O
is	O
purging	O
,	O
since	O
it	O
may	O
exacerbate	O
the	O
loss	B-ADE
of	I-ADE
intracellular	I-ADE
potassium	I-ADE
,	O
thereby	O
increasing	O
the	O
risk	O
of	O
cardiac	B-ADE
toxicity	I-ADE
.	O

-DOCSTART-	356

In	O
patients	O
with	O
chronic	O
heart	O
failure	O
,	O
spironolactone	B-Drug
added	O
to	O
conventional	O
treatment	O
may	O
lead	O
to	O
serious	B-ADE
and	I-ADE
,	I-ADE
occasionally	I-ADE
,	I-ADE
fatal	I-ADE
hyperkalaemia	I-ADE
.	O

-DOCSTART-	611

The	O
authors	O
describe	O
valproate	B-Drug
-	O
induced	O
hyperammonemia	B-ADE
and	O
mental	B-ADE
status	I-ADE
changes	I-ADE
in	O
an	O
88-year	O
-	O
old	O
man	O
,	O
the	O
first	O
known	O
reported	O
case	O
in	O
an	O
elderly	O
patient	O
.	O

-DOCSTART-	3703

The	O
biochemistry	O
of	O
paracetamol	B-Drug
hepatotoxicity	B-ADE
is	O
outlined	O
and	O
the	O
increased	O
susceptibility	O
of	O
alcoholic	O
patients	O
to	O
the	O
hepatotoxic	B-ADE
effects	I-ADE
of	O
paracetamol	B-Drug
is	O
remarked	O
upon	O
.	O

-DOCSTART-	1006

The	O
Naranjo	O
probability	O
scale	O
suggests	O
a	O
highly	O
probable	O
relationship	O
between	O
AIN	B-ADE
and	O
pantoprazole	B-Drug
therapy	O
in	O
this	O
patient	O
.	O

-DOCSTART-	2570

Suspected	O
ciprofloxacin	B-Drug
-	O
induced	O
interstitial	B-ADE
nephritis	I-ADE
.	O

-DOCSTART-	3342

These	O
cases	O
and	O
a	O
review	O
of	O
the	O
literature	O
suggested	O
that	O
hepatotoxicity	B-ADE
,	O
though	O
rare	O
,	O
should	O
be	O
added	O
to	O
the	O
list	O
of	O
adverse	O
reactions	O
to	O
D	B-Drug
-	I-Drug
penicillamine	I-Drug
.	O

-DOCSTART-	3553

Four	O
years	O
after	O
the	O
beginning	O
of	O
IFN	B-Drug
therapy	O
,	O
he	O
acutely	O
developed	O
moderate	B-ADE
hyperglycemia	I-ADE
and	O
severe	B-ADE
ketonuria	I-ADE
with	O
positive	O
islet	O
cell	O
antibody	O
,	O
and	O
then	O
28	O
units	O
/	O
day	O
of	O
insulin	O
injection	O
was	O
started	O
.	O

-DOCSTART-	1587

Adverse	O
reaction	O
in	O
a	O
patient	O
with	O
aspirin	B-Drug
-	O
induced	O
asthma	B-ADE
treated	O
with	O
zafirlukast	O
.	O

-DOCSTART-	2165

When	O
DSCG	B-Drug
was	O
withdrawn	O
,	O
urticaria	B-ADE
vanished	O
and	O
the	O
child	O
remained	O
symptom	O
-	O
free	O
.	O

-DOCSTART-	3840

Lithium	B-Drug
-	O
induced	O
Creutzfeldt	B-ADE
-	I-ADE
Jakob	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	974

After	O
initiation	O
of	O
topical	O
vitamin	B-Drug
D3	I-Drug
ointment	O
(	O
20	O
micro	O
g	O
/	O
g	O
of	O
tacalcitol	O
)	O
10	O
g	O
/	O
day	O
for	O
the	O
skin	O
lesions	O
,	O
both	O
the	O
serum	B-ADE
level	I-ADE
of	I-ADE
calcium	I-ADE
and	I-ADE
urinary	I-ADE
excretion	I-ADE
of	I-ADE
calcium	I-ADE
increased	I-ADE
gradually	O
.	O

-DOCSTART-	3245

When	O
tuberculosis	O
patients	O
on	O
isoniazid	B-Drug
eat	O
certain	O
varieties	O
of	O
fish	O
they	O
may	O
develop	O
a	O
histamine	B-ADE
reaction	I-ADE
.	O

-DOCSTART-	2953

A	O
patient	O
presented	O
with	O
a	O
painful	B-ADE
,	I-ADE
oedematous	I-ADE
,	I-ADE
cyanosed	I-ADE
hand	I-ADE
having	O
injected	O
a	O
solution	O
of	O
diamorphine	B-Drug
and	O
methylphenidate	B-Drug
into	O
his	O
radial	O
artery	O
.	O

-DOCSTART-	3154

Alternating	B-ADE
sinus	I-ADE
rhythm	I-ADE
and	O
intermittent	B-ADE
sinoatrial	I-ADE
(	I-ADE
S	I-ADE
-	I-ADE
A	I-ADE
)	I-ADE
block	I-ADE
was	O
observed	O
in	O
a	O
57-year	O
-	O
old	O
woman	O
,	O
under	O
treatment	O
for	O
angina	O
with	O
80	O
mg	O
propranolol	B-Drug
daily	O
.	O

-DOCSTART-	2373

Nitrofurantoin	B-Drug
-	O
induced	O
acute	B-ADE
liver	I-ADE
damage	I-ADE
in	O
pregnancy	O
.	O

-DOCSTART-	1163

Unusual	O
hypersensitivity	B-ADE
to	O
warfarin	B-Drug
in	O
a	O
critically	O
ill	O
patient	O
.	O

-DOCSTART-	3595

Although	O
fluoxetine	B-Drug
-	O
induced	O
headache	B-ADE
occurred	O
in	O
one	O
patient	O
,	O
the	O
other	O
five	O
reported	O
no	O
side	O
effects	O
at	O
the	O
doses	O
used	O
.	O

-DOCSTART-	2619

While	O
the	O
mechanism	O
of	O
dextran	B-Drug
-	O
associated	O
renal	B-ADE
failure	I-ADE
remains	O
unsolved	O
,	O
plasma	O
exchange	O
seems	O
to	O
be	O
effective	O
therapy	O
.	O

-DOCSTART-	1036

Cerebral	B-ADE
infarcts	I-ADE
in	O
a	O
pediatric	O
patient	O
secondary	O
to	O
phenylpropanolamine	B-Drug
,	O
a	O
recalled	O
medication	O
.	O

-DOCSTART-	2001

Life	O
-	O
threatening	O
interstitial	B-ADE
lung	I-ADE
disease	I-ADE
associated	O
with	O
trastuzumab	B-Drug
:	O
case	O
report	O
.	O

-DOCSTART-	3574

Inadvertent	O
subsequent	O
rechallenge	O
with	O
celiprolol	B-Drug
led	O
to	O
recurrence	O
of	O
the	O
pneumonitis	B-ADE
,	O
10	O
weeks	O
after	O
drug	O
readministration	O
.	O

-DOCSTART-	630

Verapamil	B-Drug
is	O
widely	O
used	O
for	O
the	O
termination	O
of	O
paroxysmal	O
supraventricular	O
tachycardia	O
(	O
PSVT	O
)	O
with	O
little	O
proarrhythmic	B-ADE
effect	I-ADE
.	O

-DOCSTART-	2452

Combining	O
methylephedrine	B-Drug
and	O
Chinese	O
herbal	O
drugs	O
might	O
carry	O
a	O
risk	O
of	O
stroke	B-ADE
.	O

-DOCSTART-	3128

Cyclophosphamide	B-Drug
can	O
rarely	O
cause	O
interstitial	B-ADE
pneumonitis	I-ADE
and	O
fibrosis	B-ADE
.	O

-DOCSTART-	1996

We	O
report	O
a	O
case	O
of	O
exfoliative	B-ADE
dermatitis	I-ADE
clearly	O
linked	O
to	O
intravenous	O
and	O
intraperitoneal	O
administration	O
of	O
tobramycin	B-Drug
.	O

-DOCSTART-	249

A	O
74-year	O
-	O
old	O
man	O
received	O
oral	O
administration	O
of	O
pilsicainide	B-Drug
,	O
a	O
pure	O
sodium	O
channel	O
blocker	O
with	O
slow	O
recovery	O
kinetics	O
,	O
to	O
convert	O
paroxysmal	O
atrial	O
fibrillation	O
to	O
sinus	O
rhythm	O
and	O
developed	O
loss	B-ADE
of	I-ADE
consciousness	I-ADE
two	O
days	O
later	O
.	O

-DOCSTART-	2090

Development	O
of	O
Crohn	B-ADE
's	I-ADE
disease	I-ADE
in	O
a	O
patient	O
with	O
multiple	O
sclerosis	O
treated	O
with	O
copaxone	B-Drug
.	O

-DOCSTART-	3963

On	O
the	O
other	O
hand	O
,	O
MTX	B-Drug
-	O
induced	O
pneumonitis	B-ADE
seems	O
to	O
be	O
very	O
rare	O
in	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
.	O

-DOCSTART-	2119

CONCLUSIONS	O
:	O
This	O
is	O
the	O
first	O
report	O
of	O
a	O
possible	O
interaction	O
between	O
propafenone	B-Drug
and	O
citalopram	B-Drug
,	O
which	O
caused	O
propafenone	O
adverse	O
effects	O
(	O
eg	O
,	O
dizziness	B-ADE
,	O
falls	B-ADE
)	O
and	O
mimicked	O
coronary	B-ADE
artery	I-ADE
disease	I-ADE
.	O

-DOCSTART-	3172

Myoglobinuria	B-ADE
and	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
associated	O
with	O
intravenous	O
vasopressin	B-Drug
infusion	O
.	O

-DOCSTART-	2347

Acute	B-ADE
bilateral	I-ADE
phrenic	I-ADE
neuropathy	I-ADE
following	O
treatment	O
with	O
adalimumab	B-Drug
.	O

-DOCSTART-	346

Ectropion	B-ADE
secondary	O
to	O
bolus	O
injection	O
of	O
5-fluorouracil	B-Drug
.	O

-DOCSTART-	4021

DISCUSSION	O
:	O
Phenolphthalein	B-Drug
is	O
the	O
active	O
ingredient	O
in	O
several	O
over	O
-	O
the	O
-	O
counter	O
laxative	O
preparations	O
and	O
has	O
only	O
rarely	O
been	O
reported	O
to	O
cause	O
TEN	B-ADE
.	O

-DOCSTART-	2945

Ampicillin	B-Drug
may	O
aggravate	O
clinical	O
and	O
experimental	O
myasthenia	B-ADE
gravis	I-ADE
.	O

-DOCSTART-	3794

Within	O
24	O
hours	O
of	O
fluid	O
restriction	O
and	O
cessation	O
of	O
desmopressin	B-Drug
,	O
her	O
symptoms	O
and	O
hyponatremia	B-ADE
resolved	O
.	O

-DOCSTART-	802

Carbamazepine	B-Drug
-	O
related	O
hyponatremia	B-ADE
following	O
cardiopulmonary	O
bypass	O
.	O

-DOCSTART-	3124

Vasomotor	B-ADE
reactions	I-ADE
after	O
gold	B-Drug
sodium	I-Drug
thiomalate	I-Drug
are	O
well	O
recognized	O
.	O

-DOCSTART-	3803

Physicians	O
should	O
be	O
aware	O
of	O
the	O
potentially	O
lethal	B-ADE
side	O
effects	O
of	O
dapsone	B-Drug
.	O

-DOCSTART-	650

The	O
authors	O
describe	O
three	O
families	O
in	O
whom	O
the	O
occurrence	O
of	O
FVS	B-ADE
in	O
all	O
the	O
siblings	O
strongly	O
suggests	O
hereditary	O
susceptibility	O
to	O
valproic	B-Drug
acid	I-Drug
-	O
induced	O
adverse	O
outcome	O
.	O

-DOCSTART-	1706

We	O
report	O
the	O
case	O
of	O
a	O
60-year	O
-	O
old	O
woman	O
who	O
developed	O
erythema	B-ADE
and	O
erosions	B-ADE
in	I-ADE
the	I-ADE
axilla	I-ADE
and	I-ADE
groin	I-ADE
while	O
on	O
PLD	B-Drug
for	O
breast	O
cancer	O
.	O

-DOCSTART-	3426

Intracranial	B-ADE
haemorrhage	I-ADE
from	O
a	O
meningioma	O
in	O
a	O
patient	O
receiving	O
aspirin	B-Drug
prophylaxis	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3229

Intrahepatic	B-ADE
cholestasis	I-ADE
and	O
cutaneous	B-ADE
bullae	I-ADE
associated	O
with	O
glibenclamide	B-Drug
therapy	O
.	O

-DOCSTART-	2662

Rifampin	B-Drug
can	O
be	O
associated	O
with	O
severe	O
adverse	O
effects	O
such	O
as	O
hepatitis	B-ADE
,	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
,	O
hemolytic	B-ADE
anemia	I-ADE
,	O
and	O
thrombocytopenia	B-ADE
.	O

-DOCSTART-	459

Amphotericin	B-Drug
B	I-Drug
-	O
induced	O
seizures	B-ADE
in	O
a	O
patient	O
with	O
AIDS	O
.	O

-DOCSTART-	345

DISCUSSION	O
:	O
Patients	O
with	O
5-FU	B-Drug
-	O
induced	O
ectropion	B-ADE
experience	O
tender	B-ADE
,	I-ADE
red	I-ADE
,	I-ADE
scaled	I-ADE
lids	I-ADE
,	O
making	O
contact	O
lens	O
wear	O
difficult	O
.	O

-DOCSTART-	3762

Patients	O
treated	O
with	O
captopril	B-Drug
who	O
develop	O
"	O
atypical	B-ADE
cholangitis	I-ADE
"	O
should	O
be	O
suspected	O
of	O
having	O
captopril	B-Drug
-	O
associated	O
liver	B-ADE
damage	I-ADE
.	O

-DOCSTART-	2760

The	O
allopurinol	B-Drug
hypersensitivity	B-ADE
syndrome	I-ADE
is	O
a	O
rare	O
adverse	O
drug	O
reaction	O
.	O

-DOCSTART-	457

This	O
eruption	B-ADE
emerged	O
after	O
1	O
month	O
of	O
therapy	O
with	O
salsalate	B-Drug
,	O
persisted	O
for	O
as	O
long	O
as	O
salsalate	O
was	O
administered	O
,	O
and	O
cleared	O
within	O
3	O
weeks	O
of	O
discontinuing	O
the	O
medication	O
.	O

-DOCSTART-	371

The	O
increased	B-ADE
libido	I-ADE
disappeared	O
after	O
fluvoxamine	B-Drug
was	O
discontinued	O
.	O

-DOCSTART-	2449

Trazodone	B-Drug
-	O
induced	O
transient	B-ADE
hypomanic	I-ADE
symptoms	I-ADE
and	O
their	O
management	O
.	O

-DOCSTART-	1496

When	O
thrombosis	B-ADE
develops	O
during	O
heparin	B-Drug
treatment	O
,	O
it	O
is	O
important	O
to	O
suspect	O
HITTs	O
and	O
to	O
assay	O
for	O
the	O
associated	O
antibodies	O
,	O
regardless	O
of	O
the	O
actual	O
platelet	O
count	O
.	O

-DOCSTART-	2777

Widespread	O
cutaneous	B-ADE
vasculitis	I-ADE
associated	O
with	O
diltiazem	B-Drug
.	O

-DOCSTART-	1244

It	O
is	O
likely	O
that	O
RA	B-Drug
contributed	O
to	O
the	O
deterioration	B-ADE
in	I-ADE
renal	I-ADE
function	I-ADE
in	O
these	O
patients	O
.	O

-DOCSTART-	1522

This	O
is	O
a	O
rare	O
case	O
of	O
ARDS	B-ADE
associated	O
with	O
lithium	B-Drug
intoxication	O
.	O

-DOCSTART-	2267

Probable	O
enoxaparin	B-Drug
-	O
induced	O
hepatotoxicity	B-ADE
.	O

-DOCSTART-	878

Both	O
patients	O
suddenly	O
became	O
hypotensive	B-ADE
after	O
injection	O
of	O
chymopapain	B-Drug
into	O
a	O
disk	O
.	O

-DOCSTART-	2859

Hypersensitivity	B-ADE
reactions	I-ADE
due	O
to	O
chloramphenicol	B-Drug
are	O
rarely	O
reported	O
in	O
the	O
literature	O
.	O

-DOCSTART-	1545

Some	O
patients	O
develop	O
hypersensitivity	B-ADE
rash	I-ADE
in	O
response	O
to	O
HCQ	B-Drug
.	O

-DOCSTART-	3260

However	O
,	O
the	O
amount	O
of	O
prednisone	B-Drug
required	O
to	O
maintain	O
normotension	O
resulted	O
in	O
Cushingoid	B-ADE
features	I-ADE
and	O
has	O
been	O
discontinued	O
.	O

-DOCSTART-	3329

The	O
potential	O
role	O
of	O
propranolol	B-Drug
in	O
inducing	O
central	B-ADE
nervous	I-ADE
system	I-ADE
disturbances	I-ADE
is	O
emphasized	O
,	O
and	O
the	O
literature	O
on	O
the	O
subject	O
is	O
reviewed	O
.	O

-DOCSTART-	1907

It	O
is	O
tempting	O
to	O
speculate	O
that	O
interferon	B-Drug
alpha	I-Drug
may	O
be	O
involved	O
in	O
the	O
pathogenesis	O
of	O
lichen	B-ADE
nitidus	I-ADE
.	O

-DOCSTART-	724

PURPOSE	O
:	O
We	O
report	O
an	O
unusual	O
paradoxical	B-ADE
effect	I-ADE
of	O
brimonidine	B-Drug
.	O

-DOCSTART-	945

The	O
authors	O
'	O
results	O
suggest	O
that	O
L	B-Drug
-	I-Drug
dopa	I-Drug
may	O
cause	O
daytime	B-ADE
somnolence	I-ADE
in	O
some	O
patients	O
with	O
Parkinson	O
's	O
disease	O
.	O

-DOCSTART-	2496

Amiodarone	B-Drug
was	O
discontinued	O
,	O
and	O
thyrotoxicosis	B-ADE
gradually	O
abated	O
.	O

-DOCSTART-	1394

Despite	O
minimal	O
short	O
-	O
term	O
side	O
effects	O
and	O
apparent	O
efficacy	O
,	O
chronic	O
treatment	O
of	O
MG	O
with	O
MM	B-Drug
may	O
be	O
associated	O
with	O
increased	O
risk	O
of	O
lymphoproliferative	B-ADE
disorders	I-ADE
.	O

-DOCSTART-	2613

The	O
most	O
likely	O
cause	O
of	O
such	O
hyponatremic	B-ADE
episode	I-ADE
is	O
vinblastine	B-Drug
.	O

-DOCSTART-	3198

Possible	O
recurrence	O
of	O
amiodarone	B-Drug
pulmonary	B-ADE
toxicity	I-ADE
following	O
corticosteroid	O
therapy	O
.	O

-DOCSTART-	3635

Myoclonus	B-ADE
and	O
seizures	B-ADE
disappeared	O
after	O
discontinuation	O
of	O
L	B-Drug
-	I-Drug
dopa	I-Drug
and	O
the	O
introduction	O
of	O
valproate	O
sodium	O
(	O
VPA	O
)	O
.	O

-DOCSTART-	1081

We	O
report	O
the	O
first	O
case	O
of	O
an	O
acute	O
flare	O
of	O
eosinophilic	B-ADE
cystitis	I-ADE
in	O
a	O
51-year	O
-	O
old	O
woman	O
after	O
bladder	O
instillation	O
with	O
dimethyl	B-Drug
sulfoxide	I-Drug
(	O
DMSO	B-Drug
)	O
for	O
presumed	O
interstitial	O
cystitis	O
.	O

-DOCSTART-	1697

Therefore	O
,	O
we	O
concluded	O
that	O
this	O
patient	O
's	O
pulmonary	B-ADE
disease	I-ADE
was	O
caused	O
by	O
calcium	B-Drug
stearate	I-Drug
,	O
an	O
additive	O
for	O
an	O
antihistaminic	O
drug	O
.	O

-DOCSTART-	3214

Charcoal	O
haemoperfusion	O
and	O
cysteamine	O
therapy	O
led	O
to	O
the	O
rapid	O
removal	O
of	O
the	O
paracetamol	B-Drug
from	O
the	O
body	O
and	O
consequently	O
prevented	O
the	O
development	O
of	O
severe	B-ADE
hepatic	I-ADE
necrosis	I-ADE
.	O

-DOCSTART-	3089

Clinical	O
and	O
morphological	O
features	O
of	O
gold	B-Drug
neuropathy	B-ADE
.	O

-DOCSTART-	1350

We	O
describe	O
the	O
development	O
of	O
ischemic	B-ADE
colitis	I-ADE
in	O
a	O
woman	O
who	O
was	O
treated	O
with	O
tegaserod	B-Drug
and	O
review	O
the	O
relationship	O
among	O
ischemic	B-ADE
colitis	I-ADE
,	O
tegaserod	B-Drug
use	O
,	O
and	O
irritable	B-ADE
bowel	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	3741

We	O
present	O
a	O
patient	O
with	O
human	O
immunodeficiency	O
virus	O
infection	O
under	O
treatment	O
with	O
foscarnet	B-Drug
for	O
CMV	O
retinitis	O
who	O
complained	O
of	O
thirst	B-ADE
and	O
polyuria	B-ADE
.	O

-DOCSTART-	3122

Cefoxitin	B-Drug
therapy	O
for	O
Mycobacterium	O
fortuitum	O
bacteremia	O
with	O
associated	O
granulomatous	B-ADE
hepatitis	I-ADE
.	O

-DOCSTART-	1660

We	O
report	O
the	O
case	O
of	O
a	O
21-year	O
-	O
old	O
female	O
patient	O
with	O
dapsone	B-Drug
hypersensitivity	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	3322

Seven	O
of	O
the	O
eight	O
cases	O
of	O
acute	B-ADE
leukemia	I-ADE
occurred	O
in	O
a	O
series	O
of	O
553	O
patients	O
treated	O
with	O
Treosulfan	B-Drug
for	O
ovarian	O
cancer	O
in	O
the	O
period	O
from	O
1970	O
to	O
1977	O
and	O
followed	O
closely	O
for	O
a	O
total	O
of	O
1159	O
patient	O
-	O
years	O
up	O
to	O
February	O
1978	O
.	O

-DOCSTART-	3698

Acceleration	B-ADE
of	I-ADE
ventricular	I-ADE
response	I-ADE
to	O
atrial	O
flutter	O
after	O
intravenous	O
adenosine	B-Drug
.	O

-DOCSTART-	1911

Pulmonary	B-ADE
toxicity	I-ADE
associated	O
with	O
erlotinib	B-Drug
.	O

-DOCSTART-	3710

We	O
report	O
the	O
occurrence	O
of	O
renal	B-ADE
failure	I-ADE
due	O
to	O
cholesterol	B-ADE
crystal	I-ADE
embolization	I-ADE
following	O
thrombolytic	O
therapy	O
with	O
intravenous	O
recombinant	B-Drug
tissue	I-Drug
-	I-Drug
type	I-Drug
plasminogen	I-Drug
activator	I-Drug
(	O
t	B-Drug
-	I-Drug
PA	I-Drug
)	O
.	O

-DOCSTART-	2474

Fatal	B-ADE
interstitial	I-ADE
lung	I-ADE
disease	I-ADE
after	O
erlotinib	B-Drug
administration	O
in	O
a	O
patient	O
with	O
radiation	O
fibrosis	O
.	O

-DOCSTART-	2155

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
describe	O
the	O
occurrence	O
of	O
acute	B-ADE
coronary	I-ADE
syndromes	I-ADE
in	O
3	O
cases	O
of	O
rituximab	B-Drug
infusions	O
.	O

-DOCSTART-	184

It	O
remains	O
to	O
be	O
seen	O
whether	O
the	O
hepatotoxicity	B-ADE
associated	O
with	O
troglitazone	B-Drug
is	O
a	O
drug	O
-	O
class	O
effect	O
or	O
specific	O
to	O
troglitazone	B-Drug
.	O

-DOCSTART-	188

Nitrofurantoin	B-Drug
-	O
induced	O
lung	B-ADE
disease	I-ADE
:	O
two	O
cases	O
demonstrating	O
resolution	O
of	O
apparently	O
irreversible	O
CT	O
abnormalities	O
.	O

-DOCSTART-	1472

ARDS	B-ADE
is	O
rarely	O
associated	O
with	O
rituximab	B-Drug
infusion	O
for	O
lympho	O
-	O
proliferative	O
disorders	O
,	O
but	O
it	O
should	O
be	O
considered	O
by	O
those	O
administering	O
rituximab	B-Drug
,	O
especially	O
when	O
a	O
patient	O
develops	O
severe	B-ADE
pulmonary	I-ADE
symptoms	I-ADE
soon	O
after	O
infusion	O
.	O

-DOCSTART-	762

Central	B-ADE
pontine	I-ADE
myelinolysis	I-ADE
manifested	O
by	O
temporary	B-ADE
blindness	I-ADE
:	O
a	O
possible	O
complication	O
of	O
lithium	B-Drug
toxicity	O
.	O

-DOCSTART-	1185

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
increased	B-ADE
cerebral	I-ADE
cortical	I-ADE
excitability	I-ADE
following	O
intoxication	O
with	O
flupirtine	B-Drug
,	O
a	O
centrally	O
acting	O
analgesic	O
and	O
antispastic	O
drug	O
.	O

-DOCSTART-	3663

Lithium	B-Drug
-	O
associated	O
transient	B-ADE
thyrotoxicosis	I-ADE
in	O
4	O
Chinese	O
women	O
with	O
autoimmune	O
thyroiditis	O
.	O

-DOCSTART-	1320

These	O
data	O
indicated	O
that	O
infliximab	B-Drug
possibly	O
triggered	O
production	B-ADE
of	I-ADE
granulocyte	I-ADE
and	I-ADE
neutrophil	I-ADE
autoantibodies	I-ADE
with	O
resultant	O
autoimmune	B-ADE
agranulocytosis	I-ADE
.	O

-DOCSTART-	3049

Allopurinol	B-Drug
-	O
associated	O
hand	B-ADE
and	I-ADE
foot	I-ADE
deformities	I-ADE
in	O
chronic	O
tophaceous	O
gout	O
.	O

-DOCSTART-	2434

Flare	O
of	O
Kaposi	B-ADE
's	I-ADE
sarcoma	I-ADE
(	O
KS	B-ADE
)	O
is	O
well	O
described	O
in	O
immunosuppressed	O
patients	O
treated	O
with	O
corticosteroids	O
and	O
rituximab	B-Drug
,	O
but	O
has	O
not	O
yet	O
been	O
reported	O
during	O
treatment	O
with	O
imatinib	O
.	O

-DOCSTART-	1364

This	O
is	O
a	O
case	O
of	O
pseudoephedrine	B-Drug
-	O
induced	O
intracerebral	B-ADE
hemorrhage	I-ADE
in	O
a	O
patient	O
with	O
an	O
underlying	O
vascular	O
malformation	O
.	O

-DOCSTART-	705

Atypical	O
endometriosis	O
may	O
act	O
as	O
a	O
precancerous	O
lesion	O
in	O
the	O
process	O
of	O
tamoxifen	B-Drug
-	O
induced	O
malignant	B-ADE
transformation	I-ADE
of	I-ADE
endometriosis	I-ADE
.	O

-DOCSTART-	2575

Severe	B-ADE
hepatotoxicity	I-ADE
from	O
phenobarbital	B-Drug
occurred	O
in	O
an	O
infant	O
boy	O
who	O
had	O
a	O
complicated	O
illness	O
with	O
chronic	O
bilateral	O
subdural	O
hematomas	O
and	O
sepsis	O
.	O

-DOCSTART-	2243

Acute	B-ADE
renal	I-ADE
failure	I-ADE
is	O
a	O
rare	O
complication	O
following	O
the	O
administration	O
of	O
intravenous	O
immunoglobulin	B-Drug
(	O
IVIG	O
)	O
.	O

-DOCSTART-	3910

A	O
drug	O
addict	O
with	O
staphylococcal	O
endocarditis	O
treated	O
with	O
methicillin	B-Drug
,	O
who	O
developed	O
massive	B-ADE
proteinuria	I-ADE
and	O
acute	B-ADE
nephritic	I-ADE
syndrome	I-ADE
is	O
described	O
.	O

-DOCSTART-	1738

We	O
report	O
a	O
case	O
of	O
Ritalin	B-Drug
-	O
associated	O
cataract	B-ADE
and	O
glaucoma	B-ADE
.	O

-DOCSTART-	1723

The	O
main	O
side	O
-	O
effects	O
of	O
Lp	B-Drug
-	I-Drug
TAE	I-Drug
combined	O
with	O
HT	O
were	O
low	B-ADE
-	I-ADE
grade	I-ADE
fever	I-ADE
,	O
localized	B-ADE
pain	I-ADE
,	O
myelo	B-ADE
-	I-ADE
suppression	I-ADE
and	O
liver	B-ADE
dysfunction	I-ADE
,	O
but	O
these	O
were	O
transient	O
and	O
eventually	O
disappeared	O
.	O

-DOCSTART-	3466

Mechanisms	O
and	O
triggering	O
factors	O
of	O
hypoglycaemia	B-ADE
induced	O
by	O
mefloquine	B-Drug
and	O
some	O
other	O
anti	O
-	O
malarial	O
quinine	O
analogues	O
are	O
discussed	O
.	O

-DOCSTART-	3828

Nitrofurantoin	B-Drug
-	O
induced	O
pulmonary	B-ADE
toxicity	I-ADE
during	O
pregnancy	O
:	O
a	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	1167

Knowledge	O
regarding	O
potential	O
adverse	O
effects	O
of	O
CAP	B-Drug
is	O
paramount	O
and	O
dose	O
modification	O
is	O
indicated	O
with	O
development	O
of	O
neurotoxicity	B-ADE
.	O

-DOCSTART-	3810

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
lithium	B-Drug
-	O
associated	O
CDI	B-ADE
and	O
NDI	B-ADE
presenting	O
concurrently	O
.	O

-DOCSTART-	2549

Bowel	B-ADE
perforation	I-ADE
associated	O
with	O
intraperitoneal	O
chromic	B-Drug
phosphate	I-Drug
instillation	O
.	O

-DOCSTART-	239

Skin	B-ADE
manifestations	I-ADE
of	O
a	O
case	O
of	O
phenylbutazone	B-Drug
-	O
induced	O
serum	B-ADE
sickness	I-ADE
-	I-ADE
like	I-ADE
reactions	I-ADE
.	O

-DOCSTART-	2735

Co	B-Drug
-	I-Drug
trimoxazole	I-Drug
red	B-ADE
cell	I-ADE
aplasia	I-ADE
in	O
leukaemia	O
.	O

-DOCSTART-	1143

Fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
is	O
a	O
rare	O
complication	O
of	O
disulfiram	B-Drug
treatment	O
for	O
alcoholism	O
.	O

-DOCSTART-	4094

We	O
conclude	O
that	O
vincristine	B-Drug
and	O
actinomycin	B-Drug
D	I-Drug
were	O
the	O
cause	O
of	O
this	O
rare	O
from	O
of	O
hepatotoxicity	B-ADE
and	O
that	O
chemotherapy	O
for	O
the	O
underlying	O
malignant	O
disease	O
could	O
be	O
given	O
safely	O
after	O
clinical	O
recovery	O
.	O

-DOCSTART-	553

Beginning	O
ductopenia	B-ADE
was	O
present	O
in	O
two	O
,	O
suggesting	O
that	O
itraconazole	B-Drug
might	O
be	O
responsible	O
for	O
the	O
occurrence	O
of	O
prolonged	O
drug	O
-	O
induced	O
cholangiopathy	B-ADE
.	O

-DOCSTART-	221

Severe	B-ADE
hemolytic	I-ADE
uremic	I-ADE
syndrome	I-ADE
in	O
an	O
advanced	O
ovarian	O
cancer	O
patient	O
treated	O
with	O
carboplatin	B-Drug
and	O
gemcitabine	B-Drug
.	O

-DOCSTART-	3266

Transient	B-ADE
anuria	I-ADE
following	O
administration	O
of	O
angiotensin	O
I	O
-	O
converting	O
enzyme	O
inhibitor	O
(	O
SQ	B-Drug
14225	I-Drug
)	O
in	O
a	O
patient	O
with	O
renal	O
artery	O
stenosis	O
of	O
the	O
solitary	O
kidney	O
successfully	O
treated	O
with	O
renal	O
autotransplantation	O
.	O

-DOCSTART-	1623

Sporadic	B-ADE
rippling	I-ADE
muscle	I-ADE
disease	I-ADE
unmasked	O
by	O
simvastatin	B-Drug
.	O

-DOCSTART-	2072

Restless	B-ADE
legs	I-ADE
syndrome	I-ADE
and	O
periodic	B-ADE
limb	I-ADE
movements	I-ADE
during	I-ADE
sleep	I-ADE
probably	O
associated	O
with	O
olanzapine	B-Drug
.	O

-DOCSTART-	1949

Multiple	B-ADE
syncopal	I-ADE
episodes	I-ADE
started	O
to	O
occur	O
during	O
thalidomide	B-Drug
treatment	O
,	O
and	O
a	O
Holter	O
electrocardiogram	O
showed	O
multiple	O
abnormalities	O
,	O
with	O
an	O
episode	O
of	O
sustained	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
.	O

-DOCSTART-	555

Hepatotoxicity	B-ADE
related	O
to	O
itraconazole	B-Drug
:	O
report	O
of	O
three	O
cases	O
.	O

-DOCSTART-	3261

Clinicians	O
should	O
be	O
aware	O
of	O
fasting	B-ADE
hypoglycemia	I-ADE
as	O
an	O
unusual	O
but	O
potentially	O
serious	O
complication	O
of	O
disopyramide	B-Drug
therapy	O
.	O

-DOCSTART-	2733

Reversible	O
valproic	B-Drug
acid	I-Drug
-	O
induced	O
dementia	B-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3557

Recurrent	B-ADE
hypotension	I-ADE
immediately	O
after	O
seizures	B-ADE
in	O
nortriptyline	B-Drug
overdose	O
.	O

-DOCSTART-	838

Multiple	B-ADE
sclerosis	I-ADE
-	I-ADE
like	I-ADE
disease	I-ADE
secondary	O
to	O
alpha	B-Drug
interferon	I-Drug
.	O

-DOCSTART-	982

All	O
patients	O
had	O
taken	O
phenytoin	B-Drug
for	O
variable	O
time	O
periods	O
(	O
range	O
16	O
-	O
80	O
days	O
;	O
mean	O
:	O
40	O
)	O
and	O
were	O
on	O
the	O
medication	O
when	O
the	O
skin	B-ADE
lesions	I-ADE
first	O
appeared	O
.	O

-DOCSTART-	2660

We	O
report	O
a	O
case	O
of	O
long	O
lasting	O
respiratory	B-ADE
depression	I-ADE
after	O
intravenous	O
administration	O
of	O
morphine	B-Drug
to	O
a	O
7	O
year	O
old	O
girl	O
with	O
haemolytic	O
uraemic	O
syndrome	O
.	O

-DOCSTART-	3899

Cardiac	B-ADE
arrest	I-ADE
after	O
esmolol	B-Drug
administration	O
:	O
a	O
review	O
of	O
acute	O
beta	O
-	O
blocker	O
toxicity	O
.	O

-DOCSTART-	218

Polyarthritis	B-ADE
,	O
hepatitis	B-ADE
and	O
anti	B-ADE
-	I-ADE
native	I-ADE
DNA	I-ADE
antibodies	I-ADE
after	O
treatment	O
with	O
ethambutol	B-Drug
and	O
rifampicin	B-Drug
.	O

-DOCSTART-	3738

Nephrogenic	B-ADE
diabetes	I-ADE
insipidus	I-ADE
and	O
renal	B-ADE
tubular	I-ADE
acidosis	I-ADE
secondary	O
to	O
foscarnet	B-Drug
therapy	O
.	O

-DOCSTART-	3227

The	O
nephrotic	B-ADE
syndrome	I-ADE
developed	O
in	O
a	O
patient	O
receiving	O
therapy	O
with	O
gold	B-Drug
for	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	4056

Nephropathy	B-ADE
caused	O
by	O
methicillin	B-Drug
therapy	O
for	O
staphylococcal	O
septicemia	O
.	O

-DOCSTART-	2606

The	O
pro	B-ADE
-	I-ADE
arrhythmic	I-ADE
effects	I-ADE
of	O
procainamide	B-Drug
may	O
be	O
explained	O
on	O
the	O
basis	O
of	O
both	O
its	O
vagolytic	O
action	O
on	O
the	O
atrioventricular	O
node	O
as	O
well	O
as	O
by	O
prolongation	O
of	O
refractoriness	O
in	O
the	O
accessory	O
pathway	O
.	O

-DOCSTART-	272

Incidence	O
of	O
seizures	B-ADE
in	O
pediatric	O
cancer	O
patients	O
treated	O
with	O
imipenem	B-Drug
/	O
cilastatin	B-Drug
.	O

-DOCSTART-	1173

Severe	B-ADE
hypo	I-ADE
-	I-ADE
alpha	I-ADE
-	I-ADE
lipoproteinemia	I-ADE
during	O
treatment	O
with	O
rosiglitazone	B-Drug
.	O

-DOCSTART-	1539

NCSE	B-ADE
,	O
an	O
epileptic	O
disorder	O
in	O
which	O
typical	O
convulsive	O
activity	O
is	O
absent	O
,	O
has	O
previously	O
been	O
reported	O
in	O
only	O
4	O
patients	O
receiving	O
ifosfamide	B-Drug
.	O

-DOCSTART-	660

Fixed	B-ADE
drug	I-ADE
eruption	I-ADE
to	O
rofecoxib	B-Drug
.	O

-DOCSTART-	998

We	O
report	O
here	O
a	O
case	O
of	O
TEN	B-ADE
after	O
administration	O
of	O
ciprofloxacin	B-Drug
.	O

-DOCSTART-	1353

The	O
reported	O
case	O
represents	O
an	O
unusual	O
association	O
between	O
medication	O
with	O
the	O
proton	O
pump	O
inhibitor	O
lansoprazole	B-Drug
and	O
the	O
development	O
of	O
collagenous	B-ADE
colitis	I-ADE
suggesting	O
the	O
importance	O
of	O
evaluation	O
of	O
drug	O
use	O
in	O
patients	O
with	O
microscopic	O
colitis	O
.	O

-DOCSTART-	1133

Refractory	B-ADE
hypoglycemia	I-ADE
from	O
ciprofloxacin	B-Drug
and	O
glyburide	B-Drug
interaction	O
.	O

-DOCSTART-	1220

Scrotal	B-ADE
ulceration	I-ADE
induced	O
by	O
all	O
-	O
trans	O
retinoic	B-Drug
acid	I-Drug
in	O
a	O
patient	O
with	O
acute	O
promyelocytic	O
leukemia	O
.	O

-DOCSTART-	508

We	O
believe	O
that	O
these	O
skin	B-ADE
eruptions	I-ADE
belong	O
to	O
a	O
spectrum	O
of	O
neutrophilic	B-ADE
dermatoses	I-ADE
that	O
can	O
be	O
induced	O
or	O
aggravated	O
by	O
G	B-Drug
-	I-Drug
CSF	I-Drug
therapy	O
.	O

-DOCSTART-	210

A	O
patient	O
with	O
an	O
allergy	O
to	O
a	O
macrolide	O
antibiotic	O
was	O
given	O
tacrolimus	B-Drug
and	O
developed	O
a	O
sudden	B-ADE
cutaneous	I-ADE
reaction	I-ADE
.	O

-DOCSTART-	733

He	O
had	O
an	O
immediate	O
hypersensitivity	B-ADE
reaction	I-ADE
during	O
the	O
initiation	O
of	O
the	O
MTX	B-Drug
infusion	O
with	O
diffuse	B-ADE
urticaria	I-ADE
,	O
facial	B-ADE
swelling	I-ADE
,	O
cough	B-ADE
,	O
and	O
chest	B-ADE
tightness	I-ADE
.	O

-DOCSTART-	2765

The	O
literature	O
of	O
vincristine	B-Drug
optic	B-ADE
nerve	I-ADE
toxicity	I-ADE
is	O
reviewed	O
.	O

-DOCSTART-	4060

Vitiligo	B-ADE
associated	O
with	O
alpha	B-Drug
-	I-Drug
interferon	I-Drug
in	O
a	O
patient	O
with	O
chronic	O
active	O
hepatitis	O
C	O
.	O

-DOCSTART-	2416

All	B-Drug
-	I-Drug
trans	I-Drug
retinoic	I-Drug
acid	I-Drug
-	O
induced	O
focal	B-ADE
myositis	I-ADE
,	O
synovitis	B-ADE
,	O
and	O
mononeuritis	B-ADE
.	O

-DOCSTART-	2624

Dapsone	B-Drug
-	O
induced	O
erythroderma	B-ADE
with	O
Beau	O
's	O
lines	O
.	O

-DOCSTART-	3405

DISCUSSION	O
:	O
Anaphylactoid	B-ADE
reactions	I-ADE
have	O
been	O
described	O
previously	O
with	O
cisplatin	B-Drug
administration	O
.	O

-DOCSTART-	3934

Delayed	B-ADE
hypersensitivity	I-ADE
to	O
flurbiprofen	B-Drug
.	O

-DOCSTART-	3344

A	O
62-year	O
-	O
old	O
Indian	O
with	O
diabetic	O
nephropathy	O
controlled	O
with	O
metformin	B-Drug
,	O
developed	O
miliary	B-ADE
tuberculosis	I-ADE
for	O
which	O
he	O
was	O
treated	O
with	O
rifampicin	O
,	O
isoniazid	O
and	O
ethambutol	O
.	O

-DOCSTART-	4013

CONCLUSION	O
:	O
We	O
believe	O
this	O
to	O
be	O
the	O
first	O
reported	O
case	O
of	O
rhGH	B-Drug
-	O
induced	O
hypercalcemia	B-ADE
in	O
an	O
HIV	O
-	O
infected	O
patient	O
.	O

-DOCSTART-	2709

However	O
,	O
there	O
are	O
few	O
reports	O
in	O
the	O
literature	O
of	O
ampicillin	B-Drug
as	O
a	O
cause	O
of	O
acute	B-ADE
interstitial	I-ADE
nephritis	I-ADE
.	O

-DOCSTART-	607

Subcutaneous	O
IL-2	B-Drug
is	O
safe	O
and	O
well	O
tolerated	O
,	O
with	O
a	O
mortality	B-ADE
rate	I-ADE
<3	I-ADE
%	O
.	O

-DOCSTART-	833

However	O
,	O
in	O
order	O
to	O
avoid	O
neuropathic	B-ADE
side	I-ADE
effects	I-ADE
,	O
patients	O
under	O
thalidomide	B-Drug
therapy	O
should	O
be	O
monitored	O
every	O
6	O
months	O
with	O
nerve	O
conduction	O
studies	O
while	O
taking	O
the	O
drug	O
.	O

-DOCSTART-	649

The	O
authors	O
report	O
the	O
first	O
case	O
of	O
bucillamine	B-Drug
-	O
induced	O
giant	B-ADE
mammary	I-ADE
hyperplasia	I-ADE
.	O

-DOCSTART-	4251

Among	O
12	O
thyrotoxic	O
patients	O
,	O
a	O
patient	O
with	O
arrhythmogenic	O
right	O
ventricular	O
dysplasia	O
,	O
who	O
had	O
been	O
taking	O
amiodarone	B-Drug
for	O
4	O
years	O
,	O
developed	O
thyrotoxicosis	B-ADE
with	O
subacute	O
onset	O
,	O
accompanied	O
by	O
transiently	B-ADE
positive	I-ADE
thyrotropin	I-ADE
(	I-ADE
TSH	I-ADE
)	I-ADE
receptor	I-ADE
antibody	I-ADE
(	O
TRAb	O
)	O
,	O
or	O
thyrotropin	B-ADE
-	I-ADE
binding	I-ADE
inhibiting	I-ADE
immunoglobulin	I-ADE
(	O
TBII	O
)	O
.	O

-DOCSTART-	2221

IFNalpha	B-Drug
-	O
induced	O
recurrence	O
of	O
Graves	B-ADE
'	I-ADE
disease	I-ADE
ten	O
years	O
after	O
thyroidectomy	O
in	O
chronic	O
viral	O
hepatitis	O
C	O
.	O

-DOCSTART-	3725

Acute	B-ADE
myeloid	I-ADE
leukemia	I-ADE
evolving	O
from	O
essential	O
thrombocythemia	O
in	O
two	O
patients	O
treated	O
with	O
hydroxyurea	B-Drug
.	O

-DOCSTART-	4208

The	O
cause	O
of	O
these	O
previously	O
unreported	O
side	O
effects	O
of	O
niacin	B-Drug
therapy	O
is	O
uncertain	O
but	O
may	O
be	O
related	O
to	O
prostaglandin	B-ADE
-	I-ADE
mediated	I-ADE
vasodilatation	I-ADE
,	O
hyperalgesia	B-ADE
of	I-ADE
sensory	I-ADE
nerve	I-ADE
receptors	I-ADE
,	O
and	O
potentiation	B-ADE
of	I-ADE
inflammation	I-ADE
in	I-ADE
the	I-ADE
gingiva	I-ADE
with	O
referral	O
of	O
pain	B-ADE
to	I-ADE
the	I-ADE
teeth	I-ADE
.	O

-DOCSTART-	3140

Two	O
patients	O
had	O
ampicillin	B-Drug
-	O
associated	O
seizures	B-ADE
.	O

-DOCSTART-	1702

This	O
is	O
the	O
first	O
case	O
of	O
HBV	B-ADE
reactivation	I-ADE
occurring	O
during	O
the	O
year	O
following	O
rituximab	B-Drug
monotherapy	O
in	O
the	O
absence	O
of	O
any	O
other	O
immunosuppressive	O
factor	O
.	O

-DOCSTART-	2062

CONCLUSIONS	O
:	O
Prolonged	O
exposure	O
to	O
itraconazole	B-Drug
,	O
administered	O
either	O
continuously	O
or	O
intermittently	O
,	O
may	O
precipitate	O
severe	B-ADE
and	I-ADE
irreversible	I-ADE
hepatotoxic	I-ADE
events	I-ADE
.	O

-DOCSTART-	2727

Recent	O
reports	O
have	O
shown	O
that	O
Decadron	O
(	O
dexamethasone	O
;	O
Merck	O
Sharp	O
&	O
Dohme	O
,	O
West	O
Point	O
,	O
Pa	O
)	O
has	O
a	O
significant	O
antiemetic	O
effect	O
on	O
cisplatin	B-Drug
-	O
induced	O
vomiting	B-ADE
.	O

-DOCSTART-	797

Angioimmunoblastic	B-ADE
lymphadenopathy	I-ADE
with	I-ADE
dysproteinemia	I-ADE
following	O
doxycycline	B-Drug
administration	O
.	O

-DOCSTART-	2528

We	O
reported	O
a	O
case	O
of	O
disulfiram	B-Drug
-	O
induced	O
hepatitis	B-ADE
with	O
unique	O
clinical	O
features	O
and	O
compared	O
our	O
case	O
with	O
others	O
in	O
the	O
literature	O
.	O

-DOCSTART-	250

When	O
pilsicainide	B-Drug
is	O
prescribed	O
in	O
patients	O
with	O
coronary	O
artery	O
disease	O
or	O
renal	O
dysfunction	O
,	O
close	O
attention	O
must	O
be	O
paid	O
to	O
avoid	O
life	B-ADE
-	I-ADE
threatening	I-ADE
arrhythmias	I-ADE
due	O
to	O
high	O
plasma	O
concentrations	O
of	O
the	O
drug	O
.	O

-DOCSTART-	2951

Esophageal	B-ADE
spasm	I-ADE
following	O
propranolol	B-Drug
overdose	O
relieved	O
by	O
glucagon	O
.	O

-DOCSTART-	398

Methadone	B-Drug
-	O
induced	O
myoclonus	B-ADE
in	O
advanced	O
cancer	O
.	O

-DOCSTART-	3607

Central	B-ADE
nervous	I-ADE
system	I-ADE
toxicity	I-ADE
associated	O
with	O
meperidine	B-Drug
use	O
in	O
hepatic	O
disease	O
.	O

-DOCSTART-	490

This	O
report	O
describes	O
an	O
unexpected	O
drug	O
-	O
induced	O
hepatitis	B-ADE
in	O
a	O
previously	O
healthy	O
young	O
woman	O
exposed	O
to	O
2	O
doses	O
of	O
amodiaquine	B-Drug
and	O
artesunate	B-Drug
.	O

-DOCSTART-	624

There	O
is	O
no	O
consensus	O
on	O
the	O
treatment	O
of	O
ticlopidine	B-Drug
-	O
induced	O
marrow	B-ADE
aplasia	I-ADE
.	O

-DOCSTART-	870

We	O
present	O
a	O
surprising	O
case	O
of	O
a	O
woman	O
schizophrenic	O
patient	O
treated	O
with	O
clozapine	B-Drug
suffering	O
from	O
EPS	B-ADE
.	O

-DOCSTART-	855

Enoxaparin	B-Drug
-	O
induced	O
generalized	B-ADE
exanthem	I-ADE
.	O

-DOCSTART-	2894

The	O
patient	O
's	O
defects	O
may	O
be	O
due	O
to	O
methimazole	B-Drug
teratogenicity	B-ADE
or	O
could	O
represent	O
a	O
previously	O
undescribed	O
syndrome	O
affecting	O
ectodermal	O
structures	O
.	O

-DOCSTART-	3057

One	O
other	O
patient	O
on	O
digoxin	B-Drug
stopped	O
taking	O
it	O
and	O
developed	O
cardiomyopathy	B-ADE
.	O

-DOCSTART-	3564

This	O
is	O
the	O
first	O
description	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
ductopenia	B-ADE
apparently	O
caused	O
by	O
clindamycin	B-Drug
.	O

-DOCSTART-	2039

Incomplete	B-ADE
posterior	I-ADE
hyaloid	I-ADE
detachment	I-ADE
after	O
intravitreal	O
pegaptanib	B-Drug
injection	O
in	O
diabetic	O
macular	O
edema	O
.	O

-DOCSTART-	2891

We	O
suggest	O
that	O
nicotinic	B-Drug
acid	I-Drug
was	O
the	O
cause	O
of	O
his	O
liver	B-ADE
disease	I-ADE
,	O
that	O
this	O
case	O
is	O
of	O
particular	O
note	O
because	O
of	O
the	O
rather	O
short	O
period	O
of	O
therapy	O
before	O
the	O
onset	O
of	O
liver	O
injury	O
and	O
the	O
severity	O
of	O
the	O
hepatic	O
failure	O
,	O
and	O
that	O
the	O
probable	O
increased	O
use	O
of	O
nicotinic	B-Drug
acid	I-Drug
for	O
serum	O
cholesterol	O
control	O
makes	O
it	O
especially	O
important	O
for	O
physicians	O
and	O
their	O
patients	O
to	O
be	O
alert	O
to	O
the	O
signs	O
of	O
hepatotoxicity	B-ADE
.	O

-DOCSTART-	3082

There	O
was	O
a	O
clear	O
relationship	O
between	O
restarting	O
the	O
Accutane	B-Drug
and	O
recurrence	O
of	O
the	O
transient	B-ADE
myopia	I-ADE
.	O

-DOCSTART-	2388

Postoperatively	O
,	O
the	O
first	O
two	O
patients	O
treated	O
with	O
1	O
to	O
2	O
cc	O
of	O
thrombin	B-Drug
were	O
slow	B-ADE
to	I-ADE
awaken	I-ADE
;	O
one	O
had	O
evidence	O
of	O
vasospasm	B-ADE
by	O
transcranial	O
Doppler	O
ultrasound	O
studies	O
and	O
multiple	B-ADE
infarcts	I-ADE
on	O
cranial	O
computerized	O
tomography	O
,	O
while	O
the	O
other	O
had	O
a	O
moderate	O
-	O
sized	O
frontal	O
hematoma	O
with	O
intracranial	O
hypertension	O
.	O

-DOCSTART-	4068

The	O
toxicity	B-ADE
and	O
plasma	O
concentrations	O
of	O
ifosfamide	B-Drug
,	O
chloroacetaldehyde	B-Drug
,	O
and	O
4-hydroxyifosfamide	B-Drug
were	O
then	O
determined	O
over	O
24	O
h	O
after	O
a	O
single	O
1.6	O
g	O
/	O
m2	O
dose	O
of	O
ifosfamide	B-Drug
.	O

-DOCSTART-	1184

Paradoxical	B-ADE
cerebral	I-ADE
cortical	I-ADE
hyperexcitability	I-ADE
following	O
flupirtine	B-Drug
overdose	O
.	O

-DOCSTART-	4212

It	O
was	O
concluded	O
that	O
potassium	B-ADE
loss	I-ADE
occurred	O
by	O
a	O
non	O
-	O
renal	O
(	O
intestinal	O
)	O
route	O
in	O
phosphate	B-Drug
-	O
induced	O
hypokalemia	B-ADE
.	O

-DOCSTART-	602

To	O
our	O
knowledge	O
,	O
this	O
case	O
is	O
the	O
first	O
published	O
report	O
of	O
levofloxacin	B-Drug
-	O
induced	O
TEN	B-ADE
.	O

-DOCSTART-	564

Cutaneous	B-ADE
sarcoidosis	I-ADE
during	O
interferon	B-Drug
alfa	I-Drug
and	O
ribavirin	B-Drug
treatment	O
of	O
hepatitis	O
C	O
virus	O
infection	O
:	O
two	O
cases	O
.	O

-DOCSTART-	2730

Adrenaline	B-Drug
dacryolith	B-ADE
:	O
detection	O
by	O
ultrasound	O
examination	O
of	O
the	O
nasolacrimal	O
duct	O
.	O

-DOCSTART-	1880

Metformin	B-Drug
-	O
associated	O
lactic	B-ADE
acidosis	I-ADE
precipitated	O
by	O
diarrhea	O
.	O

-DOCSTART-	2853

Amoxapine	B-Drug
-	O
induced	O
cognitive	B-ADE
impairment	I-ADE
in	O
two	O
patients	O
.	O

-DOCSTART-	923

Gestational	B-ADE
diabetes	I-ADE
was	O
no	O
less	O
severe	O
(	O
degree	O
of	O
hyperglycaemia	O
,	O
need	O
for	O
insulin	O
therapy	O
)	O
when	O
associated	O
with	O
norethisterone	B-Drug
.	O

-DOCSTART-	2142

Gabapentin	B-Drug
toxicity	O
in	O
renal	B-ADE
failure	I-ADE
:	O
the	O
importance	O
of	O
dose	O
adjustment	O
.	O

-DOCSTART-	2525

The	O
authors	O
intend	O
to	O
carry	O
out	O
a	O
case	O
-	O
control	O
study	O
on	O
patients	O
treated	O
with	O
tamoxifen	B-Drug
for	O
breast	O
carcinoma	O
to	O
reveal	O
the	O
possible	O
presence	O
of	O
endometrial	B-ADE
carcinoma	I-ADE
.	O

-DOCSTART-	670

Biomicroscopy	O
revealed	O
amiodarone	B-Drug
corneal	B-ADE
deposits	I-ADE
.	O

-DOCSTART-	3596

Sodium	B-Drug
valproate	I-Drug
and	O
carbamazepine	B-Drug
,	O
antiepileptic	O
drugs	O
that	O
are	O
associated	O
with	O
a	O
relatively	O
low	O
rate	O
of	O
adverse	O
cutaneous	O
reactions	O
,	O
should	O
be	O
added	O
to	O
the	O
growing	O
list	O
of	O
drugs	O
that	O
produce	O
psoriasiform	B-ADE
eruptions	I-ADE
.	O

-DOCSTART-	1102

Fatal	B-ADE
pulmonary	I-ADE
fibrosis	I-ADE
associated	O
with	O
BCNU	B-Drug
:	O
the	O
relative	O
role	O
of	O
platelet	O
-	O
derived	O
growth	O
factor	O
-	O
B	O
,	O
insulin	O
-	O
like	O
growth	O
factor	O
I	O
,	O
transforming	O
growth	O
factor	O
-	O
beta1	O
and	O
cyclooxygenase-2	O
.	O

-DOCSTART-	1944

Tardive	B-ADE
oculogyric	I-ADE
crisis	I-ADE
during	O
treatment	O
with	O
clozapine	B-Drug
:	O
report	O
of	O
three	O
cases	O
.	O

-DOCSTART-	2316

Following	O
7	O
days	O
of	O
tigecycline	B-Drug
she	O
developed	O
severe	B-ADE
abdominal	I-ADE
pain	I-ADE
and	O
elevated	B-ADE
pancreatic	I-ADE
enzymes	I-ADE
suggesting	O
acute	B-ADE
pancreatitis	I-ADE
.	O

-DOCSTART-	3777

Albendazole	B-Drug
-	O
induced	O
pseudomembranous	B-ADE
colitis	I-ADE
.	O

-DOCSTART-	1824

Since	O
its	O
FDA	O
approval	O
in	O
2002	O
,	O
there	O
are	O
no	O
known	O
citations	O
of	O
ezetimibe	B-Drug
-	O
induced	O
pancreatitis	B-ADE
.	O

-DOCSTART-	1617

First	O
case	O
of	O
ivermectin	B-Drug
-	O
induced	O
severe	B-ADE
hepatitis	I-ADE
.	O

-DOCSTART-	135

Intravenous	O
valproate	B-Drug
associated	O
with	O
significant	O
hypotension	B-ADE
in	O
the	O
treatment	O
of	O
status	O
epilepticus	O
.	O

-DOCSTART-	2395

Interstitial	B-ADE
pneumonia	I-ADE
probably	O
associated	O
with	O
sorafenib	B-Drug
treatment	O
:	O
An	O
alert	O
of	O
an	O
adverse	O
event	O
.	O

-DOCSTART-	3844

The	O
occurrence	O
of	O
neuromuscular	B-ADE
blockade	I-ADE
and	O
the	O
resulting	O
potentiation	B-ADE
of	I-ADE
muscle	I-ADE
relaxants	I-ADE
during	O
magnesium	B-Drug
sulfate	I-Drug
(	O
MgSO4	B-Drug
)	O
administration	O
is	O
well	O
known	O
.	O

-DOCSTART-	3714

Anterior	B-ADE
spinal	I-ADE
artery	I-ADE
syndrome	I-ADE
--	O
a	O
complication	O
of	O
cervical	O
intrathecal	O
phenol	B-Drug
injection	O
.	O

-DOCSTART-	1975

Pericardial	B-ADE
hemorrhage	I-ADE
due	O
to	O
acetylsalicylic	B-Drug
acid	I-Drug
in	O
a	O
patient	O
with	O
essential	O
thrombocythemia	O
.	O

-DOCSTART-	1112

Lichen	B-ADE
planus	I-ADE
induced	O
by	O
hepatitis	B-Drug
B	I-Drug
vaccination	I-Drug
:	O
a	O
new	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	3112

Three	O
cases	O
of	O
acute	B-ADE
renal	I-ADE
toxicity	I-ADE
in	O
patients	O
receiving	O
long	O
-	O
term	O
therapy	O
with	O
mitomycin	B-Drug
C	I-Drug
and	O
5-fluorouracil	B-Drug
are	O
reported	O
.	O

-DOCSTART-	1222

We	O
report	O
the	O
development	O
of	O
scrotal	B-ADE
ulcer	I-ADE
in	O
a	O
patient	O
with	O
acute	O
promyleocytic	O
leukemia	O
(	O
APL	O
)	O
within	O
10	O
days	O
of	O
treatment	O
with	O
ATRA	B-Drug
at	O
a	O
dose	O
of	O
40	O
mg	O
orally	O
twice	O
daily	O
.	O

-DOCSTART-	1023

Ramipril	B-Drug
-	O
induced	O
cutaneous	B-ADE
vasculitis	I-ADE
is	O
particularly	O
rare	O
and	O
our	O
case	O
was	O
atypical	O
because	O
the	O
patient	O
had	O
tolerated	O
lisinopril	O
before	O
.	O

-DOCSTART-	2781

Thrombo	B-ADE
-	I-ADE
embolic	I-ADE
complication	I-ADE
after	O
streptokinase	B-Drug
therapy	O
of	O
pulmonary	O
emboli	O
.	O

-DOCSTART-	20

We	O
believe	O
that	O
this	O
represents	O
an	O
unusual	O
case	O
of	O
moderate	O
-	O
dose	O
MTX	B-Drug
-	O
induced	O
neurotoxicity	B-ADE
in	O
a	O
patient	O
with	O
gastric	O
cancer	O
,	O
which	O
has	O
not	O
previously	O
been	O
reported	O
.	O

-DOCSTART-	18

Detection	O
of	O
activated	O
eosinophils	O
in	O
nasal	O
polyps	O
of	O
an	O
aspirin	B-Drug
-	O
induced	O
asthma	B-ADE
patient	O
.	O

-DOCSTART-	1559

We	O
have	O
described	O
three	O
patients	O
with	O
hepatitis	O
C	O
for	O
whom	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
and	O
ribavirin	B-Drug
were	O
prescribed	O
and	O
who	O
developed	O
two	O
successive	O
phases	O
of	O
silent	O
thyroiditis	B-ADE
followed	O
by	O
hyperthryroidism	B-ADE
relapse	O
due	O
to	O
Graves	O
'	O
disease	O
.	O

-DOCSTART-	2885

Phenytoin	O
was	O
discontinued	O
after	O
admission	O
;	O
however	O
,	O
phenytoin	B-Drug
1	O
g	O
i.v	O
.	O
was	O
given	O
for	O
a	O
tonic	O
-	O
clonic	O
seizure	O
two	O
days	O
after	O
admission	O
,	O
after	O
which	O
swelling	B-ADE
of	I-ADE
the	I-ADE
face	I-ADE
and	I-ADE
legs	I-ADE
and	O
pruritus	B-ADE
developed	O
.	O

-DOCSTART-	2895

Toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
resulted	O
after	O
19	O
days	O
of	O
treatment	O
with	O
5-fluorocytosine	B-Drug
and	O
amphotericin	B-Drug
B	I-Drug
.	O

-DOCSTART-	2651

Development	O
of	O
persistent	B-ADE
late	I-ADE
onset	I-ADE
asthma	I-ADE
following	O
treatment	O
with	O
captopril	B-Drug
.	O

-DOCSTART-	1278

Therefore	O
,	O
clinicians	O
should	O
pay	O
close	O
attention	O
to	O
possible	O
onset	O
of	O
RD	B-ADE
in	O
patients	O
with	O
multiple	O
risk	O
factors	O
for	O
TD	O
,	O
even	O
when	O
SDA	B-Drug
therapy	O
is	O
used	O
.	O

-DOCSTART-	2046

We	O
describe	O
a	O
case	O
of	O
life	O
-	O
threatening	O
hyponatremia	B-ADE
associated	O
with	O
sibutramine	B-Drug
use	O
in	O
an	O
obese	O
woman	O
.	O

-DOCSTART-	3096

It	O
is	O
concluded	O
that	O
'	O
cerebral	B-ADE
atrophy	I-ADE
'	O
on	O
CT	O
scans	O
may	O
represent	O
an	O
accumulative	O
effect	O
of	O
ACTH	B-Drug
and	O
that	O
ACTH	O
should	O
be	O
given	O
with	O
the	O
utmost	O
discretion	O
,	O
and	O
in	O
as	O
low	O
a	O
dose	O
as	O
possible	O
.	O

-DOCSTART-	2049

We	O
describe	O
a	O
patient	O
who	O
,	O
after	O
receiving	O
his	O
first	O
dose	O
of	O
pregabalin	B-Drug
to	O
relieve	O
neuropathic	O
pain	O
,	O
presented	O
with	O
a	O
negative	B-ADE
myoclonus	I-ADE
.	O

-DOCSTART-	3485

Ovarian	B-ADE
endometrioid	I-ADE
carcinoma	I-ADE
and	O
endometriosis	B-ADE
developing	O
in	O
a	O
postmenopausal	O
breast	O
cancer	O
patient	O
during	O
tamoxifen	B-Drug
therapy	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	600

We	O
describe	O
a	O
patient	O
who	O
developed	O
HUS	B-ADE
after	O
treatment	O
with	O
mitomycin	B-Drug
C	I-Drug
(	O
total	O
dose	O
144	O
mg	O
/	O
m2	O
)	O
due	O
to	O
a	O
carcinoma	O
of	O
the	O
ascending	O
colon	O
.	O

-DOCSTART-	1560

Dipyrone	B-Drug
,	O
also	O
known	O
as	O
metamizole	B-Drug
,	O
is	O
an	O
analgesic	O
and	O
antipyretic	O
drug	O
that	O
was	O
banned	O
by	O
the	O
United	O
States	O
Food	O
and	O
Drug	O
Administration	O
because	O
of	O
its	O
association	O
with	O
agranulocytosis	B-ADE
.	O

-DOCSTART-	2870

Torsade	B-ADE
de	I-ADE
pointes	I-ADE
during	O
loading	O
with	O
amiodarone	B-Drug
.	O

-DOCSTART-	1726

Liver	O
transplantation	O
for	O
fulminant	B-ADE
hepatitis	I-ADE
related	O
to	O
nevirapine	B-Drug
therapy	O
.	O

-DOCSTART-	4182

In	O
two	O
of	O
these	O
cases	O
akathisia	B-ADE
resolved	O
after	O
withdrawal	O
of	O
olanzapine	B-Drug
and	O
substitution	O
by	O
a	O
classical	O
or	O
an	O
atypical	O
neuroleptic	O
agent	O
,	O
respectively	O
.	O

-DOCSTART-	4255

In	O
patients	O
with	O
swallowing	B-ADE
dysfunction	I-ADE
and	O
pneumonia	B-ADE
,	O
a	O
history	O
of	O
mineral	B-Drug
oil	I-Drug
use	O
should	O
be	O
obtained	O
and	O
a	O
diagnosis	O
of	O
ELP	B-ADE
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnoses	O
if	O
mineral	B-Drug
oil	I-Drug
use	O
has	O
occurred	O
.	O

-DOCSTART-	3014

Pulmonary	B-ADE
eosinophilia	I-ADE
or	O
granulomas	B-ADE
,	O
classically	O
seen	O
in	O
previously	O
reported	O
cases	O
of	O
methotrexate	B-Drug
pneumonitis	B-ADE
,	O
were	O
not	O
observed	O
.	O

-DOCSTART-	1145

Tiagabine	B-Drug
overdose	O
causes	O
an	O
unusual	B-ADE
array	I-ADE
of	I-ADE
neurological	I-ADE
symptoms	I-ADE
,	O
many	O
similar	O
to	O
reported	O
adverse	O
effects	O
during	O
therapeutic	O
use	O
.	O

-DOCSTART-	3970

However	O
,	O
as	O
the	O
use	O
of	O
hepatitis	B-Drug
B	I-Drug
vaccination	I-Drug
is	O
growing	O
,	O
adverse	O
side	O
effects	O
,	O
including	O
mental	B-ADE
nerve	I-ADE
neuropathy	I-ADE
,	O
should	O
be	O
observed	O
with	O
an	O
increased	O
frequency	O
.	O

-DOCSTART-	2992

Although	O
the	O
movement	B-ADE
disorder	I-ADE
could	O
not	O
with	O
certainty	O
be	O
attributed	O
to	O
trazodone	B-Drug
alone	O
,	O
the	O
drug	O
at	O
least	O
acted	O
as	O
an	O
eliciting	O
agent	O
.	O

-DOCSTART-	3398

Acute	B-ADE
sensorineural	I-ADE
hearing	I-ADE
loss	I-ADE
following	O
intravenous	O
ketoralac	B-Drug
administration	O
.	O

-DOCSTART-	3233

Catatonia	B-ADE
associated	O
with	O
disulfiram	B-Drug
therapy	O
.	O

-DOCSTART-	3547

Contact	B-ADE
dermatitis	I-ADE
due	O
to	O
budesonide	B-Drug
:	O
report	O
of	O
five	O
cases	O
and	O
review	O
of	O
the	O
Japanese	O
literature	O
.	O

-DOCSTART-	1387

Risperidone	B-Drug
-	O
induced	O
psychosis	B-ADE
and	O
depression	B-ADE
in	O
a	O
child	O
with	O
a	O
mitochondrial	O
disorder	O
.	O

-DOCSTART-	400

Succinylcholine	B-Drug
-	O
induced	O
hyperkalemia	B-ADE
in	O
a	O
patient	O
with	O
mucositis	O
secondary	O
to	O
chemotherapy	O
.	O

-DOCSTART-	3645

Severe	O
abdominal	B-ADE
pain	I-ADE
in	O
low	O
dosage	O
clofazimine	B-Drug
.	O

-DOCSTART-	2012

A	O
short	O
review	O
on	O
imatinib	B-Drug
-	O
related	O
hepatotoxicity	B-ADE
is	O
also	O
presented	O
.	O

-DOCSTART-	1348

Potential	O
mechanisms	O
involved	O
in	O
the	O
occurrence	O
of	O
ischemic	B-ADE
colitis	I-ADE
in	O
patients	O
receiving	O
tegaserod	B-Drug
are	O
also	O
discussed	O
.	O

-DOCSTART-	3773

DISCUSSION	O
:	O
Central	B-ADE
nervous	I-ADE
system	I-ADE
(	I-ADE
CNS	I-ADE
)	I-ADE
toxicity	I-ADE
has	O
been	O
described	O
with	O
ifosfamide	B-Drug
,	O
with	O
most	O
cases	O
reported	O
in	O
the	O
pediatric	O
population	O
.	O

-DOCSTART-	830

Stevens	B-ADE
-	I-ADE
Johnson	I-ADE
syndrome	I-ADE
in	O
a	O
boy	O
with	O
nephrotic	O
syndrome	O
during	O
prednisolone	B-Drug
therapy	O
.	O

-DOCSTART-	1486

Methotrexate	B-Drug
-	O
associated	O
nephropathy	B-ADE
is	O
a	O
rare	O
complication	O
in	O
pediatric	O
oncology	O
,	O
and	O
a	O
review	O
of	O
the	O
literature	O
suggests	O
that	O
exposure	O
to	O
nephrotoxic	O
agents	O
may	O
be	O
a	O
significant	O
but	O
perhaps	O
underrecognized	O
risk	O
factor	O
for	O
its	O
development	O
.	O

-DOCSTART-	39

CASE	O
SUMMARY	O
:	O
A	O
39-year	O
-	O
old	O
white	O
Jewish	O
schizophrenic	O
man	O
treated	O
with	O
olanzapine	B-Drug
developed	O
an	O
elevated	B-ADE
serum	I-ADE
CK	I-ADE
concentration	I-ADE
with	O
a	O
peak	O
concentration	O
of	O
4000	O
IU	O
/	O
L	O
(	O
normal	O
<	O
230	O
)	O
.	O

-DOCSTART-	692

A	O
60-year	O
-	O
old	O
white	O
man	O
with	O
chronic	O
bronchitis	O
was	O
noted	O
to	O
develop	O
acute	B-ADE
respiratory	I-ADE
failure	I-ADE
and	O
metabolic	B-ADE
acidosis	I-ADE
four	O
days	O
after	O
being	O
started	O
on	O
methazolamide	B-Drug
(	O
Neptazane	B-Drug
)	O
for	O
an	O
ophthalmologic	O
problem	O
.	O

-DOCSTART-	4224

Interaction	B-ADE
between	O
tacrolimus	B-Drug
and	O
nefazodone	B-Drug
in	O
a	O
stable	O
renal	O
transplant	O
recipient	O
.	O

-DOCSTART-	3678

Acyclovir	B-Drug
-	O
induced	O
neurotoxicity	B-ADE
:	O
concentration	O
-	O
side	O
effect	O
relationship	O
in	O
acyclovir	O
overdose	O
.	O

-DOCSTART-	351

Ischaemic	B-ADE
colitis	I-ADE
in	O
a	O
patient	O
taking	O
meloxicam	B-Drug
.	O

-DOCSTART-	1100

Increased	B-ADE
lash	I-ADE
length	I-ADE
,	O
thickness	O
,	O
and	O
pigmentation	B-ADE
are	O
well	O
-	O
documented	O
side	O
effects	O
of	O
prostaglandin	B-Drug
analog	O
glaucoma	O
drops	O
.	O

-DOCSTART-	1115

Initial	O
treatment	O
with	O
heparin	B-Drug
was	O
substituted	O
with	O
thrombolysis	O
,	O
which	O
resulted	O
in	O
clinical	O
improvement	O
and	O
dissolution	O
of	O
right	O
heart	O
thrombus	O
but	O
was	O
followed	O
by	O
fatal	B-ADE
intracerebral	I-ADE
haemorrhage	I-ADE
.	O

-DOCSTART-	1532

In	O
this	O
paper	O
,	O
we	O
report	O
a	O
case	O
of	O
severe	B-ADE
hypercalcemia	I-ADE
of	O
immobilization	O
in	O
a	O
40-year	O
-	O
old	O
hemodialyzed	O
woman	O
treated	O
by	O
cinacalcet	B-Drug
HCl	I-Drug
for	O
a	O
severe	O
HPTH	O
-	O
II	O
(	O
PTH>1,000	O
pg	O
/	O
mL	O
)	O
.	O

-DOCSTART-	1108

METHODS	O
:	O
A	O
76-year	O
-	O
old	O
woman	O
with	O
primary	O
open	O
-	O
angle	O
glaucoma	O
and	O
no	O
history	O
of	O
ocular	O
surgery	O
developed	O
a	O
choroidal	B-ADE
detachment	I-ADE
12	O
hours	O
after	O
initiation	O
of	O
therapy	O
with	O
dorzolamide	B-Drug
eye	O
drops	O
.	O

-DOCSTART-	4147

CD4	B-ADE
T	I-ADE
-	I-ADE
lymphocyte	I-ADE
depletion	I-ADE
,	O
myelosuppression	B-ADE
,	O
and	O
subsequent	O
severe	B-ADE
infections	I-ADE
are	O
the	O
major	O
side	O
effects	O
of	O
fludarabine	B-Drug
phosphate	I-Drug
therapy	O
.	O

-DOCSTART-	1059

Although	O
combinations	O
of	O
belladonna	B-Drug
,	O
ergotamine	B-Drug
,	O
and	O
phenobarbital	B-Drug
have	O
been	O
used	O
for	O
medical	O
treatment	O
of	O
menopausal	O
symptoms	O
since	O
the	O
1960s	O
,	O
this	O
is	O
the	O
first	O
known	O
case	O
report	O
of	O
its	O
association	O
with	O
anticonvulsant	B-ADE
hypersensitivity	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	2078

CONCLUSION	O
:	O
Alendronate	B-Drug
led	O
to	O
nodular	B-ADE
scleritis	I-ADE
and	O
rechallenge	O
caused	O
recurrence	O
of	O
scleritis	B-ADE
.	O

-DOCSTART-	707

CONCLUSION	O
:	O
Tamoxifen	B-Drug
may	O
cause	O
malignant	B-ADE
transformation	I-ADE
of	I-ADE
endometriosis	I-ADE
through	O
atypical	O
endometriosis	O
even	O
in	O
the	O
postmenopausal	O
state	O
.	O

-DOCSTART-	3288

Nine	O
delirious	B-ADE
patients	O
suffering	O
from	O
lithium	B-Drug
intoxication	O
were	O
examined	O
with	O
the	O
Mini	O
-	O
Mental	O
State	O
Exam	O
(	O
MMS	O
)	O
to	O
describe	O
the	O
clinical	O
course	O
of	O
the	O
disorder	O
.	O

-DOCSTART-	2378

Severe	B-ADE
apnea	I-ADE
in	O
an	O
infant	O
exposed	O
to	O
lamotrigine	B-Drug
in	O
breast	O
milk	O
.	O

-DOCSTART-	3999

Propylthiouracil	B-Drug
-	O
induced	O
cutaneous	B-ADE
vasculitis	I-ADE
.	O

-DOCSTART-	2815

Halothane	B-Drug
hepatitis	B-ADE
and	O
prompt	O
resolution	O
with	O
methionine	O
therapy	O
:	O
case	O
report	O
.	O

-DOCSTART-	2189

Diabetes	B-ADE
Mellitus	I-ADE
was	O
observed	O
in	O
a	O
patient	O
given	O
carbamazepine	B-Drug
.	O

-DOCSTART-	591

CASE	O
SUMMARY	O
:	O
We	O
report	O
the	O
case	O
of	O
a	O
31-year	O
-	O
old	O
patient	O
hospitalized	O
due	O
to	O
behavioral	O
alterations	O
and	O
treated	O
with	O
oral	O
zuclopenthixol	B-Drug
,	O
an	O
antipsychotic	O
from	O
the	O
thioxanthene	O
family	O
,	O
who	O
developed	O
an	O
acute	O
,	O
painful	B-ADE
erection	I-ADE
.	O

-DOCSTART-	2970

Administration	O
of	O
pyridoxine	B-Drug
to	O
an	O
infant	O
after	O
a	O
long	O
period	O
of	O
convulsions	O
was	O
followed	O
by	O
acute	B-ADE
hypotonia	I-ADE
.	O

-DOCSTART-	2836

We	O
are	O
concerned	O
that	O
the	O
macular	B-ADE
lesion	I-ADE
was	O
a	O
retinal	O
toxic	O
effect	O
of	O
gentamicin	B-Drug
because	O
of	O
the	O
recent	O
description	O
of	O
similar	O
lesions	O
occurring	O
after	O
the	O
inadvertent	O
intraocular	O
injection	O
of	O
massive	O
doses	O
of	O
this	O
drug	O
.	O

-DOCSTART-	106

These	O
findings	O
suggest	O
that	O
bicytopenia	B-ADE
in	O
this	O
patient	O
was	O
caused	O
by	O
D	B-Drug
-	I-Drug
Pen	I-Drug
and	O
may	O
be	O
due	O
to	O
different	O
sensitivities	O
in	O
the	O
hematopoietic	O
lineage	O
.	O

-DOCSTART-	777

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
corneoscleral	B-ADE
melting	I-ADE
in	O
the	O
first	O
postoperative	O
week	O
after	O
a	O
single	O
intraoperative	O
application	O
of	O
mitomycin	B-Drug
C	I-Drug
has	O
not	O
been	O
reported	O
.	O

-DOCSTART-	1653

Allergic	B-ADE
contact	I-ADE
angioedema	I-ADE
to	O
benzoyl	B-Drug
peroxide	I-Drug
.	O

-DOCSTART-	2622

Morphea	B-ADE
after	O
bromocriptine	B-Drug
therapy	O
.	O

-DOCSTART-	2257

We	O
recommend	O
that	O
a	O
TMA	O
in	O
association	O
with	O
quinine	O
be	O
consistently	O
referred	O
to	O
as	O
quinine	B-Drug
-	O
associated	O
thrombotic	B-ADE
microangiopathy	I-ADE
(	O
quinine	O
-	O
TMA	O
)	O
to	O
better	O
distinguish	O
this	O
entity	O
from	O
idiopathic	O
TTP	O
.	O

-DOCSTART-	2993

The	O
elicitation	O
of	O
a	O
movement	B-ADE
disorder	I-ADE
by	O
trazodone	B-Drug
:	O
case	O
report	O
.	O

-DOCSTART-	3231

In	O
four	O
patients	O
,	O
spasm	B-ADE
occurred	O
spontaneous	O
and	O
in	O
one	O
patient	O
after	O
0.05	O
mg	O
of	O
ergonovine	B-Drug
.	O

-DOCSTART-	3484

There	O
is	O
a	O
dose	O
-	O
effect	O
relationship	O
between	O
doxorubicin	B-Drug
and	O
the	O
incidence	O
of	O
symptomatic	B-ADE
cardiac	I-ADE
failure	I-ADE
.	O

-DOCSTART-	2375

Primary	B-ADE
central	I-ADE
nervous	I-ADE
system	I-ADE
lymphoma	I-ADE
in	O
a	O
patient	O
treated	O
with	O
natalizumab	B-Drug
.	O

-DOCSTART-	3424

Probable	O
propafenone	B-Drug
-	O
induced	O
transient	B-ADE
global	I-ADE
amnesia	I-ADE
.	O

-DOCSTART-	2674

Acute	B-ADE
myelogenous	I-ADE
leukemia	I-ADE
in	O
patients	O
receiving	O
chlorambucil	B-Drug
as	O
long	O
-	O
term	O
adjuvant	O
chemotherapy	O
for	O
stage	O
II	O
breast	O
cancer	O
.	O

-DOCSTART-	1960

Amphotericin	B-Drug
B	I-Drug
-	O
induced	O
cutaneous	B-ADE
leucocytoclastic	I-ADE
vasculitis	I-ADE
:	O
case	O
report	O
.	O

-DOCSTART-	1970

Methotrexate	B-Drug
-	O
induced	O
papular	B-ADE
eruption	I-ADE
following	O
treatment	O
of	O
psoriasis	O
.	O

-DOCSTART-	636

Myelodysplasia	B-ADE
terminating	O
in	O
acute	B-ADE
myeloid	I-ADE
leukemia	I-ADE
in	O
a	O
hairy	O
cell	O
leukemia	O
patient	O
treated	O
with	O
2-deoxycoformycin	B-Drug
.	O

-DOCSTART-	3324

Propranolol	B-Drug
-	O
related	O
bronchospasm	B-ADE
in	O
patients	O
without	O
history	O
of	O
asthma	O
.	O

-DOCSTART-	2362

On	O
day	O
7	O
of	O
linezolid	B-Drug
treatment	O
,	O
the	O
patient	O
developed	O
severe	B-ADE
pruritus	I-ADE
,	O
macular	B-ADE
rash	I-ADE
,	O
facial	B-ADE
edema	I-ADE
,	O
eosinophilia	B-ADE
,	O
marked	B-ADE
increase	I-ADE
in	I-ADE
serum	I-ADE
creatinine	I-ADE
level	I-ADE
,	O
and	O
mild	B-ADE
hepatitis	I-ADE
.	O

-DOCSTART-	3139

Ampicillin	B-Drug
-	O
associated	O
seizures	B-ADE
.	O

-DOCSTART-	273

Proconvulsive	B-ADE
tendency	O
of	O
imipenem	B-Drug
/	O
cilastatin	B-Drug
is	O
one	O
of	O
its	O
well	O
-	O
known	O
side	O
effects	O
.	O

-DOCSTART-	2493

Trimethoprim	B-Drug
-	I-Drug
sulfamethoxazole	I-Drug
-	O
induced	O
hepatotoxicity	B-ADE
in	O
a	O
pediatric	O
patient	O
.	O

-DOCSTART-	4093

The	O
chemotherapeutics	O
,	O
including	O
vincristine	B-Drug
,	O
actinomycin	B-Drug
D	I-Drug
,	O
and	O
epirubicin	B-Drug
in	O
case	O
1	O
and	O
vincristine	B-Drug
and	O
actinomycin	B-Drug
D	I-Drug
in	O
case	O
2	O
,	O
were	O
given	O
before	O
the	O
hepatotoxicity	B-ADE
developed	O
.	O

-DOCSTART-	1437

Hepatoxicity	B-ADE
is	O
a	O
rare	O
complication	O
of	O
SRL	B-Drug
therapy	O
and	O
may	O
be	O
connected	O
with	O
some	O
diagnostic	O
and/or	O
therapeutic	O
problems	O
.	O

-DOCSTART-	326

Hepatic	B-ADE
angiosarcoma	I-ADE
occurring	O
after	O
cyclophosphamide	B-Drug
therapy	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	2847

Rebound	B-ADE
hyperglycemia	I-ADE
was	O
observed	O
with	O
both	O
intermediate	O
(	O
neutral	O
protamine	B-Drug
hagedorn	I-Drug
)	O
and	O
long	O
-	O
acting	O
(	O
protamine	B-Drug
zinc	I-Drug
iletin	I-Drug
)	O
insulins	O
,	O
and	O
the	O
range	O
of	O
insulin	O
doses	O
at	O
which	O
the	O
disorder	O
developed	O
overlapped	O
previously	O
determined	O
therapeutic	O
doses	O
for	O
these	O
insulins	O
in	O
the	O
cat	O
.	O

-DOCSTART-	3525

His	O
symptoms	O
of	O
brain	O
stem	O
compression	O
were	O
alleviated	O
and	O
the	O
role	O
of	O
phenytoin	B-Drug
in	O
the	O
production	O
of	O
his	O
craniocervical	B-ADE
abnormality	I-ADE
is	O
discussed	O
.	O

-DOCSTART-	2079

Nodular	B-ADE
scleritis	I-ADE
following	O
alendronate	B-Drug
therapy	O
.	O

-DOCSTART-	1422

Symptoms	O
and	O
signs	O
of	O
augmentation	B-ADE
were	O
related	O
to	O
low	O
plasma	O
levodopa	B-Drug
levels	O
,	O
abating	O
75	O
minutes	O
after	O
oral	O
levodopa	B-Drug
administration	O
and	O
reappearing	O
after	O
3	O
hours	O
,	O
closely	O
mirroring	O
the	O
rapid	O
rise	O
and	O
fall	O
of	O
plasma	O
levodopa	O
concentration	O
.	O

-DOCSTART-	3648

CONCLUSIONS	O
:	O
Amphotericin	B-Drug
B	I-Drug
overdose	O
can	O
be	O
fatal	B-ADE
in	O
children	O
and	O
infants	O
.	O

-DOCSTART-	2263

However	O
,	O
acute	B-ADE
cardiomyopathy	I-ADE
and	O
pericarditis	B-ADE
secondary	O
to	O
methylphenidate	B-Drug
use	O
has	O
been	O
rarely	O
reported	O
.	O

-DOCSTART-	1380

Acute	B-ADE
dystonia	I-ADE
induced	O
by	O
lamivudine	B-Drug
.	O

-DOCSTART-	1708

Warfarin	B-Drug
-	O
induced	O
skin	B-ADE
necrosis	I-ADE
and	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
following	O
mitral	O
valve	O
replacement	O
for	O
marantic	O
endocarditis	O
.	O

-DOCSTART-	1558

Interferon	B-Drug
-	I-Drug
alpha	I-Drug
-	O
induced	O
hyperthyroidism	B-ADE
:	O
a	O
three	O
-	O
stage	O
evolution	O
from	O
silent	O
thyroiditis	O
towards	O
Graves	O
'	O
disease	O
.	O

-DOCSTART-	1091

Sweet	B-ADE
's	I-ADE
syndrome	I-ADE
is	O
an	O
acute	B-ADE
febrile	I-ADE
neutrophilic	I-ADE
dermatosis	I-ADE
that	O
is	O
a	O
known	O
complication	O
of	O
the	O
administration	O
of	O
filgrastim	B-Drug
,	O
a	O
drug	O
that	O
causes	O
increased	O
neutrophil	O
proliferation	O
and	O
differentiation	O
.	O

-DOCSTART-	2657

We	O
report	O
three	O
cases	O
of	O
amiodarone	B-Drug
-	O
induced	O
torsades	B-ADE
de	I-ADE
pointe	I-ADE
.	O

-DOCSTART-	2028

The	O
clinical	O
course	O
suggested	O
that	O
recombinant	B-Drug
alpha-2b	I-Drug
peginterferon	I-Drug
plus	O
ribavirin	B-Drug
provoked	O
type	B-ADE
1	I-ADE
diabetes	I-ADE
mellitus	I-ADE
,	O
therefore	O
,	O
in	O
patients	O
who	O
are	O
candidates	O
for	O
interferon	O
therapy	O
the	O
presence	O
of	O
pancreatic	O
autoantibodies	O
and	O
the	O
fasting	O
plasma	O
glucose	O
level	O
should	O
be	O
investigated	O
before	O
and	O
during	O
treatment	O
.	O

-DOCSTART-	1734

Leishmania	B-ADE
infantum	I-ADE
leishmaniasis	I-ADE
in	O
corticosteroid	B-Drug
--	O
treated	O
patients	O
.	O

-DOCSTART-	228

RESULTS	O
:	O
Replacing	O
valproate	B-Drug
with	O
lamotrigine	O
resulted	O
in	O
a	O
decrease	O
in	O
serum	B-ADE
testosterone	I-ADE
concentrations	O
in	O
all	O
3	O
women	O
.	O

-DOCSTART-	3700

The	O
mild	O
immunosuppression	O
that	O
occurs	O
with	O
methotrexate	B-Drug
therapy	O
probably	O
places	O
patients	O
with	O
rheumatoid	O
arthritis	O
at	O
added	O
risk	O
of	O
developing	O
lymphoproliferative	B-ADE
diseases	I-ADE
,	O
but	O
coincidence	O
can	O
not	O
be	O
excluded	O
.	O

-DOCSTART-	1771

Pulmonary	B-ADE
hypertension	I-ADE
during	O
lithium	B-Drug
therapy	O
:	O
clinical	O
case	O
study	O
.	O

-DOCSTART-	2311

Stupor	B-ADE
and	O
fast	O
activity	O
on	O
electroencephalography	O
in	O
a	O
child	O
treated	O
with	O
valproate	B-Drug
.	O

-DOCSTART-	48

The	O
association	O
between	O
heparin	B-Drug
and	O
priapism	B-ADE
is	O
often	O
recognized	O
;	O
abnormal	B-ADE
platelet	I-ADE
aggregation	I-ADE
could	O
play	O
a	O
role	O
in	O
the	O
pathogenesis	O
of	O
this	O
side	O
effect	O
.	O

-DOCSTART-	1328

Clinicians	O
should	O
be	O
vigilant	O
when	O
monitoring	O
for	O
cardiotoxicity	B-ADE
in	O
patients	O
receiving	O
pentamidine	B-Drug
throughout	O
the	O
duration	O
of	O
therapy	O
.	O

-DOCSTART-	1435

Prominent	O
positive	B-ADE
U	I-ADE
waves	I-ADE
appearing	O
with	O
high	O
-	O
dose	O
intravenous	O
phenylephrine	B-Drug
.	O

-DOCSTART-	3976

Thoracoscopic	O
biopsy	O
to	O
confirm	O
metastasis	O
revealed	O
instead	O
fibrotic	B-ADE
lesions	I-ADE
apparently	O
attributable	O
to	O
bleomycin	B-Drug
or	O
cyclophosphamide	B-Drug
.	O

-DOCSTART-	1633

DIAGNOSIS	O
:	O
Severe	O
temozolomide	B-Drug
-	O
induced	O
immunosuppression	B-ADE
,	O
exacerbated	O
by	O
corticosteroids	O
,	O
with	O
profound	O
T	B-ADE
-	I-ADE
cell	I-ADE
lymphocytopenia	I-ADE
and	O
simultaneous	O
opportunistic	O
infections	B-ADE
with	I-ADE
Pneumocystis	I-ADE
jiroveci	I-ADE
pneumonia	I-ADE
,	O
brain	B-ADE
abscess	I-ADE
with	I-ADE
Listeria	I-ADE
monocytogenes	I-ADE
,	O
and	O
cutaneous	B-ADE
Kaposi	I-ADE
's	I-ADE
sarcoma	I-ADE
.	O

-DOCSTART-	157

Bronchiolitis	B-ADE
obliterans	I-ADE
organising	I-ADE
pneumonia	I-ADE
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-Drug
.	O

-DOCSTART-	3551

Methemoglobinemia	B-ADE
:	O
an	O
occupational	O
hazard	O
of	O
phenylpropanolamine	B-Drug
production	O
.	O

-DOCSTART-	788

Tacrolimus	B-Drug
(	O
FK506	B-Drug
)	O
,	O
an	O
immunosuppressant	O
,	O
has	O
been	O
associated	O
with	O
mutism	B-ADE
in	O
adults	O
after	O
liver	O
transplant	O
.	O

-DOCSTART-	1240

Cerebral	B-ADE
edema	I-ADE
associated	O
with	O
Gliadel	B-Drug
wafers	O
:	O
two	O
case	O
studies	O
.	O

-DOCSTART-	350

This	O
sulfonamide	O
like	O
nephropathy	O
should	O
be	O
differentiated	O
from	O
acetazolamide	B-Drug
-	O
related	O
calcium	B-ADE
phosphate	I-ADE
nephrolithiasis	I-ADE
.	O

-DOCSTART-	1750

We	O
report	O
the	O
case	O
of	O
a	O
man	O
,	O
treated	O
with	O
mesalazine	B-Drug
for	O
Crohn	O
's	O
disease	O
who	O
developed	O
drug	O
-	O
induced	O
pericarditis	B-ADE
.	O

-DOCSTART-	252

Provocation	O
of	O
non	B-ADE
-	I-ADE
convulsive	I-ADE
status	I-ADE
epilepticus	I-ADE
by	O
tiagabine	B-Drug
in	O
three	O
adolescent	O
patients	O
.	O

-DOCSTART-	2226

Gemcitabine	B-Drug
is	O
a	O
known	O
risk	O
factor	O
for	O
hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
(	O
HUS	B-ADE
)	O
,	O
which	O
can	O
often	O
have	O
a	O
rapidly	O
fatal	O
clinical	O
course	O
despite	O
intervention	O
with	O
steroids	O
,	O
plasmapheresis	O
and	O
hemodialysis	O
.	O

-DOCSTART-	817

Despite	O
the	O
underlying	O
hepatitis	O
C	O
,	O
this	O
case	O
represents	O
renal	B-ADE
abnormalities	I-ADE
consistent	O
with	O
IFNalpha	B-Drug
therapy	O
for	O
CML	O
.	O

-DOCSTART-	1879

Metformin	B-Drug
-	O
associated	O
lactic	B-ADE
acidosis	I-ADE
(	O
MALA	O
)	O
is	O
a	O
serious	O
metabolic	O
complication	O
that	O
occurs	O
because	O
of	O
metformin	B-Drug
accumulation	O
in	O
patients	O
who	O
become	O
dehydrated	O
or	O
developed	O
acute	O
renal	O
failure	O
.	O

-DOCSTART-	3395

Neurological	B-ADE
side	I-ADE
effects	I-ADE
in	O
two	O
patients	O
receiving	O
gold	B-Drug
injections	O
for	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	4181

Pentazocine	B-Drug
-	O
induced	O
fibrous	B-ADE
myopathy	I-ADE
and	O
localized	O
neuropathy	B-ADE
.	O

-DOCSTART-	2590

Following	O
the	O
institution	O
of	O
intravenous	O
therapy	O
with	O
acyclovir	B-Drug
,	O
the	O
patient	O
developed	O
fever	B-ADE
,	O
hemoptysis	B-ADE
,	O
and	O
a	O
pleural	B-ADE
friction	I-ADE
rub	I-ADE
.	O

-DOCSTART-	614

The	O
epivodes	O
of	O
NMS	B-ADE
occured	O
under	O
treatment	O
with	O
clozapine	B-Drug
,	O
risperidone	B-Drug
,	O
and	O
amisulpride	B-Drug
.	O

-DOCSTART-	3782

The	O
ocular	B-ADE
motor	I-ADE
disturbances	I-ADE
are	O
probably	O
an	O
expression	O
of	O
regional	O
5-FU	B-Drug
neurotoxicity	B-ADE
primarily	O
affecting	O
the	O
brain	O
stem	O
.	O

-DOCSTART-	170

Central	B-ADE
nervous	I-ADE
system	I-ADE
manifestations	I-ADE
of	O
an	O
ibuprofen	B-Drug
overdose	O
reversed	O
by	O
naloxone	O
.	O

-DOCSTART-	301

Occult	O
quinine	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
.	O

-DOCSTART-	4048

A	O
rechallenge	O
,	O
performed	O
in	O
both	O
patients	O
,	O
confirmed	O
the	O
diagnosis	O
of	O
mesalamine	B-Drug
-	O
induced	O
pancreatitis	B-ADE
.	O

-DOCSTART-	3926

CONCLUSION	O
:	O
The	O
findings	O
in	O
these	O
two	O
patients	O
suggest	O
that	O
colchicine	B-Drug
may	O
delay	B-ADE
corneal	I-ADE
wound	I-ADE
healing	I-ADE
.	O

-DOCSTART-	2127

Both	O
the	O
longitudinal	B-ADE
melanonychia	I-ADE
and	O
the	O
multiple	B-ADE
skin	I-ADE
cancers	I-ADE
first	O
appeared	O
after	O
approximately	O
6	O
months	O
of	O
hydroxyurea	B-Drug
treatment	O
.	O

-DOCSTART-	1044

Agranulocytosis	B-ADE
induced	O
by	O
vancomycin	B-Drug
in	O
an	O
ESRD	O
patient	O
on	O
CAPD	O
.	O

-DOCSTART-	2577

Atenolol	B-Drug
-	O
induced	O
pseudolymphoma	B-ADE
.	O

-DOCSTART-	1540

Nonconvulsive	B-ADE
status	I-ADE
epilepticus	I-ADE
due	O
to	O
ifosfamide	B-Drug
.	O

-DOCSTART-	3068

Anaphylactoid	B-ADE
reaction	I-ADE
to	O
50	O
%	O
solution	O
of	O
dextrose	B-Drug
.	O

-DOCSTART-	2033

Persisent	B-ADE
ocular	I-ADE
hypertension	I-ADE
following	O
intravitreal	O
ranibizumab	B-Drug
.	O

-DOCSTART-	2937

Protamine	B-Drug
-	O
induced	O
fatal	B-ADE
anaphylaxis	I-ADE
.	O

-DOCSTART-	841

We	O
describe	O
a	O
premenopausal	O
woman	O
who	O
,	O
while	O
having	O
tamoxifen	B-Drug
due	O
to	O
a	O
diagnosis	O
of	O
in	O
situ	O
ductal	O
carcinoma	O
,	O
developed	O
endometriosis	B-ADE
requiring	O
surgery	O
.	O

-DOCSTART-	382

Leflunomide	B-Drug
-	O
associated	O
weight	B-ADE
loss	I-ADE
in	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	2911

Acute	B-ADE
myocardial	I-ADE
necrosis	I-ADE
during	O
administration	O
of	O
amsacrine	B-Drug
.	O

-DOCSTART-	2444

Zidovudine	B-Drug
induced	O
pure	B-ADE
red	I-ADE
cell	I-ADE
aplasia	I-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	174

Flecainide	B-Drug
-	O
associated	O
pneumonitis	B-ADE
with	O
acute	B-ADE
respiratory	I-ADE
failure	I-ADE
in	O
a	O
patient	O
with	O
the	O
LEOPARD	O
syndrome	O
.	O

-DOCSTART-	1899

Rifampin	B-Drug
(	O
RFP	B-Drug
)	O
increases	O
hepatic	O
microsomal	O
enzyme	O
activity	O
,	O
and	O
there	O
are	O
case	O
reports	O
of	O
RFP	O
-	O
induced	O
hypothyroidism	B-ADE
,	O
all	O
associated	O
with	O
Hashimoto	B-ADE
's	I-ADE
thyroiditis	I-ADE
.	O

-DOCSTART-	3413

Anterior	B-ADE
ischemic	I-ADE
optic	I-ADE
neuropathy	I-ADE
secondary	O
to	O
interferon	B-Drug
alfa	I-Drug
.	O

-DOCSTART-	2759

Allopurinol	B-Drug
hypersensitivity	B-ADE
.	O

-DOCSTART-	421

According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
the	O
relationship	O
of	O
gemcitabine	B-Drug
treatment	O
with	O
cutaneous	B-ADE
eruption	I-ADE
in	O
our	O
patient	O
is	O
possible	O
.	O

-DOCSTART-	1981

New	O
onset	O
of	O
CD	B-ADE
may	O
be	O
considered	O
as	O
an	O
immune	B-ADE
-	I-ADE
mediated	I-ADE
injury	I-ADE
induced	O
by	O
etanercept	B-Drug
.	O

-DOCSTART-	2574

Phenobarbital	B-Drug
hepatotoxicity	B-ADE
in	O
an	O
8-month	O
-	O
old	O
infant	O
.	O

-DOCSTART-	3330

Interstitial	B-ADE
fibrosis	I-ADE
of	I-ADE
the	I-ADE
lung	I-ADE
is	O
a	O
potential	O
complication	O
of	O
methotrexate	B-Drug
therapy	O
for	O
psoriasis	O
.	O

-DOCSTART-	1144

This	O
case	O
describes	O
fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
in	O
a	O
patient	O
taking	O
disulfiram	B-Drug
with	O
no	O
previous	O
liver	O
disease	O
and	O
report	O
of	O
being	O
compliant	O
with	O
alcohol	O
abstinence	O
.	O

-DOCSTART-	1050

Development	O
of	O
Peyronie	B-ADE
's	I-ADE
disease	I-ADE
during	O
long	O
-	O
term	O
colchicine	B-Drug
treatment	O
.	O

-DOCSTART-	525

INH	B-Drug
,	O
which	O
is	O
a	O
leading	O
cause	O
of	O
drug	B-ADE
eruptions	I-ADE
in	O
the	O
above	O
group	O
of	O
drugs	O
was	O
withdrawn	O
.	O

-DOCSTART-	618

This	O
case	O
extends	O
the	O
spectrum	O
of	O
fludarabine	B-Drug
pulmonary	B-ADE
toxicity	I-ADE
to	O
include	O
pulmonary	B-ADE
nodules	I-ADE
.	O

-DOCSTART-	3293

Acne	B-ADE
provoked	O
by	O
gold	B-Drug
seems	O
not	O
to	O
have	O
been	O
described	O
elsewhere	O
.	O

-DOCSTART-	3150

Chlorpropamide	B-Drug
-	O
induced	O
hemolytic	B-ADE
anemia	I-ADE
.	O

-DOCSTART-	2663

This	O
article	O
reports	O
the	O
occurrence	O
of	O
rifampin	B-Drug
-	O
associated	O
thrombocytopenia	B-ADE
in	O
an	O
indigent	O
patient	O
after	O
a	O
four	O
-	O
month	O
lapse	O
in	O
therapy	O
for	O
pulmonary	O
tuberculosis	O
.	O

-DOCSTART-	3644

The	O
exophthalmos	B-ADE
improved	O
dramatically	O
within	O
72	O
hours	O
of	O
the	O
withdrawal	O
of	O
lithium	B-Drug
.	O

-DOCSTART-	3813

CASE	O
:	O
We	O
report	O
a	O
case	O
of	O
a	O
woman	O
with	O
severe	O
human	B-Drug
insulin	I-Drug
-	O
induced	O
lipoatrophy	B-ADE
who	O
has	O
been	O
treated	O
exclusively	O
with	O
recombinant	B-Drug
DNA	I-Drug
human	I-Drug
insulin	I-Drug
since	O
the	O
onset	O
of	O
IDDM	O
.	O

-DOCSTART-	1172

We	O
conclude	O
peripheral	B-ADE
neuropathy	I-ADE
with	O
5-FU	B-Drug
is	O
rare	O
.	O

-DOCSTART-	1814

However	O
,	O
a	O
new	O
episode	O
of	O
neutropenia	B-ADE
,	O
with	O
a	O
WBC	O
count	O
of	O
2.8	O
x	O
10(3)/mm3	O
and	O
ANC	O
of	O
0.448	O
x	O
10(3)/mm3	O
,	O
occurred	O
11	O
days	O
after	O
teicoplanin	B-Drug
initiation	O
.	O

-DOCSTART-	3937

We	O
postulate	O
that	O
cyclosporin	B-Drug
,	O
possibly	O
together	O
with	O
ganciclovir	B-Drug
,	O
can	O
produce	O
transient	B-ADE
brain	I-ADE
stem	I-ADE
or	I-ADE
neuromuscular	I-ADE
dysfunction	I-ADE
with	O
eye	B-ADE
movement	I-ADE
abnormality	I-ADE
in	O
occasional	O
patients	O
.	O

-DOCSTART-	362

Clofazimine	B-Drug
enteropathy	B-ADE
in	O
a	O
pediatric	O
bone	O
marrow	O
transplant	O
recipient	O
.	O

-DOCSTART-	931

Neutrophilic	B-ADE
eccrine	I-ADE
hidradenitis	I-ADE
mimicking	O
cutaneous	O
vasculitis	O
in	O
a	O
lupus	O
patient	O
:	O
a	O
complication	O
of	O
cyclophosphamide	B-Drug
.	O

-DOCSTART-	1894

PET	O
scintigraphy	O
of	O
etoposide	B-Drug
-	O
induced	O
pulmonary	B-ADE
toxicity	I-ADE
.	O

-DOCSTART-	497

RESULTS	O
:	O
Quetiapine	B-Drug
was	O
associated	O
with	O
leucopenia	B-ADE
in	O
two	O
patients	O
and	O
clinically	O
apparent	O
agranulocytosis	B-ADE
in	O
one	O
patient	O
.	O

-DOCSTART-	3591

Generalized	B-ADE
argyria	I-ADE
after	O
habitual	O
use	O
of	O
AgNO3	B-Drug
.	O

-DOCSTART-	2685

Paraplegia	B-ADE
following	O
intrathecal	O
cytosine	B-Drug
arabinoside	I-Drug
.	O

-DOCSTART-	88

Losartan	B-Drug
-	O
induced	O
angioedema	B-ADE
.	O

-DOCSTART-	481

After	O
extensive	O
neurological	O
'	O
work	O
up	O
'	O
,	O
we	O
realized	O
that	O
the	O
anisocoria	B-ADE
was	O
related	O
to	O
the	O
transdermal	O
scopolamine	B-Drug
patch	O
that	O
we	O
had	O
prescribed	O
for	O
weaning	O
off	O
the	O
opioid	O
.	O

-DOCSTART-	3338

After	O
ruling	O
out	O
a	O
hydrotelluric	O
source	O
of	O
fluorine	O
,	O
the	O
patient	O
's	O
fluorosis	B-ADE
was	O
linked	O
to	O
chronic	O
use	O
of	O
niflumic	B-Drug
acid	I-Drug
,	O
following	O
the	O
publication	O
in	O
1978	O
of	O
the	O
2	O
previously	O
reported	O
cases	O
affected	O
by	O
this	O
drug	O
.	O

-DOCSTART-	1471

ARDS	B-ADE
has	O
been	O
associated	O
with	O
the	O
administration	O
of	O
other	O
monoclonal	O
antibodies	O
,	O
such	O
as	O
infliximab	B-Drug
,	O
gemtuzumab	B-Drug
ozogamicin	I-Drug
,	O
and	O
OKT3	B-Drug
and	O
is	O
believed	O
to	O
be	O
directly	O
mediated	O
by	O
release	O
of	O
proinflammatory	O
cytokines	O
.	O

-DOCSTART-	2628

The	O
authors	O
suggest	O
that	O
fluoxetine	B-Drug
-	O
induced	O
akathisia	B-ADE
may	O
be	O
caused	O
by	O
serotonergically	O
mediated	O
inhibition	O
of	O
dopaminergic	O
neurotransmission	O
and	O
that	O
the	O
pathophysiology	O
of	O
fluoxetine	B-Drug
-	O
induced	O
akathisia	B-ADE
and	O
tricyclic	O
antidepressant	O
-	O
induced	O
"	O
jitteriness	O
"	O
may	O
be	O
identical	O
.	O

-DOCSTART-	912

Carbamyl	O
phosphate	O
synthetase-1	O
deficiency	O
discovered	O
after	O
valproic	B-Drug
acid	I-Drug
-	O
induced	O
coma	B-ADE
.	O

-DOCSTART-	632

Epsilon	B-Drug
-	I-Drug
aminocaproic	I-Drug
acid	I-Drug
and	O
renal	B-ADE
complications	I-ADE
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	3035

Hyperglycemia	B-ADE
and	O
diabetic	B-ADE
coma	I-ADE
:	O
possible	O
relationship	O
to	O
diuretic	O
-	O
propranolol	B-Drug
therapy	O
.	O

-DOCSTART-	1101

Trichiasis	B-ADE
associated	O
with	O
prostaglandin	B-Drug
analog	O
use	O
.	O

-DOCSTART-	3824

Sarcoma	B-ADE
complicating	O
therapy	O
with	O
cyclophosphamide	B-Drug
.	O

-DOCSTART-	808

Disseminated	B-ADE
cellulitic	I-ADE
cryptococcosis	I-ADE
in	O
the	O
setting	O
of	O
prednisone	B-Drug
monotherapy	O
for	O
pemphigus	O
vulgaris	O
.	O

-DOCSTART-	2325

DISCUSSION	O
:	O
The	O
Naranjo	O
probability	O
scale	O
indicated	O
a	O
probable	O
relationship	O
between	O
sertraline	B-Drug
treatment	O
and	O
the	O
onset	O
of	O
rhabdomyolysis	B-ADE
.	O

-DOCSTART-	10

This	O
case	O
suggests	O
that	O
BH	B-Drug
-	I-Drug
AC	I-Drug
,	O
a	O
derivative	O
of	O
cytosine	O
arabinoside	O
(	O
1-beta	O
-	O
D	O
-	O
arabinofuranosylcytosine	O
)	O
could	O
be	O
a	O
cause	O
of	O
reversible	O
encephalopathy	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	4128

Cardiac	B-ADE
arrest	I-ADE
associated	O
with	O
sulprostone	B-Drug
use	O
during	O
caesarean	O
section	O
.	O

-DOCSTART-	2593

Quinine	B-Drug
-	O
induced	O
hearing	B-ADE
loss	I-ADE
.	O

-DOCSTART-	114

The	O
second	O
is	O
a	O
29-year	O
-	O
old	O
man	O
with	O
CD	O
in	O
whom	O
nodular	B-ADE
sclerosing	I-ADE
Hodgkin	I-ADE
's	I-ADE
lymphoma	I-ADE
was	O
diagnosed	O
3	O
weeks	O
after	O
infusion	O
with	O
infliximab	B-Drug
.	O

-DOCSTART-	392

We	O
report	O
the	O
first	O
case	O
of	O
polymorphic	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
with	O
normal	O
QT	O
interval	O
associated	O
with	O
the	O
oral	O
use	O
of	O
levofloxacin	B-Drug
in	O
the	O
absence	O
of	O
other	O
etiologies	O
known	O
to	O
cause	O
these	O
arrhythmias	O
.	O

-DOCSTART-	2282

INTRODUCTION	O
:	O
In	O
resource	O
limited	O
settings	O
patients	O
on	O
antiretroviral	O
treatment	O
who	O
develop	O
stavudine	B-Drug
induced	O
hyperlactatemia	B-ADE
are	O
often	O
switched	O
to	O
zidovudine	O
on	O
the	O
basis	O
of	O
published	O
studies	O
that	O
demonstrate	O
that	O
this	O
agent	O
can	O
be	O
a	O
safe	O
alternative	O
.	O

-DOCSTART-	253

The	O
events	O
of	O
non	B-ADE
-	I-ADE
convulsive	I-ADE
status	I-ADE
epilepticus	I-ADE
subsided	O
following	O
reduction	O
in	O
tiagabine	B-Drug
dosages	O
.	O

-DOCSTART-	247

Propafenone	B-Drug
-	O
induced	O
ataxia	B-ADE
:	O
report	O
of	O
three	O
cases	O
.	O

-DOCSTART-	3482

We	O
present	O
a	O
case	O
in	O
which	O
dipyridamole	B-Drug
induced	O
high	B-ADE
-	I-ADE
grade	I-ADE
atrioventricular	I-ADE
(	I-ADE
AV	I-ADE
)	I-ADE
block	I-ADE
that	O
responded	O
promptly	O
to	O
intravenous	O
aminophylline	O
but	O
not	O
to	O
atropine	O
.	O

-DOCSTART-	15

Although	O
the	O
two	O
local	O
anesthetics	O
usually	O
do	O
not	O
cause	O
methemoglobinemia	O
,	O
we	O
suspect	O
that	O
the	O
displacement	O
of	O
lidocaine	B-Drug
from	O
protein	O
binding	O
by	O
bupivacaine	O
,	O
in	O
combination	O
with	O
metabolic	O
acidosis	O
and	O
treatment	O
with	O
other	O
oxidants	O
,	O
was	O
the	O
reason	O
for	O
the	O
development	O
of	O
methemoglobinemia	B-ADE
.	O

-DOCSTART-	3846

Hepatobiliary	B-ADE
disorders	I-ADE
associated	O
with	O
orally	O
administered	O
terbinafine	B-Drug
have	O
rarely	O
been	O
reported	O
.	O

-DOCSTART-	4270

Eosinophilia	B-ADE
has	O
been	O
encountered	O
from	O
0.2	O
to	O
61.7	O
%	O
in	O
clozapine	B-Drug
-	O
treated	O
patients	O
,	O
mostly	O
with	O
a	O
transient	O
course	O
and	O
spontaneous	O
remission	O
.	O

-DOCSTART-	713

Anaphylaxis	B-ADE
to	O
cisplatin	B-Drug
following	O
nine	O
previous	O
uncomplicated	O
cycles	O
.	O

-DOCSTART-	2209

Corneal	B-ADE
endothelial	I-ADE
dysfunction	I-ADE
associated	O
with	O
amantadine	B-Drug
toxicity	O
.	O

-DOCSTART-	387

Neurotoxicity	B-ADE
of	O
valacyclovir	B-Drug
in	O
peritoneal	O
dialysis	O
:	O
a	O
pharmacokinetic	O
study	O
.	O

-DOCSTART-	4085

BACKGROUND	O
:	O
Hypersensitivity	B-ADE
reactions	I-ADE
to	O
cyclosporine	B-Drug
are	O
rare	O
.	O

-DOCSTART-	3361

Seven	O
patients	O
with	O
hematologic	O
malignancies	O
who	O
were	O
treated	O
with	O
miconazole	B-Drug
for	O
either	O
suspected	O
or	O
proven	O
fungal	O
infections	O
developed	O
eight	O
episodes	O
of	O
major	O
adverse	O
cardiorespiratory	B-ADE
and	I-ADE
anaphylactic	I-ADE
reactions	I-ADE
.	O

-DOCSTART-	3835

The	O
delayed	O
encephalopathy	B-ADE
developed	O
9	O
and	O
22	O
months	O
respectively	O
after	O
the	O
first	O
dose	O
of	O
intrathecal	O
methotrexate	B-Drug
.	O

-DOCSTART-	2827

Gold	B-Drug
-	O
induced	O
aplastic	B-ADE
anemia	I-ADE
.	O

-DOCSTART-	4242

Disseminated	O
muscular	O
cysticercosis	O
with	O
myositis	B-ADE
induced	O
by	O
praziquantel	B-Drug
therapy	O
.	O

-DOCSTART-	3149

Acute	B-ADE
intravascular	I-ADE
hemolysis	I-ADE
developed	O
when	O
a	O
diabetic	O
patient	O
,	O
previously	O
treated	O
with	O
glyburide	B-Drug
,	O
was	O
started	O
on	O
another	O
oral	O
sulfonylurea	O
drug	O
,	O
chlorpropamide	B-Drug
.	O

-DOCSTART-	664

CONCLUSION	O
:	O
There	O
are	O
only	O
a	O
few	O
confirmed	O
cases	O
of	O
gemcitabine	B-Drug
-	O
associated	O
HUS	B-ADE
despite	O
the	O
widespread	O
use	O
of	O
the	O
drug	O
.	O

-DOCSTART-	2579

Tardive	B-ADE
dyskinesia	I-ADE
induced	O
by	O
sulpiride	B-Drug
.	O

-DOCSTART-	4267

Reversible	O
nonthrombocytopenic	B-ADE
palpable	I-ADE
purpura	I-ADE
associated	O
with	O
metoclopramide	B-Drug
.	O

-DOCSTART-	2786

Hepatotoxicity	B-ADE
associated	O
with	O
choline	B-Drug
magnesium	I-Drug
trisalicylate	I-Drug
:	O
case	O
report	O
and	O
review	O
of	O
salicylate	B-Drug
-	O
induced	O
hepatotoxicity	B-ADE
.	O

-DOCSTART-	377

OBJECTIVES	O
:	O
The	O
authors	O
described	O
a	O
case	O
of	O
Hashimoto	B-ADE
's	I-ADE
disease	I-ADE
during	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
(	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
)	O
treatment	O
for	O
chronic	O
viral	O
C	O
hepatitis	O
in	O
a	O
patient	O
with	O
the	O
specific	O
genetic	O
susceptibility	O
associated	O
with	O
the	O
thyroid	O
disease	O
.	O

-DOCSTART-	3629

No	O
explanation	O
for	O
this	O
delay	O
was	O
found	O
,	O
other	O
than	O
the	O
possibility	O
that	O
magnesium	B-Drug
sulfate	I-Drug
treatment	O
impeded	B-ADE
lactogenesis	I-ADE
.	O

-DOCSTART-	2114

Stuttering	B-ADE
priapism	I-ADE
complicating	O
warfarin	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
protein	O
C	O
deficiency	O
.	O

-DOCSTART-	1976

The	O
authors	O
describe	O
pericardial	B-ADE
hemorrhage	I-ADE
,	O
which	O
is	O
related	O
to	O
the	O
use	O
of	O
low	O
-	O
dose	O
acetylsalicylic	B-Drug
acid	I-Drug
in	O
a	O
patient	O
with	O
essential	O
thrombocythemia	O
.	O

-DOCSTART-	1817

Cutaneous	B-ADE
ulceration	I-ADE
:	O
an	O
unusual	O
complication	O
of	O
intravenous	O
pentamidine	B-Drug
therapy	O
.	O

-DOCSTART-	2949

We	O
presented	O
a	O
patient	O
with	O
status	O
asthmaticus	O
treated	O
with	O
a	O
combination	O
of	O
theophylline	B-Drug
and	O
prednisone	B-Drug
who	O
developed	O
a	O
perforated	B-ADE
gastric	I-ADE
ulcer	I-ADE
.	O

-DOCSTART-	2034

Methylphenidate	B-Drug
and	O
dextroamphetamine	B-Drug
-	O
induced	O
peripheral	B-ADE
vasculopathy	I-ADE
.	O

-DOCSTART-	329

On	O
the	O
fifth	O
day	O
after	O
administration	O
of	O
a	O
high	O
dose	O
of	O
ARA	B-Drug
-	I-Drug
C	I-Drug
(	O
2	O
g	O
/	O
m2	O
intravenously	O
every	O
12	O
hours	O
)	O
,	O
she	O
developed	O
bullous	B-ADE
lesions	I-ADE
on	I-ADE
the	I-ADE
hands	I-ADE
and	I-ADE
soles	I-ADE
that	I-ADE
disseminated	I-ADE
,	I-ADE
evolving	I-ADE
to	I-ADE
necrosis	I-ADE
,	O
sepsis	B-ADE
,	O
and	O
death	B-ADE
on	O
the	O
22nd	O
day	O
.	O

-DOCSTART-	3420

Evidence	O
is	O
shown	O
in	O
this	O
report	O
that	O
adenosine	B-Drug
was	O
associated	O
with	O
dangerous	O
worsening	O
of	O
arrhythmia	B-ADE
in	O
patients	O
with	O
atrial	O
flutter	O
.	O

-DOCSTART-	118

Hydroxyurea	B-Drug
(	O
HU	O
)	O
and	O
sodium	B-Drug
phenylbutyrate	I-Drug
(	O
SPB	O
)	O
have	O
been	O
shown	O
to	O
increase	B-ADE
fetal	I-ADE
hemoglobin	I-ADE
(	O
Hb	O
F	O
)	O
levels	O
in	O
patients	O
with	O
thalassemia	O
intermedia	O
.	O

-DOCSTART-	3209

Pure	B-ADE
red	I-ADE
cell	I-ADE
aplasia	I-ADE
associated	O
with	O
fenoprofen	B-Drug
.	O

-DOCSTART-	1717

We	O
report	O
a	O
case	O
of	O
acute	B-ADE
generalized	I-ADE
exanthematous	I-ADE
pustulosis	I-ADE
(	O
AGEP	B-ADE
)	O
in	O
a	O
50-year	O
-	O
old	O
woman	O
that	O
was	O
attributed	O
to	O
the	O
ingestion	O
of	O
nimesulide	B-Drug
.	O

-DOCSTART-	2693

Sulfasalazine	B-Drug
has	O
been	O
associated	O
with	O
bronchopulmonary	B-ADE
complications	I-ADE
of	I-ADE
inflammatory	I-ADE
bowel	I-ADE
disease	I-ADE
(	O
IBD	B-ADE
)	O
in	O
adults	O
.	O

-DOCSTART-	656

The	O
second	O
was	O
an	O
82-year	O
-	O
old	O
man	O
receiving	O
ticlopidine	B-Drug
for	O
2	O
years	O
when	O
,	O
during	O
a	O
febrile	O
episode	O
,	O
he	O
was	O
found	O
neutropenic	B-ADE
with	O
marrow	B-ADE
aplasia	I-ADE
.	O

-DOCSTART-	819

The	O
renal	O
biopsy	O
showed	O
focal	B-ADE
segmental	I-ADE
glomerulosclerosis	I-ADE
,	O
which	O
has	O
only	O
been	O
previously	O
reported	O
in	O
two	O
cases	O
of	O
CML	O
treated	O
with	O
IFNalpha	B-Drug
.	O

-DOCSTART-	3478

Well	O
-	O
differentiated	O
endometrial	B-ADE
adenocarcinoma	I-ADE
of	I-ADE
the	I-ADE
secretory	I-ADE
type	I-ADE
(	O
FIGO	O
Grade	O
1	O
)	O
with	O
minimal	O
myometrial	O
invasion	O
occurred	O
in	O
a	O
postmenopausal	O
patient	O
on	O
tamoxifen	B-Drug
therapy	O
5	O
years	O
after	O
mastectomy	O
for	O
breast	O
carcinoma	O
.	O

-DOCSTART-	2526

Disulfiram	B-Drug
-	O
induced	O
hepatitis	B-ADE
.	O

-DOCSTART-	1269

Zoledronic	B-Drug
acid	I-Drug
-	O
induced	O
severe	B-ADE
hypocalcaemia	I-ADE
in	O
a	O
prostate	O
cancer	O
patient	O
with	O
extensive	O
osteoblastic	O
bone	O
metastases	O
.	O

-DOCSTART-	952

The	O
most	O
commonly	O
recognized	O
toxic	O
effect	O
of	O
ethambutol	B-Drug
is	O
optic	B-ADE
neuropathy	I-ADE
,	O
which	O
generally	O
is	O
considered	O
uncommon	O
and	O
reversible	O
in	O
medical	O
literature	O
.	O

-DOCSTART-	1022

Here	O
we	O
report	O
ramipril	B-Drug
-	O
induced	O
cutaneous	B-ADE
vasculitis	I-ADE
in	O
a	O
patient	O
who	O
required	O
steroid	O
therapy	O
to	O
control	O
it	O
.	O

-DOCSTART-	1741

Visual	B-ADE
hallucinations	I-ADE
after	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
in	O
vascular	O
age	O
-	O
related	O
macular	O
degeneration	O
.	O

-DOCSTART-	1742

A	O
case	O
of	O
metoclopramide	B-Drug
-	O
induced	O
oculogyric	B-ADE
crisis	I-ADE
in	O
a	O
16-year	O
-	O
old	O
girl	O
with	O
cystic	O
fibrosis	O
.	O

-DOCSTART-	3872

The	O
use	O
of	O
beclomethasone	B-Drug
diproprionate	I-Drug
inhaler	O
complicated	O
by	O
the	O
development	O
of	O
an	O
eosinophilic	B-ADE
pneumonia	I-ADE
reaction	I-ADE
.	O

-DOCSTART-	2129

Hydroxyurea	B-Drug
associated	O
with	O
concomitant	O
occurrence	O
of	O
diffuse	B-ADE
longitudinal	I-ADE
melanonychia	I-ADE
and	O
multiple	B-ADE
squamous	I-ADE
cell	I-ADE
carcinomas	I-ADE
in	O
an	O
elderly	O
subject	O
.	O

-DOCSTART-	2960

Review	O
of	O
this	O
and	O
previously	O
reported	O
cases	O
indicates	O
the	O
need	O
for	O
early	O
diagnosis	O
of	O
amiodarone	B-Drug
pneumonitis	B-ADE
,	O
immediate	O
withdrawal	O
of	O
amiodarone	O
,	O
and	O
prompt	O
but	O
continued	O
steroid	O
therapy	O
to	O
ensure	O
full	O
recovery	O
.	O

-DOCSTART-	483

De	B-ADE
novo	I-ADE
absence	I-ADE
status	I-ADE
of	O
late	O
onset	O
following	O
withdrawal	O
of	O
lorazepam	B-Drug
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3117

Intravenous	O
diazepam	B-Drug
exacerbated	O
the	O
seizures	B-ADE
.	O

-DOCSTART-	596

The	O
capacity	O
of	O
zuclopenthixol	B-Drug
to	O
induce	O
priapism	B-ADE
is	O
thought	O
to	O
be	O
due	O
to	O
its	O
antagonist	O
activity	O
on	O
alpha	O
-	O
adrenergic	O
receptors	O
.	O

-DOCSTART-	545

In	O
this	O
case	O
,	O
interferon	B-Drug
alpha	I-Drug
induced	O
polymyositis	B-ADE
and	O
cardiomyopathy	B-ADE
is	O
diagnosed	O
in	O
a	O
33-yr	O
-	O
old	O
male	O
patient	O
with	O
history	O
of	O
chronic	O
hepatitis	O
B	O
.	O

-DOCSTART-	405

However	O
,	O
adenosine	B-Drug
shortens	O
the	O
antegrade	O
refractoriness	O
of	O
accessory	O
atrioventricular	O
connections	O
and	O
may	O
cause	O
acceleration	B-ADE
of	I-ADE
the	I-ADE
ventricular	I-ADE
rate	I-ADE
during	O
atrial	O
fibrillation	O
.	O

-DOCSTART-	1227

CONCLUSIONS	O
:	O
Symptoms	O
and	O
pathologic	O
changes	O
of	O
colitis	B-ADE
are	O
associated	O
with	O
exposure	O
to	O
rofecoxib	B-Drug
.	O

-DOCSTART-	814

Infliximab	B-Drug
therapy	O
may	O
cause	O
a	O
lupus	B-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
that	O
is	O
reversible	O
upon	O
discontinuing	O
this	O
agent	O
.	O

-DOCSTART-	2473

Pulmonary	B-ADE
oedema	I-ADE
after	O
hexoprenaline	B-Drug
administration	O
in	O
preterm	O
labour	O
.	O

-DOCSTART-	3463

Case	O
study	O
:	O
a	O
modified	O
topical	O
treatment	O
regimen	O
for	O
sodium	O
warfarin	B-Drug
-	O
induced	O
necrotizing	B-ADE
fasciitis	I-ADE
.	O

-DOCSTART-	2808

Reye	B-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
following	O
treatment	O
with	O
the	O
pantothenic	O
acid	O
antagonist	O
,	O
calcium	B-Drug
hopantenate	I-Drug
.	O

-DOCSTART-	2281

DISCUSSION	O
:	O
This	O
case	O
shows	O
that	O
switching	O
to	O
zidovudine	B-Drug
potentially	O
can	O
lead	O
to	O
a	O
hyperlactatemia	B-ADE
relapse	I-ADE
.	O

-DOCSTART-	1268

Four	O
days	O
after	O
intravenous	O
Zoledronic	B-Drug
acid	I-Drug
,	O
the	O
patient	O
presented	O
to	O
emergency	O
room	O
with	O
complaints	O
of	O
carpopedal	B-ADE
spasm	I-ADE
and	O
bronchospasm	B-ADE
.	O

-DOCSTART-	3618

A	O
high	O
dose	O
of	O
cotrimoxazole	B-Drug
induced	O
hyperkalaemia	B-ADE
with	O
the	O
elevation	B-ADE
of	I-ADE
serum	I-ADE
creatinine	I-ADE
and	I-ADE
blood	I-ADE
urea	I-ADE
,	O
and	O
increased	B-ADE
urinary	I-ADE
N	I-ADE
-	I-ADE
acetyl	I-ADE
glucosaminase	I-ADE
after	O
several	O
days	O
of	O
the	O
drug	O
administration	O
in	O
these	O
patients	O
;	O
one	B-ADE
patient	I-ADE
became	I-ADE
unconscious	I-ADE
.	O

-DOCSTART-	348

Presented	O
is	O
a	O
case	O
of	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
induced	O
by	O
acetazolamide	B-Drug
therapy	O
for	O
glaucoma	O
.	O

-DOCSTART-	2082

In	O
addition	O
,	O
there	O
is	O
a	O
report	O
on	O
prolonged	B-ADE
ECT	I-ADE
seizure	I-ADE
related	O
to	O
ciprofloxacin	B-Drug
,	O
which	O
has	O
an	O
epileptogenic	O
property	O
with	O
a	O
similar	O
action	O
to	O
beta	O
-	O
lactam	O
antibiotics	O
.	O

-DOCSTART-	1060

Anticonvulsant	B-ADE
hypersensitivity	I-ADE
syndrome	I-ADE
associated	O
with	O
Bellamine	B-Drug
S	I-Drug
,	O
a	O
therapy	O
for	O
menopausal	O
symptoms	O
.	O

-DOCSTART-	582

Life	O
-	O
threatening	O
anaphylactoid	B-ADE
reaction	I-ADE
to	O
amifostine	B-Drug
used	O
with	O
concurrent	O
chemoradiotherapy	O
for	O
nasopharyngeal	O
cancer	O
in	O
a	O
patient	O
with	O
dermatomyositis	O
:	O
a	O
case	O
report	O
with	O
literature	O
review	O
.	O

-DOCSTART-	3135

Tamoxifen	B-Drug
retinopathy	B-ADE
.	O

-DOCSTART-	1451

Thyroid	B-ADE
dysfunction	I-ADE
has	O
been	O
reported	O
in	O
patients	O
with	O
malignant	O
disease	O
treated	O
with	O
recombinant	B-Drug
alpha	I-Drug
interferon	I-Drug
.	O

-DOCSTART-	471

Cicatricial	B-ADE
entropion	I-ADE
associated	O
with	O
chronic	O
dipivefrin	B-Drug
application	O
.	O

-DOCSTART-	1752

CASE	O
REPORT	O
:	O
We	O
report	O
a	O
case	O
of	O
acute	B-ADE
severe	I-ADE
hepatitis	I-ADE
resulting	O
from	O
erlotinib	B-Drug
monotherapy	O
in	O
a	O
patient	O
with	O
locally	O
advanced	O
pancreatic	O
cancer	O
.	O

-DOCSTART-	2665

Withdrawal	B-ADE
emergent	I-ADE
syndrome	I-ADE
in	O
an	O
infant	O
associated	O
with	O
maternal	O
haloperidol	B-Drug
therapy	O
.	O

-DOCSTART-	1730

The	O
use	O
of	O
cyclosporin	B-Drug
has	O
been	O
associated	O
with	O
the	O
development	O
of	O
cholelithiasis	B-ADE
in	O
transplant	O
recipients	O
.	O

-DOCSTART-	125

After	O
abstinence	O
from	O
oolong	B-Drug
tea	I-Drug
his	O
delirium	B-ADE
resolved	O
.	O

-DOCSTART-	2081

Two	O
weeks	O
following	O
rechallenge	O
with	O
alendronate	B-Drug
sodium	I-Drug
resulted	O
in	O
recurrence	O
of	O
his	O
scleritis	B-ADE
.	O

-DOCSTART-	1823

Ezetimibe	B-Drug
-	O
induced	O
acute	B-ADE
pancreatitis	I-ADE
.	O

-DOCSTART-	2843

With	O
the	O
increasing	O
use	O
of	O
Cyclosporine	B-Drug
A	I-Drug
in	O
transplant	O
patients	O
,	O
the	O
incidence	O
of	O
herpes	B-ADE
esophagitis	I-ADE
may	O
increase	O
.	O

-DOCSTART-	1713

CONCLUSION	O
:	O
These	O
cases	O
suggest	O
that	O
moxifloxacin	B-Drug
may	O
interfere	O
with	O
the	O
healing	O
of	O
corneal	B-ADE
ulcers	I-ADE
.	O

-DOCSTART-	637

To	O
the	O
best	O
of	O
our	O
knowledge	O
only	O
two	O
previous	O
cases	O
of	O
AML	B-ADE
have	O
been	O
linked	O
to	O
treatment	O
of	O
HCL	O
with	O
purine	O
analogs	O
,	O
both	O
with	O
2-chlorodeoxyadenosine	B-Drug
.	O

-DOCSTART-	1311

The	O
mean	O
time	O
from	O
starting	O
MMF	B-Drug
to	O
the	O
development	O
of	O
neutropenia	B-ADE
was	O
4	O
months	O
.	O

-DOCSTART-	3939

The	O
possible	O
effects	O
of	O
tamoxifen	O
upon	O
the	O
uterus	O
are	O
discussed	O
in	O
this	O
article	O
,	O
in	O
view	O
of	O
reports	O
of	O
tamoxifen	B-Drug
associated	O
with	O
endometrial	B-ADE
carcinoma	I-ADE
and	O
endometriosis	B-ADE
.	O

-DOCSTART-	915

In	O
this	O
report	O
we	O
present	O
four	O
patients	O
treated	O
with	O
a	O
combination	O
of	O
different	O
psychotropic	O
drugs	O
,	O
in	O
whom	O
asterixis	B-ADE
was	O
triggered	O
either	O
by	O
adding	O
carbamazepine	B-Drug
(	O
CBZ	B-Drug
)	O
to	O
a	O
treatment	O
regimen	O
,	O
or	O
by	O
increasing	O
its	O
dosage	O
.	O

-DOCSTART-	2508

Persistent	B-ADE
light	I-ADE
reactivity	I-ADE
from	O
systemic	O
quinine	B-Drug
.	O

-DOCSTART-	3250

This	O
is	O
,	O
to	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
the	O
first	O
report	O
of	O
a	O
case	O
in	O
which	O
agranulocytosis	B-ADE
followed	O
treatment	O
with	O
both	O
propylthiouracil	B-Drug
and	O
methimazole	B-Drug
in	O
the	O
same	O
patient	O
.	O

-DOCSTART-	567

CONCLUSIONS	O
:	O
Although	O
mirtazapine	B-Drug
offers	O
clinicians	O
a	O
combination	O
of	O
strong	O
efficacy	O
and	O
good	O
safety	O
,	O
we	O
suggest	O
bearing	O
SS	B-ADE
in	O
mind	O
when	O
prescribing	O
this	O
drug	O
,	O
especially	O
in	O
frail	O
,	O
elderly	O
patients	O
with	O
underlying	O
chronic	O
conditions	O
.	O

-DOCSTART-	2773

Case	O
report	O
:	O
dapsone	B-Drug
hypersensitivity	B-ADE
syndrome	I-ADE
associated	O
with	O
treatment	O
of	O
the	O
bite	O
of	O
a	O
brown	O
recluse	O
spider	O
.	O

-DOCSTART-	3382

Used	O
injudiciously	O
,	O
naloxone	B-Drug
can	O
lead	O
to	O
withdrawal	B-ADE
syndrome	I-ADE
,	O
return	O
of	O
severe	B-ADE
pain	I-ADE
,	O
and	O
other	O
adverse	O
effects	O
.	O

-DOCSTART-	3603

Based	O
on	O
our	O
experience	O
and	O
on	O
previously	O
published	O
data	O
,	O
serum	O
ammonia	O
levels	O
appear	O
to	O
be	O
indicated	O
in	O
all	O
ED	O
patients	O
on	O
valproic	B-Drug
acid	I-Drug
therapy	O
who	O
present	O
with	O
altered	B-ADE
mental	I-ADE
status	I-ADE
.	O

-DOCSTART-	110

Described	O
here	O
are	O
2	O
patients	O
who	O
developed	O
thrombotic	B-ADE
microangiopathy	I-ADE
of	O
the	O
kidneys	O
after	O
receiving	O
high	O
cumulative	O
doses	O
of	O
the	O
new	O
anticancer	O
drug	O
gemcitabine	B-Drug
.	O

-DOCSTART-	3497

A	O
15-year	O
follow	O
-	O
up	O
of	O
phenytoin	B-Drug
-	O
induced	O
unilateral	B-ADE
gingival	I-ADE
hyperplasia	I-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	1926

Leflunomide	B-Drug
-	O
associated	O
infections	B-ADE
in	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	2833

The	O
neurotoxicity	B-ADE
seen	O
with	O
HDARAC	B-Drug
is	O
dose	O
-	O
related	O
and	O
has	O
occurred	O
in	O
up	O
to	O
60	O
percent	O
of	O
treated	O
patients	O
.	O

-DOCSTART-	1138

L	B-Drug
-	I-Drug
asparaginase	I-Drug
-	O
induced	O
severe	B-ADE
necrotizing	I-ADE
pancreatitis	I-ADE
successfully	O
treated	O
with	O
percutaneous	O
drainage	O
.	O

-DOCSTART-	1830

In	O
this	O
report	O
,	O
we	O
describe	O
a	O
patient	O
receiving	O
lenalidomide	B-Drug
in	O
whom	O
dyspnea	B-ADE
,	O
fever	B-ADE
,	O
hypoxia	B-ADE
,	O
and	O
diffuse	B-ADE
pulmonary	I-ADE
infiltrates	I-ADE
developed	O
.	O

-DOCSTART-	4088

METHODS	O
:	O
We	O
report	O
a	O
patient	O
who	O
had	O
an	O
anaphylactic	B-ADE
reaction	I-ADE
during	O
the	O
intravenous	O
infusion	O
of	O
cyclosporine	B-Drug
.	O

-DOCSTART-	3224

Although	O
the	O
data	O
indicate	O
an	O
immune	O
-	O
complex	O
cause	O
for	O
gold	B-Drug
-	I-Drug
salt	I-Drug
nephropathy	B-ADE
,	O
the	O
incident	O
antigen	O
(	O
or	O
antigens	O
)	O
and	O
mechanism	O
of	O
action	O
remain	O
unidentified	O
.	O

-DOCSTART-	1401

After	O
discontinuing	O
captopril	B-Drug
and	O
starting	O
systemic	O
steroids	O
,	O
her	O
symptomatology	O
rapidly	O
improved	O
,	O
and	O
her	O
eosinophilia	B-ADE
and	O
radiographic	B-ADE
abnormalities	I-ADE
both	O
resolved	O
.	O

-DOCSTART-	3681

PURPOSE	O
:	O
To	O
investigate	O
the	O
concentration	O
-	O
side	O
effect	O
relationship	O
in	O
a	O
patient	O
with	O
severe	O
acyclovir	B-Drug
-	O
induced	O
neurotoxicity	B-ADE
and	O
to	O
summarize	O
the	O
information	O
available	O
in	O
the	O
literature	O
about	O
central	B-ADE
nervous	I-ADE
system	I-ADE
side	I-ADE
effects	I-ADE
due	O
to	O
acyclovir	B-Drug
.	O

-DOCSTART-	2550

Delayed	O
bowel	B-ADE
injury	I-ADE
is	O
an	O
infrequently	O
observed	O
complication	O
of	O
chromic	B-Drug
phosphate	I-Drug
administration	O
.	O

-DOCSTART-	4069

Toxicity	B-ADE
,	O
pharmacokinetics	O
,	O
and	O
in	O
vitro	O
hemodialysis	O
clearance	O
of	O
ifosfamide	B-Drug
and	O
metabolites	O
in	O
an	O
anephric	O
pediatric	O
patient	O
with	O
Wilms	O
'	O
tumor	O
.	O

-DOCSTART-	860

Cefuroxime	B-Drug
-	O
induced	O
immune	B-ADE
hemolysis	I-ADE
.	O

-DOCSTART-	3271

Two	O
years	O
later	O
,	O
24	O
hours	O
following	O
an	O
increase	O
in	O
the	O
dose	O
of	O
disopyramide	B-Drug
from	O
300	O
to	O
600	O
mg	O
/	O
day	O
,	O
AVT	B-ADE
with	O
syncope	B-ADE
occurred	O
;	O
isoproterenol	O
abolished	O
the	O
arrhythmia	O
instantly	O
.	O

-DOCSTART-	1799

Based	O
on	O
the	O
Naranjo	O
probability	O
scale	O
,	O
serotonin	B-ADE
syndrome	I-ADE
was	O
a	O
probable	O
adverse	O
reaction	O
associated	O
with	O
co	O
-	O
administration	O
of	O
citalopram	B-Drug
and	O
fentanyl	B-Drug
.	O

-DOCSTART-	2837

A	O
woman	O
with	O
a	O
20-year	O
history	O
of	O
acral	O
pustular	O
psoriasis	O
of	O
Hallopeau	O
and	O
recurrent	O
pustular	O
lesions	O
of	O
the	O
forearms	O
and	O
lower	O
legs	O
,	O
developed	O
a	O
B	B-ADE
-	I-ADE
cell	I-ADE
lymphoma	I-ADE
of	O
the	O
lip	O
following	O
4	O
1/2	O
years	O
of	O
treatment	O
with	O
razoxane	B-Drug
.	O

-DOCSTART-	3080

The	O
case	O
resembles	O
two	O
previously	O
reported	O
cases	O
of	O
optic	B-ADE
neuropathy	I-ADE
which	O
occurred	O
in	O
patients	O
with	O
Wilson	O
's	O
disease	O
who	O
were	O
receiving	O
penicillamine	B-Drug
.	O

-DOCSTART-	155

The	O
presented	O
patient	O
was	O
treated	O
with	O
200	O
mg	O
TCA	B-Drug
and	O
developed	O
Cushing	B-ADE
's	I-ADE
syndrome	I-ADE
6	O
weeks	O
later	O
(	O
cortisol	O
and	O
ACTH	O
concentrations	O
were	O
below	O
limits	O
of	O
detection	O
,	O
TCA	O
concentrations	O
were	O
>	O
3	O
micrograms	O
/	O
l	O
)	O
.	O

-DOCSTART-	869

This	O
finding	O
suggests	O
that	O
fluvoxamine	B-Drug
can	O
precipitate	O
Schneiderian	B-ADE
first	I-ADE
-	I-ADE
rank	I-ADE
symptoms	I-ADE
in	O
some	O
susceptible	O
patients	O
.	O

-DOCSTART-	474

PURPOSE	O
:	O
To	O
report	O
patients	O
who	O
presented	O
to	O
the	O
oculoplastics	O
department	O
for	O
repair	O
of	O
cicatrical	B-ADE
entropion	I-ADE
after	O
topical	O
use	O
of	O
dipivefrin	B-Drug
.	O

-DOCSTART-	2440

METHOD	O
:	O
The	O
authors	O
followed	O
a	O
patient	O
with	O
chronic	O
HCV	O
who	O
received	O
interferon	B-Drug
and	O
ribavirin	B-Drug
and	O
who	O
developed	O
hallucinations	B-ADE
ultimately	O
requiring	O
psychiatric	O
hospitalization	O
.	O

-DOCSTART-	2641

Metoclopramide	B-Drug
-	O
induced	O
parkinsonism	B-ADE
.	O

-DOCSTART-	1261

The	O
hearing	B-ADE
impairment	I-ADE
and	O
tinnitus	B-ADE
were	O
gradually	O
reduced	O
after	O
PTU	B-Drug
withdrawal	O
and	O
corticosteroid	O
and	O
azathioprine	O
treatment	O
.	O

-DOCSTART-	2616

A	O
typical	O
case	O
of	O
dextran-40	B-Drug
associated	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
is	O
presented	O
.	O

-DOCSTART-	1940

Mycobacterium	B-ADE
marinum	I-ADE
infection	I-ADE
complicating	O
Crohn	O
's	O
disease	O
,	O
treated	O
with	O
infliximab	B-Drug
.	O

-DOCSTART-	2516

A	O
case	O
of	O
severe	B-ADE
acute	I-ADE
hepatitis	I-ADE
caused	O
by	O
cyproterone	B-Drug
acetate	I-Drug
in	O
a	O
71	O
year	O
old	O
man	O
with	O
prostatic	O
carcinoma	O
is	O
reported	O
with	O
a	O
review	O
of	O
the	O
literature	O
on	O
hepatic	O
reactions	O
to	O
this	O
drug	O
.	O

-DOCSTART-	338

Quinine	B-Drug
induced	O
coagulopathy	B-ADE
--	O
a	O
near	O
fatal	O
experience	O
.	O

-DOCSTART-	2699

It	O
is	O
suggested	O
that	O
the	O
patient	O
had	O
sulfasalazine	B-Drug
-	O
induced	O
lupus	B-ADE
,	O
which	O
manifested	O
with	O
serositis	B-ADE
and	O
pulmonary	B-ADE
parenchymal	I-ADE
involvement	I-ADE
in	O
the	O
absence	O
of	O
joint	O
symptoms	O
.	O

-DOCSTART-	1260

RESULTS	O
:	O
In	O
a	O
22-year	O
-	O
old	O
Thai	O
woman	O
with	O
Graves	O
'	O
disease	O
,	O
tinnitus	B-ADE
,	O
hearing	B-ADE
impairment	I-ADE
in	I-ADE
the	I-ADE
left	I-ADE
ear	I-ADE
(	I-ADE
with	I-ADE
progression	I-ADE
to	I-ADE
the	I-ADE
right	I-ADE
ear	I-ADE
)	I-ADE
,	O
and	O
vertigo	B-ADE
developed	O
after	O
3	O
years	O
of	O
therapy	O
with	O
PTU	B-Drug
.	O

-DOCSTART-	3695

The	O
pulmonary	B-ADE
toxicity	I-ADE
is	O
probably	O
induced	O
by	O
piritrexim	B-Drug
.	O

-DOCSTART-	2459

Tremor	B-ADE
:	O
a	O
newly	O
described	O
adverse	O
event	O
with	O
long	O
-	O
term	O
itraconazole	B-Drug
therapy	O
.	O

-DOCSTART-	1805

We	O
report	O
the	O
case	O
of	O
an	O
11-year	O
-	O
old	O
female	O
treated	O
for	O
mediastinal	O
T	O
-	O
cell	O
lymphoma	O
who	O
presented	O
renal	B-ADE
failure	I-ADE
following	O
the	O
second	O
cycle	O
of	O
high	O
-	O
dose	O
methotrexate	B-Drug
(	O
HDMTX	B-Drug
)	O
.	O

-DOCSTART-	1957

This	O
is	O
the	O
first	O
report	O
on	O
the	O
histopathological	O
findings	O
of	O
thyroid	O
tissue	O
from	O
a	O
patient	O
with	O
amiodarone	B-Drug
-	O
induced	O
hypothyroidism	B-ADE
.	O

-DOCSTART-	2828

Three	O
patients	O
receiving	O
gold	B-Drug
salt	O
treatment	O
for	O
rheumatoid	O
arthritis	O
developed	O
severe	O
aplastic	B-ADE
anemia	I-ADE
.	O

-DOCSTART-	3215

Anaphylactoid	B-ADE
shock	I-ADE
,	O
disseminated	B-ADE
intravascular	I-ADE
coagulation	I-ADE
,	O
and	O
anuric	B-ADE
renal	I-ADE
failure	I-ADE
requiring	O
dialysis	O
occurred	O
in	O
a	O
patient	O
receiving	O
zomepirac	B-Drug
sodium	O
for	O
toothache	O
.	O

-DOCSTART-	171

Ibuprofen	B-Drug
overdose	O
is	O
usually	O
characterized	O
by	O
GI	B-ADE
upset	I-ADE
,	O
dizziness	B-ADE
,	O
and	O
mild	B-ADE
sedation	I-ADE
.	O

-DOCSTART-	2149

Hemorrhage	B-ADE
from	O
a	O
falx	O
meningioma	O
after	O
internal	O
use	O
of	O
low	O
-	O
dose	O
aspirin	B-Drug
.	O

-DOCSTART-	2475

High	O
-	O
resolution	O
computed	O
tomography	O
scan	O
findings	O
were	O
consistent	O
with	O
ILD	O
,	O
which	O
was	O
sufficient	O
to	O
diagnose	O
as	O
erlotinib	B-Drug
-	O
induced	O
ILD	B-ADE
.	O

-DOCSTART-	2903

Severe	B-ADE
hyperkalemia	I-ADE
occurred	O
in	O
a	O
patient	O
with	O
radiation	O
pneumonitis	O
and	O
glaucoma	O
shortly	O
after	O
beginning	O
prednisone	B-Drug
therapy	O
.	O

-DOCSTART-	3253

The	O
literature	O
on	O
thiabendazole	B-Drug
-	O
induced	O
cholestasis	B-ADE
and	O
its	O
association	O
with	O
sicca	B-ADE
complex	I-ADE
is	O
reviewed	O
.	O

-DOCSTART-	1306

CONCLUSION	O
:	O
There	O
may	O
be	O
an	O
association	O
between	O
raloxifene	B-Drug
and	O
the	O
development	O
of	O
malignant	B-ADE
mixed	I-ADE
mesodermal	I-ADE
tumor	I-ADE
.	O

-DOCSTART-	1994

Temozolomide	B-Drug
was	O
restarted	O
2	O
months	O
later	O
;	O
the	O
patient	O
again	O
developed	O
a	O
fever	B-ADE
.	O

-DOCSTART-	1871

CONCLUSION	O
:	O
Acetic	B-Drug
acid	I-Drug
is	O
corrosive	O
and	O
may	O
cause	O
vagina	B-ADE
bleeding	I-ADE
.	O

-DOCSTART-	3532

Hypo	B-ADE
-	I-ADE
oestrogenic	I-ADE
and	I-ADE
anabolic	I-ADE
/	I-ADE
androgenic	I-ADE
side	I-ADE
-	I-ADE
effects	I-ADE
of	O
danazol	B-Drug
are	O
well	O
known	O
by	O
the	O
gynaecologist	O
and	O
some	O
of	O
them	O
are	O
present	O
in	O
>	O
50	O
%	O
of	O
patients	O
being	O
treated	O
for	O
endometriosis	O
.	O

-DOCSTART-	601

Levofloxacin	B-Drug
-	O
induced	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
in	O
an	O
elderly	O
patient	O
.	O

-DOCSTART-	2030

BACKGROUND	O
:	O
To	O
describe	O
the	O
occurrence	O
of	O
ocular	B-ADE
hypertension	I-ADE
in	O
four	O
patients	O
following	O
injection	O
of	O
ranibizumab	B-Drug
intravitreally	O
.	O

-DOCSTART-	675

CONCLUSION	O
:	O
Long	O
-	O
term	O
treatment	O
with	O
rifabutin	B-Drug
may	O
have	O
a	O
reversible	O
and	O
previously	O
undescribed	O
side	B-ADE
-	I-ADE
effect	I-ADE
on	I-ADE
retinal	I-ADE
function	I-ADE
.	O

-DOCSTART-	3724

She	O
had	O
been	O
taking	O
nabumetone	B-Drug
for	O
6	O
months	O
,	O
but	O
had	O
discontinued	O
the	O
agent	O
2	O
weeks	O
before	O
admission	O
due	O
to	O
progressive	O
edema	B-ADE
.	O

-DOCSTART-	2755

Isotretinoin	B-Drug
,	O
a	O
drug	O
used	O
for	O
the	O
treatment	O
of	O
acne	O
,	O
has	O
been	O
shown	O
to	O
have	O
teratogenic	B-ADE
effects	I-ADE
.	O

-DOCSTART-	3909

The	O
reversal	O
of	O
heparin	O
by	O
protamine	B-Drug
may	O
cause	O
severe	B-ADE
hemodynamic	I-ADE
deterioration	I-ADE
,	O
characterized	O
by	O
systemic	B-ADE
hypotension	I-ADE
,	O
pulmonary	B-ADE
hypertension	I-ADE
,	O
and	O
bronchoconstriction	B-ADE
.	O

-DOCSTART-	2683

MR	O
findings	O
in	O
methotrexate	B-Drug
-	O
induced	O
CNS	B-ADE
abnormalities	I-ADE
.	O

-DOCSTART-	2415

OBJECTIVE	O
:	O
Clozapine	B-Drug
causes	O
few	O
extrapyramidal	B-ADE
symptoms	I-ADE
and	O
is	O
recommended	O
as	O
a	O
treatment	O
drug	O
for	O
severe	O
tardive	O
dyskinesia	O
(	O
TD	O
)	O
.	O

-DOCSTART-	1533

Here	O
,	O
we	O
present	O
a	O
case	O
of	O
sirolimus	B-Drug
-	O
associated	O
interstitial	B-ADE
pneumonitis	I-ADE
in	O
a	O
cardiac	O
transplant	O
recipient	O
that	O
resolved	O
completely	O
with	O
withdrawal	O
of	O
the	O
drug	O
and	O
treatment	O
with	O
corticosteroids	O
.	O

-DOCSTART-	1307

Malignant	B-ADE
mixed	I-ADE
mullerian	I-ADE
tumor	I-ADE
of	I-ADE
the	I-ADE
uterus	I-ADE
in	O
a	O
patient	O
taking	O
raloxifene	B-Drug
.	O

-DOCSTART-	2058

Renal	B-ADE
injury	I-ADE
due	O
to	O
anastrozole	B-Drug
has	O
not	O
been	O
published	O
in	O
the	O
English	O
literature	O
.	O

-DOCSTART-	2751

Hepatopathy	B-ADE
subsided	O
after	O
the	O
cessation	O
of	O
carbamazepine	B-Drug
and	O
lynestrenol	B-Drug
.	O

-DOCSTART-	426

Vancomycin	B-Drug
is	O
the	O
most	O
frequently	O
implicated	O
drug	O
,	O
but	O
other	O
agents	O
have	O
been	O
reported	O
to	O
cause	O
LABD	B-ADE
.	O

-DOCSTART-	3544

Phenylpropanolamine	B-Drug
-	O
induced	O
psychosis	B-ADE
.	O

-DOCSTART-	3720

The	O
azathioprine	B-Drug
dose	O
was	O
low	O
(	O
1	O
mg	O
/	O
kg	O
)	O
and	O
pancytopenia	B-ADE
occurred	O
after	O
56	O
days	O
therapy	O
.	O

-DOCSTART-	4072

Such	O
a	O
rapid	O
and	O
relentless	O
progression	O
of	O
methyldopa	B-Drug
-	O
induced	O
liver	B-ADE
injury	I-ADE
is	O
undoubtedly	O
rare	O
,	O
but	O
it	O
may	O
be	O
prevented	O
by	O
careful	O
supervision	O
of	O
patients	O
who	O
exhibit	O
liver	O
function	O
abnormalities	O
early	O
in	O
the	O
course	O
of	O
therapy	O
.	O

-DOCSTART-	3294

Lichen	B-ADE
planus	I-ADE
and	O
acne	B-ADE
provoked	O
by	O
gold	B-Drug
.	O

-DOCSTART-	4124

Glomerulonephritis	B-ADE
in	O
procainamide	B-Drug
induced	O
lupus	B-ADE
erythematosus	I-ADE
:	O
report	O
of	O
a	O
case	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	1798

Osteomyelitis	B-ADE
occurring	O
during	O
infliximab	B-Drug
treatment	O
of	O
severe	O
psoriasis	O
.	O

-DOCSTART-	2532

We	O
report	O
a	O
patient	O
who	O
developed	O
heparin	B-Drug
associated	O
thrombocytopenia	B-ADE
during	O
continuous	O
arteriovenous	O
haemofiltration	O
and	O
discuss	O
its	O
implications	O
and	O
alternative	O
anticoagulant	O
treatment	O
.	O

-DOCSTART-	1216

Two	O
of	O
our	O
patients	O
developed	O
TD	B-ADE
after	O
23	O
months	O
and	O
34	O
months	O
of	O
ziprasidone	B-Drug
monotherapy	O
,	O
respectively	O
.	O

-DOCSTART-	1878

Occasionally	O
,	O
despite	O
good	O
therapeutic	O
response	O
,	O
clozapine	B-Drug
must	O
be	O
stopped	O
due	O
to	O
dangerous	O
side	O
effects	O
such	O
as	O
agranulocytosis	B-ADE
.	O

-DOCSTART-	1594

After	O
excluding	O
other	O
causes	O
of	O
long	O
QT	O
syndrome	O
,	O
the	O
HCQ	B-Drug
was	O
suspected	O
as	O
the	O
cause	O
of	O
her	O
ventricular	B-ADE
tachycardia	I-ADE
.	O

-DOCSTART-	673

While	O
both	O
amiodarone	B-Drug
and	O
digoxin	B-Drug
can	O
cause	O
permanent	O
visual	B-ADE
changes	I-ADE
,	O
the	O
ocular	B-ADE
effects	I-ADE
are	O
often	O
reversible	O
.	O

-DOCSTART-	203

BACKGROUND	O
:	O
Cyanamide	B-Drug
,	O
an	O
aversive	O
agent	O
widely	O
used	O
in	O
Japan	O
,	O
is	O
known	O
to	O
induce	O
various	O
degrees	O
of	O
hepatic	B-ADE
lesion	I-ADE
with	I-ADE
ground	I-ADE
-	I-ADE
glass	I-ADE
inclusion	I-ADE
bodies	I-ADE
.	O

-DOCSTART-	4144

In	O
rare	O
cases	O
mitomycin	B-Drug
C	I-Drug
(	O
MMC	B-Drug
)	O
may	O
induce	O
cancer	O
-	O
associated	O
hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
,	O
which	O
is	O
characterized	O
by	O
hemolytic	B-ADE
anemia	I-ADE
,	O
thrombocytopenia	B-ADE
and	O
progressive	B-ADE
renal	I-ADE
failure	I-ADE
.	O

-DOCSTART-	1870

5-Fluorouracil	B-Drug
cardiotoxicity	B-ADE
complicating	O
treatment	O
of	O
stage	O
IIB	O
cervical	O
cancer	O
--	O
case	O
report	O
.	O

-DOCSTART-	2880

A	O
fatal	B-ADE
massive	I-ADE
pulmonary	I-ADE
embolus	I-ADE
developed	O
in	O
a	O
patient	O
treated	O
with	O
streptokinase	B-Drug
for	O
acute	O
deep	O
vein	O
thrombosis	O
.	O

-DOCSTART-	2848

Captopril	B-Drug
-	O
induced	O
lichen	B-ADE
planus	I-ADE
pemphigoides	I-ADE
with	O
pemphigus	O
-	O
like	O
features	O
.	O

-DOCSTART-	204

Case	O
2	O
:	O
A	O
43-year	O
-	O
old	O
male	O
alcoholic	O
remained	O
completely	O
abstinent	O
with	O
cyanamide	B-Drug
treatment	O
for	O
5	O
years	O
and	O
complained	O
of	O
general	B-ADE
fatigue	I-ADE
.	O

-DOCSTART-	3460

Severe	B-ADE
hepatotoxicity	I-ADE
related	O
to	O
benzarone	B-Drug
:	O
a	O
report	O
of	O
three	O
cases	O
with	O
two	O
fatalities	O
.	O

-DOCSTART-	2251

Bisphosphonate	B-Drug
-	O
related	O
osteonecrosis	B-ADE
of	I-ADE
the	I-ADE
jaw	I-ADE
(	O
BRONJ	O
)	O
is	O
reported	O
in	O
up	O
to	O
18.6	O
%	O
of	O
patients	O
treated	O
with	O
intravenous	O
bisphosphonates	O
and	O
can	O
result	O
in	O
significant	O
morbidity	O
.	O

-DOCSTART-	2647

Clofazimine	B-Drug
induced	O
nail	B-ADE
changes	I-ADE
.	O

-DOCSTART-	988

Mechanism	O
of	O
topiramate	B-Drug
-	O
induced	O
acute	B-ADE
-	I-ADE
onset	I-ADE
myopia	I-ADE
and	O
angle	B-ADE
closure	I-ADE
glaucoma	I-ADE
.	O

-DOCSTART-	3542

Actinomycin	B-Drug
D	I-Drug
associated	O
hepatic	B-ADE
veno	I-ADE
-	I-ADE
occlusive	I-ADE
disease	I-ADE
--	O
a	O
report	O
of	O
2	O
cases	O
.	O

-DOCSTART-	1951

A	O
patient	O
developed	O
typical	O
ECM	B-ADE
after	O
subcutaneous	O
selfinjection	O
of	O
glatiramer	B-Drug
acetate	I-Drug
for	O
multiple	O
sclerosis	O
.	O

-DOCSTART-	4020

Clinicians	O
should	O
include	O
phenolphthalein	B-Drug
in	O
their	O
list	O
of	O
possible	O
causes	O
of	O
drug	O
-	O
induced	O
TEN	B-ADE
.	O

-DOCSTART-	749

We	O
believe	O
the	O
temporal	O
association	O
of	O
the	O
abnormal	B-ADE
liver	I-ADE
enzymes	I-ADE
in	O
this	O
patient	O
,	O
in	O
the	O
absence	O
of	O
other	O
offending	O
agents	O
,	O
argues	O
strongly	O
in	O
favor	O
of	O
6-TG	B-Drug
as	O
a	O
cause	O
of	O
liver	B-ADE
enzyme	I-ADE
abnormalities	I-ADE
.	O

-DOCSTART-	3971

Mental	B-ADE
nerve	I-ADE
neuropathy	I-ADE
as	O
a	O
result	O
of	O
hepatitis	B-Drug
B	I-Drug
vaccination	I-Drug
.	O

-DOCSTART-	4246

The	O
authors	O
report	O
a	O
case	O
of	O
a	O
patient	O
who	O
received	O
alteplase	B-Drug
for	O
acute	O
myocardial	O
infarction	O
and	O
developed	O
spontaneous	O
subfascial	B-ADE
hematoma	I-ADE
without	O
any	O
evidence	O
of	O
direct	O
trauma	O
.	O

-DOCSTART-	2050

Muzolimine	B-Drug
-	O
induced	O
severe	B-ADE
neuromyeloencephalopathy	I-ADE
:	O
report	O
of	O
seven	O
cases	O
.	O

-DOCSTART-	1543

Cutaneous	B-ADE
mycobacterial	I-ADE
infection	I-ADE
post	O
intravesical	O
BCG	B-Drug
installation	O
.	O

-DOCSTART-	2980

Atrial	B-ADE
fibrillation	I-ADE
was	O
induced	O
by	O
diltiazem	B-Drug
in	O
two	O
patients	O
and	O
verapamil	B-Drug
induced	O
syncope	B-ADE
in	O
one	O
patient	O
.	O

-DOCSTART-	2484

Thrombocytosis	B-ADE
associated	O
with	O
enoxaparin	B-Drug
:	O
A	O
very	O
rare	O
cause	O
in	O
newborns	O
.	O

-DOCSTART-	1591

Statin	B-Drug
-	O
associated	O
myasthenia	B-ADE
gravis	I-ADE
:	O
report	O
of	O
4	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	3929

The	O
authors	O
suggest	O
that	O
in	O
patients	O
with	O
corneal	B-ADE
ulcers	I-ADE
refractory	I-ADE
to	I-ADE
conventional	I-ADE
treatment	I-ADE
who	O
are	O
receiving	O
colchicine	B-Drug
,	O
cessation	O
of	O
colchicine	O
therapy	O
should	O
be	O
considered	O
.	O

-DOCSTART-	3168

The	O
first	O
reported	O
case	O
,	O
in	O
an	O
adult	O
,	O
of	O
cholestyramine	B-Drug
induced	O
hyperchloremic	B-ADE
metabolic	I-ADE
acidosis	I-ADE
is	O
a	O
70	O
year	O
old	O
female	O
with	O
a	O
two	O
year	O
history	O
of	O
primary	O
biliary	O
cirrhosis	O
confirmed	O
by	O
histologic	O
and	O
immunologic	O
criteria	O
.	O

-DOCSTART-	669

An	O
amiodarone	B-Drug
optic	B-ADE
neuropathy	I-ADE
has	O
been	O
described	O
.	O

-DOCSTART-	2589

Fever	B-ADE
,	O
pulmonary	B-ADE
infiltrates	I-ADE
,	O
and	O
pleural	B-ADE
effusion	I-ADE
following	O
acyclovir	B-Drug
therapy	O
for	O
herpes	O
zoster	O
ophthalmicus	O
.	O

-DOCSTART-	1808

We	O
report	O
a	O
71-year	O
male	O
with	O
castration	O
-	O
resistant	O
metastatic	O
prostate	O
cancer	O
who	O
was	O
treated	O
with	O
weekly	O
docetaxel	B-Drug
for	O
12	O
weeks	O
and	O
developed	O
significant	O
eye	B-ADE
irritation	I-ADE
and	I-ADE
dryness	I-ADE
during	O
treatment	O
.	O

-DOCSTART-	1953

This	O
case	O
is	O
remarkable	O
since	O
1	O
)	O
ECM	O
developed	O
after	O
subcutaneous	O
and	O
not	O
after	O
intramuscular	O
injection	O
,	O
2	O
)	O
the	O
injection	O
was	O
given	O
by	O
the	O
patient	O
himself	O
,	O
and	O
3	O
)	O
glatiramer	B-Drug
acetate	I-Drug
can	O
induce	O
skin	B-ADE
necrosis	I-ADE
as	O
a	O
side	O
effect	O
.	O

-DOCSTART-	1056

This	O
profile	O
should	O
trigger	O
a	O
"	O
red	O
flag	O
"	O
as	O
to	O
the	O
possibility	O
of	O
phenobarbital	B-Drug
behavioral	B-ADE
side	I-ADE
effects	I-ADE
or	O
exacerbation	B-ADE
of	I-ADE
preexisting	I-ADE
maladaptive	I-ADE
behaviors	I-ADE
.	O

-DOCSTART-	3059

A	O
healthy	O
,	O
30-year	O
-	O
old	O
man	O
,	O
exposed	O
to	O
sulindac	B-Drug
on	O
two	O
separate	O
occasions	O
,	O
had	O
an	O
incapacitating	O
isolated	B-ADE
idential	I-ADE
sensory	I-ADE
neuropathy	I-ADE
.	O

-DOCSTART-	2265

According	O
to	O
the	O
Naranjo	O
et	O
al	O
.	O
adverse	O
-	O
reaction	O
probability	O
scale	O
,	O
enoxaparin	B-Drug
was	O
the	O
probable	O
cause	O
of	O
hepatotoxicity	B-ADE
in	O
this	O
patient	O
.	O

-DOCSTART-	3748

The	O
nodules	B-ADE
regressed	O
after	O
withdrawal	O
of	O
methotrexate	B-Drug
therapy	O
in	O
one	O
patient	O
and	O
were	O
arrested	O
with	O
the	O
addition	O
of	O
hydroxychloroquine	O
in	O
the	O
other	O
.	O

-DOCSTART-	1524

Prior	O
to	O
surgery	O
,	O
levodopa	B-Drug
induced	O
dyskinesia	B-ADE
had	O
improved	O
(	O
<	O
or	O
=	O
50	O
%	O
)	O
under	O
treatment	O
with	O
amantadine	O
(	O
400	O
mg	O
/	O
day	O
,	O
po	O
)	O
in	O
all	O
three	O
patients	O
.	O

-DOCSTART-	2077

We	O
report	O
five	O
cases	O
of	O
restless	B-ADE
legs	I-ADE
syndrome	I-ADE
(	O
RLS	B-ADE
)	O
and	O
periodic	B-ADE
limb	I-ADE
movements	I-ADE
during	I-ADE
sleep	I-ADE
(	O
PLMS	B-ADE
)	O
that	O
were	O
probably	O
associated	O
with	O
olanzapine	B-Drug
.	O

-DOCSTART-	3870

However	O
,	O
other	O
factors	O
or	O
drugs	O
(	O
e.g.	O
cresol	B-Drug
)	O
are	O
thought	O
to	O
induce	O
MH	B-ADE
.	O

-DOCSTART-	4238

Syndrome	B-ADE
of	I-ADE
inappropriate	I-ADE
antidiuretic	I-ADE
hormone	I-ADE
associated	O
with	O
vinorelbine	B-Drug
therapy	O
.	O

-DOCSTART-	3642

Regression	O
of	O
thyrotoxic	B-ADE
ophthalmopathy	I-ADE
following	O
lithium	B-Drug
withdrawal	O
.	O

-DOCSTART-	3718

Azathioprine	B-Drug
can	O
cause	O
severe	O
myelosuppression	B-ADE
.	O

-DOCSTART-	804

After	O
5-ASA	B-Drug
was	O
discontinued	O
,	O
the	O
polyneuropathy	B-ADE
symptoms	O
recovered	O
gradually	O
.	O

-DOCSTART-	2213

Biopsy	O
-	O
proven	O
acute	B-ADE
interstitial	I-ADE
nephritis	I-ADE
associated	O
with	O
the	O
tyrosine	O
kinase	O
inhibitor	O
sunitinib	B-Drug
:	O
a	O
class	O
effect	O
?	O

-DOCSTART-	509

There	O
is	O
a	O
putative	O
role	O
of	O
liothyronine	B-Drug
administration	O
in	O
precipitating	O
or	O
activating	O
hyperthyroidism	B-ADE
.	O

-DOCSTART-	1360

CASE	O
REPORT	O
:	O
We	O
report	O
a	O
case	O
of	O
intracerebral	B-ADE
hemorrhage	I-ADE
occurring	O
in	O
a	O
middle	O
-	O
aged	O
man	O
who	O
suffered	O
from	O
chronic	O
sinusitis	O
and	O
had	O
been	O
ingesting	O
pseudoephedrine	B-Drug
daily	O
for	O
one	O
year	O
.	O

-DOCSTART-	3668

Foscarnet	B-Drug
-	O
induced	O
severe	B-ADE
hypomagnesemia	I-ADE
and	O
other	O
electrolyte	B-ADE
disorders	I-ADE
.	O

-DOCSTART-	3435

We	O
have	O
successfully	O
overcome	O
severe	B-ADE
neutropenia	I-ADE
in	O
an	O
RA	O
patient	O
treated	O
with	O
gold	B-Drug
salts	O
,	O
using	O
granulocyte	O
colony	O
-	O
stimulating	O
factor	O
(	O
G	O
-	O
CSF	O
)	O
,	O
reducing	O
the	O
duration	O
of	O
neutropenia	O
and	O
risk	O
of	O
infection	O
.	O

-DOCSTART-	885

Gynaecomastia	B-ADE
is	O
a	O
rarely	O
reported	O
adverse	O
drug	O
reaction	O
due	O
to	O
isoniazid	B-Drug
therapy	O
.	O

-DOCSTART-	1433

Marked	B-ADE
QT	I-ADE
prolongation	I-ADE
and	O
torsades	B-ADE
de	I-ADE
pointes	I-ADE
secondary	O
to	O
acute	B-ADE
ischemia	I-ADE
in	O
an	O
elderly	O
man	O
taking	O
dofetilide	B-Drug
for	O
atrial	O
fibrillation	O
:	O
a	O
cautionary	O
tale	O
.	O

-DOCSTART-	2599

Autopsy	O
findings	O
were	O
consistent	O
with	O
bleomycin	B-Drug
and	O
oxygen	B-Drug
-	O
induced	O
pulmonary	B-ADE
damage	I-ADE
.	O

-DOCSTART-	576

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
possible	O
association	O
of	O
thrombocytopenia	B-ADE
with	O
lansoprazole	B-Drug
and	O
discontinue	O
the	O
drug	O
if	O
thrombocytopenia	O
becomes	O
apparent	O
.	O

-DOCSTART-	52

Findings	O
on	O
discontinuation	O
and	O
rechallenge	O
supported	O
the	O
assumption	O
that	O
the	O
hair	B-ADE
loss	I-ADE
was	O
a	O
side	O
effect	O
of	O
the	O
paroxetine	B-Drug
.	O

-DOCSTART-	787

Rapid	O
identification	O
of	O
speech	B-ADE
loss	I-ADE
linked	O
to	O
FK506	B-Drug
may	O
be	O
important	O
because	O
reduction	O
or	O
cessation	O
of	O
the	O
drug	O
may	O
be	O
associated	O
with	O
reverse	O
of	O
speech	O
loss	O
.	O

-DOCSTART-	3219

Cimetidine	B-Drug
is	O
a	O
rare	O
cause	O
of	O
drug	O
-	O
induced	O
fever	B-ADE
.	O

-DOCSTART-	3992

Acute	B-ADE
leukaemia	I-ADE
during	O
tamoxifen	B-Drug
therapy	O
.	O

-DOCSTART-	3430

In	O
the	O
presented	O
case	O
fluvoxamine	B-Drug
-	O
induced	O
akathisia	B-ADE
in	O
an	O
OCD	O
patient	O
was	O
partially	O
resistant	O
to	O
the	O
anticholinergic	O
agent	O
biperiden	O
,	O
and	O
was	O
successfully	O
treated	O
with	O
the	O
5-HT2A/5-HT2C	O
antagonist	O
mianserin	O
.	O

-DOCSTART-	2224

Interstitial	B-ADE
granulomatous	I-ADE
dermatitis	I-ADE
associated	O
with	O
darifenacin	B-Drug
.	O

-DOCSTART-	1178

These	O
cases	O
were	O
chosen	O
for	O
study	O
because	O
they	O
were	O
all	O
deaths	B-ADE
as	O
a	O
result	O
of	O
suicidal	O
ingestion	O
of	O
drugs	O
in	O
which	O
quetiapine	B-Drug
was	O
considered	O
a	O
significant	O
factor	O
.	O

-DOCSTART-	1989

She	O
was	O
treated	O
with	O
acyclovir	B-Drug
and	O
subsequently	O
developed	O
VZV	B-ADE
antigen	I-ADE
-	I-ADE
positive	I-ADE
zoster	I-ADE
.	O

-DOCSTART-	4191

NMS	B-ADE
is	O
a	O
drug	O
-	O
related	O
response	O
to	O
various	O
medications	O
,	O
such	O
as	O
Haloperidol	B-Drug
,	O
which	O
the	O
patient	O
was	O
receiving	O
.	O

-DOCSTART-	1207

Psoriasis	B-ADE
triggered	O
by	O
toll	O
-	O
like	O
receptor	O
7	O
agonist	O
imiquimod	B-Drug
in	O
the	O
presence	O
of	O
dermal	O
plasmacytoid	O
dendritic	O
cell	O
precursors	O
.	O

-DOCSTART-	2667

Ibuprofen	B-Drug
rarely	O
causes	O
lower	O
gastrointestinal	B-ADE
adverse	I-ADE
reactions	I-ADE
but	O
has	O
been	O
implicated	O
in	O
systemic	O
and	O
local	O
side	O
effects	O
in	O
patients	O
with	O
lupus	O
.	O

-DOCSTART-	3464

This	O
case	O
study	O
describes	O
an	O
atypical	O
case	O
of	O
refractory	O
,	O
sodium	B-Drug
warfarin	I-Drug
-	O
induced	O
necrotizing	B-ADE
fasciitis	I-ADE
and	O
myonecrosis	B-ADE
.	O

-DOCSTART-	438

RESULTS	O
:	O
The	O
estimated	O
number	O
of	O
Accutane	B-Drug
prescriptions	O
for	O
reproductive	O
-	O
aged	O
women	O
has	O
more	O
than	O
doubled	O
in	O
the	O
past	O
10	O
years	O
;	O
it	O
is	O
the	O
most	O
widely	O
used	O
teratogenic	B-ADE
drug	O
in	O
the	O
United	O
States	O
,	O
with	O
approximately	O
2.5	O
per	O
1,000	O
reproductive	O
-	O
aged	O
women	O
exposed	O
to	O
Accutane	O
in	O
1999	O
.	O

-DOCSTART-	2032

Ocular	B-ADE
hypertension	I-ADE
occurred	O
1	O
month	O
after	O
the	O
second	O
ranibizumab	B-Drug
injection	O
in	O
patients	O
1	O
and	O
3	O
,	O
and	O
1	O
month	O
after	O
the	O
first	O
ranibizumab	O
in	O
patient	O
2	O
.	O

-DOCSTART-	3756

Clostridium	B-ADE
difficile	I-ADE
colitis	I-ADE
associated	O
with	O
cisplatin	B-Drug
-	O
based	O
chemotherapy	O
in	O
ovarian	O
cancer	O
patients	O
.	O

-DOCSTART-	1421

Polysomnographic	O
and	O
pharmacokinetic	O
findings	O
in	O
levodopa	B-Drug
-	O
induced	O
augmentation	O
of	O
restless	B-ADE
legs	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	3100

Acute	B-ADE
leukopenia	I-ADE
associated	O
with	O
silver	B-Drug
sulfadiazine	I-Drug
therapy	O
.	O

-DOCSTART-	1904

Simvastatin	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
following	O
cyclosporine	B-Drug
treatment	O
for	O
uveitis	O
.	O

-DOCSTART-	3134

Four	O
patients	O
receiving	O
high	O
-	O
dose	O
tamoxifen	B-Drug
for	O
greater	O
than	O
1	O
year	O
have	O
demonstrated	O
similar	O
retinal	B-ADE
changes	I-ADE
.	O

-DOCSTART-	3381

Vortex	B-ADE
keratopathy	I-ADE
associated	O
with	O
atovaquone	B-Drug
.	O

-DOCSTART-	1511

Trimethoprim	B-Drug
-	I-Drug
sulfamethoxazole	I-Drug
-	O
induced	O
aseptic	B-ADE
meningitis	I-ADE
.	O

-DOCSTART-	1206

OBSERVATIONS	O
:	O
We	O
observed	O
aggravation	B-ADE
and	I-ADE
spreading	I-ADE
of	I-ADE
a	I-ADE
psoriatic	I-ADE
plaque	I-ADE
when	O
treated	O
topically	O
with	O
the	O
toll	O
-	O
like	O
receptor	O
(	O
TLR	O
)	O
7	O
agonist	O
imiquimod	B-Drug
.	O

-DOCSTART-	4164

The	O
noted	O
increase	B-ADE
in	I-ADE
the	I-ADE
theophylline	I-ADE
level	I-ADE
after	O
zafirlukast	B-Drug
administration	O
is	O
in	O
contrast	O
to	O
the	O
original	O
reports	O
by	O
the	O
manufacturer	O
.	O

-DOCSTART-	2513

A	O
case	O
is	O
described	O
of	O
severe	B-ADE
splenic	I-ADE
hemorrhage	I-ADE
and	I-ADE
rupture	I-ADE
which	O
developed	O
3	O
h	O
after	O
completion	O
of	O
tPA	B-Drug
infusion	O
for	O
suspected	O
acute	O
myocardial	O
infarction	O
.	O

-DOCSTART-	3076

Multiple	O
complications	O
of	O
propylthiouracil	B-Drug
treatment	O
:	O
granulocytopenia	B-ADE
,	O
eosinophilia	B-ADE
,	O
skin	B-ADE
reaction	I-ADE
and	O
hepatitis	B-ADE
with	O
lymphocyte	B-ADE
sensitization	I-ADE
.	O

-DOCSTART-	3854

In	O
addition	O
,	O
an	O
immediate	O
erythematous	B-ADE
macule	I-ADE
was	O
observed	O
on	O
the	O
photopatch	O
test	O
site	O
of	O
mequitazine	B-Drug
directly	O
after	O
UV	O
exposure	O
which	O
was	O
similar	O
to	O
the	O
immediate	B-ADE
erythema	I-ADE
noted	O
in	O
chlorpromazine	O
photoallergy	O
.	O

-DOCSTART-	2298

Polymyoclonus	B-ADE
seizure	I-ADE
resulting	O
from	O
accidental	O
injection	O
of	O
tranexamic	B-Drug
acid	I-Drug
in	O
spinal	O
anesthesia	O
.	O

-DOCSTART-	85

Paradoxical	O
seizures	B-ADE
in	O
phenytoin	B-Drug
toxicity	O
.	O

-DOCSTART-	3143

Pemphigus	B-ADE
foliaceus	I-ADE
was	O
seen	O
in	O
a	O
patient	O
with	O
pulmonary	O
tuberculosis	O
during	O
rifampicin	B-Drug
therapy	O
.	O

-DOCSTART-	93

Pediatric	O
heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
:	O
management	O
with	O
Danaparoid	O
(	O
orgaran	O
)	O
.	O

-DOCSTART-	3167

It	O
is	O
presumed	O
that	O
her	O
hyperchloremic	B-ADE
metabolic	I-ADE
acidosis	I-ADE
was	O
secondary	O
to	O
cholestyramine	B-Drug
because	O
of	O
the	O
similarity	O
to	O
pediatric	O
reports	O
;	O
the	O
rapid	O
and	O
lasting	O
response	O
to	O
intravenous	O
sodium	O
bicarbonate	O
;	O
the	O
absence	O
of	O
another	O
etiology	O
;	O
normal	O
serum	O
potassium	O
,	O
chloride	O
and	O
bicarbonate	O
despite	O
continued	O
spironolactone	O
therapy	O
after	O
recovery	O
.	O

-DOCSTART-	1709

Exposure	O
of	O
the	O
fetus	O
to	O
indomethacin	B-Drug
by	O
administration	O
of	O
the	O
drug	O
to	O
the	O
mother	O
may	O
cause	O
many	O
side	O
effects	O
,	O
including	O
premature	B-ADE
closure	I-ADE
of	I-ADE
the	I-ADE
ductus	I-ADE
arteriosus	I-ADE
.	O

-DOCSTART-	1618

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
ivermectin	B-Drug
-	O
induced	O
severe	B-ADE
liver	I-ADE
disease	I-ADE
published	O
in	O
the	O
literature	O
.	O

-DOCSTART-	2016

CONCLUSIONS	O
:	O
Clinicians	O
treating	O
elderly	O
patients	O
with	O
olanzapine	B-Drug
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
rapidly	O
developing	O
hyperglycemia	B-ADE
and	O
monitor	O
such	O
patients	O
accordingly	O
.	O

-DOCSTART-	2758

A	O
case	O
of	O
allopurinol	B-Drug
hypersensitivity	B-ADE
,	O
possibly	O
the	O
first	O
in	O
a	O
black	O
African	O
,	O
is	O
reported	O
.	O

-DOCSTART-	3611

Mitomycin	B-Drug
C	I-Drug
(	O
MMC	B-Drug
)	O
is	O
an	O
alkylating	O
agent	O
that	O
has	O
been	O
recently	O
associated	O
with	O
the	O
hemolytic	B-ADE
-	I-ADE
uremic	I-ADE
syndrome	I-ADE
(	O
HUS	B-ADE
)	O
.	O

-DOCSTART-	1961

Palpable	B-ADE
purpuric	I-ADE
skin	I-ADE
lesions	I-ADE
on	O
the	O
anterior	O
surface	O
of	O
both	O
legs	O
appeared	O
on	O
the	O
55th	O
day	O
of	O
amphotericin	B-Drug
B	I-Drug
treatment	O
.	O

-DOCSTART-	265

Minocycline	B-Drug
as	O
a	O
cause	O
of	O
drug	O
-	O
induced	O
autoimmune	B-ADE
hepatitis	I-ADE
.	O

-DOCSTART-	2069

Anaphylactic	B-ADE
reaction	I-ADE
to	O
recombinant	B-Drug
insulin	I-Drug
-	I-Drug
like	I-Drug
growth	I-Drug
factor	I-Drug
-	I-Drug
I	I-Drug
.	O

-DOCSTART-	3565

Three	O
years	O
later	O
,	O
treatment	O
with	O
ampicillin	B-Drug
caused	O
another	O
episode	O
of	O
cholestatic	B-ADE
hepatitis	I-ADE
with	O
cholestasis	B-ADE
and	O
duct	B-ADE
paucity	I-ADE
on	O
rebiopsy	O
.	O

-DOCSTART-	3809

This	O
case	O
emphasizes	O
the	O
importance	O
of	O
the	O
evaluation	O
of	O
lithium	B-Drug
-	O
associated	O
polyuria	B-ADE
with	O
a	O
direct	O
measurement	O
of	O
plasma	O
vasopressin	O
,	O
interpreted	O
with	O
simultaneous	O
plasma	O
and	O
urine	O
osmolality	O
to	O
secure	O
the	O
correct	O
diagnosis	O
and	O
ensure	O
appropriate	O
therapeutic	O
management	O
.	O

-DOCSTART-	1828

Hepatic	B-ADE
damage	I-ADE
after	O
danazol	B-Drug
treatment	O
.	O

-DOCSTART-	3636

Myoclonus	B-ADE
and	O
seizures	B-ADE
in	O
a	O
patient	O
with	O
parkinsonism	O
:	O
induction	O
by	O
levodopa	B-Drug
and	O
its	O
confirmation	O
on	O
SEPs	O
.	O

-DOCSTART-	2066

CONCLUSIONS	O
:	O
Intrathecal	O
baclofen	B-Drug
can	O
impair	B-ADE
sexual	I-ADE
function	I-ADE
and	O
ejaculation	O
in	O
some	O
patients	O
.	O

-DOCSTART-	3449

RESULTS	O
:	O
At	O
our	O
institution	O
,	O
no	O
children	O
appeared	O
with	O
acute	O
INH	B-Drug
neurotoxicity	B-ADE
in	O
the	O
period	O
1985	O
through	O
1990	O
,	O
whereas	O
seven	O
patients	O
were	O
treated	O
from	O
1991	O
through	O
1993	O
.	O

-DOCSTART-	1915

It	O
has	O
been	O
reported	O
that	O
fluoroquinolone	B-Drug
antimicrobials	O
prolong	O
the	O
corrected	O
QT	O
interval	O
but	O
rarely	O
cause	O
torsade	B-ADE
de	I-ADE
pointes	I-ADE
.	O

-DOCSTART-	1488

The	O
authors	O
present	O
a	O
case	O
report	O
of	O
a	O
granulomatous	B-ADE
reaction	I-ADE
leading	O
to	O
urethral	B-ADE
prolapse	I-ADE
,	O
3	O
months	O
after	O
the	O
transurethral	O
injection	O
of	O
calcium	B-Drug
hydroxylapatite	I-Drug
.	O

-DOCSTART-	1816

Teicoplanin	B-Drug
-	O
induced	O
agranulocytosis	B-ADE
that	O
followed	O
vancomycin	B-Drug
-	O
induced	O
agranulocytosis	B-ADE
suggests	O
a	O
possible	O
cross	O
-	O
reactivity	O
between	O
the	O
2	O
drugs	O
.	O

-DOCSTART-	2239

To	O
our	O
knowledge	O
,	O
these	O
cases	O
represent	O
the	O
first	O
reports	O
of	O
TDF	B-Drug
-	O
associated	O
irreversible	B-ADE
renal	I-ADE
failure	I-ADE
and	O
rickets	B-ADE
in	O
pediatric	O
patients	O
.	O

-DOCSTART-	1929

Sulfasalazine	B-Drug
-	O
induced	O
hypersensitivity	B-ADE
syndrome	I-ADE
and	O
hemophagocytic	B-ADE
syndrome	I-ADE
associated	O
with	O
reactivation	O
of	O
Epstein	O
-	O
Barr	O
virus	O
.	O

-DOCSTART-	2875

Cyclosporin	B-Drug
side	O
effects	O
included	O
hirsutism	B-ADE
,	O
hypertension	B-ADE
,	O
increased	B-ADE
blood	I-ADE
levels	I-ADE
of	I-ADE
urea	I-ADE
and	I-ADE
creatinine	I-ADE
,	O
and	O
abnormalities	B-ADE
in	I-ADE
liver	I-ADE
function	I-ADE
tests	I-ADE
.	O

-DOCSTART-	3476

This	O
unusual	O
pattern	O
of	O
low	B-ADE
-	I-ADE
grade	I-ADE
endometrial	I-ADE
carcinoma	I-ADE
adds	O
to	O
the	O
spectrum	O
of	O
uterine	B-ADE
neoplasia	I-ADE
associated	O
with	O
tamoxifen	B-Drug
therapy	O
.	O

-DOCSTART-	160

The	O
spectrum	O
of	O
nitrofurantoin	B-Drug
lung	B-ADE
injury	I-ADE
continues	O
to	O
widen	O
.	O

-DOCSTART-	337

The	O
day	O
after	O
clozapine	B-Drug
was	O
stopped	O
,	O
while	O
he	O
was	O
still	O
receiving	O
clomipramine	B-Drug
150	O
mg	O
/	O
d	O
,	O
he	O
began	O
behaving	B-ADE
oddly	I-ADE
,	O
started	O
sweating	B-ADE
profusely	I-ADE
,	O
shivering	B-ADE
,	O
and	O
became	O
tremulous	B-ADE
,	O
agitated	B-ADE
,	O
and	O
confused	B-ADE
.	O

-DOCSTART-	2115

This	O
therapy	O
was	O
also	O
complicated	O
by	O
Warfarin	B-Drug
-	O
induced	O
skin	B-ADE
necrosis	I-ADE
.	O

-DOCSTART-	40

DISCUSSION	O
:	O
Olanzapine	B-Drug
,	O
like	O
other	O
atypical	O
antipsychotic	O
drugs	O
,	O
may	O
cause	O
muscle	B-ADE
injury	I-ADE
with	I-ADE
concomitant	I-ADE
elevations	I-ADE
of	I-ADE
serum	I-ADE
CK	I-ADE
of	O
muscle	O
origin	O
.	O

-DOCSTART-	3020

In	O
one	O
child	O
,	O
a	O
second	O
course	O
of	O
carbamazepine	B-Drug
resulted	O
in	O
a	O
return	O
of	O
the	O
dystonia	B-ADE
.	O

-DOCSTART-	2942

Atrioventricular	B-ADE
block	I-ADE
complicating	O
amiodarone	B-Drug
-	O
induced	O
hypothyroidism	B-ADE
in	O
a	O
patient	O
with	O
pre	O
-	O
excitation	O
and	O
rate	O
-	O
dependent	O
bilateral	O
bundle	O
branch	O
block	O
.	O

-DOCSTART-	2987

EEG	B-ADE
abnormalities	I-ADE
were	O
observed	O
in	O
two	O
of	O
the	O
nine	O
children	O
during	O
chlorambucil	B-Drug
therapy	O
.	O

-DOCSTART-	112

The	O
first	O
patient	O
was	O
a	O
61-year	O
-	O
old	O
man	O
with	O
a	O
30-year	O
history	O
of	O
fistulizing	O
CD	O
in	O
whom	O
B	B-ADE
-	I-ADE
cell	I-ADE
non	I-ADE
-	I-ADE
Hodgkin	I-ADE
's	I-ADE
lymphoma	I-ADE
was	O
diagnosed	O
9	O
months	O
after	O
treatment	O
with	O
infliximab	B-Drug
.	O

-DOCSTART-	1567

Fatal	B-ADE
lung	I-ADE
fibrosis	I-ADE
caused	O
by	O
paclitaxel	B-Drug
toxicity	O
has	O
not	O
been	O
reported	O
In	O
this	O
report	O
,	O
we	O
describe	O
the	O
case	O
of	O
a	O
62-year	O
-	O
old	O
woman	O
who	O
received	O
six	O
cycles	O
of	O
paclitaxel	B-Drug
and	O
carboplatin	B-Drug
as	O
combination	O
chemotherapy	O
for	O
advanced	O
ovarian	O
cancer	O
.	O

-DOCSTART-	202

The	O
authors	O
present	O
a	O
case	O
of	O
t	B-ADE
-	I-ADE
AML	I-ADE
that	O
developed	O
in	O
a	O
child	O
with	O
metastatic	O
neuroblastoma	O
18	O
months	O
after	O
he	O
received	O
oral	O
etoposide	B-Drug
,	O
given	O
for	O
palliation	O
purpose	O
.	O

-DOCSTART-	2966

Insulin	B-Drug
-	O
induced	O
cardiac	B-ADE
failure	I-ADE
.	O

-DOCSTART-	1631

We	O
report	O
on	O
a	O
patient	O
with	O
acromegaly	O
who	O
developed	O
severe	O
drug	O
-	O
induced	O
hepatitis	B-ADE
during	O
combined	O
treatment	O
with	O
the	O
long	O
-	O
acting	O
somatostatin	O
-	O
analog	O
octreotide	B-Drug
and	O
the	O
GH	O
receptor	O
antagonist	O
pegvisomant	B-Drug
.	O

-DOCSTART-	2617

Renal	B-ADE
failure	I-ADE
associated	O
with	O
the	O
use	O
of	O
dextran-40	B-Drug
.	O

-DOCSTART-	2835

Macular	B-ADE
infarction	I-ADE
after	O
endophthalmitis	O
treated	O
with	O
vitrectomy	O
and	O
intravitreal	O
gentamicin	B-Drug
.	O

-DOCSTART-	1041

Ciprofloxacin	B-Drug
-	O
induced	O
psychosis	B-ADE
.	O

-DOCSTART-	3789

Metipranolol	B-Drug
associated	O
granulomatous	B-ADE
anterior	I-ADE
uveitis	I-ADE
:	O
not	O
so	O
uncommon	O
as	O
thought	O
.	O

-DOCSTART-	1174

We	O
report	O
three	O
patients	O
,	O
all	O
of	O
whom	O
had	O
preexisting	O
diabetic	O
dyslipidemia	O
,	O
who	O
showed	O
a	O
profound	O
reduction	B-ADE
in	I-ADE
plasma	I-ADE
HDL	I-ADE
cholesterol	I-ADE
and	I-ADE
apolipoprotein	I-ADE
AI	I-ADE
levels	I-ADE
soon	O
after	O
the	O
initiation	O
of	O
rosiglitazone	B-Drug
therapy	O
.	O

-DOCSTART-	3774

Ifosfamide	B-Drug
-	O
induced	O
nonconvulsive	B-ADE
status	I-ADE
epilepticus	I-ADE
.	O

-DOCSTART-	1012

CASE	O
SUMMARY	O
:	O
Two	O
children	O
with	O
attention	O
deficit	O
disorder	O
treated	O
with	O
methylphenidate	B-Drug
as	O
a	O
simple	O
drug	O
developed	O
fixed	B-ADE
drug	I-ADE
eruption	I-ADE
of	I-ADE
the	I-ADE
scrotum	I-ADE
.	O

-DOCSTART-	3512

Flumazenil	O
reversal	O
of	O
benzodiazepine	B-Drug
-	O
induced	O
sedation	B-ADE
for	O
a	O
patient	O
with	O
severe	O
pre	O
-	O
ECT	O
anxiety	O
.	O

-DOCSTART-	2361

Linezolid	B-Drug
-	O
associated	O
acute	B-ADE
interstitial	I-ADE
nephritis	I-ADE
and	O
drug	B-ADE
rash	I-ADE
with	I-ADE
eosinophilia	I-ADE
and	I-ADE
systemic	I-ADE
symptoms	I-ADE
(	O
DRESS	B-ADE
)	O
syndrome	O
.	O

-DOCSTART-	3751

Jaundice	B-ADE
induced	O
by	O
streptokinase	B-Drug
.	O

-DOCSTART-	24

The	O
clinical	O
course	O
suggests	O
that	O
the	O
interstitial	B-ADE
pneumonitis	I-ADE
was	O
induced	O
by	O
hydroxyurea	B-Drug
.	O

-DOCSTART-	2322

Aripiprazole	B-Drug
-	O
induced	O
hiccups	B-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3687

Rhabdomyolysis	B-ADE
associated	O
with	O
the	O
use	O
of	O
intravenous	O
vasopressin	B-Drug
.	O

-DOCSTART-	1869

Investigation	O
confirmed	O
the	O
diagnosis	O
of	O
rhabdomyolysis	O
,	O
and	O
discontinuation	O
of	O
colchicine	B-Drug
resulted	O
in	O
resolution	O
of	O
clinical	O
and	O
biochemical	O
features	O
of	O
rhabdomylysis	B-ADE
.	O

-DOCSTART-	2125

BACKGROUND	O
:	O
Hydroxyurea	B-Drug
is	O
a	O
cytostatic	O
agent	O
used	O
to	O
treat	O
myeloproliferative	O
disorders	O
and	O
long	O
-	O
term	O
treatment	O
is	O
associated	O
with	O
mucocutaneous	B-ADE
adverse	I-ADE
events	I-ADE
and	O
nail	B-ADE
hyperpigmentation	I-ADE
.	O

-DOCSTART-	2893

Choanal	B-ADE
atresia	I-ADE
and	O
athelia	B-ADE
:	O
methimazole	B-Drug
teratogenicity	B-ADE
or	O
a	O
new	O
syndrome	O
?	O

-DOCSTART-	3924

Immunosuppression	O
elicited	O
by	O
the	O
extensive	O
administration	O
of	O
prednisolone	B-Drug
was	O
suspected	O
for	O
the	O
initiation	O
of	O
the	O
generalized	O
mite	B-ADE
infestation	I-ADE
.	O

-DOCSTART-	1165

5-fluorouracil	B-Drug
(	O
5-FU	B-Drug
)	O
-	O
associated	O
peripheral	B-ADE
neuropathy	I-ADE
is	O
an	O
uncommon	O
event	O
.	O

-DOCSTART-	987

CONCLUSIONS	O
:	O
Topiramate	B-Drug
may	O
be	O
associated	O
with	O
ciliochoroidal	B-ADE
effusion	I-ADE
with	O
forward	O
displacement	B-ADE
of	I-ADE
the	I-ADE
lens	I-ADE
-	I-ADE
iris	I-ADE
diaphragm	I-ADE
and	O
anterior	B-ADE
chamber	I-ADE
shallowing	I-ADE
,	O
resulting	O
in	O
acute	B-ADE
myopia	I-ADE
and	O
angle	B-ADE
-	I-ADE
closure	I-ADE
glaucoma	I-ADE
.	O

-DOCSTART-	599

Erythropoietin	O
is	O
beneficial	O
in	O
mitomycin	B-Drug
-	O
induced	O
hemolytic	B-ADE
-	I-ADE
uremic	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	3110

Alopecia	B-ADE
,	O
nausea	B-ADE
,	O
and	O
vomiting	B-ADE
were	O
attributed	O
to	O
the	O
cyclophosphamide	B-Drug
component	O
of	O
the	O
therapy	O
.	O

-DOCSTART-	757

This	O
is	O
a	O
case	O
report	O
of	O
subtle	O
,	O
mild	O
hypothermia	B-ADE
in	O
a	O
54-year	O
old	O
female	O
patient	O
receiving	O
risperidone	B-Drug
for	O
schizophrenia	O
.	O

-DOCSTART-	1797

Infliximab	B-Drug
and	O
its	O
serious	O
adverse	O
effects	O
are	O
discussed	O
,	O
and	O
other	O
cases	O
of	O
osteomyelitis	B-ADE
with	O
infliximab	B-Drug
use	O
are	O
also	O
reviewed	O
.	O

-DOCSTART-	2719

However	O
,	O
we	O
recently	O
saw	O
two	O
patients	O
with	O
renal	O
tuberculosis	O
treated	O
with	O
ethambutol	B-Drug
in	O
whom	O
visual	B-ADE
loss	I-ADE
from	O
toxic	B-ADE
optic	I-ADE
neuropathies	I-ADE
was	O
severe	O
and	O
irreversible	O
despite	O
careful	O
ophthalmological	O
monitoring	O
and	O
prompt	O
discontinuation	O
of	O
the	O
agent	O
at	O
the	O
first	O
sign	O
of	O
impaired	O
visual	O
function	O
.	O

-DOCSTART-	12

In	O
one	O
case	O
,	O
the	O
readministration	O
of	O
riluzole	B-Drug
was	O
followed	O
by	O
the	O
relapse	O
of	O
hepatitis	B-ADE
.	O

-DOCSTART-	858

Behavioral	O
side	O
effects	O
associated	O
with	O
clonazepam	B-Drug
may	O
include	O
agitation	B-ADE
,	O
aggression	B-ADE
,	O
hyperactivity	B-ADE
,	O
irritability	B-ADE
,	O
property	B-ADE
destruction	I-ADE
,	O
and	O
temper	B-ADE
tantrums	I-ADE
.	O

-DOCSTART-	2498

BACKGROUND	O
:	O
Aphthous	B-ADE
stomatitis	I-ADE
,	O
a	O
common	O
mucocutaneous	O
disorder	O
,	O
is	O
a	O
well	O
accepted	O
complication	O
of	O
sirolimus	B-Drug
therapy	O
.	O

-DOCSTART-	2304

The	O
mechanism	O
by	O
which	O
sunitinib	B-Drug
induces	O
gynaecomastia	B-ADE
is	O
thought	O
to	O
be	O
associated	O
with	O
an	O
unknown	O
direct	O
action	O
on	O
breast	O
hormonal	O
receptors	O
.	O

-DOCSTART-	2864

Worsening	B-ADE
of	I-ADE
neurologic	I-ADE
syndrome	I-ADE
in	O
patients	O
with	O
Wilson	O
's	O
disease	O
with	O
initial	O
penicillamine	B-Drug
therapy	O
.	O

-DOCSTART-	1461

Based	O
on	O
the	O
history	O
and	O
clinical	O
features	O
,	O
a	O
diagnosis	O
of	O
insulin	B-Drug
-	O
induced	O
lipohypertrophy	B-ADE
was	O
made	O
.	O

-DOCSTART-	1355

Abdominal	B-ADE
wall	I-ADE
ulceration	I-ADE
and	O
mucinosis	B-ADE
secondary	O
to	O
recombinant	B-Drug
human	I-Drug
interferon	I-Drug
-	I-Drug
beta-1b	I-Drug
.	O

-DOCSTART-	2608

This	O
is	O
a	O
unique	O
autopsy	O
case	O
of	O
hepatocellular	B-ADE
carcinoma	I-ADE
closely	O
related	O
to	O
diethylstilbestrol	B-Drug
(	O
DES	B-Drug
)	O
therapy	O
for	O
prostatic	O
cancer	O
.	O

-DOCSTART-	2273

In	O
this	O
case	O
,	O
CIPS	B-ADE
was	O
considered	O
to	O
be	O
probably	O
associated	O
with	O
cyclosporine	B-Drug
according	O
to	O
the	O
Naranjo	O
probability	O
scale	O
.	O

-DOCSTART-	1826

This	O
is	O
the	O
first	O
histologically	O
confirmed	O
case	O
of	O
NASH	B-ADE
that	O
was	O
aggravated	O
by	O
raloxifene	B-Drug
.	O

-DOCSTART-	1598

CONCLUSIONS	O
:	O
The	O
increasing	O
prevalence	O
of	O
Type	O
2	O
diabetes	O
and	O
its	O
treatment	O
with	O
metformin	B-Drug
might	O
result	O
in	O
more	O
cases	O
of	O
lactic	B-ADE
acidosis	I-ADE
.	O

-DOCSTART-	2292

Isoniazid	B-Drug
induced	O
gynaecomastia	B-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3885

Methotrexate	B-Drug
is	O
an	O
effective	O
but	O
potentially	B-ADE
toxic	I-ADE
treatment	O
for	O
psoriasis	O
.	O

-DOCSTART-	807

When	O
SASP	O
was	O
changed	O
to	O
5-aminosalicylic	B-Drug
acid	I-Drug
(	O
5-ASA	B-Drug
)	O
,	O
his	O
skin	O
eruptions	O
were	O
resolved	O
,	O
however	O
,	O
he	O
developed	O
weakness	B-ADE
and	O
atrophy	B-ADE
in	O
his	O
right	O
arm	O
as	O
well	O
as	O
progressive	O
worsening	B-ADE
of	I-ADE
the	I-ADE
dysesthesia	I-ADE
in	O
his	O
legs	O
and	O
gait	B-ADE
disturbance	I-ADE
.	O

-DOCSTART-	3136

These	O
findings	O
suggest	O
that	O
the	O
corneal	B-ADE
and	I-ADE
retinal	I-ADE
changes	I-ADE
are	O
the	O
result	O
of	O
a	O
toxic	O
effect	O
of	O
tamoxifen	B-Drug
when	O
used	O
in	O
the	O
doses	O
and	O
duration	O
described	O
.	O

-DOCSTART-	3156

This	O
was	O
accepted	O
as	O
evidence	O
for	O
propranolol	B-Drug
being	O
the	O
cause	O
of	O
this	O
conduction	B-ADE
disorder	I-ADE
.	O

-DOCSTART-	1326

After	O
only	O
the	O
third	O
dose	O
of	O
pentamidine	B-Drug
,	O
it	O
was	O
noted	O
that	O
the	O
patient	O
's	O
heart	B-ADE
rate	I-ADE
had	I-ADE
decreased	I-ADE
to	O
48	O
beats	O
/	O
minute	O
.	O

-DOCSTART-	866

Schneiderian	B-ADE
first	I-ADE
-	I-ADE
rank	I-ADE
symptoms	I-ADE
associated	O
with	O
fluvoxamine	B-Drug
treatment	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	758

Akathisia	B-ADE
is	O
a	O
relatively	O
rare	O
side	O
effect	O
with	O
the	O
newer	O
atypical	O
antipsychotic	O
agents	O
,	O
particularly	O
clozapine	B-Drug
,	O
and	O
is	O
easily	O
misdiagnosed	O
in	O
children	O
.	O

-DOCSTART-	330

Toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
after	O
the	O
use	O
of	O
high	O
-	O
dose	O
cytosine	B-Drug
arabinoside	I-Drug
.	O

-DOCSTART-	4057

Review	O
of	O
the	O
literature	O
relating	O
to	O
methicillin	B-Drug
-	O
induced	O
nephropathy	B-ADE
suggests	O
a	O
hypersensitivity	O
origin	O
for	O
this	O
disorder	O
,	O
but	O
immunologic	O
and	O
ultrastructural	O
investigation	O
to	O
date	O
has	O
failed	O
to	O
elucidate	O
pathogenesis	O
.	O

-DOCSTART-	1204

Previous	O
studies	O
have	O
demonstrated	O
the	O
interaction	O
of	O
MTX	B-Drug
and	O
a	O
variety	O
of	O
non	O
-	O
steroidal	O
,	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
with	O
various	O
clinical	O
manifestations	O
including	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
,	O
pancytopenia	B-ADE
,	O
vomiting	B-ADE
,	O
diarrhea	B-ADE
,	O
elevated	B-ADE
liver	I-ADE
transaminases	I-ADE
,	O
jaundice	B-ADE
,	O
mucosal	B-ADE
ulcerations	I-ADE
,	O
and	O
pyrexia	B-ADE
.	O

-DOCSTART-	3912

METHODS	O
/	O
RESULTS	O
:	O
This	O
paper	O
presents	O
a	O
new	O
case	O
of	O
rifabutin	B-Drug
uveitis	B-ADE
and	O
a	O
review	O
of	O
the	O
various	O
published	O
reports	O
to	O
date	O
.	O

-DOCSTART-	3688

These	O
multiple	O
overlapping	O
factors	O
probably	O
lead	O
to	O
rhabdomyolysis	B-ADE
in	O
a	O
minority	O
of	O
patients	O
receiving	O
vasopressin	B-Drug
infusion	O
.	O

-DOCSTART-	2563

Symptomatic	B-ADE
hypoglycemia	I-ADE
secondary	O
to	O
a	O
glipizide	B-Drug
-	O
trimethoprim	B-Drug
/	O
sulfamethoxazole	B-Drug
drug	O
interaction	O
.	O

-DOCSTART-	1159

An	O
objective	O
causality	O
assessment	O
indicated	O
a	O
probable	O
relationship	O
between	O
clotting	B-ADE
abnormality	I-ADE
and	O
warfarin	B-Drug
administration	O
,	O
although	O
the	O
degree	O
of	O
elevation	O
of	O
the	O
INR	O
was	O
unusual	O
in	O
the	O
light	O
of	O
the	O
daily	O
warfarin	O
dose	O
and	O
duration	O
of	O
its	O
exposure	O
.	O

-DOCSTART-	2632

Peripheral	B-ADE
nerve	I-ADE
dysfunction	I-ADE
is	O
a	O
potentially	O
serious	O
complication	O
of	O
high	O
-	O
dose	O
cytosine	B-Drug
arabinoside	I-Drug
.	O

-DOCSTART-	526

Isonicotinic	B-Drug
acid	I-Drug
hydrazide	I-Drug
induced	O
anagen	B-ADE
effluvium	I-ADE
and	O
associated	O
lichenoid	B-ADE
eruption	I-ADE
.	O

-DOCSTART-	1334

Vigabatrin	B-Drug
-	O
induced	O
visual	B-ADE
field	I-ADE
defects	I-ADE
are	O
at	O
present	O
the	O
most	O
important	O
safety	O
issue	O
in	O
the	O
use	O
of	O
the	O
drug	O
.	O

-DOCSTART-	2252

Bisphosphonate	B-Drug
-	O
related	O
osteonecrosis	B-ADE
of	I-ADE
the	I-ADE
skull	I-ADE
base	I-ADE
.	O

-DOCSTART-	3987

Lovastatin	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
possibly	O
associated	O
with	O
clarithromycin	B-Drug
and	O
azithromycin	B-Drug
.	O

-DOCSTART-	799

Anaphylaxis	B-ADE
from	O
isoniazid	B-Drug
is	O
a	O
possible	O
side	O
effect	O
to	O
this	O
commonly	O
prescribed	O
antibiotic	O
.	O

-DOCSTART-	984

In	O
conclusion	O
,	O
RSDS	B-ADE
is	O
a	O
relevant	O
osteoarticular	O
complication	O
in	O
patients	O
receiving	O
either	O
anticalcineurinic	O
drug	O
(	O
CyA	B-Drug
or	O
tacrolimus	B-Drug
)	O
,	O
even	O
under	O
monotherapy	O
or	O
with	O
a	O
low	O
steroid	O
dose	O
.	O

-DOCSTART-	291

Nail	B-ADE
staining	I-ADE
from	O
hydroquinone	B-Drug
cream	O
.	O

-DOCSTART-	2099

Angio	B-ADE
-	I-ADE
oedema	I-ADE
as	O
an	O
unusual	O
tolerable	O
side	O
effect	O
of	O
voriconazole	B-Drug
therapy	O
.	O

-DOCSTART-	2645

Life	O
-	O
threatening	O
acute	B-ADE
hyponatraemia	I-ADE
induced	O
by	O
low	O
dose	O
cyclophosphamide	B-Drug
and	O
indomethacin	B-Drug
.	O

-DOCSTART-	1001

Patients	O
receiving	O
amifostine	B-Drug
who	O
develop	O
only	O
fever	B-ADE
should	O
be	O
evaluated	O
for	O
an	O
adverse	O
drug	O
reaction	O
,	O
as	O
well	O
as	O
for	O
sepsis	B-ADE
and	O
fevers	B-ADE
of	I-ADE
neutropenia	I-ADE
,	O
and	O
it	O
may	O
be	O
necessary	O
to	O
discontinue	O
the	O
drug	O
.	O

-DOCSTART-	1858

Delusional	B-ADE
parasitosis	I-ADE
associated	O
with	O
phenelzine	B-Drug
.	O

-DOCSTART-	344

Differential	O
diagnoses	O
included	O
ocular	O
rosacea	O
with	O
cicatrizing	O
conjunctivitis	O
and	O
5-FU	B-Drug
-	O
induced	O
ectropion	B-ADE
.	O

-DOCSTART-	51

Acute	B-ADE
neutrophilic	I-ADE
dermatosis	I-ADE
induced	O
by	O
all	B-Drug
-	I-Drug
trans	I-Drug
-	I-Drug
retinoic	I-Drug
acid	I-Drug
treatment	O
for	O
acute	O
promyelocytic	O
leukemia	O
.	O

-DOCSTART-	4064

Ticlopidine	B-Drug
is	O
an	O
oral	O
antiplatelet	O
agent	O
frequently	O
utilized	O
in	O
the	O
treatment	O
of	O
cerebrovascular	O
disease	O
and	O
is	O
rarely	O
associated	O
with	O
severe	B-ADE
bone	I-ADE
marrow	I-ADE
suppression	I-ADE
,	O
typically	O
aplastic	B-ADE
anemia	I-ADE
.	O

-DOCSTART-	2927

We	O
report	O
a	O
case	O
of	O
penile	B-ADE
fibrosis	I-ADE
after	O
intracavernous	O
self	O
-	O
injection	O
of	O
a	O
combination	O
of	O
phentolamine	B-Drug
and	O
papaverine	B-Drug
.	O

-DOCSTART-	2140

We	O
report	O
the	O
first	O
case	O
of	O
a	O
54-year	O
-	O
old	O
Turkish	O
woman	O
who	O
presented	O
with	O
ceftriaxone	B-Drug
-	O
induced	O
FDE	B-ADE
.	O

-DOCSTART-	3694

Piritrexim	B-Drug
-	O
induced	O
pulmonary	B-ADE
toxicity	I-ADE
.	O

-DOCSTART-	3305

Nephrotic	B-ADE
syndrome	I-ADE
associated	O
with	O
lithium	B-Drug
therapy	O
.	O

-DOCSTART-	648

Retrospectively	O
,	O
bucillamine	B-Drug
was	O
believed	O
to	O
be	O
the	O
cause	O
of	O
the	O
giant	B-ADE
hypertrophy	I-ADE
because	O
of	O
its	O
structural	O
similarity	O
to	O
D	B-Drug
-	I-Drug
penicillamine	I-Drug
,	O
which	O
was	O
the	O
subject	O
of	O
an	O
abundance	O
of	O
reports	O
of	O
mammary	B-ADE
hyperplasia	I-ADE
.	O

-DOCSTART-	500

It	O
is	O
hoped	O
that	O
this	O
case	O
report	O
creates	O
awareness	O
that	O
ofloxacin	B-Drug
-	O
induced	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
is	O
possible	O
.	O

-DOCSTART-	1445

The	O
authors	O
report	O
five	O
additional	O
cases	O
of	O
capecitabine	B-Drug
-	O
induced	O
multifocal	B-ADE
leukoencephalopathy	I-ADE
.	O

-DOCSTART-	2026

There	O
are	O
,	O
however	O
,	O
case	O
studies	O
describing	O
patients	O
experiencing	O
recurrences	O
of	O
tics	B-ADE
following	O
treatment	O
with	O
atomoxetine	B-Drug
.	O

-DOCSTART-	1849

The	O
patient	O
developed	O
grade	O
3	O
capecitabine	B-Drug
-	O
induced	O
headache	B-ADE
.	O

-DOCSTART-	3390

Chlormadinone	B-Drug
acetate	I-Drug
withdrawal	B-ADE
syndrome	I-ADE
under	O
combined	O
androgen	O
blockade	O
for	O
advanced	O
prostate	O
cancer	O
.	O

-DOCSTART-	971

Treatment	O
with	O
infliximab	B-Drug
is	O
known	O
to	O
produce	O
an	O
increase	B-ADE
of	I-ADE
autoantibodies	I-ADE
(	O
antinuclear	B-ADE
antibodies	I-ADE
,	O
anti	B-ADE
-	I-ADE
double	I-ADE
-	I-ADE
stranded	I-ADE
DNA	I-ADE
)	O
,	O
but	O
not	O
clinical	O
disease	O
.	O

-DOCSTART-	2471

We	O
report	O
a	O
case	O
of	O
a	O
23-year	O
-	O
old	O
man	O
who	O
developed	O
a	O
vancomycin	B-Drug
-	O
induced	O
anaphylactic	B-ADE
reaction	I-ADE
in	O
the	O
treatment	O
of	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
infection	O
.	O

-DOCSTART-	597

After	O
identification	O
of	O
the	O
index	O
patient	O
,	O
additional	O
inquiry	O
revealed	O
that	O
the	O
patient	O
's	O
mother	O
was	O
hospitalized	O
previously	O
for	O
overwhelming	O
sepsis	B-ADE
associated	O
with	O
metamizole	B-Drug
use	O
.	O

-DOCSTART-	1916

Torsade	B-ADE
de	I-ADE
pointes	I-ADE
associated	O
with	O
moxifloxacin	B-Drug
:	O
a	O
rare	O
but	O
potentially	O
fatal	O
adverse	O
event	O
.	O

-DOCSTART-	3160

Pulmonary	B-ADE
fibrosis	I-ADE
subsequent	O
to	O
high	O
doses	O
of	O
CCNU	B-Drug
for	O
chronic	O
myeloid	O
leukemia	O
.	O

-DOCSTART-	3486

The	O
association	O
with	O
prolonged	O
unopposed	O
estrogen	O
-	O
like	O
stimulation	O
with	O
tamoxifen	B-Drug
as	O
a	O
possible	O
factor	O
in	O
the	O
development	O
of	O
ovarian	B-ADE
endometrioid	I-ADE
carcinoma	I-ADE
is	O
discussed	O
.	O

-DOCSTART-	2344

Complications	O
of	O
chemotherapy	O
for	O
a	O
synovial	O
sarcoma	O
in	O
an	O
eight	O
-	O
year	O
old	O
boy	O
included	O
cisplatinum	B-Drug
nephrotoxicity	B-ADE
and	O
adriamycin	B-Drug
cardiotoxicity	B-ADE
.	O

-DOCSTART-	1922

Pneumocystis	B-ADE
carinii	I-ADE
pneumonia	I-ADE
as	O
a	O
complication	O
of	O
methotrexate	B-Drug
treatment	O
of	O
asthma	O
.	O

-DOCSTART-	938

RTA	B-ADE
is	O
one	O
type	O
of	O
nephrotoxicity	B-ADE
induced	O
by	O
FK506	B-Drug
,	O
and	O
it	O
is	O
reversible	O
in	O
mild	O
cases	O
when	O
appropriately	O
treated	O
.	O

-DOCSTART-	940

The	O
mechanism	O
of	O
RTA	B-ADE
induced	O
by	O
FK506	B-Drug
has	O
not	O
yet	O
been	O
clearly	O
elucidated	O
.	O

-DOCSTART-	2502

Three	O
nephrotic	O
patients	O
who	O
had	O
reduced	O
renal	O
function	O
and	O
active	O
renal	O
disease	O
with	O
progressive	O
deterioration	O
of	O
renal	O
function	O
prior	O
to	O
the	O
use	O
of	O
MP	B-Drug
developed	O
transient	B-ADE
renal	I-ADE
failure	I-ADE
following	O
an	O
MP	B-Drug
pulse	O
therapy	O
.	O

-DOCSTART-	3605

Hyperammonemia	B-ADE
secondary	O
to	O
valproic	B-Drug
acid	I-Drug
as	O
a	O
cause	O
of	O
lethargy	B-ADE
in	O
a	O
postictal	O
patient	O
.	O

-DOCSTART-	4059

Methysergide	B-Drug
-	O
induced	O
retroperitoneal	B-ADE
fibrosis	I-ADE
:	O
successful	O
outcome	O
and	O
two	O
new	O
laboratory	O
features	O
.	O

-DOCSTART-	1300

We	O
report	O
a	O
case	O
of	O
interstitial	B-ADE
pneumonitis	I-ADE
induced	O
by	O
bicalutamide	B-Drug
and/or	O
leuprorelin	B-Drug
acetate	I-Drug
given	O
as	O
therapy	O
for	O
prostate	O
cancer	O
,	O
in	O
which	O
the	O
pneumonitis	O
was	O
successfully	O
managed	O
by	O
steroid	O
treatment	O
.	O

-DOCSTART-	109

This	O
case	O
report	O
describes	O
a	O
patient	O
who	O
was	O
previously	O
prescribed	O
alendronate	B-Drug
(	O
Fosamax	B-Drug
)	O
and	O
presented	O
with	O
postoperative	O
hypophosphatemia	B-ADE
and	O
hypocalcemic	B-ADE
tetany	I-ADE
after	O
bowel	O
preparation	O
with	O
Fleet	B-Drug
Phospho	I-Drug
-	I-Drug
Soda	I-Drug
.	O

-DOCSTART-	1573

Subfulminant	B-ADE
hepatitis	I-ADE
B	I-ADE
after	O
infliximab	B-Drug
in	O
Crohn	O
's	O
disease	O
:	O
need	O
for	O
HBV	O
-	O
screening	O
?	O

-DOCSTART-	716

A	O
second	O
possibility	O
is	O
an	O
interaction	O
between	O
clarithromycin	B-Drug
and	O
isradipine	B-Drug
,	O
potentially	O
increasing	B-ADE
the	I-ADE
hepatic	I-ADE
toxicity	I-ADE
of	O
isradipine	B-Drug
.	O

-DOCSTART-	784

Systemic	B-ADE
capillary	I-ADE
leak	I-ADE
syndrome	I-ADE
after	O
granulocyte	B-Drug
colony	I-Drug
-	I-Drug
stimulating	I-Drug
factor	I-Drug
(	O
G	B-Drug
-	I-Drug
CSF	I-Drug
)	O
.	O

-DOCSTART-	1255

These	O
cases	O
highlight	O
the	O
occurrence	O
of	O
livedo	B-ADE
reticularis	I-ADE
as	O
an	O
uncommon	O
side	O
-	O
effect	O
of	O
interferon	B-Drug
alpha	I-Drug
treatment	O
.	O

-DOCSTART-	319

Stevens	B-ADE
-	I-ADE
Johnson	I-ADE
syndrome	I-ADE
caused	O
by	O
the	O
antiretroviral	O
drug	O
nevirapine	B-Drug
.	O

-DOCSTART-	1009

Propecia	B-Drug
-	O
associated	O
bilateral	B-ADE
cataract	I-ADE
.	O

-DOCSTART-	1053

A	O
second	O
episode	O
of	O
jaundice	B-ADE
followed	O
the	O
intravaginal	O
administration	O
of	O
a	O
mixture	O
of	O
furazolidone	B-Drug
and	O
nifuroxime	B-Drug
.	O

-DOCSTART-	3949

Acute	B-ADE
asthma	I-ADE
associated	O
with	O
sustained	O
-	O
release	O
verapamil	B-Drug
.	O

-DOCSTART-	721

The	O
most	O
likely	O
cause	O
of	O
liver	B-ADE
failure	I-ADE
in	O
this	O
patient	O
was	O
,	O
therefore	O
,	O
clarithromycin	B-Drug
,	O
which	O
undergoes	O
hepatic	O
metabolism	O
and	O
has	O
been	O
reported	O
to	O
cause	O
fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
.	O

-DOCSTART-	3979

Clinical	O
signs	O
of	O
hypermagnesemia	B-ADE
are	O
an	O
uncommon	O
complication	O
following	O
oral	O
administration	O
of	O
magnesium	B-Drug
sulfate	I-Drug
.	O

-DOCSTART-	2939

Controversy	O
concerning	O
the	O
nephrotoxicity	B-ADE
of	O
lithium	B-Drug
is	O
discussed	O
,	O
and	O
recommendations	O
for	O
the	O
evaluation	O
of	O
renal	B-ADE
failure	I-ADE
during	O
lithium	B-Drug
therapy	O
are	O
provided	O
.	O

-DOCSTART-	995

Three	O
distinct	O
types	O
of	O
minocycline	B-Drug
-	O
induced	O
cutaneous	B-ADE
pigmentation	I-ADE
have	O
been	O
described	O
.	O

-DOCSTART-	3962

Methotrexate	B-Drug
-	O
induced	O
pneumonitis	B-ADE
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
and	O
psoriatic	O
arthritis	O
:	O
report	O
of	O
five	O
cases	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	2830

Because	O
the	O
cerebellar	B-ADE
toxicity	I-ADE
may	O
be	O
worsened	O
by	O
continuation	O
of	O
therapy	O
after	O
initial	O
onset	O
of	O
symptoms	O
,	O
prompt	O
termination	O
of	O
HDARAC	B-Drug
is	O
recommended	O
.	O

-DOCSTART-	2441

OBJECTIVE	O
:	O
The	O
authors	O
described	O
a	O
case	O
of	O
interferon	B-Drug
-	O
induced	O
psychosis	B-ADE
as	O
a	O
framework	O
to	O
review	O
the	O
literature	O
and	O
discuss	O
the	O
decision	O
to	O
pursue	O
antiviral	O
treatment	O
in	O
psychiatrically	O
ill	O
patients	O
with	O
hepatitis	O
C	O
.	O

-DOCSTART-	2095

Terlipressin	B-Drug
-	O
induced	O
ventricular	B-ADE
arrhythmia	I-ADE
.	O

-DOCSTART-	962

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
colchicine	B-Drug
-	O
induced	O
myopathy	B-ADE
in	O
a	O
teenager	O
with	O
familial	O
Mediterranean	O
fever	O
(	O
FMF	O
)	O
.	O

-DOCSTART-	1664

METHOD	O
:	O
Case	O
analysis	O
of	O
a	O
poly	O
-	O
drug	O
overdose	O
(	O
venlafaxine	B-Drug
,	O
topiramate	B-Drug
,	O
divalproex	B-Drug
sodium	I-Drug
,	O
risperidone	B-Drug
,	O
and	O
carbamazepine	B-Drug
)	O
presenting	O
with	O
mixed	O
SS	B-ADE
/	O
NMS	B-ADE
features	O
and	O
whose	O
clinical	O
management	O
suggests	O
a	O
practical	O
algorithm	O
for	O
treatment	O
of	O
undifferentiated	O
SS	O
/	O
NMS	O
in	O
critical	O
care	O
settings	O
.	O

-DOCSTART-	1807

Docetaxel	B-Drug
-	O
induced	O
Meibomian	B-ADE
duct	I-ADE
inflammation	I-ADE
and	I-ADE
blockage	I-ADE
leading	O
to	O
chalazion	B-ADE
formation	O
.	O

-DOCSTART-	2367

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
spontaneous	O
remission	O
of	O
MTX	B-Drug
-	O
associated	O
gastric	B-ADE
LPD	I-ADE
after	O
discontinuation	O
of	O
MTX	O
therapy	O
.	O

-DOCSTART-	723

CONCLUSION	O
:	O
Under	O
certain	O
circumstances	O
topical	O
brimonidine	B-Drug
can	O
cause	O
paradoxical	B-ADE
raised	I-ADE
IOP	I-ADE
necessitating	O
vigilance	O
in	O
follow	O
-	O
up	O
of	O
patients	O
on	O
topical	O
brimonidine	O
.	O

-DOCSTART-	2950

A	O
case	O
of	O
propranolol	B-Drug
overdose	O
complicated	O
by	O
esophageal	B-ADE
spasm	I-ADE
preventing	O
extrication	O
of	O
an	O
orogastric	O
lavage	O
tube	O
and	O
relieved	O
by	O
intravenous	O
glucagon	O
is	O
presented	O
.	O

-DOCSTART-	381

CONCLUSION	O
:	O
Significant	O
weight	B-ADE
loss	I-ADE
is	O
a	O
potential	O
adverse	O
event	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
leflunomide	B-Drug
.	O

-DOCSTART-	922

This	O
case	O
report	O
describes	O
a	O
38-year	O
-	O
old	O
male	O
in	O
whom	O
SIADH	B-ADE
was	O
strongly	O
suspected	O
secondary	O
to	O
Tegretol	B-Drug
therapy	O
to	O
control	O
a	O
seizure	O
disorder	O
.	O

-DOCSTART-	2255

Thrombocytopenia	B-ADE
with	O
or	O
without	O
microangiopathy	O
following	O
quinine	B-Drug
is	O
often	O
referred	O
to	O
as	O
quinine	O
"	O
hypersensitivity	O
.	O
"	O
When	O
schistocytes	O
are	O
present	O
it	O
is	O
frequently	O
termed	O
"	O
quinine	B-Drug
-	O
associated	O
TTP	B-ADE
/	I-ADE
HUS	I-ADE
.	O
"	O
A	O
severe	O
deficiency	O
of	O
the	O
vWF	O
-	O
cleaving	O
protease	O
,	O
ADAMTS13	O
,	O
is	O
associated	O
with	O
idiopathic	O
TTP	O
.	O

-DOCSTART-	2381

Dasatinib	B-Drug
-	O
induced	O
pleural	B-ADE
effusions	I-ADE
:	O
a	O
lymphatic	O
network	O
disorder	O
?	O

-DOCSTART-	686

We	O
herein	O
report	O
this	O
rare	O
case	O
of	O
acute	O
onset	O
of	O
nephrotic	B-ADE
syndrome	I-ADE
during	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
retreatment	O
.	O

-DOCSTART-	361

Clofazimine	B-Drug
enteropathy	B-ADE
caused	O
by	O
crystal	O
deposition	O
can	O
be	O
life	B-ADE
-	I-ADE
threatening	I-ADE
.	O

-DOCSTART-	2477

RESULTS	O
:	O
We	O
recently	O
experienced	O
a	O
case	O
of	O
fatal	O
erlotinib	B-Drug
-	O
induced	O
ILD	B-ADE
,	O
diagnosed	O
based	O
on	O
clinical	O
and	O
radiologic	O
findings	O
,	O
which	O
occurred	O
in	O
a	O
patient	O
with	O
radiation	O
fibrosis	O
.	O

-DOCSTART-	432

Myasthenia	B-ADE
gravis	I-ADE
during	O
low	O
-	O
dose	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
therapy	O
for	O
chronic	O
hepatitis	O
C	O
.	O

-DOCSTART-	1945

Metronidazole	B-Drug
neuropathy	B-ADE
.	O

-DOCSTART-	2604

In	O
addition	O
,	O
the	O
tachycardia	B-ADE
persisted	O
and	O
was	O
repeatedly	O
spontaneously	O
reinitiated	O
for	O
prolonged	O
periods	O
after	O
procainamide	B-Drug
.	O

-DOCSTART-	1303

PURPOSE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
report	O
on	O
the	O
possible	O
development	O
of	O
corneal	B-ADE
endothelial	I-ADE
deposits	I-ADE
resulting	O
from	O
the	O
use	O
of	O
rifabutin	B-Drug
.	O

-DOCSTART-	770

His	O
fever	O
resolved	O
,	O
but	O
he	O
developed	O
symptoms	O
consistent	O
with	O
those	O
of	O
chloroquine	B-ADE
toxicity	I-ADE
.	O

-DOCSTART-	14

Lupus	B-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
caused	O
by	O
5-aminosalicylic	B-Drug
acid	I-Drug
in	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
.	O

-DOCSTART-	3778

Although	O
a	O
few	O
case	O
reports	O
link	O
metronidazole	B-Drug
with	O
the	O
development	O
of	O
pseudomembranous	B-ADE
colitis	I-ADE
,	O
albendazole	O
has	O
not	O
been	O
associated	O
with	O
the	O
development	O
of	O
this	O
condition	O
.	O

-DOCSTART-	4197

Within	O
6	O
months	O
of	O
pranlukast	B-Drug
withdrawal	O
,	O
anemia	B-ADE
resolved	O
and	O
urinary	O
sediment	O
and	O
renal	O
function	O
normalized	O
.	O

-DOCSTART-	2385

Amikacin	B-Drug
-	O
induced	O
type	B-ADE
5	I-ADE
Bartter	I-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
with	O
severe	B-ADE
hypocalcemia	I-ADE
.	O

-DOCSTART-	2561

Insulin	B-ADE
-	I-ADE
dependent	I-ADE
diabetes	I-ADE
mellitus	I-ADE
developed	O
in	O
a	O
young	O
woman	O
8	O
weeks	O
after	O
the	O
initiation	O
of	O
danazol	B-Drug
for	O
treatment	O
of	O
pelvic	O
endometriosis	O
.	O

-DOCSTART-	234

Muscle	O
biopsy	O
revealed	O
variation	B-ADE
in	I-ADE
muscle	I-ADE
fiber	I-ADE
size	I-ADE
and	O
few	O
vacuolated	B-ADE
fibers	I-ADE
which	O
were	O
features	O
of	O
colchicine	B-Drug
-	O
induced	O
myopathy	B-ADE
.	O

-DOCSTART-	388

She	O
developed	O
neurotoxicity	B-ADE
with	O
an	O
adjustment	O
dosage	O
of	O
valacyclovir	B-Drug
for	O
a	O
cutaneous	O
zoster	O
infection	O
.	O

-DOCSTART-	1288

However	O
,	O
one	O
patient	O
exhibited	O
severe	B-ADE
hypersensitivity	I-ADE
reactions	I-ADE
including	O
cardiac	B-ADE
arrest	I-ADE
and	O
apnea	B-ADE
,	O
and	O
another	O
four	O
patients	O
developed	O
eruptions	B-ADE
,	O
hypotension	B-ADE
,	O
and	O
tachycardia	B-ADE
soon	O
after	O
administration	O
of	O
CBDCA	B-Drug
.	O

-DOCSTART-	1054

A	O
case	O
of	O
phenobarbital	B-Drug
exacerbation	B-ADE
of	I-ADE
a	I-ADE
preexisting	I-ADE
maladaptive	I-ADE
behavior	I-ADE
partially	O
suppressed	O
by	O
chlorpromazine	O
and	O
misinterpreted	O
as	O
chlorpromazine	O
efficacy	O
.	O

-DOCSTART-	3684

Thus	O
,	O
the	O
eosinophilia	B-ADE
myalgia	I-ADE
syndrome	I-ADE
can	O
be	O
associated	O
with	O
parenteral	O
tryptophan	B-Drug
administration	O
.	O

-DOCSTART-	949

In	O
this	O
article	O
lithium	O
is	O
not	O
discussed	O
,	O
although	O
there	O
are	O
a	O
number	O
of	O
concerns	O
about	O
lithium	B-Drug
's	O
potential	O
teratogenicity	B-ADE
,	O
and	O
it	O
has	O
been	O
implicated	O
in	O
Epstein	B-ADE
's	I-ADE
anomaly	I-ADE
,	O
a	O
congenital	O
heart	O
defect	O
among	O
infants	O
born	O
to	O
women	O
taking	O
lithium	B-Drug
;	O
as	O
with	O
other	O
medications	O
,	O
however	O
,	O
the	O
data	O
have	O
specific	O
limitations	O
.	O

-DOCSTART-	994

This	O
fourth	O
type	O
of	O
cutaneous	O
minocycline	B-Drug
hyperpigmentation	B-ADE
may	O
be	O
a	O
variant	O
of	O
Type	O
I	O
,	O
but	O
based	O
on	O
clinical	O
,	O
pathological	O
and	O
microanalytical	O
differences	O
,	O
appears	O
to	O
be	O
a	O
new	O
entity	O
.	O

-DOCSTART-	1252

We	O
report	O
a	O
44-year	O
-	O
old	O
woman	O
with	O
t	O
-	O
MDS	O
(	O
refractory	B-ADE
anemia	I-ADE
with	I-ADE
excess	I-ADE
blasts	I-ADE
)	O
following	O
treatment	O
of	O
recurrent	O
anaplastic	O
astrocytoma	O
with	O
temozolomide	B-Drug
(	O
TMZ	B-Drug
)	O
.	O

-DOCSTART-	1142

Disulfiram	B-Drug
-	O
induced	O
fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
in	O
an	O
active	O
duty	O
soldier	O
.	O

-DOCSTART-	1466

An	O
objective	O
causality	O
assessment	O
suggests	O
that	O
the	O
JHR	B-ADE
in	O
our	O
patient	O
was	O
probably	O
related	O
to	O
penicillin	B-Drug
.	O

-DOCSTART-	2333

Possible	O
mechanisms	O
for	O
damage	B-ADE
to	I-ADE
the	I-ADE
urothelium	I-ADE
by	O
ketamine	B-Drug
are	O
suggested	O
.	O

-DOCSTART-	3715

We	O
have	O
seen	O
a	O
case	O
of	O
terminal	O
malignant	O
melanoma	O
in	O
which	O
clinical	O
manifestations	O
,	O
indicative	O
of	O
anterior	B-ADE
spinal	I-ADE
artery	I-ADE
syndrome	I-ADE
,	O
developed	O
following	O
the	O
injection	O
of	O
0.3	O
ml	O
of	O
10	O
%	O
phenol	B-Drug
-	I-Drug
glycerine	I-Drug
into	O
the	O
cervical	O
subarachnoid	O
space	O
at	O
the	O
C4	O
-	O
-C5	O
level	O
for	O
the	O
control	O
of	O
severe	O
right	O
arm	O
pain	O
.	O

-DOCSTART-	990

Doxycycline	B-Drug
-	O
induced	O
photo	B-ADE
-	I-ADE
onycholysis	I-ADE
.	O

-DOCSTART-	926

Masculinization	B-ADE
of	I-ADE
a	I-ADE
female	I-ADE
fetus	I-ADE
occurred	O
in	O
5	O
of	O
39	O
(	O
12.8	O
%	O
)	O
exposed	O
to	O
norethisterone	B-Drug
;	O
all	O
were	O
cases	O
of	O
clitoral	B-ADE
hypertrophy	I-ADE
not	O
requiring	O
surgical	O
treatment	O
.	O

-DOCSTART-	2654

A	O
patient	O
with	O
chronic	O
myeloid	O
leukaemia	O
treated	O
with	O
busulphan	B-Drug
for	O
4	O
-	O
5	O
years	O
,	O
developed	O
signs	O
of	O
busulphan	O
toxicity	O
and	O
portal	B-ADE
hypertension	I-ADE
with	O
ascites	B-ADE
,	O
oesophageal	B-ADE
varices	I-ADE
and	O
jaundice	B-ADE
.	O

-DOCSTART-	914

Asterixis	B-ADE
induced	O
by	O
carbamazepine	B-Drug
therapy	O
.	O

-DOCSTART-	1665

Fever	B-ADE
and	O
maculopapular	B-ADE
rashes	I-ADE
appeared	O
at	O
10	O
days	O
after	O
phenytoin	B-Drug
initiation	O
,	O
and	O
then	O
the	O
drug	O
was	O
discontinued	O
.	O

-DOCSTART-	3252

Intrahepatic	B-ADE
cholestasis	I-ADE
and	O
sicca	B-ADE
complex	I-ADE
after	O
thiabendazole	B-Drug
.	O

-DOCSTART-	277

Acute	B-ADE
pancreatitis	I-ADE
in	O
a	O
child	O
with	O
idiopathic	O
ulcerative	O
colitis	O
on	O
long	O
-	O
term	O
5-aminosalicylic	B-Drug
acid	I-Drug
therapy	O
.	O

-DOCSTART-	4204

Naproxen	B-Drug
-	O
associated	O
sudden	B-ADE
sensorineural	I-ADE
hearing	I-ADE
loss	I-ADE
.	O

-DOCSTART-	3051

A	O
patient	O
with	O
coccidioidal	O
meningitis	O
was	O
treated	O
with	O
intrathecally	O
administered	O
amphotericin	B-Drug
B	I-Drug
,	O
and	O
an	O
acute	B-ADE
toxic	I-ADE
delirium	I-ADE
with	O
EEG	B-ADE
abnormalities	I-ADE
developed	O
.	O

-DOCSTART-	818

Interferon	B-Drug
-	I-Drug
alpha	I-Drug
-	O
induced	O
focal	B-ADE
segmental	I-ADE
glomerulosclerosis	I-ADE
in	O
chronic	O
myelogenous	O
leukemia	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	1731

Hepatotoxicity	B-ADE
induced	O
by	O
cyproterone	B-Drug
acetate	I-Drug
:	O
a	O
report	O
of	O
three	O
cases	O
.	O

-DOCSTART-	2902

Severe	B-ADE
hyperkalemia	I-ADE
as	O
a	O
complication	O
of	O
timolol	B-Drug
,	O
a	O
topically	O
applied	O
beta	O
-	O
adrenergic	O
antagonist	O
.	O

-DOCSTART-	577

DISCUSSION	O
:	O
After	O
exclusion	O
of	O
other	O
causes	O
,	O
the	O
onset	O
of	O
thrombocytopenia	B-ADE
after	O
administration	O
of	O
lansoprazole	B-Drug
,	O
the	O
resolution	O
of	O
the	O
adverse	O
reaction	O
after	O
discontinuation	O
of	O
the	O
drug	O
,	O
and	O
the	O
fact	O
that	O
no	O
other	O
medicines	O
were	O
introduced	O
during	O
this	O
time	O
frame	O
lead	O
us	O
to	O
believe	O
that	O
this	O
was	O
most	O
likely	O
an	O
idiosyncratic	O
thrombocytopenic	B-ADE
response	O
to	O
lansoprazole	B-Drug
.	O

-DOCSTART-	3723

Nabumetone	B-Drug
-	O
associated	O
interstitial	B-ADE
nephritis	I-ADE
.	O

-DOCSTART-	3536

Systemic	O
disease	O
,	O
most	O
commonly	O
renal	O
dysfunction	O
,	O
preceded	O
all	O
30	O
reported	O
cases	O
of	O
acyclovir	B-Drug
neurotoxicity	B-ADE
.	O

-DOCSTART-	1238

Thalidomide	B-Drug
was	O
withdrawn	O
from	O
world	O
markets	O
in	O
1961	O
following	O
recognition	O
of	O
its	O
teratogenic	B-ADE
effects	I-ADE
.	O

-DOCSTART-	585

Agranulocytosis	B-ADE
during	O
clozapine	B-Drug
therapy	O
.	O

-DOCSTART-	4065

Hemodialysis	O
was	O
also	O
shown	O
to	O
reverse	O
ifosfamide	B-Drug
-	O
related	O
neurotoxicity	B-ADE
.	O

-DOCSTART-	3815

Human	B-Drug
insulin	I-Drug
-	O
induced	O
lipoatrophy	B-ADE
.	O

-DOCSTART-	1829

Hypersensitivity	B-ADE
pneumonitis	I-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
associated	O
with	O
the	O
use	O
of	O
lenalidomide	B-Drug
.	O

-DOCSTART-	1913

This	O
case	O
and	O
other	O
published	O
evidence	O
should	O
alert	O
physicians	O
to	O
the	O
possibility	O
of	O
fatal	O
erlotinib	B-Drug
-	O
induced	O
ILD	B-ADE
.	O

-DOCSTART-	864

Argatroban	B-Drug
is	O
hepatically	O
cleared	O
and	O
may	O
be	O
the	O
preferred	O
direct	O
thrombin	O
inhibitor	O
in	O
the	O
presence	O
of	O
significant	O
renal	O
impairment	O
,	O
but	O
conversely	O
has	O
prolonged	O
effects	O
in	O
hepatic	B-ADE
failure	I-ADE
.	O

-DOCSTART-	4018

Two	O
patients	O
with	O
ovarian	O
cancer	O
who	O
had	O
received	O
multiple	O
courses	O
of	O
cisplatin	B-Drug
without	O
complications	O
experienced	O
hypersensitivity	B-ADE
reactions	I-ADE
to	O
cisplatin	B-Drug
:	O
one	O
,	O
involving	O
intrahepatic	O
artery	O
infusion	O
,	O
manifested	O
general	B-ADE
erythema	I-ADE
,	O
dyspnea	B-ADE
,	O
and	O
hypotension	B-ADE
;	O
the	O
other	O
,	O
involving	O
intravenous	O
infusion	O
,	O
manifested	O
abdominal	B-ADE
pain	I-ADE
,	O
general	B-ADE
erythema	I-ADE
,	O
and	O
fever	B-ADE
.	O

-DOCSTART-	44

This	O
patient	O
,	O
who	O
had	O
a	O
history	O
of	O
osteoarthritis	O
,	O
had	O
severe	O
hepatitis	B-ADE
5	O
weeks	O
after	O
being	O
started	O
on	O
diclofenac	B-Drug
for	O
increasing	O
pain	O
in	O
the	O
joints	O
.	O

-DOCSTART-	2169

DISCUSSION	O
:	O
The	O
main	O
adverse	O
effects	O
of	O
leflunomide	B-Drug
consist	O
of	O
diarrhea	B-ADE
,	O
nausea	B-ADE
,	O
liver	B-ADE
enzyme	I-ADE
elevation	I-ADE
,	O
hypertension	B-ADE
,	O
alopecia	B-ADE
,	O
and	O
allergic	B-ADE
skin	I-ADE
reactions	I-ADE
.	O

-DOCSTART-	4092

We	O
present	O
the	O
first	O
case	O
of	O
a	O
patient	O
with	O
priapism	B-ADE
after	O
oral	O
intake	O
of	O
the	O
phenothiazine	O
prothipendylhydrochloride	B-Drug
.	O

-DOCSTART-	2825

This	O
case	O
supports	O
the	O
view	O
that	O
in	O
gold	B-Drug
-	O
induced	O
pneumonitis	B-ADE
a	O
prolonged	O
treatment	O
with	O
corticosteroids	O
may	O
be	O
necessary	O
,	O
as	O
lung	O
function	O
continued	O
to	O
improve	O
.	O

-DOCSTART-	3255

Intracranial	B-ADE
hemorrhage	I-ADE
and	O
focal	B-ADE
seizures	I-ADE
secondary	O
to	O
use	O
of	O
L	B-Drug
-	I-Drug
asparaginase	I-Drug
during	O
induction	O
therapy	O
of	O
acute	O
lymphocytic	O
leukemia	O
.	O

-DOCSTART-	726

Although	O
gabapentin	B-Drug
withdrawal	O
has	O
been	O
previously	O
reported	O
and	O
usually	O
consists	O
of	O
anxiety	B-ADE
,	O
diaphoresis	B-ADE
,	O
and	O
palpitations	B-ADE
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
generalized	B-ADE
seizures	I-ADE
and	O
status	B-ADE
epilepticus	I-ADE
secondary	O
to	O
gabapentin	B-Drug
withdrawal	O
.	O

-DOCSTART-	2600

Bleomycin	B-Drug
pneumonitis	B-ADE
potentiated	O
by	O
oxygen	O
administration	O
.	O

-DOCSTART-	1181

Itch	B-ADE
and	O
skin	B-ADE
rash	I-ADE
from	O
chocolate	O
during	O
fluoxetine	B-Drug
and	O
sertraline	B-Drug
treatment	O
:	O
case	O
report	O
.	O

-DOCSTART-	629

Two	O
cases	O
of	O
polymorphic	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
induced	O
by	O
the	O
administration	O
of	O
verapamil	B-Drug
against	O
paroxysmal	O
supraventricular	O
tachycardia	O
.	O

-DOCSTART-	1028

After	O
infliximab	B-Drug
treatment	O
,	O
additional	O
sleep	O
studies	O
revealed	O
an	O
increase	B-ADE
in	I-ADE
the	I-ADE
number	I-ADE
of	I-ADE
apneic	I-ADE
events	I-ADE
and	O
SaO2	B-ADE
dips	I-ADE
suggesting	O
that	O
TNFalpha	O
plays	O
an	O
important	O
role	O
in	O
the	O
pathophysiology	O
of	O
sleep	O
apnea	O
.	O

-DOCSTART-	1211

Allergic	O
side	O
effects	O
of	O
AZA	B-Drug
are	O
rare	O
,	O
and	O
reported	O
allergic	B-ADE
skin	I-ADE
eruptions	I-ADE
from	O
AZA	B-Drug
are	O
very	O
limited	O
in	O
Japan	O
.	O

-DOCSTART-	4098

Second	B-ADE
cancers	I-ADE
including	O
various	O
types	O
of	O
hematological	B-ADE
malignancy	I-ADE
have	O
been	O
reported	O
in	O
patients	O
with	O
hairy	O
cell	O
leukemia	O
treated	O
with	O
chemotherapy	O
or	O
interferon	B-Drug
alfa	I-Drug
.	O

-DOCSTART-	2596

The	O
ototoxicity	B-ADE
of	O
quinine	B-Drug
can	O
accurately	O
be	O
studied	O
with	O
ultrahigh	O
frequency	O
audiometry	O
(	O
up	O
to	O
20	O
kHz	O
)	O
.	O

-DOCSTART-	3155

The	O
abnormal	B-ADE
rhythm	I-ADE
disappeared	O
with	O
the	O
withdrawal	O
of	O
propranolol	B-Drug
and	O
when	O
the	O
drug	O
was	O
restarted	O
a	O
2/1	O
S	O
-	O
A	O
block	O
was	O
seen	O
.	O

-DOCSTART-	447

We	O
report	O
a	O
case	O
of	O
papillary	B-ADE
necrosis	I-ADE
in	O
a	O
patient	O
treated	O
with	O
indinavir	B-Drug
.	O

-DOCSTART-	2973

In	O
all	O
the	O
patients	O
,	O
pellagra	B-ADE
symptoms	O
appeared	O
during	O
isoniazid	B-Drug
therapy	O
.	O

-DOCSTART-	4126

A	O
case	O
of	O
prolonged	O
suxamethonium	B-Drug
apnoea	B-ADE
successfully	O
terminated	O
by	O
the	O
infusion	O
of	O
a	O
commercial	O
preparation	O
of	O
serumcholinesterase	O
is	O
reported	O
.	O

-DOCSTART-	190

Fluoxetine	B-Drug
-	O
related	O
death	B-ADE
in	O
a	O
child	O
with	O
cytochrome	O
P-450	O
2D6	O
genetic	O
deficiency	O
.	O

-DOCSTART-	1860

The	O
use	O
of	O
rituximab	B-Drug
has	O
been	O
uncommonly	O
associated	O
with	O
delayed	B-ADE
pulmonary	I-ADE
toxicity	I-ADE
.	O

-DOCSTART-	633

Neonatal	O
mydriasis	B-ADE
:	O
intravenous	O
lidocaine	B-Drug
adverse	O
reaction	O
.	O

-DOCSTART-	1952

Embolia	B-ADE
cutis	I-ADE
medicamentosa	I-ADE
following	O
subcutaneous	O
injection	O
of	O
glatiramer	B-Drug
acetate	I-Drug
.	O

-DOCSTART-	243

This	O
is	O
the	O
second	O
report	O
of	O
lactic	B-ADE
acidosis	I-ADE
in	O
a	O
patient	O
on	O
stavudine	B-Drug
and	O
lamivudine	B-Drug
.	O

-DOCSTART-	514

This	O
report	O
presents	O
a	O
case	O
of	O
acute	B-ADE
lung	I-ADE
injury	I-ADE
developing	O
within	O
hours	O
after	O
administration	O
of	O
mefloquine	B-Drug
for	O
a	O
low	O
-	O
level	O
Plasmodium	O
falciparum	O
malaria	O
,	O
which	O
was	O
persistent	O
despite	O
halofantrine	O
therapy	O
.	O

-DOCSTART-	1788

The	O
most	O
serious	O
dental	O
side	O
effect	O
of	O
bisphosphonate	B-Drug
treatment	O
(	O
particularly	O
when	O
it	O
is	O
administered	O
intravenously	O
)	O
is	O
,	O
paradoxically	O
,	O
osteonecrosis	B-ADE
of	I-ADE
the	I-ADE
mandible	I-ADE
or	O
the	O
maxilla	O
represented	O
by	O
exposed	O
nonhealing	O
bone	O
.	O

-DOCSTART-	25

This	O
is	O
the	O
first	O
case	O
of	O
hydroxyurea	B-Drug
-	O
induced	O
acute	B-ADE
interstitial	I-ADE
pneumonitis	I-ADE
reported	O
in	O
the	O
literature	O
.	O

-DOCSTART-	1832

Thus	O
,	O
the	O
patient	O
's	O
clinical	O
course	O
and	O
workup	O
strongly	O
support	O
a	O
diagnosis	O
of	O
lenalidomide	B-Drug
-	O
induced	O
hypersensitivity	B-ADE
pneumonitis	I-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1761

The	O
case	O
is	O
presented	O
of	O
a	O
72-year	O
-	O
old	O
man	O
with	O
hormone	O
-	O
refractory	O
prostate	O
cancer	O
and	O
weekly	O
administration	O
of	O
30	O
mg	O
/	O
m2	O
docetaxel	B-Drug
who	O
developed	O
subacute	B-ADE
interstitial	I-ADE
pneumonitis	I-ADE
-	I-ADE
related	I-ADE
pulmonary	I-ADE
fibrosis	I-ADE
after	O
seven	O
doses	O
and	O
died	O
despite	O
mechanical	O
ventilation	O
and	O
high	O
-	O
dose	O
corticosteroid	O
treatment	O
.	O

-DOCSTART-	1850

We	O
hypothesize	O
that	O
capecitabine	B-Drug
-	O
induced	O
headache	B-ADE
is	O
vascular	O
in	O
nature	O
.	O

-DOCSTART-	3159

Although	O
lung	O
specimens	O
were	O
lacking	O
from	O
these	O
three	O
patients	O
,	O
it	O
is	O
suggested	O
that	O
the	O
pulmonary	B-ADE
toxicity	I-ADE
of	O
CCNU	B-Drug
may	O
be	O
dose	O
-	O
related	O
.	O

-DOCSTART-	1390

Gemcitabine	B-Drug
therapy	O
has	O
been	O
associated	O
with	O
radiation	B-ADE
recall	I-ADE
reactions	I-ADE
when	O
used	O
in	O
the	O
treatment	O
of	O
carcinoma	O
.	O

-DOCSTART-	2334

Presentation	O
of	O
three	O
palliative	O
care	O
patients	O
who	O
were	O
given	O
ketamine	B-Drug
as	O
an	O
analgesic	O
and	O
subsequently	O
developed	O
significant	O
and	O
debilitating	O
urological	B-ADE
symptoms	I-ADE
.	O

-DOCSTART-	528

Linear	B-ADE
IgA	I-ADE
bullous	I-ADE
dermatosis	I-ADE
occurring	O
after	O
carbamazepine	B-Drug
.	O

-DOCSTART-	3331

Progressive	B-ADE
interstitial	I-ADE
fibrosis	I-ADE
with	O
roentgenographic	O
honeycombing	O
developed	O
in	O
the	O
case	O
of	O
a	O
psoriatic	O
patient	O
who	O
had	O
been	O
on	O
a	O
regimen	O
of	O
methotrexate	B-Drug
for	O
18	O
years	O
.	O

-DOCSTART-	2156

The	O
occurrence	O
of	O
symptoms	O
that	O
could	O
be	O
ascribed	O
to	O
an	O
acute	B-ADE
coronary	I-ADE
syndrome	I-ADE
should	O
always	O
be	O
taken	O
seriously	O
during	O
the	O
first	O
rituximab	B-Drug
infusion	O
and	O
investigated	O
aggressively	O
.	O

-DOCSTART-	4039

Skin	B-ADE
necrosis	I-ADE
is	O
a	O
rare	O
complication	O
of	O
subcutaneous	O
heparin	B-Drug
therapy	O
that	O
usually	O
occurs	O
at	O
injection	O
sites	O
.	O

-DOCSTART-	255

There	O
have	O
been	O
many	O
reports	O
of	O
probable	O
lithium	B-Drug
-	O
induced	O
organic	B-ADE
brain	I-ADE
syndromes	I-ADE
occurring	O
when	O
serum	O
lithium	O
levels	O
are	O
within	O
or	O
close	O
to	O
the	O
therapeutic	O
range	O
.	O

-DOCSTART-	2008

Hyponatraemia	B-ADE
developed	O
after	O
rechallenge	O
with	O
controlled	O
release	O
carbamazepine	B-Drug
.	O

-DOCSTART-	2717

Neurologic	B-ADE
toxicity	I-ADE
associated	O
with	O
hepatic	O
artery	O
infusion	O
HAI	O
of	O
FUdR	B-Drug
.	O

-DOCSTART-	2218

Methotrexate	B-Drug
induced	O
sprue	B-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	2675

After	O
the	O
chlorambucil	B-Drug
was	O
discontinued	O
,	O
the	O
wbc	O
count	O
began	O
to	O
slowly	O
rise	O
and	O
the	O
patient	O
developed	O
clinical	O
AML	B-ADE
.	O

-DOCSTART-	3282

Papilledema	B-ADE
without	O
peripheral	O
neuropathy	O
in	O
a	O
patient	O
taking	O
perhexiline	B-Drug
maleate	I-Drug
.	O

-DOCSTART-	1093

Sudden	B-ADE
cardiac	I-ADE
death	I-ADE
due	O
to	O
hypersensitivity	B-ADE
myocarditis	I-ADE
during	O
clozapine	B-Drug
treatment	O
.	O

-DOCSTART-	3313

On	O
the	O
second	O
day	O
of	O
hospitalization	O
,	O
it	O
was	O
noted	O
that	O
the	O
patient	O
's	O
dyspnea	B-ADE
and	O
sinus	B-ADE
bradycardia	I-ADE
could	O
be	O
related	O
to	O
a	O
recent	O
increase	O
in	O
his	O
timolol	B-Drug
dosage	O
.	O

-DOCSTART-	328

ARA	B-Drug
-	I-Drug
C	I-Drug
is	O
frequently	O
associated	O
with	O
dermatologic	B-ADE
toxicity	I-ADE
,	O
but	O
this	O
is	O
only	O
the	O
second	O
case	O
of	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
described	O
in	O
connection	O
with	O
this	O
drug	O
.	O

-DOCSTART-	394

Special	O
care	O
should	O
be	O
taken	O
when	O
pulmonary	B-ADE
symptoms	I-ADE
appear	O
in	O
association	O
with	O
ticlopidine	B-Drug
treatment	O
.	O

-DOCSTART-	3240

Desipramine	B-Drug
-	O
associated	O
SIADH	B-ADE
in	O
an	O
elderly	O
woman	O
:	O
case	O
report	O
.	O

-DOCSTART-	641

Mitomycin	B-Drug
-	I-Drug
C	I-Drug
induced	O
hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	1266

It	O
is	O
well	O
-	O
recognized	O
that	O
flucloxacillin	B-Drug
may	O
occasionally	O
result	O
in	O
fatal	B-ADE
hepatic	I-ADE
injury	I-ADE
.	O

-DOCSTART-	2379

The	O
Naranjo	O
probability	O
scale	O
indicated	O
a	O
probable	O
relationship	O
between	O
apnea	B-ADE
and	O
exposure	O
to	O
lamotrigine	B-Drug
through	O
breast	O
-	O
feeding	O
in	O
this	O
infant	O
.	O

-DOCSTART-	809

In	O
both	O
cases	O
,	O
high	B-ADE
fever	I-ADE
,	O
skin	B-ADE
rash	I-ADE
,	O
liver	B-ADE
dysfunction	I-ADE
and	O
atypical	B-ADE
lymphocytosis	I-ADE
developed	O
3	O
weeks	O
after	O
initiating	O
treatment	O
with	O
SASP	B-Drug
.	O

-DOCSTART-	206

Case	O
4	O
:	O
A	O
61-year	O
-	O
old	O
male	O
alcoholic	O
who	O
remained	O
completely	O
abstinent	O
while	O
taking	O
cyanamide	B-Drug
for	O
3	O
years	O
showed	O
slight	O
elevation	B-ADE
of	I-ADE
serum	I-ADE
transaminases	I-ADE
.	O

-DOCSTART-	2702

Sulfasalazine	B-Drug
-	O
induced	O
lupus	B-ADE
erythematosus	I-ADE
.	O

-DOCSTART-	2961

Heparin	B-Drug
-	O
induced	O
hyperkalemia	B-ADE
.	O

-DOCSTART-	1789

Adverse	O
effects	O
of	O
amiodarone	B-Drug
including	O
pulmonary	B-ADE
toxicity	I-ADE
,	O
hepatotoxicity	B-ADE
,	O
aggravation	B-ADE
of	I-ADE
arrhythmia	I-ADE
,	O
and	O
thyroid	B-ADE
diseases	I-ADE
are	O
well	O
understood	O
.	O

-DOCSTART-	3479

Esophageal	B-ADE
candidiasis	I-ADE
following	O
omeprazole	B-Drug
therapy	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

-DOCSTART-	510

Triiodothyronine	B-Drug
-	O
induced	O
thyrotoxicosis	B-ADE
in	O
ophthalmic	O
Graves	O
disease	O
.	O

-DOCSTART-	1877

Drug	O
-	O
induced	O
eosinophilia	B-ADE
is	O
a	O
non	O
-	O
dose	O
-	O
dependent	O
side	O
effect	O
of	O
clozapine	B-Drug
.	O

-DOCSTART-	1658

It	O
may	O
cause	O
a	O
severe	O
adverse	O
drug	O
reaction	O
with	O
multiorgan	O
involvement	O
known	O
as	O
dapsone	B-Drug
hypersensitivity	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	2995

A	O
review	O
of	O
the	O
literature	O
showed	O
no	O
previous	O
description	O
of	O
this	O
pattern	O
in	O
benzodiazepine	B-Drug
coma	B-ADE
.	O

-DOCSTART-	522

We	O
report	O
a	O
case	O
of	O
hepatolithiasis	B-ADE
(	O
intrahepatic	O
stone	O
)	O
complicated	O
by	O
gram	O
-	O
negative	O
sepsis	O
in	O
a	O
37	O
year	O
old	O
male	O
with	O
acromegaly	O
being	O
treated	O
with	O
octreotide	B-Drug
.	O

-DOCSTART-	1208

Since	O
imiquimod	B-Drug
induces	O
large	B-ADE
amounts	I-ADE
of	I-ADE
type	I-ADE
I	I-ADE
interferon	I-ADE
production	I-ADE
from	O
TLR7-expressing	O
plasmacytoid	O
dendritic	O
cell	O
precursors	O
(	O
PDCs	O
)	O
,	O
the	O
natural	O
interferon	O
-	O
producing	O
cells	O
of	O
the	O
peripheral	O
blood	O
,	O
we	O
asked	O
whether	O
PDCs	O
are	O
present	O
in	O
psoriatic	O
skin	O
.	O

-DOCSTART-	605

After	O
5	O
days	O
of	O
treatment	O
with	O
IL-2	B-Drug
,	O
the	O
patient	O
developed	O
a	O
hemorrhagic	B-ADE
lesion	I-ADE
that	O
progressed	O
to	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
,	O
as	O
well	O
as	O
grade	O
4	O
pancytopenia	B-ADE
.	O

-DOCSTART-	2159

Laryngeal	B-ADE
dyspnea	I-ADE
in	O
relation	O
to	O
an	O
interaction	O
between	O
acenocoumarol	B-Drug
and	O
topical	O
econazole	B-Drug
lotion	O
.	O

-DOCSTART-	2132

It	O
is	O
the	O
first	O
case	O
of	O
ciprofloxacin	B-Drug
-	O
induced	O
VBDS	B-ADE
successfully	O
treated	O
with	O
tacrolimus	O
.	O

-DOCSTART-	1626

This	O
case	O
highlights	O
the	O
possible	O
development	O
of	O
acute	B-ADE
coronary	I-ADE
syndrome	I-ADE
as	O
a	O
side	O
effect	O
of	O
Capecitabine	B-Drug
therapy	O
.	O

-DOCSTART-	4222

After	O
1	O
week	O
of	O
nefazodone	B-Drug
therapy	O
the	O
patient	O
experienced	O
headache	B-ADE
,	O
confusion	B-ADE
,	O
and	O
"	O
gray	B-ADE
areas	I-ADE
"	O
in	O
her	O
vision	O
,	O
without	O
abnormal	O
ophthalmologic	O
findings	O
.	O

-DOCSTART-	745

Neuroleptic	B-ADE
malignant	I-ADE
syndrome	I-ADE
in	O
an	O
adolescent	O
receiving	O
olanzapine	B-Drug
-	O
lithium	B-Drug
combination	O
therapy	O
.	O

-DOCSTART-	1191

Localized	B-ADE
panniculitis	I-ADE
and	O
subsequent	O
lipoatrophy	B-ADE
with	O
subcutaneous	O
glatiramer	B-Drug
acetate	I-Drug
(	O
Copaxone	B-Drug
)	O
injection	O
for	O
the	O
treatment	O
of	O
multiple	O
sclerosis	O
.	O

-DOCSTART-	3589

This	O
prompted	O
us	O
to	O
suspect	O
that	O
ddI	B-Drug
might	O
be	O
responsible	O
for	O
fulminant	B-ADE
hepatitis	I-ADE
in	O
all	O
three	O
AIDS	O
patients	O
.	O

-DOCSTART-	1694

Though	O
proteinuria	B-ADE
and	O
nephrotic	B-ADE
syndrome	I-ADE
is	O
a	O
rare	O
adverse	O
effect	O
of	O
IFN	B-Drug
-	I-Drug
beta-1b	I-Drug
therapy	O
,	O
physicians	O
treating	O
MS	O
patients	O
with	O
this	O
agent	O
should	O
pay	O
careful	O
attention	O
to	O
new	O
clinical	O
symptoms	O
and	O
laboratory	O
findings	O
.	O

-DOCSTART-	347

Exacerbation	O
of	O
5-FU	B-Drug
dermatologic	B-ADE
toxicities	I-ADE
in	O
patients	O
with	O
preexisting	O
conditions	O
suggests	O
the	O
importance	O
of	O
aggressive	O
ocular	O
prophylaxis	O
,	O
using	O
frequent	O
ocular	O
lubrication	O
and	O
topical	O
steroid	O
preparations	O
with	O
concurrent	O
medical	O
management	O
of	O
pre	O
-	O
existing	O
dermatologic	O
conditions	O
.	O

-DOCSTART-	3297

These	O
results	O
indicate	O
that	O
lithium	B-Drug
may	O
cause	O
biochemical	B-ADE
hyperparathyroidism	I-ADE
.	O

-DOCSTART-	2983

IV	O
propranolol	B-Drug
was	O
used	O
as	O
the	O
initial	O
treatment	O
for	O
his	O
hyperadrenergic	O
state	O
,	O
resulting	O
in	O
a	O
decrease	B-ADE
in	I-ADE
heart	I-ADE
rate	I-ADE
but	O
a	O
paroxsymal	B-ADE
increase	I-ADE
in	I-ADE
blood	I-ADE
pressure	I-ADE
.	O

-DOCSTART-	41

Marked	O
elevation	B-ADE
of	I-ADE
serum	I-ADE
creatine	I-ADE
kinase	I-ADE
associated	O
with	O
olanzapine	B-Drug
therapy	O
.	O

-DOCSTART-	3021

The	O
currently	O
available	O
clinical	O
and	O
neuropharmacologic	O
data	O
suggest	O
that	O
carbamazepine	B-Drug
may	O
be	O
an	O
antagonist	O
of	O
dopamine	O
and	O
that	O
this	O
property	O
is	O
responsible	O
for	O
the	O
production	O
of	O
dystonia	B-ADE
.	O

-DOCSTART-	385

RESULTS	O
:	O
Five	O
of	O
70	O
patients	O
who	O
had	O
begun	O
leflunomide	B-Drug
therapy	O
had	O
significant	O
weight	B-ADE
loss	I-ADE
that	O
could	O
not	O
be	O
linked	O
to	O
other	O
identifiable	O
etiologies	O
.	O

-DOCSTART-	2389

Thrombin	B-Drug
is	O
highly	O
effective	O
for	O
stopping	O
intractable	O
arterial	O
hemorrhage	O
during	O
stereotactic	O
brain	O
biopsy	O
;	O
however	O
,	O
it	O
is	O
a	O
vasospastic	O
agent	O
and	O
may	O
have	O
been	O
responsible	O
for	O
the	O
cerebral	B-ADE
infarctions	I-ADE
in	O
one	O
patient	O
.	O

-DOCSTART-	2578

Although	O
tardive	B-ADE
dyskinesia	I-ADE
is	O
a	O
known	O
adverse	O
reaction	O
of	O
sustained	O
treatment	O
with	O
traditional	O
neuroleptic	O
agents	O
,	O
it	O
was	O
only	O
rarely	O
reported	O
in	O
association	O
with	O
sulpiride	B-Drug
,	O
a	O
selective	O
D2-receptor	O
antagonist	O
.	O

-DOCSTART-	1762

The	O
patient	O
presented	O
with	O
fulminant	B-ADE
microangiopathic	I-ADE
hemolytic	I-ADE
anemia	I-ADE
and	O
thrombocytopenia	B-ADE
within	O
48	O
hr	O
of	O
initiating	O
therapy	O
with	O
trimethoprim	B-Drug
-	O
sulfamethoxazole	B-Drug
.	O

-DOCSTART-	3616

Possible	O
mechanisms	O
by	O
which	O
clonidine	B-Drug
decreases	O
spasticity	O
are	O
described	O
,	O
probable	O
mechanisms	O
of	O
induced	O
bradycardia	B-ADE
are	O
reviewed	O
,	O
and	O
specific	O
treatment	O
recommendations	O
for	O
the	O
use	O
of	O
clonidine	B-Drug
in	O
spinal	O
cord	O
injured	O
patients	O
are	O
presented	O
.	O

-DOCSTART-	3946

Eleven	O
days	O
after	O
initiation	O
of	O
therapy	O
with	O
amiodarone	B-Drug
,	O
the	O
patient	O
experienced	O
syncope	B-ADE
and	O
was	O
noted	O
to	O
have	O
recurrent	O
episodes	O
of	O
polymorphous	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
.	O

-DOCSTART-	2678

Prior	O
neurologic	O
illness	O
and	O
the	O
syndrome	O
of	O
irreversible	O
lithium	B-Drug
-	O
effectuated	O
neurotoxicity	B-ADE
(	O
SILENT	O
)	O
.	O

-DOCSTART-	992

A	O
new	O
type	O
of	O
minocycline	B-Drug
-	O
induced	O
cutaneous	B-ADE
hyperpigmentation	I-ADE
.	O

-DOCSTART-	3882

Insulin	B-Drug
-	O
induced	O
lipoatrophy	B-ADE
in	O
type	O
I	O
diabetes	O
.	O

-DOCSTART-	86

We	O
present	O
three	O
patients	O
with	O
paradoxical	O
seizures	B-ADE
;	O
their	O
serum	O
phenytoin	B-Drug
levels	O
were	O
43.5	O
mcg	O
/	O
mL	O
,	O
46.5	O
mcg	O
/	O
mL	O
and	O
38.3	O
mcg	O
/	O
mL	O
.	O

-DOCSTART-	1121

CONCLUSION	O
:	O
Therapy	O
with	O
indapamide	B-Drug
may	O
induce	O
diabetes	B-ADE
in	O
essential	O
hypertension	O
patients	O
.	O

-DOCSTART-	452

PURPOSE	O
:	O
To	O
report	O
that	O
acute	O
lamotrigine	B-Drug
poisoning	O
may	O
result	O
in	O
severe	O
encephalopathy	B-ADE
.	O

-DOCSTART-	2343

Adriamycin	B-Drug
-	O
induced	O
cardiomyopathy	B-ADE
aggravated	O
by	O
cis	B-Drug
-	I-Drug
platinum	I-Drug
nephrotoxicity	B-ADE
requiring	O
dialysis	O
.	O

-DOCSTART-	2978

Reye	B-ADE
syndrome	I-ADE
(	O
RS	B-ADE
)	O
is	O
believed	O
to	O
occur	O
infrequently	O
among	O
children	O
receiving	O
long	O
-	O
term	O
aspirin	B-Drug
therapy	O
.	O

-DOCSTART-	1813

CONCLUSIONS	O
:	O
For	O
all	O
patients	O
with	O
vancomycin	B-Drug
-	O
induced	O
neutropenia	B-ADE
,	O
possible	O
cross	O
-	O
reactivity	O
of	O
teicoplanin	O
should	O
be	O
monitored	O
.	O

-DOCSTART-	1530

We	O
suggest	O
that	O
sarcoidosis	B-ADE
may	O
develop	O
in	O
chronic	O
hepatitis	O
C	O
patients	O
during	O
interferon	B-Drug
alpha	I-Drug
and/or	O
ribavirin	B-Drug
treatment	O
,	O
and	O
diagnostic	O
tests	O
for	O
this	O
adverse	O
effect	O
should	O
be	O
performed	O
during	O
the	O
follow	O
-	O
ups	O
.	O

-DOCSTART-	3055

Doxorubicin	B-Drug
cardiotoxicity	B-ADE
:	O
possible	O
role	O
of	O
digoxin	O
in	O
its	O
prevention	O
.	O

-DOCSTART-	2178

In	O
patients	O
with	O
methotrexate	B-Drug
-	O
induced	O
anaphylaxis	B-ADE
,	O
discontinuation	O
of	O
treatment	O
may	O
increase	O
the	O
risk	O
of	O
death	O
due	O
to	O
cancer	O
progression	O
.	O

-DOCSTART-	3768

On	O
the	O
fifth	O
day	O
of	O
tocolysis	O
with	O
magnesium	B-Drug
sulfate	I-Drug
,	O
nifedipine	B-Drug
,	O
terbutaline	B-Drug
and	O
betamethasone	B-Drug
,	O
edema	B-ADE
developed	O
in	O
both	O
labia	O
.	O

-DOCSTART-	2637

Reinstitution	O
of	O
penicillamine	O
treatment	O
caused	O
a	O
recurrence	O
thus	O
proving	O
a	O
causal	O
relationship	O
between	O
penicillamine	B-Drug
and	O
the	O
described	O
nail	B-ADE
-	I-ADE
changes	I-ADE
.	O

-DOCSTART-	2797

Benzocaine	B-Drug
-	O
induced	O
methemoglobinemia	B-ADE
has	O
been	O
reported	O
in	O
man	O
,	O
dogs	O
,	O
and	O
cats	O
.	O

-DOCSTART-	2919

The	O
latter	O
form	O
(	O
Macrodantin	B-Drug
)	O
is	O
reported	O
to	O
engender	O
less	O
gastrointestinal	O
intolerance	O
but	O
it	O
can	O
produce	O
the	O
same	O
adverse	O
effects	O
as	O
the	O
conventional	O
form	O
--	O
liver	B-ADE
damage	I-ADE
,	O
acute	B-ADE
and	I-ADE
chronic	I-ADE
pulmonary	I-ADE
reactions	I-ADE
,	O
peripheral	B-ADE
neuropathy	I-ADE
,	O
blood	B-ADE
dyscrasias	I-ADE
and	O
allergic	B-ADE
reactions	I-ADE
--	O
and	O
does	O
so	O
just	O
as	O
rapidly	O
and	O
floridly	O
;	O
one	O
such	O
case	O
is	O
reported	O
here	O
.	O

-DOCSTART-	1018

BACKGROUND	O
:	O
The	O
risk	O
/	O
benefit	O
ratio	O
of	O
warfarin	B-Drug
therapy	O
changes	O
in	O
the	O
over	O
75s	O
,	O
when	O
haemorrhagic	B-ADE
side	I-ADE
-	I-ADE
effects	I-ADE
become	O
more	O
common	O
.	O

-DOCSTART-	3682

A	O
16-year	O
-	O
old	O
white	O
male	O
with	O
acute	O
biphenotypic	O
leukemia	O
developed	O
evidence	O
of	O
the	O
eosinophilia	B-ADE
myalgia	I-ADE
syndrome	I-ADE
associated	O
with	O
total	O
parenteral	O
nutritional	O
support	O
with	O
solutions	O
containing	O
tryptophan	B-Drug
,	O
which	O
were	O
given	O
during	O
his	O
initial	O
induction	O
chemotherapy	O
and	O
also	O
after	O
autologous	O
marrow	O
transplantation	O
.	O

-DOCSTART-	3026

Squamous	B-ADE
-	I-ADE
cell	I-ADE
carcinoma	I-ADE
arising	O
in	O
a	O
basal	O
-	O
cell	O
epithelioma	O
treated	O
with	O
5-fluorouracil	B-Drug
.	O

-DOCSTART-	2023

Bilateral	B-ADE
anterior	I-ADE
uveitis	I-ADE
associated	O
with	O
clomiphene	B-Drug
citrate	I-Drug
.	O

-DOCSTART-	456

Lichenoid	B-ADE
drug	I-ADE
eruption	I-ADE
to	O
salsalate	B-Drug
.	O

-DOCSTART-	1492

Torsemide	B-Drug
appears	O
to	O
also	O
be	O
a	O
part	O
of	O
a	O
long	O
list	O
of	O
agents	O
that	O
can	O
cause	O
pancreatitis	B-ADE
.	O

-DOCSTART-	453

Stupor	B-ADE
from	O
lamotrigine	B-Drug
toxicity	O
.	O

-DOCSTART-	1932

Uncontrolled	O
headache	B-ADE
induced	O
by	O
oxcarbazepine	B-Drug
.	O

-DOCSTART-	1276

Risperidone	B-Drug
withdrawal	O
-	O
related	O
respiratory	B-ADE
dyskinesia	I-ADE
:	O
a	O
case	O
diagnosed	O
by	O
spirography	O
and	O
fibroscopy	O
.	O

-DOCSTART-	2297

Two	O
patients	O
with	O
HLH	O
developed	O
etoposide	B-Drug
-	O
related	O
secondary	B-ADE
acute	I-ADE
myeloid	I-ADE
leukemia	I-ADE
(	O
sAML	B-ADE
)	O
following	O
therapy	O
for	O
HLH	O
.	O

-DOCSTART-	1628

After	O
rechallenge	O
with	O
monotherapy	O
pegvisomant	B-Drug
,	O
however	O
,	O
the	O
hepatic	B-ADE
enzyme	I-ADE
disturbances	I-ADE
reappeared	O
within	O
a	O
few	O
weeks	O
,	O
indicating	O
that	O
most	O
likely	O
pegvisomant	B-Drug
alone	O
and	O
not	O
the	O
long	O
-	O
acting	O
somatostatin	O
analog	O
or	O
the	O
combination	O
of	O
these	O
two	O
drugs	O
was	O
responsible	O
for	O
this	O
case	O
of	O
drug	O
-	O
induced	O
hepatitis	B-ADE
.	O

-DOCSTART-	2754

Atrial	B-ADE
fibrillation	I-ADE
following	O
methylprednisolone	B-Drug
pulse	O
therapy	O
.	O

-DOCSTART-	3957

The	O
rash	B-ADE
seen	O
in	O
this	O
patient	O
,	O
who	O
was	O
treated	O
with	O
cephalexin	B-Drug
,	O
may	O
be	O
similar	O
to	O
the	O
rash	B-ADE
seen	O
with	O
ampicillin	B-Drug
treatment	O
of	O
patients	O
with	O
infectious	O
mononucleosis	O
.	O

-DOCSTART-	3521

The	O
diagnosis	O
was	O
supported	O
by	O
the	O
temporal	O
course	O
of	O
renal	B-ADE
deterioration	I-ADE
during	O
exposure	O
to	O
cefuroxime	B-Drug
and	O
improvement	O
on	O
its	O
discontinuation	O
;	O
the	O
pattern	O
repeated	O
with	O
rechallenge	O
.	O

-DOCSTART-	2301

At	O
the	O
end	O
of	O
his	O
fifth	O
cycle	O
of	O
sunitinib	B-Drug
therapy	O
,	O
the	O
patient	O
complained	O
of	O
the	O
development	B-ADE
of	I-ADE
abnormally	I-ADE
large	I-ADE
mammary	I-ADE
glands	I-ADE
associated	O
with	O
pain	B-ADE
and	O
peri	B-ADE
-	I-ADE
areolar	I-ADE
erythema	I-ADE
.	O

-DOCSTART-	2278

A	O
case	O
of	O
tuberculosis	B-ADE
in	O
a	O
patient	O
on	O
Efalizumab	B-Drug
and	O
Etanercept	B-Drug
for	O
treatment	O
of	O
refractory	O
palmopustular	O
psoriasis	O
and	O
psoriatic	O
arthritis	O
.	O

-DOCSTART-	4009

Clozapine	B-Drug
induced	O
polyserositis	B-ADE
.	O

-DOCSTART-	2788

They	O
continued	O
to	O
rise	O
for	O
five	O
more	O
days	O
before	O
salicylate	B-Drug
hepatotoxicity	B-ADE
was	O
suspected	O
.	O

-DOCSTART-	3775

OBJECTIVE	O
:	O
To	O
describe	O
a	O
patient	O
with	O
ifosfamide	B-Drug
-	O
induced	O
nonconvulsive	B-ADE
status	I-ADE
epilepticus	I-ADE
.	O

-DOCSTART-	2351

On	O
day	O
4	O
,	O
following	O
3	O
doses	O
of	O
dalteparin	B-Drug
,	O
the	O
patient	O
developed	O
acute	B-ADE
respiratory	I-ADE
distress	I-ADE
attributable	O
to	O
a	O
massive	O
right	O
hemothorax	O
confirmed	O
by	O
computed	O
tomography	O
pulmonary	O
angiography	O
(	O
CTPA	O
)	O
and	O
intercostal	O
drainage	O
of	O
1500	O
mL	O
of	O
frank	O
blood	O
.	O

-DOCSTART-	2601

Oxygen	B-Drug
potentiation	O
of	O
bleomycin	B-Drug
-	O
induced	O
pulmonary	B-ADE
toxicity	I-ADE
is	O
discussed	O
.	O

-DOCSTART-	3587

We	O
report	O
on	O
three	O
observations	O
of	O
parkinsonian	O
patients	O
with	O
levo	B-Drug
-	I-Drug
dopa	I-Drug
-	O
induced	O
diphasic	B-ADE
dyskinesias	I-ADE
,	O
who	O
received	O
subcutaneous	O
apomorphine	O
to	O
reduce	O
the	O
duration	O
of	O
abnormal	O
movements	O
.	O

-DOCSTART-	0

Intravenous	O
azithromycin	B-Drug
-	O
induced	O
ototoxicity	B-ADE
.	O

-DOCSTART-	1936

Reports	O
of	O
colonic	B-ADE
perforation	I-ADE
as	O
a	O
result	O
of	O
the	O
administration	O
of	O
calcium	B-Drug
polystyrene	I-Drug
sulfonate	I-Drug
and	O
sorbitol	B-Drug
are	O
rare	O
.	O

-DOCSTART-	2356

CONCLUSIONS	O
:	O
Patients	O
receiving	O
intravitreal	O
injections	O
of	O
bevacizumab	B-Drug
should	O
be	O
evaluated	O
for	O
potential	O
systemic	O
risk	O
factors	O
such	O
as	O
carotid	B-ADE
insufficiency	I-ADE
,	O
coagulopathy	B-ADE
and	O
poorly	B-ADE
controlled	I-ADE
diabetes	I-ADE
mellitus	I-ADE
.	O

-DOCSTART-	3763

Development	O
of	O
nephrotic	B-ADE
syndrome	I-ADE
in	O
a	O
patient	O
with	O
acute	O
myeloblastic	O
leukemia	O
after	O
treatment	O
with	O
macrophage	B-Drug
-	I-Drug
colony	I-Drug
-	I-Drug
stimulating	I-Drug
factor	I-Drug
.	O

-DOCSTART-	3218

Cimetidine	B-Drug
-	O
induced	O
fever	B-ADE
.	O

-DOCSTART-	1725

Thus	O
,	O
tacrolimus	B-Drug
-	O
induced	O
HUS	B-ADE
is	O
a	O
rare	O
cause	O
of	O
ARF	B-ADE
in	O
nephrotic	O
syndrome	O
.	O

-DOCSTART-	111

Thrombotic	B-ADE
microangiopathy	I-ADE
with	O
renal	B-ADE
failure	I-ADE
in	O
two	O
patients	O
undergoing	O
gemcitabine	B-Drug
chemotherapy	O
.	O

-DOCSTART-	1966

According	O
to	O
the	O
Naranjo	O
probability	O
scale	O
,	O
the	O
papular	B-ADE
eruption	I-ADE
was	O
probably	O
caused	O
by	O
methotrexate	B-Drug
.	O

-DOCSTART-	2376

The	O
first	O
patient	O
is	O
undergoing	O
hemodialysis	O
and	O
,	O
though	O
responding	O
to	O
sunitinib	B-Drug
,	O
is	O
having	O
significant	O
fatigue	B-ADE
and	O
hypertension	B-ADE
.	O

-DOCSTART-	884

After	O
four	O
months	O
,	O
while	O
receiving	O
RH	B-Drug
,	O
he	O
developed	O
painful	O
bilateral	B-ADE
gynaecomastia	I-ADE
.	O

-DOCSTART-	4119

A	O
28	O
year	O
old	O
white	O
schizophrenic	O
male	O
has	O
been	O
under	O
risperidone	B-Drug
monotherapy	O
for	O
about	O
one	O
year	O
when	O
he	O
developed	O
dyskinetic	B-ADE
movements	I-ADE
.	O

-DOCSTART-	318

Severe	B-ADE
rash	I-ADE
,	O
including	O
the	O
Stevens	B-ADE
-	I-ADE
Johnson	I-ADE
syndrome	I-ADE
(	O
SJS	B-ADE
)	O
,	O
is	O
the	O
major	O
toxicity	O
of	O
nevirapine	B-Drug
and	O
is	O
described	O
in	O
the	O
package	O
labeling	O
with	O
a	O
prominent	O
,	O
boxed	O
warning	O
.	O

-DOCSTART-	868

This	O
communication	O
describes	O
a	O
patient	O
who	O
developed	O
Schneiderian	B-ADE
first	I-ADE
-	I-ADE
rank	I-ADE
symptoms	I-ADE
in	O
the	O
course	O
of	O
treatment	O
with	O
fluvoxamine	B-Drug
.	O

-DOCSTART-	3488

Cerebral	B-ADE
demyelinating	I-ADE
disease	I-ADE
developed	O
in	O
a	O
patient	O
during	O
adjuvant	O
therapy	O
with	O
levamisole	B-Drug
for	O
malignant	O
melanoma	O
.	O

-DOCSTART-	3040

Five	O
cases	O
of	O
clindamycin	B-Drug
-	O
associated	O
pseudomembranous	B-ADE
colitis	I-ADE
in	O
leukaemic	O
patients	O
are	O
reported	O
.	O

-DOCSTART-	1968

DISCUSSION	O
:	O
Methotrexate	B-Drug
-	O
induced	O
papular	B-ADE
eruption	I-ADE
is	O
rarely	O
reported	O
shortly	O
after	O
beginning	O
methotrexate	O
therapy	O
in	O
patients	O
with	O
acute	O
exacerbation	O
of	O
collagen	O
vascular	O
diseases	O
.	O

-DOCSTART-	223

An	O
evaluation	O
of	O
ovarian	O
structure	O
and	O
function	O
should	O
be	O
considered	O
in	O
women	O
of	O
reproductive	O
age	O
being	O
treated	O
with	O
valproate	B-Drug
for	O
epilepsy	O
,	O
especially	O
if	O
they	O
develop	O
menstrual	B-ADE
cycle	I-ADE
disturbances	I-ADE
during	O
treatment	O
.	O

-DOCSTART-	1335

We	O
explored	O
ophthalmic	B-ADE
and	I-ADE
neurologic	I-ADE
findings	I-ADE
in	O
two	O
children	O
who	O
have	O
been	O
exposed	O
prenatally	O
to	O
VGB	B-Drug
.	O

-DOCSTART-	2541

We	O
describe	O
two	O
cases	O
of	O
sulfadiazine	B-Drug
-	O
induced	O
crystalluria	B-ADE
and	O
renal	B-ADE
failure	I-ADE
in	O
patients	O
with	O
acquired	O
immunodeficiency	O
syndrome	O
,	O
review	O
the	O
pertinent	O
literature	O
,	O
and	O
discuss	O
the	O
pathogenesis	O
.	O

-DOCSTART-	2313

Localized	B-ADE
dyskeratotic	I-ADE
plaque	I-ADE
with	O
milia	B-ADE
associated	O
with	O
sorafenib	B-Drug
.	O

-DOCSTART-	706

BACKGROUND	O
:	O
Ovarian	B-ADE
cancer	I-ADE
arising	O
from	O
an	O
endometriotic	O
cyst	O
in	O
a	O
postmenopausal	O
woman	O
under	O
tamoxifen	B-Drug
therapy	O
is	O
rare	O
.	O

-DOCSTART-	3102

Acute	B-ADE
renal	I-ADE
failure	I-ADE
most	O
likely	O
was	O
secondary	O
to	O
the	O
nephrotoxic	O
effect	O
of	O
captopril	B-Drug
on	O
chronically	O
hypoperfused	O
kidneys	O
.	O

-DOCSTART-	4156

Administration	O
of	O
steroid	O
and	O
decreasing	O
the	O
dose	O
of	O
PTU	B-Drug
produced	O
a	O
good	O
clinical	O
response	O
and	O
the	O
ANCA	B-ADE
disappeared	O
.	O

-DOCSTART-	1835

Ethambutol	B-Drug
toxicity	O
manifesting	O
as	O
acute	B-ADE
onset	I-ADE
psychosis	I-ADE
.	O

-DOCSTART-	2302

However	O
,	O
re	O
-	O
initiation	O
of	O
sunitinib	B-Drug
treatment	O
was	O
followed	O
by	O
bilateral	B-ADE
breast	I-ADE
enlargement	I-ADE
again	O
.	O

-DOCSTART-	3249

The	O
patient	O
was	O
given	O
methimazole	B-Drug
instead	O
of	O
propylthiouracil	O
but	O
,	O
10	O
weeks	O
later	O
,	O
agranulocytosis	B-ADE
again	O
occurred	O
.	O

-DOCSTART-	1991

Clinicians	O
should	O
be	O
aware	O
that	O
an	O
erythematous	O
and	O
exfoliative	B-ADE
rash	I-ADE
may	O
be	O
induced	O
by	O
temozolomide	B-Drug
,	O
and	O
be	O
familiar	O
with	O
the	O
pharmacologic	O
and	O
supportive	O
measures	O
necessary	O
for	O
its	O
treatment	O
.	O

-DOCSTART-	4084

Anaphylaxis	B-ADE
to	O
intravenous	O
cyclosporine	B-Drug
and	O
tolerance	O
to	O
oral	O
cyclosporine	O
:	O
case	O
report	O
and	O
review	O
.	O

-DOCSTART-	3506

Hemodialysis	O
should	O
be	O
performed	O
for	O
rapid	O
reversal	O
of	O
mannitol	B-Drug
-	O
induced	O
ARF	B-ADE
.	O

-DOCSTART-	2531

Severe	O
heparin	B-Drug
associated	O
thrombocytopenia	B-ADE
is	O
a	O
rare	O
complication	O
of	O
heparin	B-Drug
therapy	O
.	O

-DOCSTART-	3563

The	O
second	O
patient	O
,	O
who	O
developed	O
cholestasis	B-ADE
after	O
receiving	O
trimethoprim	B-Drug
-	I-Drug
sulfamethoxazole	I-Drug
,	O
had	O
marked	O
duct	B-ADE
paucity	I-ADE
in	O
the	O
liver	O
biopsy	O
.	O

-DOCSTART-	862

After	O
39	O
hours	O
on	O
argatroban	B-Drug
,	O
the	O
infusion	O
was	O
stopped	O
when	O
minor	O
bleeding	B-ADE
was	O
observed	O
with	O
a	O
concurrent	O
activated	O
partial	O
thromboplastin	O
time	O
(	O
aPTT	O
)	O
of	O
100	O
seconds	O
.	O

-DOCSTART-	2929

The	O
possible	O
role	O
of	O
interferon	B-Drug
beta	I-Drug
in	O
the	O
pathogenesis	O
of	O
sarcoidosis	B-ADE
in	O
this	O
patient	O
is	O
discussed	O
.	O

-DOCSTART-	679

A	O
case	O
is	O
presented	O
of	O
a	O
patient	O
who	O
experienced	O
benzodiazepine	B-ADE
withdrawal	I-ADE
symptoms	I-ADE
on	O
discontinuation	O
of	O
nefazodone	B-Drug
,	O
an	O
antidepressant	O
that	O
inhibits	O
the	O
cytochrome	O
P450	O
3A4	O
isoenzyme	O
.	O

-DOCSTART-	1644

Presented	O
is	O
a	O
case	O
story	O
of	O
a	O
woman	O
with	O
classical	O
rheumatoid	O
arthritis	O
,	O
who	O
during	O
introduction	O
of	O
sulphasalazine	B-Drug
(	O
SASP	B-Drug
)	O
therapy	O
developed	O
a	O
severe	O
and	O
lasting	O
psoriasis	B-ADE
-	I-ADE
like	I-ADE
skin	I-ADE
reaction	I-ADE
.	O

-DOCSTART-	3791

A	O
review	O
of	O
the	O
literature	O
found	O
11	O
children	O
and	O
2	O
adults	O
in	O
whom	O
intranasal	O
desmopressin	B-Drug
was	O
associated	O
with	O
hyponatremia	B-ADE
,	O
all	O
of	O
whom	O
experienced	O
seizures	B-ADE
or	O
altered	B-ADE
mental	I-ADE
status	I-ADE
.	O

-DOCSTART-	1767

Acute	B-ADE
endophthalmitis	I-ADE
following	O
intravitreal	O
bevacizumab	B-Drug
(	O
Avastin	B-Drug
)	O
injection	O
.	O

-DOCSTART-	1550

Trimethoprim	B-Drug
-	I-Drug
sulfamethoxazole	I-Drug
-	O
induced	O
hypersensitivity	B-ADE
syndrome	I-ADE
associated	O
with	O
reactivation	O
of	O
human	O
herpesvirus-6	O
.	O

-DOCSTART-	1883

The	O
dermatology	O
literature	O
heretofore	O
has	O
not	O
noted	O
that	O
anemia	B-ADE
is	O
a	O
side	O
effect	O
of	O
patients	O
taking	O
MMF	B-Drug
to	O
treat	O
pemphigus	O
.	O

-DOCSTART-	3137

Mammary	B-ADE
gigantism	I-ADE
is	O
a	O
rare	O
complication	O
of	O
D	B-Drug
-	I-Drug
penicillamine	I-Drug
treatment	O
.	O

-DOCSTART-	563

We	O
speculate	O
that	O
platelet	O
activation	O
induced	O
by	O
pFVIII	B-Drug
may	O
have	O
contributed	O
to	O
thrombosis	B-ADE
and	O
suggest	O
that	O
pFVIII	O
be	O
used	O
with	O
caution	O
in	O
elderly	O
patients	O
with	O
pre	O
-	O
existing	O
cardiovascular	O
risk	O
factors	O
.	O

-DOCSTART-	3036

Two	O
patients	O
developed	O
diabetic	B-ADE
coma	I-ADE
when	O
taking	O
a	O
combination	O
of	O
a	O
thiazide	B-Drug
diuretic	O
and	O
propranolol	B-Drug
.	O

-DOCSTART-	1516

Ptosis	B-ADE
occurring	O
24	O
h	O
after	O
chloroquine	B-Drug
therapy	O
,	O
with	O
full	O
recovery	O
48	O
h	O
after	O
cessation	O
of	O
chloroquine	B-Drug
,	O
has	O
not	O
been	O
described	O
previously	O
.	O

-DOCSTART-	2981

A	O
54-year	O
-	O
old	O
man	O
,	O
treated	O
with	O
amiodarone	B-Drug
,	O
developed	O
thyrotoxicosis	B-ADE
.	O

-DOCSTART-	658

Ticlopidine	B-Drug
-	O
induced	O
aplastic	B-ADE
anemia	I-ADE
:	O
two	O
new	O
case	O
reports	O
,	O
review	O
,	O
and	O
meta	O
-	O
analysis	O
of	O
55	O
additional	O
cases	O
.	O

-DOCSTART-	918

Hemorrhagic	B-ADE
cystitis	I-ADE
is	O
a	O
significant	O
toxic	O
effect	O
of	O
cyclophosphamide	B-Drug
therapy	O
.	O

-DOCSTART-	1714

RESULTS	O
:	O
Both	O
cases	O
presented	O
here	O
describe	O
corneal	B-ADE
ulcers	I-ADE
that	O
persisted	O
and	O
showed	O
signs	O
of	O
worsening	O
during	O
weeks	O
of	O
frequent	O
topical	O
dosing	O
with	O
moxifloxacin	B-Drug
.	O

-DOCSTART-	1853

We	O
postulate	O
that	O
gastritis	B-ADE
caused	O
by	O
dexamethasone	B-Drug
,	O
mucositis	B-ADE
caused	O
by	O
doxorubicin	B-Drug
,	O
and	O
the	O
unique	O
anatomic	O
nature	O
of	O
a	O
Meckel	O
diverticulum	O
may	O
have	O
contributed	O
to	O
this	O
extremely	O
unlikely	O
and	O
previously	O
unreported	O
event	O
.	O

-DOCSTART-	2196

Initiation	O
of	O
posaconazole	B-Drug
led	O
to	O
clinical	O
improvement	O
until	O
the	O
patient	O
's	O
demise	O
from	O
bacteremic	O
vancomycin	O
-	O
resistant	O
enterococcal	B-ADE
peritonitis	I-ADE
.	O

-DOCSTART-	4078

We	O
reported	O
3	O
patients	O
who	O
developed	O
acute	B-ADE
generalized	I-ADE
dystonia	I-ADE
and	O
akinetic	B-ADE
rigid	I-ADE
syndrome	I-ADE
following	O
an	O
initial	O
therapy	O
with	O
d	B-Drug
-	I-Drug
penicillamine	I-Drug
125	O
-	O
500	O
mg	O
daily	O
.	O

-DOCSTART-	393

So	O
far	O
,	O
few	O
cases	O
of	O
pulmonary	B-ADE
side	I-ADE
effects	I-ADE
caused	O
by	O
ticlopidine	B-Drug
have	O
been	O
reported	O
.	O

-DOCSTART-	2414

However	O
,	O
several	O
case	O
reports	O
have	O
suggested	O
that	O
clozapine	B-Drug
could	O
also	O
cause	O
TD	B-ADE
.	O

-DOCSTART-	3193

Fatal	B-ADE
pulmonary	I-ADE
fibrosis	I-ADE
following	O
1,3-bis(2-chloroethyl	B-Drug
)	I-Drug
-	I-Drug
1-nitrosourea	I-Drug
(	O
BCNU	B-Drug
)	O
therapy	O
.	O

-DOCSTART-	324

Atrial	B-ADE
fibrillation	I-ADE
occurring	O
in	O
a	O
patient	O
taking	O
etanercept	B-Drug
plus	O
methotrexate	B-Drug
for	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	3742

Choroidal	B-ADE
hemorrhage	I-ADE
associated	O
with	O
systemic	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
.	O

-DOCSTART-	2714

Vancomycin	B-Drug
-	O
induced	O
vasculitis	B-ADE
.	O

-DOCSTART-	503

This	O
report	O
rules	O
out	O
other	O
causes	O
of	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
and	O
implicates	O
ofloxacin	B-Drug
in	O
what	O
appears	O
to	O
be	O
an	O
atypical	O
presentation	O
of	O
drug	O
-	O
induced	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
.	O

-DOCSTART-	367

CONCLUSION	O
:	O
The	O
present	O
findings	O
suggest	O
that	O
fluvoxamine	B-Drug
can	O
cause	O
increased	B-ADE
libido	I-ADE
in	O
some	O
patients	O
.	O

-DOCSTART-	3501

Hypokalemia	B-ADE
after	O
normal	O
doses	O
of	O
neubulized	O
albuterol	B-Drug
(	O
salbutamol	B-Drug
)	O
.	O

-DOCSTART-	2488

This	O
case	O
presentation	O
is	O
of	O
a	O
patient	O
who	O
had	O
the	O
clinical	O
appearance	O
of	O
epiglottitis	B-ADE
,	O
but	O
actually	O
had	O
an	O
oro	B-ADE
-	I-ADE
pharyngeal	I-ADE
dystonic	I-ADE
reaction	I-ADE
to	O
prochlorperazine	B-Drug
.	O

-DOCSTART-	2137

We	O
describe	O
the	O
first	O
case	O
of	O
disseminated	B-ADE
salmonellosis	I-ADE
in	O
a	O
patient	O
treated	O
with	O
temozolomide	B-Drug
.	O

-DOCSTART-	4121

This	O
report	O
presents	O
a	O
potential	O
case	O
of	O
risperidone	B-Drug
-	O
induced	O
tardive	B-ADE
dyskinesia	I-ADE
.	O

-DOCSTART-	2507

We	O
report	O
a	O
girl	O
with	O
the	O
Rett	O
syndrome	O
who	O
had	O
acute	B-ADE
encephalopathy	I-ADE
probably	O
induced	O
by	O
calcium	B-Drug
hopantenate	I-Drug
(	O
HOPA	B-Drug
)	O
.	O

-DOCSTART-	3246

Fulminant	B-ADE
hepatitis	I-ADE
associated	O
with	O
disulfiram	B-Drug
.	O

-DOCSTART-	2573

Severe	B-ADE
acute	I-ADE
encephalopathy	I-ADE
following	O
inadvertent	O
intrathecal	O
doxorubicin	B-Drug
administration	O
.	O

-DOCSTART-	4160

A	O
drug	B-ADE
interaction	I-ADE
between	O
zafirlukast	B-Drug
and	O
theophylline	B-Drug
.	O

-DOCSTART-	571

Pulmonary	B-ADE
toxicity	I-ADE
secondary	O
to	O
procarbazine	B-Drug
.	O

-DOCSTART-	1385

CONCLUSIONS	O
:	O
This	O
observation	O
of	O
"	O
on	O
-	O
off	O
"	O
risperidone	B-Drug
treatment	O
suggests	O
that	O
risperidone	B-Drug
may	O
have	O
worsened	O
both	O
psychiatric	B-ADE
and	I-ADE
physical	I-ADE
manifestations	I-ADE
of	O
the	O
mitochondrial	O
disorder	O
in	O
this	O
adolescent	O
.	O

-DOCSTART-	3894

Zolpidem	B-Drug
tissue	O
concentrations	O
in	O
a	O
multiple	O
drug	O
related	O
death	B-ADE
involving	O
Ambien	B-Drug
.	O

-DOCSTART-	1982

New	O
onset	O
of	O
Crohn	B-ADE
's	I-ADE
disease	I-ADE
during	O
treatment	O
of	O
active	O
ankylosing	O
spondylitis	O
with	O
etanercept	B-Drug
.	O

-DOCSTART-	794

While	O
40	O
mg	O
/	O
day	O
of	O
prednisolone	B-Drug
improved	O
hepatic	O
dysfunction	O
dramatically	O
,	O
her	O
diabetic	B-ADE
milieu	I-ADE
deteriorated	I-ADE
seriously	O
.	O

-DOCSTART-	189

We	O
present	O
two	O
cases	O
of	O
nitrofurantoin	B-Drug
-	O
induced	O
pulmonary	B-ADE
toxicity	I-ADE
in	O
which	O
the	O
initial	O
HRCT	O
showed	O
a	O
widespread	B-ADE
reticular	I-ADE
pattern	I-ADE
and	O
associated	O
distortion	B-ADE
of	I-ADE
the	I-ADE
lung	I-ADE
parenchyma	I-ADE
,	O
thought	O
to	O
represent	O
established	O
fibrosis	B-ADE
.	O

-DOCSTART-	3922

Mesalamine	B-Drug
-	O
induced	O
hypersensitivity	B-ADE
pneumonitis	I-ADE
.	O

-DOCSTART-	3905

Psychotic	B-ADE
disorder	I-ADE
associated	O
with	O
isoniazid	B-Drug
.	O

-DOCSTART-	1473

Dyspnea	B-ADE
,	O
hypoxemia	B-ADE
,	O
and	O
pleuritic	B-ADE
chest	I-ADE
pain	I-ADE
occurred	O
within	O
24	O
hours	O
of	O
rituximab	B-Drug
administration	O
,	O
and	O
there	O
was	O
no	O
other	O
apparent	O
explanation	O
.	O

-DOCSTART-	1084

Therapy	O
with	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
may	O
be	O
associated	O
with	O
a	O
number	O
of	O
neuropsychiatric	B-ADE
symptoms	I-ADE
,	O
such	O
as	O
Parkinsonism	B-ADE
,	O
akathisia	B-ADE
,	O
seizure	B-ADE
,	O
and	O
depressive	B-ADE
disorders	I-ADE
.	O

-DOCSTART-	102

Emphasis	O
is	O
given	O
to	O
the	O
differentiation	O
of	O
diphenylhydantoin	B-Drug
induced	O
gingival	B-ADE
hyperplasia	I-ADE
from	O
the	O
angiomatous	O
enlargement	O
of	O
the	O
gingiva	O
before	O
any	O
treatment	O
is	O
planned	O
.	O

-DOCSTART-	2749

Camptocormia	B-ADE
,	O
a	O
new	O
side	O
effect	O
of	O
sodium	B-Drug
valproate	I-Drug
.	O

-DOCSTART-	3132

Toxic	B-ADE
hepatitis	I-ADE
induced	O
by	O
disulfiram	B-Drug
in	O
a	O
non	O
-	O
alcoholic	O
.	O

-DOCSTART-	2782

Renal	B-ADE
hypophosphatemia	I-ADE
in	O
this	O
patient	O
was	O
caused	O
by	O
the	O
erroneous	O
intake	O
of	O
1	O
g	O
doxycycline	B-Drug
.	O

-DOCSTART-	1669

Acute	B-ADE
renal	I-ADE
failure	I-ADE
during	O
lisinopril	B-Drug
and	O
losartan	B-Drug
therapy	O
for	O
proteinuria	O
.	O

-DOCSTART-	3869

After	O
therapy	O
for	O
diabetic	O
coma	O
with	O
insulin	B-Drug
(	O
containing	O
the	O
preservative	O
cresol	B-Drug
)	O
and	O
electrolyte	O
solutions	O
was	O
started	O
,	O
the	O
patient	O
complained	O
of	O
increasing	B-ADE
myalgia	I-ADE
,	O
developed	O
a	O
high	B-ADE
fever	I-ADE
and	O
respiratory	B-ADE
and	I-ADE
metabolic	I-ADE
acidosis	I-ADE
and	O
lost	B-ADE
consciousness	I-ADE
.	O

-DOCSTART-	2740

A	O
woman	O
38-year	O
-	O
old	O
,	O
suffering	O
for	O
about	O
ten	O
years	O
from	O
multiple	O
sclerosis	O
and	O
treated	O
with	O
repeated	O
therapy	O
cycles	O
of	O
intrathecal	O
Depo	B-Drug
-	I-Drug
Medrol	I-Drug
,	O
developed	O
a	O
spastic	B-ADE
paraparesis	I-ADE
at	I-ADE
the	I-ADE
lower	I-ADE
limbs	I-ADE
.	O

-DOCSTART-	1383

The	O
authors	O
think	O
that	O
although	O
lamivudine	B-Drug
is	O
widely	O
used	O
and	O
well	O
tolerated	O
,	O
it	O
can	O
cause	O
ADRs	B-ADE
,	O
which	O
are	O
reversible	O
after	O
drug	O
withdrawal	O
.	O

-DOCSTART-	53

Hair	B-ADE
loss	I-ADE
associated	O
with	O
paroxetine	B-Drug
treatment	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3818

Seizures	B-ADE
associated	O
with	O
ofloxacin	B-Drug
therapy	O
.	O

-DOCSTART-	1956

Histopathology	O
of	O
the	O
thyroid	O
in	O
amiodarone	B-Drug
-	O
induced	O
hypothyroidism	B-ADE
.	O

-DOCSTART-	431

We	O
present	O
the	O
case	O
of	O
a	O
patient	O
who	O
had	O
undergone	O
cholecystectomy	O
previously	O
,	O
but	O
in	O
whom	O
morphine	B-Drug
given	O
in	O
the	O
Emergency	O
Department	O
precipitated	O
pain	B-ADE
consistent	O
with	O
biliary	B-ADE
colic	I-ADE
;	O
the	O
pain	O
resolved	O
promptly	O
after	O
administration	O
of	O
naloxone	O
.	O

-DOCSTART-	1214

We	O
report	O
AZA	B-Drug
-	O
induced	O
drug	B-ADE
eruption	I-ADE
that	O
developed	O
in	O
two	O
cases	O
of	O
systemic	O
scleroderma	O
with	O
polymyositis	O
.	O

-DOCSTART-	1568

Fatal	B-ADE
pulmonary	I-ADE
fibrosis	I-ADE
induced	O
by	O
paclitaxel	B-Drug
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	790

Does	O
the	O
use	O
of	O
insulin	B-Drug
in	O
a	O
patient	O
with	O
liver	O
dysfunction	O
increase	O
water	O
retention	O
in	O
the	O
body	O
,	O
i.e.	O
cause	O
insulin	O
oedema	B-ADE
?	O

-DOCSTART-	2630

Three	O
patients	O
who	O
had	O
experienced	O
neuroleptic	O
-	O
induced	O
akathisia	O
in	O
the	O
past	O
reported	O
that	O
the	O
symptoms	O
of	O
fluoxetine	B-Drug
-	O
induced	O
akathisia	B-ADE
were	O
identical	O
,	O
although	O
somewhat	O
milder	O
.	O

-DOCSTART-	455

This	O
article	O
describes	O
the	O
case	O
of	O
a	O
25-year	O
-	O
old	O
man	O
found	O
dead	B-ADE
at	O
home	O
who	O
had	O
been	O
prescribed	O
olanzapine	B-Drug
for	O
schizophrenia	O
.	O

-DOCSTART-	513

This	O
is	O
the	O
second	O
report	O
of	O
acute	B-ADE
lung	I-ADE
injury	I-ADE
and	O
diffuse	B-ADE
alveolar	I-ADE
damage	I-ADE
caused	O
by	O
mefloquine	B-Drug
.	O

-DOCSTART-	2633

Peripheral	B-ADE
nervous	I-ADE
system	I-ADE
disturbances	I-ADE
caused	O
by	O
cytosine	B-Drug
arabinoside	I-Drug
have	O
rarely	O
been	O
reported	O
.	O

-DOCSTART-	1589

Shortly	O
after	O
chemotherapy	O
and	O
an	O
injection	O
of	O
pegfilgrastim	B-Drug
,	O
the	O
patient	O
developed	O
poorly	O
defined	O
,	O
rapidly	B-ADE
progressive	I-ADE
erythema	I-ADE
,	O
edema	B-ADE
,	O
and	O
pain	B-ADE
in	I-ADE
his	I-ADE
right	I-ADE
forearm	I-ADE
.	O

-DOCSTART-	1690

Recurrent	B-ADE
hyponatremia	I-ADE
associated	O
with	O
citalopram	B-Drug
and	O
mirtazapine	B-Drug
.	O

-DOCSTART-	1882

Red	B-ADE
blood	I-ADE
cell	I-ADE
anemia	I-ADE
in	O
a	O
patient	O
with	O
pemphigus	O
vulgaris	O
induced	O
by	O
the	O
use	O
of	O
mycophenolate	B-Drug
mofetil	I-Drug
and	O
prednisone	B-Drug
.	O

-DOCSTART-	1037

Phenylpropanolamine	B-Drug
(	O
PPA	B-Drug
)	O
recently	O
has	O
been	O
publicly	O
implicated	O
as	O
a	O
cause	O
of	O
stroke	B-ADE
and	O
other	O
neurologic	B-ADE
events	I-ADE
.	O

-DOCSTART-	970

This	O
is	O
the	O
first	O
case	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
onset	O
of	O
prolonged	O
infliximab	B-Drug
-	O
induced	O
lupus	B-ADE
.	O

-DOCSTART-	2160

Adrenal	B-ADE
suppression	I-ADE
in	I-ADE
a	I-ADE
fetus	I-ADE
due	O
to	O
administration	O
of	O
methylprednisolone	B-Drug
has	O
hitherto	O
been	O
rarely	O
published	O
.	O

-DOCSTART-	3358

Oesophageal	B-ADE
ulceration	I-ADE
due	O
to	O
emepronium	B-Drug
bromide	I-Drug
.	O

-DOCSTART-	1119

After	O
3-	O
to	O
13-month	O
period	O
of	O
therapy	O
without	O
indapamide	B-Drug
,	O
glucose	O
levels	O
of	O
all	O
patients	O
decreased	O
and	O
diabetes	B-ADE
disappeared	O
.	O

-DOCSTART-	2364

Increased	O
awareness	O
is	O
needed	O
on	O
the	O
possible	O
occurrence	O
of	O
LPD	B-ADE
resembling	O
gastric	O
cancer	O
in	O
rheumatoid	O
arthritis	O
patients	O
treated	O
with	O
MTX	B-Drug
.	O

-DOCSTART-	2935

The	O
condition	O
should	O
be	O
suspected	O
in	O
patients	O
who	O
develop	O
unexplained	O
abdominal	B-ADE
pain	I-ADE
or	O
collapse	B-ADE
following	O
vasopressin	B-Drug
treatment	O
.	O

-DOCSTART-	1047

It	O
is	O
very	O
likely	O
that	O
the	O
dexamethasone	B-Drug
used	O
in	O
the	O
antiemetic	O
drug	O
regimen	O
contributed	O
to	O
the	O
development	O
of	O
osteonecrosis	B-ADE
in	O
these	O
patients	O
.	O

-DOCSTART-	1611

Angioedema	B-ADE
,	O
a	O
rare	O
side	O
effect	O
of	O
carbamazepine	B-Drug
,	O
involves	O
vascular	O
leakage	O
in	O
dermis	O
and	O
subcutis	O
mediated	O
by	O
immunoglobulin	O
E	O
and/or	O
bradykinins	O
.	O

-DOCSTART-	3676

These	O
cases	O
demonstrate	O
that	O
CBZ	B-Drug
can	O
induce	O
simple	O
motor	B-ADE
tics	I-ADE
in	O
children	O
.	O

-DOCSTART-	3129

Cyclophosphamide	B-Drug
pneumonitis	B-ADE
.	O

-DOCSTART-	1182

Pulmonary	B-ADE
lymphohistiocytic	I-ADE
reactions	I-ADE
temporally	O
related	O
to	O
etanercept	B-Drug
therapy	O
.	O

-DOCSTART-	2933

Pseudomembranous	B-ADE
colitis	I-ADE
readily	O
occurs	O
in	O
at	O
least	O
certain	O
population	O
groups	O
receiving	O
trimethoprim	B-Drug
-	O
sulfamethoxazole	B-Drug
.	O

-DOCSTART-	2060

We	O
believe	O
that	O
the	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
in	O
our	O
patient	O
was	O
associated	O
with	O
anastrozole	B-Drug
.	O

-DOCSTART-	3496

Renal	B-ADE
failure	I-ADE
appeared	O
8	O
to	O
17	O
days	O
after	O
beginning	O
gentamicin	B-Drug
therapy	O
and	O
was	O
characterized	O
by	O
creatinine	O
clearances	O
4	O
to	O
10	O
ml	O
/	O
min	O
,	O
urine	O
to	O
plasma	O
creatinine	O
ratios	O
less	O
than	O
20	O
,	O
urinary	O
sodium	O
concentrations	O
16	O
to	O
60	O
mEq	O
/	O
liter	O
,	O
proteinuria	O
,	O
and	O
cylindruria	O
.	O

-DOCSTART-	1243

Cis	B-Drug
-	I-Drug
retinoic	I-Drug
acid	I-Drug
(	O
RA	B-Drug
)	O
may	O
further	O
increase	O
the	O
risk	O
of	O
developing	O
BMTN	B-ADE
.	O

-DOCSTART-	3414

CONCLUSION	O
:	O
Anterior	B-ADE
ischemic	I-ADE
optic	I-ADE
neuropathy	I-ADE
may	O
complicate	O
treatment	O
with	O
interferon	B-Drug
alfa	I-Drug
.	O

-DOCSTART-	3078

Optic	B-ADE
neuropathy	I-ADE
associated	O
with	O
penicillamine	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	2429

The	O
electrocardiogram	O
(	O
ECG	O
)	O
,	O
which	O
was	O
read	O
as	O
normal	O
prior	O
to	O
ritodrine	B-Drug
infusion	O
,	O
demonstrated	O
a	O
type	B-ADE
I	I-ADE
second	I-ADE
-	I-ADE
degree	I-ADE
AV	I-ADE
block	I-ADE
which	O
disappeared	O
upon	O
discontinuation	O
of	O
ritodrine	B-Drug
therapy	O
.	O

-DOCSTART-	1149

In	O
this	O
report	O
,	O
two	O
newborns	O
with	O
congenital	O
heart	O
anomalies	O
demonstrated	O
the	O
harlequin	B-ADE
color	I-ADE
change	I-ADE
,	O
one	O
whose	O
skin	O
findings	O
showed	O
a	O
course	O
related	O
to	O
the	O
dose	O
of	O
systemic	O
prostaglandin	B-Drug
E1	I-Drug
,	O
suggesting	O
a	O
possible	O
association	O
.	O

-DOCSTART-	2006

Diffuse	B-ADE
alveolar	I-ADE
hemorrhage	I-ADE
after	O
leflunomide	B-Drug
therapy	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	484

The	O
aim	O
of	O
this	O
report	O
is	O
to	O
describe	O
the	O
clinical	O
and	O
electroencephalographic	O
findings	O
seen	O
in	O
an	O
elderly	O
woman	O
without	O
previous	O
history	O
of	O
seizures	O
who	O
developed	O
a	O
nonconvulsive	B-ADE
generalized	I-ADE
status	I-ADE
epilepticus	I-ADE
following	O
acute	O
withdrawal	O
of	O
lorazepam	B-Drug
.	O

-DOCSTART-	1938

Psychosis	B-ADE
in	O
a	O
12-year	O
-	O
old	O
HIV	O
-	O
positive	O
girl	O
with	O
an	O
increased	O
serum	O
concentration	O
of	O
efavirenz	B-Drug
.	O

-DOCSTART-	3195

Thrombotic	B-ADE
thrombocytopenic	I-ADE
purpura	I-ADE
(	O
TTP	B-ADE
)	O
developed	O
in	O
a	O
patient	O
with	O
seropositive	O
rheumatoid	O
arthritis	O
(	O
RA	O
)	O
after	O
2	O
1/2	O
months	O
of	O
treatment	O
with	O
penicillamine	B-Drug
.	O

-DOCSTART-	2540

Sulfadiazine	B-Drug
crystalluria	B-ADE
revisited	O
.	O

-DOCSTART-	4054

Ritonavir	B-Drug
should	O
be	O
added	O
to	O
the	O
list	O
of	O
drugs	O
that	O
can	O
induce	O
adverse	B-ADE
cutaneous	I-ADE
reactions	I-ADE
in	O
HIV	O
patients	O
.	O

-DOCSTART-	2004

Photo	B-ADE
-	I-ADE
onycholysis	I-ADE
caused	O
by	O
olanzapine	B-Drug
and	O
aripiprazole	B-Drug
.	O

-DOCSTART-	828

We	O
describe	O
3	O
cases	O
of	O
diphenhydramine	B-Drug
-	O
induced	O
cardiac	B-ADE
toxicity	I-ADE
that	O
were	O
responsive	O
to	O
bicarbonate	O
.	O

-DOCSTART-	187

Troglitazone	B-Drug
-	O
induced	O
fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
.	O

-DOCSTART-	4271

Successful	O
challenge	O
with	O
clozapine	B-Drug
in	O
a	O
history	O
of	O
eosinophilia	B-ADE
.	O

-DOCSTART-	3142

Pemphigus	B-ADE
foliaceus	I-ADE
induced	O
by	O
rifampicin	B-Drug
.	O

-DOCSTART-	2394

However	O
,	O
a	O
recent	O
post	O
-	O
marketing	O
survey	O
in	O
Japan	O
revealed	O
that	O
interstitial	B-ADE
pneumonia	I-ADE
occurred	O
in	O
4	O
among	O
approximately	O
2	O
000	O
Japanese	O
patients	O
treated	O
with	O
sorafenib	B-Drug
.	O

-DOCSTART-	1758

RESULTS	O
:	O
A	O
clinical	O
diagnosis	O
of	O
fixed	B-ADE
drug	I-ADE
eruption	I-ADE
owing	O
to	O
use	O
of	O
the	O
PDE5	O
inhibitor	O
tadalafil	B-Drug
(	O
Cialis	B-Drug
)	O
was	O
made	O
.	O

-DOCSTART-	4062

A	O
case	O
is	O
reported	O
of	O
an	O
elderly	O
woman	O
who	O
developed	O
febrile	B-ADE
agranulocytosis	I-ADE
several	O
weeks	O
after	O
commencing	O
ticlopidine	B-Drug
but	O
who	O
had	O
a	O
favorable	O
outcome	O
after	O
cessation	O
of	O
that	O
drug	O
and	O
treatment	O
with	O
filgastrim	O
.	O

-DOCSTART-	2969

A	O
case	O
of	O
pyridoxine	B-Drug
-	O
dependent	O
seizures	B-ADE
is	O
reported	O
.	O

-DOCSTART-	3079

Optic	B-ADE
neuropathy	I-ADE
developed	O
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
who	O
had	O
been	O
receiving	O
D	B-Drug
-	I-Drug
penicillamine	I-Drug
for	O
about	O
1	O
year	O
.	O

-DOCSTART-	1825

Selective	O
estrogen	O
receptor	O
modulator	O
raloxifene	B-Drug
-	O
associated	O
aggravation	B-ADE
of	I-ADE
nonalcoholic	I-ADE
steatohepatitis	I-ADE
.	O

-DOCSTART-	2315

According	O
to	O
the	O
Naranjo	O
adverse	O
drug	O
reaction	O
probability	O
scale	O
,	O
tigecycline	B-Drug
was	O
the	O
probable	O
cause	O
of	O
her	O
acute	B-ADE
pancreatitis	I-ADE
.	O

-DOCSTART-	939

Surgeons	O
and	O
physicians	O
should	O
therefore	O
be	O
aware	O
of	O
the	O
potential	O
for	O
RTA	B-ADE
to	O
occur	O
with	O
FK506	B-Drug
after	O
any	O
organ	O
transplantation	O
.	O

-DOCSTART-	3956

The	O
case	O
of	O
a	O
patient	O
with	O
infectious	O
mononucleosis	O
treated	O
with	O
cephalexin	B-Drug
who	O
later	O
showed	O
a	O
rash	B-ADE
is	O
presented	O
and	O
the	O
previous	O
literature	O
is	O
reviewed	O
.	O

-DOCSTART-	465

The	O
time	O
course	O
of	O
events	O
suggested	O
that	O
amphotericin	B-Drug
B	I-Drug
was	O
the	O
cause	O
of	O
the	O
seizures	B-ADE
in	O
this	O
AIDS	O
patient	O
.	O

-DOCSTART-	4162

One	O
explanation	O
for	O
the	O
noted	O
increase	B-ADE
in	I-ADE
the	I-ADE
theophylline	I-ADE
level	I-ADE
is	O
that	O
metabolism	O
occurs	O
mainly	O
by	O
cytochrome	O
P450	O
(	O
CYP	O
1A2	O
)	O
,	O
an	O
enzyme	O
that	O
is	O
known	O
to	O
be	O
inhibited	O
with	O
high	O
concentrations	O
of	O
zafirlukast	B-Drug
.	O

-DOCSTART-	4226

We	O
report	O
the	O
case	O
of	O
intoxication	B-ADE
of	O
a	O
41-year	O
-	O
old	O
female	O
patient	O
suffering	O
from	O
major	O
depression	O
with	O
mirtazapine	B-Drug
complicated	O
by	O
severe	O
hypothermia	O
.	O

-DOCSTART-	3766

These	O
evolutional	O
changes	O
in	O
both	O
proteinuria	O
and	O
glomerular	O
histology	O
suggest	O
a	O
close	O
linkage	O
between	O
the	O
M	B-Drug
-	I-Drug
CSF	I-Drug
treatment	O
and	O
macrophage	B-ADE
-	I-ADE
related	I-ADE
glomerular	I-ADE
injury	I-ADE
.	O

-DOCSTART-	1218

Asthenozoospermia	B-ADE
:	O
possible	O
association	O
with	O
long	O
-	O
term	O
exposure	O
to	O
an	O
anti	O
-	O
epileptic	O
drug	O
of	O
carbamazepine	B-Drug
.	O

-DOCSTART-	2948

A	O
study	O
following	O
large	O
patient	O
groups	O
on	O
theophylline	B-Drug
and	O
a	O
combination	O
of	O
theophylline	B-Drug
and	O
steroids	O
might	O
clarify	O
the	O
risk	O
of	O
ulcer	B-ADE
formation	O
in	O
patients	O
being	O
treated	O
with	O
these	O
medications	O
for	O
asthma	O
.	O

-DOCSTART-	928

An	O
adverse	O
reaction	O
to	O
IFN	B-Drug
was	O
strongly	O
suspected	O
as	O
the	O
cause	O
of	O
CHF	B-ADE
.	O

-DOCSTART-	1592

We	O
report	O
4	O
patients	O
who	O
developed	O
symptoms	O
of	O
myasthenia	B-ADE
gravis	I-ADE
within	O
2	O
weeks	O
of	O
starting	O
treatment	O
with	O
a	O
statin	B-Drug
drug	O
.	O

-DOCSTART-	608

Toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
associated	O
with	O
interleukin-2	B-Drug
.	O

-DOCSTART-	3399

Both	O
PAN	B-Drug
and	O
methotrexate	B-Drug
have	O
been	O
independently	O
demonstrated	O
to	O
cause	O
sensorineural	B-ADE
hearing	I-ADE
loss	I-ADE
.	O

-DOCSTART-	3443

Acute	O
INH	B-Drug
neurotoxicity	B-ADE
was	O
not	O
suspected	O
on	O
the	O
first	O
admission	O
;	O
however	O
,	O
when	O
readmitted	O
4	O
weeks	O
later	O
with	O
another	O
seizure	O
,	O
the	O
diagnosis	O
of	O
acute	O
INH	B-Drug
neurotoxicity	B-ADE
was	O
made	O
.	O

-DOCSTART-	3516

The	O
cough	B-ADE
continued	O
for	O
the	O
duration	O
of	O
therapy	O
with	O
quinapril	B-Drug
.	O

-DOCSTART-	538

Captopril	B-Drug
is	O
an	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
and	O
their	O
cutaneous	B-ADE
side	I-ADE
-	I-ADE
effects	I-ADE
are	O
documented	O
,	O
but	O
little	O
has	O
been	O
published	O
concerning	O
the	O
usefulness	O
of	O
patch	O
test	O
when	O
they	O
occur	O
.	O

-DOCSTART-	3465

Clinicians	O
who	O
manage	O
cachectic	O
patients	O
,	O
particularly	O
those	O
with	O
protracted	O
diarrhoea	O
and/or	O
receiving	O
anti	O
-	O
malarial	O
drugs	O
including	O
mefloquine	B-Drug
,	O
should	O
be	O
aware	O
of	O
the	O
risk	O
of	O
severe	B-ADE
hypoglycaemia	I-ADE
.	O

-DOCSTART-	3522

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
suspected	O
DIAN	B-ADE
due	O
to	O
cefuroxime	B-Drug
.	O

-DOCSTART-	2607

Multicentric	B-ADE
hepatocellular	I-ADE
carcinoma	I-ADE
following	O
phosphate	B-Drug
diethylstilbestrol	I-Drug
therapy	O
for	O
prostatic	O
cancer	O
.	O

-DOCSTART-	1681

Hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
following	O
the	O
infusion	O
of	O
oxaliplatin	B-Drug
:	O
case	O
report	O
.	O

-DOCSTART-	2283

Anaphylactic	B-ADE
reaction	I-ADE
to	O
bacitracin	B-Drug
ointment	O
.	O

-DOCSTART-	3637

Myoclonus	B-ADE
was	O
induced	O
and	O
enhanced	O
by	O
L	B-Drug
-	I-Drug
dopa	I-Drug
,	O
developing	O
into	O
generalized	B-ADE
seizures	I-ADE
.	O

-DOCSTART-	3504

Propoxyphene	B-Drug
-	O
induced	O
wide	B-ADE
QRS	I-ADE
complex	I-ADE
dysrhythmia	I-ADE
responsive	O
to	O
sodium	O
bicarbonate	O
--	O
a	O
case	O
report	O
.	O

-DOCSTART-	1811

CONCLUSION	O
:	O
Gemcitabine	B-Drug
-	O
induced	O
recall	B-ADE
pneumonitis	I-ADE
is	O
a	O
rarely	O
reported	O
phenomenon	O
and	O
should	O
be	O
taken	O
into	O
account	O
even	O
after	O
extended	O
time	O
interval	O
to	O
the	O
previous	O
radiotherapy	O
.	O

-DOCSTART-	340

Dose	O
-	O
dependent	O
olanzapine	B-Drug
-	O
associated	O
leukopenia	B-ADE
:	O
three	O
case	O
reports	O
.	O

-DOCSTART-	647

Gigantomastia	B-ADE
induced	O
by	O
bucillamine	B-Drug
.	O

-DOCSTART-	955

The	O
case	O
history	O
and	O
toxicological	O
findings	O
of	O
an	O
infant	O
fatality	B-ADE
involving	O
pseudoephedrine	B-Drug
,	O
brompheniramine	B-Drug
,	O
and	O
dextromethorphan	B-Drug
are	O
presented	O
.	O

-DOCSTART-	1384

Pleuropulmonary	B-ADE
fibrosis	I-ADE
after	O
long	O
-	O
term	O
treatment	O
with	O
the	O
dopamine	O
agonist	O
pergolide	B-Drug
for	O
Parkinson	O
Disease	O
.	O

-DOCSTART-	2912

In	O
addition	O
to	O
the	O
recognized	O
arrhythmic	O
complications	O
,	O
the	O
authors	O
emphasize	O
myocardial	B-ADE
necrosis	I-ADE
as	O
a	O
possible	O
further	O
manifestation	O
of	O
amsacrine	B-Drug
-	O
related	O
cardiotoxicity	B-ADE
.	O

-DOCSTART-	3287

In	O
one	O
patient	O
,	O
treatment	O
with	O
DCA	B-Drug
was	O
associated	O
with	O
a	O
decrease	B-ADE
in	I-ADE
blood	I-ADE
lactate	I-ADE
levels	I-ADE
from	O
11.2	O
mM	O
before	O
treatment	O
to	O
0.8	O
mM	O
16	O
h	O
later	O
.	O

-DOCSTART-	708

Ovarian	B-ADE
endometrioid	I-ADE
adenocarcinoma	I-ADE
arising	O
from	O
an	O
endometriotic	O
cyst	O
in	O
a	O
postmenopausal	O
woman	O
under	O
tamoxifen	B-Drug
therapy	O
for	O
breast	O
cancer	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	800

Isoniazid	B-Drug
-	O
induced	O
anaphylaxis	B-ADE
.	O

-DOCSTART-	2975

Pellagra	B-ADE
encephalopathy	I-ADE
among	O
tuberculous	O
patients	O
:	O
its	O
relation	O
to	O
isoniazid	B-Drug
therapy	O
.	O

-DOCSTART-	1046

We	O
describe	O
a	O
continuous	O
ambulatory	O
peritoneal	O
dialysis	O
(	O
CAPD	O
)	O
patient	O
that	O
developed	O
vancomycin	B-Drug
-	O
induced	O
agranulocytosis	B-ADE
during	O
treatment	O
for	O
methicillin	O
-	O
resistant	O
Staphylococcus	O
aureus	O
(	O
MRSA	O
)	O
-	O
associated	O
external	O
cuff	O
infection	O
and	O
pneumonia	O
.	O

-DOCSTART-	1080

Eosinophilic	B-ADE
cystitis	I-ADE
after	O
bladder	O
instillation	O
with	O
dimethyl	B-Drug
sulfoxide	I-Drug
.	O

-DOCSTART-	183

However	O
,	O
as	O
illustrated	O
by	O
these	O
and	O
other	O
cases	O
reported	O
to	O
date	O
,	O
the	O
onset	O
of	O
troglitazone	B-Drug
-	O
induced	O
liver	B-ADE
injury	I-ADE
is	O
insidious	O
and	O
temporally	O
variable	O
.	O

-DOCSTART-	1905

Generalized	B-ADE
lichen	I-ADE
nitidus	I-ADE
with	O
involvement	O
of	O
the	O
palms	O
following	O
interferon	B-Drug
alpha	I-Drug
treatment	O
.	O

-DOCSTART-	3514

Cough	B-ADE
induced	O
by	O
quinapril	B-Drug
with	O
resolution	O
after	O
changing	O
to	O
fosinopril	O
.	O

-DOCSTART-	1549

This	O
is	O
the	O
first	O
case	O
of	O
TMP	B-Drug
-	I-Drug
SMX	I-Drug
-	O
induced	O
hypersensitivity	B-ADE
syndrome	I-ADE
associated	O
with	O
the	O
reactivation	O
of	O
a	O
latent	O
viral	O
infection	O
.	O

-DOCSTART-	3000

Rifampicin	B-Drug
-	O
induced	O
renal	B-ADE
failure	I-ADE
.	O

-DOCSTART-	894

Acute	B-ADE
myopathy	I-ADE
with	O
selective	O
degeneration	B-ADE
of	I-ADE
myosin	I-ADE
filaments	I-ADE
following	O
status	O
asthmaticus	O
treated	O
with	O
methylprednisolone	B-Drug
and	O
vecuronium	B-Drug
.	O

-DOCSTART-	1324

High	B-ADE
-	I-ADE
grade	I-ADE
endometrial	I-ADE
stromal	I-ADE
sarcoma	I-ADE
after	O
tamoxifen	B-Drug
therapy	O
for	O
breast	O
cancer	O
.	O

-DOCSTART-	2056

CONCLUSIONS	O
:	O
Anastrozole	B-Drug
may	O
be	O
the	O
causative	O
factor	O
in	O
patients	O
with	O
sclerosing	B-ADE
glomerulonephritis	I-ADE
.	O

-DOCSTART-	1763

Thrombotic	B-ADE
thrombocytopenic	I-ADE
purpura	I-ADE
induced	O
by	O
trimethoprim	B-Drug
-	O
sulfamethoxazole	B-Drug
in	O
a	O
Jehovah	O
's	O
Witness	O
.	O

-DOCSTART-	445

The	O
HIV	O
protease	O
inhibitor	O
indinavir	B-Drug
may	O
cause	O
nephrolithiasis	B-ADE
and	O
interstitial	B-ADE
nephritis	I-ADE
.	O

-DOCSTART-	3704

Two	O
fatal	B-ADE
cases	O
of	O
poisoning	O
by	O
paracetamol	B-Drug
are	O
described	O
.	O

-DOCSTART-	127

The	O
clinical	O
course	O
suggests	O
that	O
caffeine	B-Drug
,	O
which	O
is	O
present	O
in	O
oolong	O
tea	O
,	O
was	O
mainly	O
responsible	O
for	O
the	O
rhabdomyolysis	B-ADE
as	O
well	O
as	O
the	O
delirium	B-ADE
,	O
although	O
severe	O
hyponatremia	B-ADE
has	O
been	O
reported	O
to	O
cause	O
rhabdomyolysis	B-ADE
on	O
rare	O
occasions	O
.	O

-DOCSTART-	1131

Easily	O
reversible	O
hypoxemia	B-ADE
and	O
hypotension	B-ADE
induced	O
by	O
nimodipine	B-Drug
.	O

-DOCSTART-	4002

Children	O
receiving	O
zonisamide	B-Drug
should	O
be	O
monitored	O
for	O
oligohidrosis	B-ADE
and	O
the	O
development	O
of	O
neurological	B-ADE
symptoms	I-ADE
associated	O
with	O
an	O
elevation	O
of	O
body	O
temperature	O
.	O

-DOCSTART-	1548

A	O
27-year	O
-	O
old	O
man	O
who	O
had	O
a	O
history	O
of	O
bronchial	O
asthma	O
,	O
eosinophilic	O
enteritis	O
,	O
and	O
eosinophilic	O
pneumonia	O
presented	O
with	O
fever	B-ADE
,	O
skin	B-ADE
eruptions	I-ADE
,	O
cervical	B-ADE
lymphadenopathy	I-ADE
,	O
hepatosplenomegaly	B-ADE
,	O
atypical	B-ADE
lymphocytosis	I-ADE
,	O
and	O
eosinophilia	B-ADE
two	O
weeks	O
after	O
receiving	O
trimethoprim	B-Drug
(	O
TMP	B-Drug
)	O
-	O
sulfamethoxazole	B-Drug
(	O
SMX	B-Drug
)	O
treatment	O
.	O

-DOCSTART-	2576

Skin	B-ADE
rash	I-ADE
began	O
after	O
2	O
weeks	O
of	O
treatment	O
,	O
and	O
signs	O
of	O
hepatocellular	B-ADE
failure	I-ADE
developed	O
3	O
weeks	O
after	O
phenobarbital	B-Drug
had	O
been	O
started	O
.	O

-DOCSTART-	3792

Intranasal	O
desmopressin	B-Drug
-	O
induced	O
hyponatremia	B-ADE
.	O

-DOCSTART-	803

We	O
discuss	O
the	O
association	O
between	O
carbamazepine	B-Drug
and	O
hyponatremia	B-ADE
and	O
the	O
causes	O
of	O
hyponatremia	O
after	O
cardiopulmonary	O
bypass	O
.	O

-DOCSTART-	1459

Subacute	B-ADE
cholestatic	I-ADE
hepatitis	I-ADE
likely	O
related	O
to	O
the	O
use	O
of	O
senna	B-Drug
for	O
chronic	O
constipation	O
.	O

-DOCSTART-	3003

Subsequent	O
in	O
vivo	O
/	O
vitro	O
studies	O
clearly	O
demonstrated	O
that	O
the	O
neurological	B-ADE
effects	I-ADE
were	O
due	O
to	O
a	O
synergistic	O
action	O
of	O
desferrioxamine	B-Drug
and	O
prochlorperazine	B-Drug
,	O
probably	O
resulting	O
in	O
exceptional	O
fluxes	O
of	O
intra	O
/	O
extra	O
cellular	O
iron	O
/	O
copper	O
disturbing	O
noradrenergic	O
and	O
serotonergic	O
systems	O
.	O

-DOCSTART-	3567

RESULTS	O
:	O
Ethambutol	B-Drug
,	O
and	O
to	O
a	O
lesser	O
extent	O
isoniazid	B-Drug
,	O
are	O
both	O
implicated	O
in	O
the	O
development	B-ADE
of	I-ADE
visually	I-ADE
related	I-ADE
side	I-ADE
effects	I-ADE
.	O

-DOCSTART-	2152

We	O
report	O
a	O
case	O
in	O
which	O
hemorrhage	B-ADE
occurred	O
in	O
an	O
asymptomatic	O
falx	O
meningioma	O
known	O
beforehand	O
,	O
after	O
the	O
internal	O
use	O
of	O
low	O
-	O
dose	O
aspirin	B-Drug
for	O
16	O
months	O
.	O

-DOCSTART-	2035

We	O
report	O
4	O
patients	O
,	O
2	O
on	O
methylphenidate	B-Drug
and	O
2	O
on	O
dextroamphetamine	B-Drug
who	O
presented	O
with	O
acral	B-ADE
cyanosis	I-ADE
,	O
livedo	B-ADE
reticularis	I-ADE
,	O
or	O
Raynaud	B-ADE
phenomenon	I-ADE
.	O

-DOCSTART-	4140

She	O
was	O
treated	O
with	O
Pancrease	B-Drug
MT	I-Drug
16	I-Drug
,	O
but	O
had	O
consistent	O
vomiting	B-ADE
1	O
to	O
2	O
hours	O
after	O
administration	O
of	O
enzymes	O
.	O

-DOCSTART-	444

Physicians	O
should	O
be	O
aware	O
that	O
indinavir	B-Drug
nephrolithiasis	B-ADE
may	O
cause	O
papillary	B-ADE
necrosis	I-ADE
.	O

-DOCSTART-	3230

These	O
features	O
have	O
not	O
previously	O
been	O
reported	O
as	O
side	O
effects	O
of	O
glibenclamide	O
therapy	O
,	O
but	O
intrahepatic	B-ADE
cholestasis	I-ADE
may	O
occur	O
with	O
chlorpropamide	B-Drug
,	O
a	O
similar	O
sulphonylurea	O
agent	O
.	O

-DOCSTART-	715

Although	O
isradipine	B-Drug
has	O
been	O
associated	O
with	O
hepatocellular	B-ADE
injury	I-ADE
,	O
there	O
are	O
no	O
reports	O
of	O
fulminant	O
liver	O
failure	O
with	O
this	O
agent	O
,	O
and	O
our	O
patient	O
had	O
been	O
treated	O
for	O
>	O
2	O
years	O
without	O
signs	O
of	O
toxicity	O
.	O

-DOCSTART-	1299

Successful	O
recovery	O
from	O
interstitial	B-ADE
pneumonitis	I-ADE
,	O
induced	O
by	O
bicalutamide	B-Drug
and	O
leuprorelin	B-Drug
acetate	I-Drug
given	O
as	O
treatment	O
for	O
prostate	O
cancer	O
.	O

-DOCSTART-	4256

Lipoid	B-ADE
pneumonia	I-ADE
:	O
a	O
silent	O
complication	O
of	O
mineral	B-Drug
oil	I-Drug
aspiration	O
.	O

-DOCSTART-	2208

Corneal	B-ADE
edema	I-ADE
recurred	O
when	O
the	O
administration	O
of	O
amantadine	B-Drug
was	O
resumed	O
.	O

-DOCSTART-	1294

Fluphenazine	B-Drug
-	O
induced	O
neuroleptic	B-ADE
malignant	I-ADE
syndrome	I-ADE
in	O
a	O
schizophrenic	O
patient	O
.	O

-DOCSTART-	2228

Rituximab	O
-	O
based	O
therapy	O
for	O
gemcitabine	B-Drug
-	O
induced	O
hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
in	O
a	O
patient	O
with	O
metastatic	O
pancreatic	O
adenocarcinoma	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3257

The	O
cause	O
is	O
presumed	O
to	O
be	O
secondary	O
to	O
hypercoagulability	O
due	O
to	O
asparaginase	B-Drug
-	O
induced	O
antithrombin	B-ADE
III	I-ADE
deficiency	I-ADE
.	O

-DOCSTART-	2481

Cisplatin	B-Drug
-	O
induced	O
syndrome	B-ADE
of	I-ADE
inappropriate	I-ADE
antidiuretic	I-ADE
hormone	I-ADE
(	O
SIADH	B-ADE
)	O
in	O
a	O
patient	O
with	O
neuroendocrine	O
tumor	O
of	O
the	O
cervix	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	226

OBJECTIVE	O
:	O
To	O
describe	O
the	O
development	O
of	O
valproate	B-Drug
-	O
related	O
reproductive	B-ADE
endocrine	I-ADE
disorders	I-ADE
in	O
women	O
with	O
epilepsy	O
.	O

-DOCSTART-	1090

Sweet	B-ADE
's	I-ADE
syndrome	I-ADE
associated	O
with	O
sargramostim	B-Drug
(	O
granulocyte	O
-	O
macrophage	O
colony	O
stimulating	O
factor	O
)	O
treatment	O
.	O

-DOCSTART-	2219

Only	O
3	O
cases	O
of	O
imatinib	B-Drug
-	O
induced	O
tumor	B-ADE
lysis	I-ADE
syndrome	I-ADE
have	O
been	O
reported	O
.	O

-DOCSTART-	2370

Are	O
nasal	O
decongestants	O
safer	O
than	O
rhinitis	O
?	O
A	O
case	O
of	O
oxymetazoline	B-Drug
-	O
induced	O
syncope	B-ADE
.	O

-DOCSTART-	674

Infant	O
twins	O
sustained	O
severe	O
circumoral	B-ADE
and	I-ADE
pharyngeal	I-ADE
burns	I-ADE
from	O
a	O
concentrated	O
solution	O
of	O
benzalkonium	B-Drug
(	O
Zephiran	B-Drug
)	O
chloride	O
prescribed	O
for	O
treatment	O
of	O
candidiasis	O
.	O

-DOCSTART-	3369

A	O
case	O
of	O
barbiturate	B-Drug
-	O
induced	O
submassive	B-ADE
hepatic	I-ADE
necrosis	I-ADE
is	O
presented	O
and	O
the	O
literature	O
is	O
reviewed	O
.	O

-DOCSTART-	731

We	O
report	O
the	O
first	O
case	O
of	O
doxycycline	B-Drug
-	O
induced	O
hypoglycemia	B-ADE
in	O
a	O
young	O
nondiabetic	O
man	O
.	O

-DOCSTART-	2238

Tenofovir	B-Drug
-	O
associated	O
nephrotoxicity	B-ADE
in	O
two	O
HIV	O
-	O
infected	O
adolescent	O
males	O
.	O

-DOCSTART-	583

The	O
most	O
common	O
side	O
effects	O
associated	O
with	O
amifostine	B-Drug
are	O
nausea	B-ADE
,	O
vomiting	B-ADE
,	O
hypotension	B-ADE
,	O
hypocalcemia	B-ADE
and	O
allergic	B-ADE
reactions	I-ADE
.	O

-DOCSTART-	1120

After	O
stopping	O
indapamide	B-Drug
,	O
glucose	B-ADE
tolerance	I-ADE
impairing	I-ADE
may	O
be	O
reversed	O
.	O

-DOCSTART-	2244

The	O
exact	O
mechanism	O
of	O
IVIG	B-Drug
-	O
associated	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
remains	O
unclear	O
.	O

-DOCSTART-	1992

Due	O
to	O
the	O
severity	O
of	O
the	O
rash	B-ADE
,	O
temozolomide	B-Drug
was	O
permanently	O
discontinued	O
.	O

-DOCSTART-	3760

Captopril	B-Drug
-	O
associated	O
"	O
pseudocholangitis	B-ADE
'	O
.	O

-DOCSTART-	642

Mitomycin	B-Drug
-	I-Drug
C	I-Drug
is	O
used	O
widely	O
in	O
the	O
treatment	O
of	O
malignancies	O
and	O
is	O
associated	O
with	O
serious	O
dose	O
related	O
adverse	O
effects	O
including	O
the	O
occurrence	O
of	O
hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1503

Possible	O
interaction	O
between	O
lopinavir	B-Drug
/	O
ritonavir	B-Drug
and	O
valproic	B-Drug
Acid	I-Drug
exacerbates	O
bipolar	B-ADE
disorder	I-ADE
.	O

-DOCSTART-	1647

Vincristine	B-Drug
induced	O
cranial	B-ADE
polyneuropathy	I-ADE
.	O

-DOCSTART-	719

Fulminant	B-ADE
liver	I-ADE
failure	I-ADE
associated	O
with	O
clarithromycin	B-Drug
.	O

-DOCSTART-	4187

Seizures	B-ADE
occurred	O
in	O
two	O
patients	O
with	O
probable	O
Alzheimer	O
's	O
disease	O
who	O
were	O
receiving	O
long	O
-	O
term	O
treatment	O
with	O
metrifonate	B-Drug
,	O
an	O
irreversible	O
acetylcholinesterase	O
inhibitor	O
.	O

-DOCSTART-	3593

Seizures	B-ADE
associated	O
with	O
fluoxetine	B-Drug
therapy	O
are	O
uncommon	O
.	O

-DOCSTART-	1140

Pancreatitis	B-ADE
has	O
been	O
noted	O
to	O
be	O
a	O
complication	O
in	O
2	O
-	O
16	O
%	O
of	O
patients	O
undergoing	O
treatment	O
with	O
L	B-Drug
-	I-Drug
asparaginase	I-Drug
for	O
a	O
variety	O
of	O
pediatric	O
neoplasms	O
.	O

-DOCSTART-	927

Norethisterone	B-Drug
in	O
these	O
69	O
pregnancies	O
accounted	O
for	O
33.3	O
%	O
(	O
5	O
of	O
15	O
)	O
cases	O
of	O
clitoral	B-ADE
hypertrophy	I-ADE
diagnosed	O
in	O
100,756	O
consecutive	O
births	O
.	O

-DOCSTART-	3508

Mannitol	B-Drug
-	O
induced	O
ARF	B-ADE
responds	O
promptly	O
to	O
hemodialysis	O
with	O
rapid	O
resolution	O
of	O
anuria	O
and	O
recovery	O
of	O
renal	O
failure	O
.	O

-DOCSTART-	1637

Spontaneous	B-ADE
splenic	I-ADE
infarction	I-ADE
associated	O
with	O
sumatriptan	B-Drug
use	O
.	O

-DOCSTART-	1791

Under	O
the	O
suspicion	O
of	O
amiodarone	B-Drug
-	O
induced	O
acute	B-ADE
pancreatitis	I-ADE
,	O
amiodarone	O
was	O
substituted	O
by	O
propafenone	O
.	O

-DOCSTART-	2736

When	O
co	B-Drug
-	I-Drug
trimoxazole	I-Drug
was	O
stopped	O
the	O
red	B-ADE
cell	I-ADE
aplasia	I-ADE
resolved	O
.	O

-DOCSTART-	2890

Nicotinic	B-Drug
acid	I-Drug
-	O
induced	O
fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
.	O

-DOCSTART-	3103

In	O
a	O
patient	O
with	O
severe	O
renovascular	O
hypertension	O
,	O
nonoliguric	B-ADE
acute	I-ADE
renal	I-ADE
failure	I-ADE
developed	O
after	O
she	O
received	O
captopril	B-Drug
treatment	O
.	O

-DOCSTART-	741

Rapamycin	B-Drug
/	O
sirolimus	B-Drug
-	O
induced	O
pneumonitis	B-ADE
has	O
been	O
described	O
previously	O
in	O
renal	O
transplant	O
recipients	O
,	O
and	O
this	O
report	O
describes	O
a	O
stable	O
heart	O
-	O
lung	O
transplant	O
recipient	O
who	O
developed	O
a	O
pulmonary	B-ADE
infiltrate	I-ADE
that	O
reversed	O
after	O
ceasing	O
SR	B-Drug
therapy	O
.	O

-DOCSTART-	1417

We	O
report	O
here	O
a	O
rare	O
case	O
of	O
ritodrine	B-Drug
-	I-Drug
hydrochloride	I-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
in	O
a	O
pregnant	O
patient	O
with	O
myotonic	O
dystrophy	O
.	O

-DOCSTART-	1389

Gemcitabine	B-Drug
-	O
induced	O
pericardial	B-ADE
effusion	I-ADE
and	O
tamponade	B-ADE
after	O
unblocked	O
cardiac	O
irradiation	O
.	O

-DOCSTART-	997

Ciprofloxacin	B-Drug
-	O
induced	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
in	O
a	O
patient	O
with	O
systemic	O
lupus	O
erythematosus	O
.	O

-DOCSTART-	1526

Triazolam	B-Drug
-	O
induced	O
nocturnal	B-ADE
bingeing	I-ADE
with	O
amnesia	B-ADE
.	O

-DOCSTART-	3581

Bromocriptine	B-Drug
-	O
induced	O
schizophrenia	B-ADE
.	O

-DOCSTART-	1514

In	O
this	O
paper	O
,	O
we	O
report	O
a	O
patient	O
with	O
primary	O
anti	O
-	O
phospholipid	O
syndrome	O
treated	O
by	O
corticosteroid	B-Drug
,	O
who	O
developed	O
disseminated	B-ADE
nocardiosis	I-ADE
.	O

-DOCSTART-	2956

Cardiac	B-ADE
decompensation	I-ADE
following	O
verapamil	B-Drug
therapy	O
in	O
infants	O
with	O
supraventricular	O
tachycardia	O
.	O

-DOCSTART-	3111

Haemolytic	B-ADE
-	I-ADE
uraemic	I-ADE
syndrome	I-ADE
complicating	O
long	O
-	O
term	O
mitomycin	B-Drug
C	I-Drug
and	O
5-fluorouracil	B-Drug
therapy	O
for	O
gastric	O
carcinoma	O
.	O

-DOCSTART-	3572

Zidovudine	B-Drug
use	O
in	O
pregnancy	O
:	O
a	O
report	O
on	O
104	O
cases	O
and	O
the	O
occurrence	O
of	O
birth	B-ADE
defects	I-ADE
.	O

-DOCSTART-	2094

During	O
intravenous	O
treatment	O
with	O
terlipressin	B-Drug
for	O
recurrent	O
gastrointestinal	O
(	O
GI	O
)	O
bleeding	O
,	O
a	O
50-year	O
-	O
old	O
male	O
with	O
no	O
history	O
of	O
heart	O
disease	O
developed	O
a	O
newly	O
prolonged	B-ADE
QT	I-ADE
interval	I-ADE
and	O
torsade	B-ADE
de	I-ADE
pointes	I-ADE
.	O

-DOCSTART-	4215

Transtubular	B-ADE
potassium	I-ADE
gradient	I-ADE
(	I-ADE
TTKG	I-ADE
)	I-ADE
also	I-ADE
decreased	I-ADE
and	O
an	O
inverse	O
correlation	O
was	O
found	O
between	O
TTKG	O
and	O
doses	O
of	O
phosphate	B-Drug
(	O
r	O
=	O
-0.37	O
;	O
p	O
<	O
0.02	O
;	O
N	O
=	O
38	O
)	O
.	O

-DOCSTART-	2831

Cytarabine	B-Drug
-	O
induced	O
cerebellar	B-ADE
syndrome	I-ADE
:	O
case	O
report	O
and	O
literature	O
review	O
.	O

-DOCSTART-	1515

Chloroquine	B-Drug
-	O
induced	O
bilateral	B-ADE
ptosis	I-ADE
.	O

-DOCSTART-	2584

This	O
is	O
the	O
third	O
report	O
of	O
reversible	O
hepatic	B-ADE
decompensation	I-ADE
associated	O
with	O
prolonged	O
MTX	B-Drug
therapy	O
in	O
patients	O
with	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	1209

The	O
exacerbation	B-ADE
of	I-ADE
psoriasis	I-ADE
was	O
accompanied	O
by	O
a	O
massive	O
induction	O
of	O
lesional	O
type	O
I	O
interferon	O
activity	O
,	O
detected	O
by	O
MxA	O
expression	O
after	O
imiquimod	B-Drug
therapy	O
.	O

-DOCSTART-	2392

Ciprofloxacin	O
is	O
among	O
the	O
standard	O
treatments	O
for	O
infected	O
ischemic	O
ulcers	O
;	O
in	O
the	O
rare	O
case	O
of	O
ciprofloxacin	B-Drug
-	O
induced	O
hemorrhagic	B-ADE
vasculitis	I-ADE
,	O
it	O
might	O
be	O
interpreted	O
as	O
progression	O
of	O
infection	O
,	O
instead	O
of	O
a	O
complication	O
of	O
the	O
treatment	O
,	O
thus	O
leading	O
to	O
faulty	O
diagnosis	O
and	O
treatment	O
.	O

-DOCSTART-	1962

We	O
present	O
a	O
case	O
of	O
cutaneous	B-ADE
leucocytoclastic	I-ADE
vasculitis	I-ADE
in	O
which	O
amphotericin	B-Drug
B	I-Drug
might	O
presumably	O
be	O
the	O
aetiological	O
factor	O
.	O

-DOCSTART-	1596

CONCLUSION	O
:	O
The	O
chronic	O
use	O
of	O
HCQ	B-Drug
for	O
rheumatic	O
diseases	O
,	O
or	O
as	O
an	O
anti	O
-	O
malarial	O
drug	O
,	O
should	O
be	O
balanced	O
against	O
the	O
risk	O
of	O
developing	O
potentially	O
lethal	O
cardiac	B-ADE
arrhythmias	I-ADE
.	O

-DOCSTART-	3821

A	O
patient	O
is	O
described	O
with	O
the	O
characteristic	O
features	O
of	O
phenytoin	B-Drug
hypersensitivity	I-ADE
syndrome	I-ADE
(	O
PHS	O
)	O
including	O
fever	B-ADE
,	O
erythroderma	B-ADE
,	O
tibial	B-ADE
and	I-ADE
facial	I-ADE
oedema	I-ADE
,	O
pinhead	B-ADE
-	I-ADE
sized	I-ADE
facial	I-ADE
pustules	I-ADE
and	O
abnormal	B-ADE
liver	I-ADE
function	I-ADE
tests	I-ADE
.	O

-DOCSTART-	1315

That	O
review	O
suggested	O
that	O
patients	O
receiving	O
anti	B-Drug
-	I-Drug
D	I-Drug
IGIV	I-Drug
be	O
monitored	O
for	O
those	O
and	O
other	O
potential	O
complications	O
of	O
hemoglobinemia	B-ADE
,	O
particularly	O
disseminated	B-ADE
intravascular	I-ADE
coagulation	I-ADE
(	O
DIC	B-ADE
)	O
.	O

-DOCSTART-	677

Retinal	B-ADE
dysfunction	I-ADE
and	O
anterior	B-ADE
segment	I-ADE
deposits	I-ADE
in	O
a	O
patient	O
treated	O
with	O
rifabutin	B-Drug
.	O

-DOCSTART-	725

RESULTS	O
:	O
Brimonidine	B-Drug
was	O
observed	O
to	O
cause	O
IOP	B-ADE
elevation	I-ADE
,	O
confirmed	O
on	O
rechallenge	O
,	O
scoring	O
8	O
(	O
strong	O
probability	O
)	O
on	O
an	O
adverse	O
drug	O
reaction	O
probability	O
score	O
.	O

-DOCSTART-	968

A	O
diagnosis	O
of	O
infliximab	B-Drug
-	O
induced	O
lupus	B-ADE
was	O
made	O
and	O
the	O
drug	O
treatment	O
was	O
withdrawn	O
.	O

-DOCSTART-	3613

Pulmonary	B-ADE
hemorrhage	I-ADE
is	O
an	O
uncommon	O
feature	O
in	O
the	O
HUS	B-ADE
,	O
and	O
seems	O
to	O
appear	O
especially	O
in	O
the	O
HUS	B-ADE
associated	O
with	O
MMC	B-Drug
therapy	O
.	O

-DOCSTART-	4218

We	O
report	O
a	O
case	O
of	O
severe	O
respiratory	B-ADE
failure	I-ADE
due	O
to	O
gold	B-Drug
salt	O
toxicity	O
in	O
a	O
patient	O
suffering	O
from	O
rheumatoid	O
arthritis	O
requiring	O
mechanical	O
ventilation	O
.	O

-DOCSTART-	3612

Pulmonary	B-ADE
hemorrhage	I-ADE
as	O
a	O
clinical	O
manifestation	O
of	O
hemolytic	B-ADE
-	I-ADE
uremic	I-ADE
syndrome	I-ADE
associated	O
with	O
mitomycin	B-Drug
C	I-Drug
therapy	O
.	O

-DOCSTART-	2249

We	O
report	O
a	O
patient	O
with	O
type	O
2	O
diabetes	O
mellitus	O
who	O
,	O
while	O
treated	O
with	O
the	O
antitumor	O
necrosis	O
factor	O
-	O
alpha	O
blocking	O
agent	O
etanercept	B-Drug
for	O
severe	O
plaque	O
psoriasis	O
,	O
experienced	O
persistent	B-ADE
hypoglycemia	I-ADE
requiring	O
the	O
lowering	O
and	O
eventual	O
elimination	O
of	O
his	O
previous	O
insulin	O
regimen	O
.	O

-DOCSTART-	225

CONCLUSIONS	O
:	O
The	O
3	O
cases	O
presented	O
here	O
illustrate	O
the	O
development	O
of	O
reproductive	B-ADE
endocrine	I-ADE
disorders	I-ADE
after	O
the	O
initiation	O
of	O
valproate	B-Drug
therapy	O
in	O
women	O
with	O
epilepsy	O
.	O

-DOCSTART-	3519

Cefuroxime	B-Drug
-	O
induced	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
.	O

-DOCSTART-	2202

Syringotropic	B-ADE
hypersensitivity	I-ADE
reaction	I-ADE
associated	O
with	O
infliximab	B-Drug
and	O
leflunomide	B-Drug
combination	O
therapy	O
in	O
a	O
child	O
with	O
psoriatic	O
arthritis	O
.	O

-DOCSTART-	2013

Imatinib	B-Drug
mesylate	I-Drug
-	O
related	O
fatal	B-ADE
acute	I-ADE
hepatic	I-ADE
failure	I-ADE
in	O
a	O
patient	O
with	O
chronic	O
myeloid	O
leukaemia	O
and	O
chronic	O
hepatitis	O
B	O
infection	O
.	O

-DOCSTART-	3856

Mequitazine	O
seemed	O
to	O
play	O
a	O
part	O
similar	O
to	O
chlorpromazine	O
,	O
and	O
absence	O
of	O
mequitazine	B-Drug
-	O
induced	O
photosensitivity	B-ADE
may	O
be	O
due	O
to	O
a	O
relatively	O
low	O
dosage	O
of	O
the	O
drug	O
.	O

-DOCSTART-	1918

Both	O
colchicine	B-Drug
and	O
statin	B-Drug
therapy	O
may	O
be	O
associated	O
with	O
myopathy	B-ADE
,	O
which	O
usually	O
occurs	O
after	O
several	O
months	O
of	O
therapy	O
.	O

-DOCSTART-	3652

Hypertension	B-ADE
develops	O
in	O
most	O
patients	O
after	O
transplantation	O
when	O
immunosuppression	O
is	O
based	O
on	O
cyclosporine	B-Drug
and	O
prednisone	B-Drug
.	O

-DOCSTART-	1064

Gemcitabine	B-Drug
-	O
related	O
radiation	B-ADE
recall	I-ADE
preferentially	O
involves	O
internal	O
tissue	O
and	O
organs	O
.	O

-DOCSTART-	3177

Gynecomastia	B-ADE
developed	O
in	O
two	O
epileptic	O
patients	O
some	O
months	O
after	O
the	O
addition	O
of	O
oral	O
fluoresone	B-Drug
750	O
mg	O
daily	O
to	O
the	O
phenobarbital	B-Drug
and	O
phenytoin	B-Drug
already	O
being	O
administered	O
.	O

-DOCSTART-	744

Concomitant	O
administration	O
of	O
lithium	B-Drug
with	O
olanzapine	B-Drug
may	O
place	O
patients	O
at	O
risk	O
for	O
NMS	B-ADE
.	O

-DOCSTART-	3392

Nephrotic	B-ADE
syndrome	I-ADE
related	O
to	O
systemic	B-ADE
lupus	I-ADE
erythematosus	I-ADE
after	O
griseofulvin	B-Drug
therapy	O
.	O

-DOCSTART-	822

We	O
report	O
the	O
first	O
case	O
,	O
to	O
our	O
knowledge	O
,	O
of	O
rituximab	B-Drug
-	O
related	O
autoimmune	B-ADE
hemolytic	I-ADE
anemia	I-ADE
.	O

-DOCSTART-	3235

This	O
is	O
the	O
first	O
report	O
of	O
a	O
catatonic	B-ADE
syndrome	I-ADE
occurring	O
in	O
a	O
patient	O
receiving	O
disulfiram	B-Drug
treatment	O
.	O

-DOCSTART-	3002

Cerebral	B-ADE
and	I-ADE
ocular	I-ADE
toxicity	I-ADE
induced	O
by	O
desferrioxamine	B-Drug
.	O

-DOCSTART-	1272

The	O
relation	O
between	O
tacrolimus	B-Drug
treatment	O
and	O
staining	O
was	O
suggested	O
by	O
the	O
appearance	O
of	O
pigmentation	B-ADE
during	O
topical	O
tacrolimus	B-Drug
treatment	O
and	O
its	O
clinical	O
disappearance	O
when	O
treatment	O
was	O
stopped	O
.	O

-DOCSTART-	2767

Niacin	B-Drug
causes	O
a	O
reversible	B-ADE
toxic	I-ADE
cystoid	I-ADE
maculopathy	I-ADE
that	O
occurs	O
in	O
approximately	O
0.67	O
%	O
of	O
patients	O
taking	O
high	O
doses	O
of	O
the	O
drug	O
.	O

-DOCSTART-	1886

Clinical	O
profile	O
of	O
oxcarbazepine	B-Drug
-	O
related	O
angioneurotic	B-ADE
edema	I-ADE
:	O
case	O
report	O
and	O
review	O
.	O

-DOCSTART-	1212

DLST	O
is	O
a	O
good	O
diagnostic	O
tool	O
for	O
AZA	B-Drug
allergy	B-ADE
,	O
especially	O
for	O
severe	O
drug	O
allergy	O
cases	O
.	O

-DOCSTART-	2790

Captopril	B-Drug
-	O
related	O
(	O
and	O
-induced	O
?	O
)	O
asthma	B-ADE
.	O

-DOCSTART-	2337

Colitis	B-ADE
as	O
a	O
manifestation	O
of	O
infliximab	B-Drug
-	O
associated	O
disseminated	B-ADE
cryptococcosis	I-ADE
.	O

-DOCSTART-	275

Gabapentin	B-Drug
-	O
induced	O
mood	B-ADE
changes	I-ADE
with	O
hypomanic	B-ADE
features	O
in	O
adults	O
.	O

-DOCSTART-	376

Hashimoto	B-ADE
's	I-ADE
disease	I-ADE
during	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
therapy	O
in	O
a	O
patient	O
with	O
pre	O
-	O
treatment	O
negative	O
anti	O
-	O
thyroid	O
autoantibodies	O
and	O
with	O
the	O
specific	O
genetic	O
susceptibility	O
to	O
the	O
thyroid	O
disease	O
.	O

-DOCSTART-	935

Can	O
roxithromycin	B-Drug
and	O
betamethasone	B-Drug
induce	O
acute	B-ADE
pancreatitis	I-ADE
?	O
A	O
case	O
report	O
.	O

-DOCSTART-	1177

In	O
all	O
cases	O
,	O
drugs	O
in	O
addition	O
to	O
quetiapine	O
were	O
detected	O
,	O
but	O
in	O
cases	O
#	O
1	O
and	O
#	O
2	O
,	O
the	O
cause	O
of	O
death	B-ADE
was	O
considered	O
to	O
be	O
a	O
quetiapine	B-Drug
overdose	O
and	O
the	O
other	O
drugs	O
were	O
not	O
considered	O
to	O
be	O
contributory	O
.	O

-DOCSTART-	4114

The	O
authors	O
suggest	O
that	O
risperidone	B-Drug
may	O
increase	B-ADE
affect	I-ADE
in	O
patients	O
with	O
schizophrenia	O
and	O
that	O
some	O
patients	O
,	O
especially	O
those	O
with	O
anxiety	O
,	O
may	O
have	O
difficulty	O
managing	O
the	O
increase	O
.	O

-DOCSTART-	2047

Our	O
findings	O
reveal	O
that	O
even	O
in	O
patients	O
without	O
a	O
history	O
of	O
seizures	O
,	O
pregabalin	B-Drug
can	O
cause	O
a	O
cortical	B-ADE
negative	I-ADE
myoclonus	I-ADE
.	O

-DOCSTART-	4015

The	O
hypercalcemia	B-ADE
responded	O
to	O
discontinuation	O
of	O
rhGH	B-Drug
and	O
a	O
single	O
dose	O
of	O
intravenous	O
pamidronate	O
disodium	O
and	O
has	O
not	O
recurred	O
in	O
8	O
months	O
of	O
follow	O
-	O
up	O
.	O

-DOCSTART-	1479

Gemcitabine	B-Drug
should	O
be	O
added	O
to	O
the	O
list	O
of	O
drugs	O
known	O
to	O
cause	O
radiation	B-ADE
recall	I-ADE
.	O

-DOCSTART-	1146

A	O
case	O
of	O
sideroblastic	B-ADE
anemia	I-ADE
is	O
presented	O
in	O
a	O
patient	O
with	O
a	O
left	O
ventricular	O
assist	O
device	O
drive	O
-	O
line	O
infection	O
who	O
was	O
receiving	O
linezolid	B-Drug
,	O
an	O
antibiotic	O
used	O
for	O
serious	O
infections	O
with	O
gram	O
-	O
positive	O
organisms	O
.	O

-DOCSTART-	2136

Disseminated	B-ADE
salmonellosis	I-ADE
in	O
a	O
patient	O
treated	O
with	O
temozolomide	B-Drug
.	O

-DOCSTART-	130

After	O
the	O
addition	O
of	O
citalopram	B-Drug
,	O
a	O
desmethylclomipramine	B-ADE
plasma	I-ADE
level	I-ADE
increase	I-ADE
and	O
an	O
8-hydroacy	B-ADE
-	I-ADE
desmethylclomipramine	I-ADE
plasma	I-ADE
level	I-ADE
decrease	I-ADE
were	O
observed	O
.	O

-DOCSTART-	334

He	O
was	O
diagnosed	O
with	O
possible	O
serotonin	B-ADE
syndrome	I-ADE
;	O
his	O
symptoms	O
resolved	O
after	O
clomipramine	B-Drug
was	O
stopped	O
but	O
before	O
clozapine	O
was	O
restarted	O
eight	O
days	O
later	O
.	O

-DOCSTART-	4252

Since	O
amiodarone	O
was	O
first	O
marketed	O
in	O
1992	O
in	O
Japan	O
,	O
the	O
incidence	O
of	O
amiodarone	B-Drug
-	O
induced	O
thyrotoxicosis	B-ADE
(	O
AIT	B-ADE
)	O
has	O
been	O
increasing	O
.	O

-DOCSTART-	3300

Although	O
transient	O
increases	O
in	O
ectopy	O
after	O
bretylium	B-Drug
therapy	O
have	O
been	O
described	O
,	O
presumably	O
due	O
to	O
catecholamine	O
release	O
,	O
the	O
occurrence	O
of	O
life	O
-	O
threatening	O
ventricular	B-ADE
arrhythmia	I-ADE
leading	O
to	O
cardiac	B-ADE
arrest	I-ADE
has	O
not	O
previously	O
been	O
emphasized	O
.	O

-DOCSTART-	2635

Nail	B-ADE
-	I-ADE
changes	I-ADE
induced	O
by	O
penicillamine	B-Drug
.	O

-DOCSTART-	1314

Disseminated	B-ADE
intravascular	I-ADE
coagulation	I-ADE
associated	O
with	O
acute	B-ADE
hemoglobinemia	I-ADE
or	O
hemoglobinuria	B-ADE
following	O
Rh(0)(D	B-Drug
)	I-Drug
immune	I-Drug
globulin	I-Drug
intravenous	O
administration	O
for	O
immune	O
thrombocytopenic	O
purpura	O
.	O

-DOCSTART-	3299

Disopyramide	B-Drug
-	O
induced	O
heart	B-ADE
block	I-ADE
.	O

-DOCSTART-	1476

Symptomatic	B-ADE
hypocalcaemia	I-ADE
and	O
renal	B-ADE
impairment	I-ADE
associated	O
with	O
bisphosphonate	B-Drug
treatment	O
in	O
patients	O
with	O
multiple	O
myeloma	O
.	O

-DOCSTART-	2369

Sorafenib	B-Drug
induced	O
tumor	B-ADE
lysis	I-ADE
syndrome	I-ADE
in	O
an	O
advanced	O
hepatocellular	O
carcinoma	O
patient	O
.	O

-DOCSTART-	1923

Pneumocystis	B-ADE
pneumonia	I-ADE
should	O
be	O
considered	O
in	O
asthmatic	O
patients	O
taking	O
methotrexate	B-Drug
who	O
present	O
with	O
fever	B-ADE
,	O
pulmonary	B-ADE
infiltrates	I-ADE
,	O
and	O
hypoxia	B-ADE
.	O

-DOCSTART-	3311

A	O
case	O
of	O
timolol	B-Drug
-	O
associated	O
heart	B-ADE
failure	I-ADE
in	O
a	O
73-year	O
old	O
white	O
man	O
is	O
reported	O
.	O

-DOCSTART-	251

The	O
cases	O
are	O
important	O
in	O
documenting	O
that	O
drug	O
-	O
induced	O
dystonias	O
do	O
occur	O
in	O
patients	O
with	O
dementia	O
,	O
that	O
risperidone	B-Drug
appears	O
to	O
have	O
contributed	O
to	O
dystonia	B-ADE
among	O
elderly	O
patients	O
,	O
and	O
that	O
the	O
categorization	O
of	O
dystonic	O
reactions	O
needs	O
further	O
clarification	O
.	O

-DOCSTART-	1065

The	O
authors	O
also	O
determined	O
that	O
their	O
case	O
of	O
myositis	B-ADE
developing	O
in	O
the	O
rectus	O
abdominus	O
muscle	O
of	O
a	O
patient	O
with	O
pancreatic	O
adenocarcinoma	O
was	O
the	O
manifestation	O
of	O
radiation	B-ADE
recall	I-ADE
,	O
thereby	O
bringing	O
the	O
number	O
of	O
patients	O
who	O
developed	O
radiation	B-ADE
recall	I-ADE
to	O
gemcitabine	B-Drug
and	O
were	O
discussed	O
in	O
the	O
current	O
study	O
to	O
13	O
.	O

-DOCSTART-	2946

Myasthenic	O
patients	O
receiving	O
ampicillin	B-Drug
should	O
be	O
closely	O
monitored	O
for	O
possible	O
acute	B-ADE
exacerbations	I-ADE
.	O

-DOCSTART-	3689

In	O
one	O
case	O
,	O
disulfiram	B-Drug
was	O
the	O
only	O
potential	O
teratogen	B-ADE
exposed	O
to	O
the	O
fetus	O
.	O

-DOCSTART-	668

RESULTS	O
:	O
Including	O
our	O
own	O
patient	O
,	O
a	O
total	O
of	O
26	O
cases	O
of	O
gemcitabine	B-Drug
-	O
associated	O
HUS	B-ADE
were	O
identified	O
.	O

-DOCSTART-	871

Hyperpigmentation	B-ADE
during	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
therapy	O
for	O
chronic	O
hepatitis	O
C	O
virus	O
infection	O
.	O

-DOCSTART-	1338

CONCLUSION	O
:	O
During	O
and	O
after	O
IFN	B-Drug
therapy	O
,	O
OCT	O
is	O
a	O
useful	O
examination	O
technique	O
for	O
revealing	O
macular	B-ADE
edema	I-ADE
in	O
patients	O
who	O
have	O
decreased	B-ADE
vision	I-ADE
.	O

-DOCSTART-	2188

Carbamazepine	B-Drug
-	O
induced	O
Diabetes	B-ADE
mellitus	I-ADE
.	O

-DOCSTART-	3877

When	O
the	O
patient	O
was	O
treated	O
again	O
with	O
fludarabine	B-Drug
nine	O
months	O
later	O
,	O
the	O
DAT	B-ADE
became	I-ADE
positive	I-ADE
with	I-ADE
anti	I-ADE
-	I-ADE
IgG	I-ADE
and	I-ADE
anti	I-ADE
-	I-ADE
C3d	I-ADE
antiglobulins	I-ADE
after	O
the	O
second	O
course	O
of	O
treatment	O
.	O

-DOCSTART-	3491

A	O
case	O
of	O
noncardiogenic	B-ADE
pulmonary	I-ADE
edema	I-ADE
by	O
ethanolamine	B-Drug
oleate	I-Drug
.	O

-DOCSTART-	1454

We	O
report	O
a	O
case	O
admitted	O
with	O
a	O
first	O
-	O
detected	O
,	O
symptomatic	B-ADE
paroxysmal	I-ADE
atrial	I-ADE
fibrillation	I-ADE
in	O
a	O
healthy	O
patient	O
after	O
self	O
-	O
medication	O
with	O
vardenafil	B-Drug
.	O

-DOCSTART-	1156

We	O
describe	O
2	O
patients	O
with	O
severe	O
erosive	O
rheumatoid	O
arthritis	O
and	O
rheumatoid	O
vasculitis	O
,	O
respectively	O
,	O
in	O
whom	O
infliximab	B-Drug
therapy	O
was	O
associated	O
with	O
peripheral	B-ADE
neuropathy	I-ADE
due	O
to	O
necrotizing	B-ADE
vasculitis	I-ADE
in	O
one	O
patient	O
and	O
to	O
progression	B-ADE
of	I-ADE
preexisting	I-ADE
mononeuritis	I-ADE
multiplex	I-ADE
in	O
the	O
other	O
.	O

-DOCSTART-	3943

Discontinuation	O
of	O
the	O
itraconazole	B-Drug
caused	O
resolution	O
of	O
the	O
drug	B-ADE
eruption	I-ADE
.	O

-DOCSTART-	3569

Toxic	B-ADE
optic	I-ADE
neuropathy	I-ADE
associated	O
with	O
ethambutol	B-Drug
:	O
implications	O
for	O
current	O
therapy	O
.	O

-DOCSTART-	3236

Hepatic	B-ADE
reactions	I-ADE
to	O
cyclofenil	B-Drug
.	O

-DOCSTART-	3409

Etoposide	B-Drug
-	O
related	O
myocardial	B-ADE
infarction	I-ADE
.	O

-DOCSTART-	1978

Conventional	O
and	O
diffusion	O
-	O
weighted	O
MRI	O
findings	O
of	O
methotrexate	B-Drug
related	O
sub	B-ADE
-	I-ADE
acute	I-ADE
neurotoxicity	I-ADE
.	O

-DOCSTART-	4014

Hypercalcemia	B-ADE
in	O
an	O
AIDS	O
patient	O
treated	O
with	O
growth	B-Drug
hormone	I-Drug
.	O

-DOCSTART-	4177

We	O
describe	O
a	O
renal	O
transplant	O
recipient	O
maintained	O
on	O
cyclosporine	B-Drug
and	O
prednisone	B-Drug
developing	O
Nocardia	B-ADE
Asteroides	I-ADE
brain	I-ADE
abscess	I-ADE
.	O

-DOCSTART-	333

The	O
first	O
known	O
report	O
of	O
quetiapine	B-Drug
exacerbating	B-ADE
OCS	I-ADE
in	O
a	O
43-year	O
-	O
old	O
man	O
with	O
obsessive	O
-	O
compulsive	O
disorder	O
(	O
OCD	O
)	O
,	O
trichotillomania	O
,	O
delusional	O
disorder	O
and	O
bipolar	O
II	O
disorder	O
is	O
presented	O
.	O

-DOCSTART-	1751

Acute	O
drug	O
induced	O
hepatitis	B-ADE
due	O
to	O
erlotinib	B-Drug
.	O

-DOCSTART-	4152

Leukaemoid	B-ADE
monocytosis	I-ADE
in	O
M4	O
AML	O
following	O
chemotherapy	O
and	O
G	B-Drug
-	I-Drug
CSF	I-Drug
.	O

-DOCSTART-	902

Our	O
series	O
of	O
3	O
patients	O
supports	O
a	O
causal	O
connection	O
between	O
bleomycin	B-Drug
and	O
scleroderma	B-ADE
.	O

-DOCSTART-	1508

Therapy	O
with	O
IFN	B-Drug
-	I-Drug
beta	I-Drug
has	O
rarely	O
been	O
associated	O
with	O
the	O
development	O
of	O
autoimmune	B-ADE
disorders	I-ADE
.	O

-DOCSTART-	2938

Ototoxicity	B-ADE
as	O
a	O
result	O
of	O
cis	B-Drug
-	I-Drug
platinum	I-Drug
administration	O
is	O
well	O
documented	O
.	O

-DOCSTART-	2487

Visceral	B-ADE
leishmaniasis	I-ADE
and	O
macrophagic	B-ADE
activation	I-ADE
syndrome	I-ADE
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
under	O
treatment	O
with	O
adalimumab	B-Drug
.	O

-DOCSTART-	681

ADH	B-ADE
hypersecretion	I-ADE
in	O
relation	O
to	O
plasma	O
osmolality	O
was	O
reversed	O
by	O
mizoribin	B-Drug
withdrawal	O
,	O
suggesting	O
that	O
bredinin	B-Drug
might	O
adversely	O
induce	O
SIADH	B-ADE
.	O

-DOCSTART-	620

Epoprostenol	B-Drug
may	O
be	O
associated	O
rarely	O
with	O
severe	O
erythroderma	B-ADE
.	O

-DOCSTART-	3146

It	O
is	O
concluded	O
that	O
SIADH	B-ADE
is	O
an	O
important	O
side	O
effect	O
of	O
lorcainide	B-Drug
therapy	O
.	O

-DOCSTART-	3722

We	O
describe	O
the	O
first	O
documented	O
case	O
of	O
azathioprine	B-Drug
-	O
induced	O
severe	O
myelosuppression	B-ADE
due	O
to	O
thiopurine	O
methyltransferase	O
deficiency	O
in	O
autoimmune	O
liver	O
disease	O
.	O

-DOCSTART-	1837

Recombinant	B-Drug
human	I-Drug
interferon	I-Drug
-	I-Drug
alpha	I-Drug
has	O
been	O
used	O
in	O
the	O
treatment	O
of	O
several	O
cancers	O
,	O
but	O
there	O
have	O
been	O
several	O
reports	O
that	O
it	O
may	O
exacerbate	B-ADE
psoriasis	I-ADE
or	I-ADE
trigger	I-ADE
off	I-ADE
its	I-ADE
onset	I-ADE
.	O

-DOCSTART-	3058

One	O
patient	O
on	O
ouabain	B-Drug
also	O
developed	O
cardiomyopathy	B-ADE
.	O

-DOCSTART-	2045

The	O
known	O
side	O
effects	O
of	O
sibutramine	B-Drug
,	O
ie	O
,	O
hypertension	B-ADE
and	O
tachycardia	B-ADE
,	O
depend	O
on	O
its	O
adrenergic	O
and	O
serotoninergic	O
effects	O
.	O

-DOCSTART-	644

Systemic	B-ADE
vasculitis	I-ADE
complicating	O
hairy	O
cell	O
leukaemia	O
treatment	O
with	O
cladribine	B-Drug
.	O

-DOCSTART-	322

Oral	O
intake	O
and	O
acarbose	B-Drug
were	O
withheld	O
and	O
the	O
ileus	B-ADE
spontaneously	O
resolved	O
after	O
2	O
days	O
.	O

-DOCSTART-	2852

One	O
of	O
the	O
subjects	O
who	O
was	O
using	O
extemporaneous	O
topical	O
minoxidil	B-Drug
had	O
hypertension	B-ADE
and	O
arteriosclerotic	B-ADE
disease	I-ADE
and	O
the	O
other	O
died	O
of	O
a	O
myocardial	B-ADE
infarction	I-ADE
.	O

-DOCSTART-	3709

Cholesterol	B-ADE
crystal	I-ADE
embolization	I-ADE
-	O
associated	O
renal	B-ADE
failure	I-ADE
after	O
therapy	O
with	O
recombinant	O
tissue	B-Drug
-	I-Drug
type	I-Drug
plasminogen	I-Drug
activator	I-Drug
.	O

-DOCSTART-	2435

Kaposi	B-ADE
's	I-ADE
sarcoma	I-ADE
in	O
a	O
patient	O
treated	O
with	O
imatinib	B-Drug
mesylate	I-Drug
for	O
chronic	O
myeloid	O
leukemia	O
.	O

-DOCSTART-	1854

Bortezomib	B-Drug
-	O
induced	O
paralytic	B-ADE
ileus	I-ADE
is	O
a	O
potential	O
gastrointestinal	B-ADE
side	I-ADE
effect	I-ADE
of	O
this	O
first	O
-	O
in	O
-	O
class	O
anticancer	O
proteasome	O
inhibitor	O
.	O

-DOCSTART-	3473

Sotalol	B-Drug
-	O
induced	O
bradycardia	B-ADE
reversed	O
by	O
glucagon	O
.	O

-DOCSTART-	1251

Treatment	O
-	O
related	O
myelodysplastic	B-ADE
syndrome	I-ADE
after	O
temozolomide	B-Drug
for	O
recurrent	O
high	O
-	O
grade	O
glioma	O
.	O

-DOCSTART-	1057

Pilocarpine	B-ADE
toxicity	I-ADE
and	O
the	O
treatment	O
of	O
xerostomia	O
.	O

-DOCSTART-	1493

Heparin	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
complicated	O
with	O
massive	B-ADE
thrombosis	I-ADE
of	I-ADE
the	I-ADE
inferior	I-ADE
vena	I-ADE
cava	I-ADE
after	O
filter	O
placement	O
.	O

-DOCSTART-	588

The	O
male	O
patient	O
was	O
treated	O
with	O
225-mg	O
/	O
day	O
clozapine	B-Drug
and	O
the	O
time	O
to	O
the	O
diagnosis	O
of	O
agranulocytosis	B-ADE
was	O
6	O
weeks	O
.	O

-DOCSTART-	891

A	O
patient	O
with	O
Parkinson	O
's	O
disease	O
,	O
initially	O
treated	O
with	O
bromocriptine	B-Drug
and	O
subsequently	O
with	O
cabergoline	B-Drug
,	O
developed	O
progressive	O
pleuropulmonary	B-ADE
abnormalities	I-ADE
during	O
the	O
latter	O
therapy	O
.	O

-DOCSTART-	1735

However	O
,	O
an	O
association	O
of	O
Ritalin	B-Drug
with	O
glaucoma	B-ADE
has	O
been	O
reported	O
.	O

-DOCSTART-	3764

It	O
should	O
be	O
emphasized	O
that	O
the	O
recurrence	O
of	O
nephrotic	B-ADE
syndrome	I-ADE
was	O
observed	O
after	O
the	O
following	O
chemotherapy	O
,	O
including	O
M	B-Drug
-	I-Drug
CSF	I-Drug
,	O
whereas	O
the	O
bone	O
marrow	O
still	O
remained	O
completely	O
remitted	O
.	O

-DOCSTART-	1249

Quetiapine	B-Drug
-	O
induced	O
myoclonus	B-ADE
.	O

-DOCSTART-	2113

We	O
describe	O
a	O
case	O
of	O
PRES	B-ADE
in	O
a	O
patient	O
with	O
collapsing	O
focal	O
glomeruloesclerosis	O
(	O
collapsing	O
FGS	O
)	O
with	O
complete	O
recovery	O
after	O
withdrawal	O
of	O
cyclosporine	B-Drug
(	O
CSA	B-Drug
)	O
.	O

-DOCSTART-	3994

We	O
report	O
two	O
cases	O
that	O
developed	O
acute	B-ADE
myeloid	I-ADE
leukaemia	I-ADE
(	O
AML	B-ADE
)	O
during	O
tamoxifen	B-Drug
therapy	O
for	O
breast	O
cancer	O
.	O

-DOCSTART-	1450

Sustained	B-ADE
hypothyroidism	I-ADE
induced	O
by	O
recombinant	B-Drug
alpha	I-Drug
interferon	I-Drug
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

-DOCSTART-	3475

Secretory	B-ADE
endometrial	I-ADE
adenocarcinoma	I-ADE
in	O
a	O
patient	O
on	O
tamoxifen	B-Drug
for	O
breast	O
cancer	O
:	O
a	O
report	O
of	O
a	O
case	O
.	O

-DOCSTART-	1555

Autoimmune	B-ADE
thyroid	I-ADE
disease	I-ADE
is	O
a	O
common	O
side	O
-	O
effect	O
of	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
(	O
IFN	B-Drug
-	I-Drug
alpha	I-Drug
)	O
treatment	O
of	O
viral	O
hepatitis	O
C	O
.	O

-DOCSTART-	312

Major	O
points	O
illustrated	O
are	O
,	O
(	O
1	O
)	O
occurrence	O
of	O
HIT	B-ADE
with	O
any	O
dose	O
or	O
form	O
of	O
heparin	B-Drug
;	O
(	O
2	O
)	O
misperceptions	O
on	O
the	O
diagnostic	O
criteria	O
;	O
(	O
3	O
)	O
correct	O
(	O
thrombin	O
inhibitors	O
)	O
and	O
incorrect	O
(	O
platelet	O
transfusions	O
and	O
warfarin	O
)	O
management	O
;	O
(	O
4	O
)	O
influence	O
of	O
management	O
strategy	O
on	O
clinical	O
outcomes	O
;	O
(	O
5	O
)	O
severity	O
of	O
the	O
syndrome	O
;	O
and	O
(	O
6	O
)	O
potential	O
for	O
both	O
anamnestic	O
response	O
to	O
heparin	O
and	O
disappearance	O
of	O
HIT	O
antibodies	O
over	O
time	O
.	O

-DOCSTART-	2504

It	O
is	O
believed	O
that	O
this	O
is	O
the	O
first	O
reported	O
case	O
of	O
reversible	O
azathioprine	B-Drug
-	O
induced	O
cholestasis	B-ADE
associated	O
with	O
histological	O
evidence	O
of	O
bile	O
duct	O
injury	O
.	O

-DOCSTART-	2105

We	O
report	O
a	O
case	O
of	O
pediatric	O
bupropion	B-Drug
ingestion	O
resulting	O
in	O
multiple	B-ADE
seizures	I-ADE
.	O

-DOCSTART-	2041

Enalaprilat	B-Drug
induced	O
acute	B-ADE
parotitis	I-ADE
.	O

-DOCSTART-	789

Tacrolimus	B-Drug
(	O
FK506	B-Drug
)	O
-	O
induced	O
mutism	B-ADE
after	O
liver	O
transplant	O
.	O

-DOCSTART-	2288

Leukopenia	B-ADE
due	O
to	O
parvovirus	O
B19	O
in	O
a	O
Crohn	O
's	O
disease	O
patient	O
using	O
azathioprine	B-Drug
.	O

-DOCSTART-	1312

The	O
side	O
effects	O
of	O
MMF	B-Drug
,	O
such	O
as	O
bone	B-ADE
marrow	I-ADE
toxicity	I-ADE
,	O
have	O
been	O
reported	O
.	O

-DOCSTART-	779

The	O
patient	O
received	O
only	O
the	O
ophthalmic	O
sulfonamide	B-Drug
,	O
and	O
it	O
was	O
used	O
for	O
one	O
day	O
,	O
but	O
he	O
developed	O
Stevens	B-ADE
-	I-ADE
Johnson	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1263

During	O
the	O
anti	O
-	O
tuberculous	O
therapy	O
,	O
visual	B-ADE
loss	I-ADE
can	O
be	O
related	O
to	O
ethambutol	B-Drug
toxicity	O
or	O
the	O
tuberculosis	O
infection	O
itself	O
.	O

-DOCSTART-	2813

Myoclonic	B-ADE
spasms	I-ADE
following	O
intrathecal	O
morphine	B-Drug
.	O

-DOCSTART-	1648

We	O
describe	O
a	O
5-year	O
-	O
old	O
girl	O
showed	O
recovery	O
of	O
vincristine	B-Drug
induced	O
cranial	B-ADE
polyneuropathy	I-ADE
with	O
pyridoxine	O
and	O
pyridostigmine	O
treatment	O
.	O

-DOCSTART-	2286

Hypoglycemia	B-ADE
induced	O
by	O
long	O
-	O
acting	O
somatostatin	B-Drug
analogues	O
in	O
a	O
patient	O
with	O
nonfunctional	O
neuroendocrine	O
tumor	O
.	O

-DOCSTART-	45

2-CdA	B-Drug
induces	O
lymphocytopenia	B-ADE
,	O
which	O
may	O
explain	O
the	O
improvement	O
in	O
this	O
patient	O
's	O
psoriasis	O
.	O

-DOCSTART-	1342

Late	O
development	O
of	O
diabetes	B-ADE
mellitus	I-ADE
after	O
interferon	B-Drug
-	I-Drug
alfa	I-Drug
and	O
ribavirin	B-Drug
therapy	O
for	O
chronic	O
hepatitis	O
C	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	1973

Ten	O
hours	O
after	O
the	O
second	O
methotrexate	B-Drug
injection	O
,	O
the	O
patient	O
experienced	O
a	O
diffuse	B-ADE
pruritic	I-ADE
papular	I-ADE
eruption	I-ADE
located	O
mainly	O
on	O
the	O
limbs	O
.	O

-DOCSTART-	1838

We	O
report	O
four	O
patients	O
,	O
three	O
of	O
whom	O
first	O
developed	O
psoriasis	B-ADE
and	O
one	O
who	O
had	O
an	O
aggravation	O
of	O
the	O
condition	O
during	O
treatment	O
with	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
.	O

-DOCSTART-	1902

Cyclosporine	B-Drug
is	O
a	O
potent	O
inhibitor	O
of	O
simvastatin	O
metabolism	O
,	O
and	O
may	O
therefore	O
facilitate	O
simvastatin	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
.	O

-DOCSTART-	578

He	O
was	O
started	O
on	O
oral	O
lansoprazole	B-Drug
60	O
mg	O
twice	O
daily	O
and	O
,	O
on	O
hospital	O
day	O
2	O
,	O
his	O
platelet	B-ADE
count	I-ADE
decreased	I-ADE
to	O
102	O
x	O
10(3)/mm(3	O
)	O
;	O
on	O
hospital	O
day	O
3	O
,	O
the	O
platelet	O
count	O
was	O
36	O
x	O
10(3)/mm(3	O
)	O
.	O

-DOCSTART-	1470

Acute	B-ADE
respiratory	I-ADE
distress	I-ADE
syndrome	I-ADE
after	O
rituximab	B-Drug
infusion	O
.	O

-DOCSTART-	2246

Temsirolimus	B-Drug
-	O
induced	O
glomerulopathy	B-ADE
.	O

-DOCSTART-	2025

Development	O
of	O
tics	B-ADE
in	O
a	O
thirteen	O
-	O
year	O
-	O
old	O
male	O
following	O
atomoxetine	B-Drug
use	O
.	O

-DOCSTART-	3317

The	O
authors	O
report	O
a	O
longitudinal	O
case	O
study	O
of	O
a	O
woman	O
with	O
a	O
history	O
of	O
bipolar	O
affective	O
disorder	O
in	O
which	O
L	B-Drug
-	I-Drug
dopa	I-Drug
shortened	B-ADE
the	I-ADE
manic	I-ADE
-	I-ADE
depressive	I-ADE
cycle	I-ADE
length	O
when	O
administered	O
in	O
a	O
double	O
-	O
blind	O
trial	O
.	O

-DOCSTART-	1317

This	O
review	O
presents	O
the	O
first	O
case	O
series	O
of	O
DIC	B-ADE
associated	O
with	O
acute	B-ADE
hemoglobinemia	I-ADE
or	O
hemoglobinuria	B-ADE
following	O
anti	B-Drug
-	I-Drug
D	I-Drug
IGIV	I-Drug
administration	O
for	O
ITP	O
.	O

-DOCSTART-	1836

Psoriasis	B-ADE
induced	O
by	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
.	O

-DOCSTART-	3468

Quinine	B-Drug
and	O
its	O
isomer	O
quinidine	B-Drug
are	O
well	O
-	O
known	O
causes	O
of	O
iatrogenic	B-ADE
hypoglycaemia	I-ADE
,	O
due	O
to	O
excessive	O
insulin	O
secretion	O
.	O

-DOCSTART-	622

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
and	O
undifferentiated	O
connective	O
tissue	O
disease	O
who	O
,	O
after	O
2	O
months	O
of	O
treatment	O
with	O
epoprostenol	B-Drug
,	O
presented	O
with	O
rapidly	B-ADE
progressive	I-ADE
erythema	I-ADE
,	O
scaling	B-ADE
,	O
nausea	B-ADE
and	O
vomiting	B-ADE
,	O
and	O
fever	B-ADE
.	O

-DOCSTART-	2554

Bromide	B-ADE
intoxication	I-ADE
secondary	O
to	O
pyridostigmine	B-Drug
bromide	I-Drug
therapy	O
.	O

-DOCSTART-	3975

Bleomycin	B-Drug
and	O
cyclophosphamide	B-Drug
toxicity	O
simulating	O
metastatic	B-ADE
nodules	I-ADE
to	O
the	O
lungs	O
in	O
childhood	O
cancer	O
.	O

-DOCSTART-	2266

CONCLUSION	O
:	O
A	O
woman	O
receiving	O
enoxaparin	B-Drug
every	O
12	O
hours	O
developed	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	B-ADE
after	O
the	O
second	O
dose	O
.	O

-DOCSTART-	3242

The	O
spectrum	O
of	O
renal	B-ADE
lesions	I-ADE
occurring	O
during	O
antituberculous	O
therapy	O
,	O
particularly	O
in	O
association	O
with	O
rifampin	B-Drug
,	O
may	O
be	O
wider	O
than	O
previously	O
suspected	O
.	O

-DOCSTART-	2085

CONCLUSION	O
:	O
The	O
new	O
quinolone	O
derivatives	O
(	O
levofloxacin	B-Drug
,	O
sparfloxacin	B-Drug
,	O
grepafloxacin	B-Drug
,	O
trovafloxacin	B-Drug
,	O
gatifloxacin	B-Drug
and	O
moxifloxacin	B-Drug
)	O
,	O
also	O
called	O
gyrase	O
inhibitors	O
,	O
are	O
known	O
for	O
their	O
potential	O
to	O
cause	O
central	O
nervous	O
system	O
-	O
related	O
adverse	O
effects	O
,	O
including	O
headache	B-ADE
,	O
dizziness	B-ADE
and	O
insomnia	B-ADE
.	O

-DOCSTART-	3309

Acute	B-ADE
acoustic	I-ADE
nerve	I-ADE
palsy	I-ADE
associated	O
with	O
vincristine	B-Drug
therapy	O
.	O

-DOCSTART-	2695

Administration	O
of	O
amantadine	B-Drug
was	O
associated	O
with	O
psychotic	B-ADE
decompensations	I-ADE
in	O
two	O
schizophrenic	O
patients	O
being	O
maintained	O
on	O
concomitant	O
neuroleptic	O
medication	O
.	O

-DOCSTART-	100

Prolongation	B-ADE
of	I-ADE
the	I-ADE
QT	I-ADE
interval	I-ADE
and	O
ventricular	B-ADE
tachyarrhymias	I-ADE
have	O
been	O
described	O
in	O
patients	O
on	O
amiodarone	B-Drug
therapy	O
.	O

-DOCSTART-	470

Carbamazepine	B-Drug
induced	O
right	B-ADE
bundle	I-ADE
branch	I-ADE
block	I-ADE
in	O
a	O
Greenlandic	O
patient	O
.	O

-DOCSTART-	1716

Acute	B-ADE
generalized	I-ADE
exanthematous	I-ADE
pustulosis	I-ADE
induced	O
by	O
nimesulide	B-Drug
.	O

-DOCSTART-	963

Angioedema	B-ADE
and	O
dysphagia	B-ADE
caused	O
by	O
contact	O
allergy	O
to	O
inhaled	O
budesonide	B-Drug
.	O

-DOCSTART-	1580

We	O
report	O
three	O
cases	O
of	O
IFN	B-Drug
beta	I-Drug
induced	O
hepatitis	B-ADE
in	O
MS	O
and	O
discuss	O
the	O
pathology	O
findings	O
and	O
possible	O
mechanisms	O
of	O
drug	O
-	O
induced	O
liver	B-ADE
injury	I-ADE
.	O

-DOCSTART-	295

Diarrhea	B-ADE
-	I-ADE
associated	I-ADE
over	I-ADE
-	I-ADE
anticoagulation	I-ADE
in	O
a	O
patient	O
taking	O
warfarin	B-Drug
:	O
therapeutic	O
role	O
of	O
cholestyramine	O
.	O

-DOCSTART-	1748

The	O
pathogenic	O
mechanisms	O
involved	O
in	O
the	O
development	O
of	O
adriamycin	B-Drug
cardiomyopathy	B-ADE
are	O
reviewed	O
,	O
and	O
the	O
possible	O
synergistic	O
effect	O
of	O
other	O
antitumor	O
antibiotics	O
is	O
discussed	O
.	O

-DOCSTART-	3495

Gentamicin	B-Drug
-	O
associated	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
.	O

-DOCSTART-	3187

Cephalosporins	B-Drug
are	O
most	O
likely	O
associated	O
with	O
Vitamin	B-ADE
K	I-ADE
deficiency	I-ADE
.	O

-DOCSTART-	4184

One	O
should	O
therefore	O
be	O
aware	O
of	O
possible	O
extrapyramidal	B-ADE
side	I-ADE
effects	I-ADE
with	O
olanzapine	B-Drug
that	O
are	O
reduced	O
compared	O
to	O
classical	O
neuroleptic	O
drugs	O
but	O
not	O
completely	O
eliminated	O
.	O

-DOCSTART-	3029

The	O
patient	O
whose	O
case	O
is	O
reviewed	O
had	O
migraine	B-ADE
headaches	I-ADE
and	O
received	O
methysergide	B-Drug
maleate	O
for	O
13	O
years	O
.	O

-DOCSTART-	1753

CONCLUSIONS	O
:	O
Acute	B-ADE
severe	I-ADE
hepatitis	I-ADE
though	O
rare	O
is	O
occasionally	O
observed	O
with	O
EGFR	O
inhibitors	O
gefitinib	B-Drug
or	O
erlotinib	B-Drug
.	O

-DOCSTART-	4079

Ballistic	B-ADE
movements	I-ADE
due	O
to	O
ischemic	B-ADE
infarcts	I-ADE
after	O
intravenous	O
heroin	B-Drug
overdose	O
:	O
report	O
of	O
two	O
cases	O
.	O

-DOCSTART-	4146

We	O
report	O
a	O
case	O
of	O
MMC	B-Drug
-	O
related	O
hemolytic	B-ADE
uremic	I-ADE
syndrome	I-ADE
,	O
and	O
discuss	O
the	O
etiologic	O
parameters	O
,	O
clinical	O
aspects	O
,	O
prognosis	O
and	O
treatment	O
modalities	O
of	O
this	O
severe	O
syndrome	O
.	O

-DOCSTART-	996

We	O
report	O
two	O
patients	O
with	O
acne	O
vulgaris	O
with	O
a	O
fourth	O
type	O
of	O
minocycline	B-Drug
-	O
induced	O
cutaneous	B-ADE
pigmentation	I-ADE
.	O

-DOCSTART-	2092

She	O
had	O
been	O
on	O
Copaxone	B-Drug
20	O
mg	O
/	O
day	O
treatment	O
for	O
2	O
years	O
when	O
she	O
first	O
exhibited	O
gastrointestinal	B-ADE
symptoms	I-ADE
.	O

-DOCSTART-	122

We	O
conclude	O
that	O
low	O
-	O
dose	O
HU	B-Drug
therapy	O
in	O
patients	O
with	O
thalassemia	O
intermedia	O
may	O
increase	B-ADE
total	I-ADE
Hb	I-ADE
levels	O
sufficiently	O
to	O
eliminate	O
the	O
need	O
for	O
transfusions	O
.	O

-DOCSTART-	3314

Fatal	B-ADE
ventricular	I-ADE
fibrillation	I-ADE
after	O
treatment	O
with	O
digoxin	B-Drug
in	O
a	O
27-year	O
-	O
old	O
man	O
with	O
mitral	O
leaflet	O
prolapse	O
syndrome	O
.	O

-DOCSTART-	396

We	O
report	O
a	O
case	O
of	O
interstitial	B-ADE
pulmonary	I-ADE
disease	I-ADE
that	O
occurred	O
together	O
with	O
lymphocytic	B-ADE
colitis	I-ADE
during	O
treatment	O
with	O
ticlopidine	B-Drug
.	O

-DOCSTART-	3936

One	O
patient	O
had	O
MRI	B-ADE
T2	I-ADE
abnormalities	I-ADE
compatible	O
with	O
cyclosporin	B-Drug
neurotoxicity	B-ADE
.	O

-DOCSTART-	2384

Severe	B-ADE
cardiomyopathy	I-ADE
following	O
treatment	O
with	O
the	O
tumour	O
necrosis	O
factor	O
-	O
alpha	O
inhibitor	O
adalimumab	B-Drug
for	O
Crohn	O
's	O
disease	O
.	O

-DOCSTART-	1528

Development	O
of	O
sarcoidosis	B-ADE
during	O
interferon	B-Drug
alpha	I-Drug
2b	I-Drug
and	O
ribavirin	B-Drug
combination	O
therapy	O
for	O
chronic	O
hepatitis	O
C	O
--	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	979

2-Chloro	B-Drug
-	I-Drug
deoxyadenosine	I-Drug
induces	O
durable	O
complete	O
remission	O
in	O
Castleman	O
's	O
disease	O
but	O
may	O
accelerate	O
its	O
transformation	O
to	O
non	B-ADE
-	I-ADE
Hodgkin	I-ADE
's	I-ADE
lymphoma	I-ADE
.	O

-DOCSTART-	3323

The	O
probability	O
of	O
developing	O
acute	B-ADE
leukemia	I-ADE
in	O
this	O
study	O
was	O
not	O
significantly	O
correlated	O
to	O
the	O
total	O
cumulative	O
dosage	O
of	O
Treosulfan	B-Drug
.	O

-DOCSTART-	213

Nonconvulsive	B-ADE
status	I-ADE
epilepticus	I-ADE
:	O
the	O
role	O
of	O
morphine	B-Drug
and	O
its	O
antagonist	O
.	O

-DOCSTART-	872

These	O
skin	B-ADE
lesions	I-ADE
may	O
be	O
induced	O
or	O
worsened	O
during	O
antiviral	O
therapy	O
with	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
(	O
IFN	B-Drug
)	O
.	O

-DOCSTART-	415

An	O
obese	O
patient	O
,	O
not	O
diabetic	O
,	O
treated	O
with	O
metformin	B-Drug
for	O
some	O
weeks	O
,	O
was	O
referred	O
to	O
us	O
with	O
severe	B-ADE
inferior	I-ADE
digestive	I-ADE
hemorrhage	I-ADE
,	O
diagnosed	O
with	O
Meckel	O
's	O
diverticulum	O
.	O

-DOCSTART-	1406

Since	O
recent	O
studies	O
have	O
reported	O
no	O
negative	O
interactions	O
with	O
concurrent	O
use	O
,	O
we	O
here	O
report	O
three	O
cases	O
(	O
one	O
case	O
of	O
a	O
prolonged	B-ADE
seizure	I-ADE
,	O
a	O
serotonin	B-ADE
syndrome	I-ADE
and	O
a	O
focal	B-ADE
seizure	I-ADE
)	O
of	O
severe	O
lithium	B-Drug
-	O
induced	O
side	O
effects	O
while	O
patients	O
underwent	O
ECT	O
without	O
complications	O
and	O
lithium	O
serum	O
levels	O
were	O
still	O
subtherapeutic	O
.	O

-DOCSTART-	3914

Uveitis	B-ADE
associated	O
with	O
rifabutin	B-Drug
therapy	O
:	O
a	O
clinical	O
alert	O
.	O

-DOCSTART-	2713

The	O
possible	O
development	O
of	O
a	O
drug	O
-	O
induced	O
vasculitis	B-ADE
or	O
lupus	B-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
should	O
be	O
added	O
to	O
the	O
list	O
of	O
rare	O
toxic	O
effects	O
of	O
vancomycin	B-Drug
.	O

-DOCSTART-	2967

Self	B-ADE
-	I-ADE
limited	I-ADE
edema	I-ADE
is	O
a	O
well	O
-	O
recognized	O
complication	O
of	O
insulin	B-Drug
therapy	O
.	O

-DOCSTART-	1187

Celiac	B-ADE
disease	I-ADE
onset	O
after	O
pegylated	B-Drug
interferon	I-Drug
and	O
ribavirin	B-Drug
treatment	O
of	O
chronic	O
hepatitis	O
C	O
.	O

-DOCSTART-	1954

Although	O
it	O
is	O
difficult	O
to	O
be	O
certain	O
of	O
the	O
direct	O
link	O
of	O
amiodarone	O
on	O
the	O
basis	O
of	O
a	O
single	O
case	O
,	O
it	O
is	O
reasonable	O
to	O
presume	O
that	O
this	O
histopathology	O
is	O
associated	O
with	O
amiodarone	B-Drug
-	O
induced	O
hypothyroidism	B-ADE
and	O
that	O
involution	O
changes	O
represent	O
the	O
hypofunctional	O
status	O
of	O
this	O
drug	O
-	O
induced	O
disorder	O
.	O

-DOCSTART-	1812

Radiation	B-ADE
recall	I-ADE
pneumonitis	I-ADE
induced	O
by	O
gemcitabine	B-Drug
.	O

-DOCSTART-	4250

Amiodarone	B-Drug
-	O
induced	O
thyrotoxicosis	B-ADE
associated	O
with	O
thyrotropin	B-ADE
receptor	I-ADE
antibody	I-ADE
.	O

-DOCSTART-	3889

After	O
treatment	O
with	O
cimetidine	B-Drug
,	O
there	O
was	O
a	O
rapid	O
deterioration	O
with	O
decreased	B-ADE
oxygen	I-ADE
saturation	I-ADE
and	I-ADE
arterial	I-ADE
PO2	I-ADE
values	O
.	O

-DOCSTART-	740

Interstitial	B-ADE
pneumonitis	I-ADE
associated	O
with	O
sirolimus	B-Drug
:	O
a	O
dilemma	O
for	O
lung	O
transplantation	O
.	O

-DOCSTART-	1423

Videopolysomnographic	O
and	O
pharmacokinetic	O
studies	O
with	O
monitoring	O
of	O
plasma	O
levodopa	B-Drug
levels	O
demonstrated	O
marked	B-ADE
motor	I-ADE
hyperactivity	I-ADE
during	O
augmentation	O
,	O
with	O
anarchic	B-ADE
discharges	I-ADE
of	I-ADE
motor	I-ADE
unit	I-ADE
potentials	I-ADE
,	O
tonic	B-ADE
grouped	I-ADE
discharges	I-ADE
and	O
flexor	B-ADE
spasms	I-ADE
,	O
associated	O
with	O
painful	B-ADE
dysesthesia	I-ADE
.	O

-DOCSTART-	1895

Detection	O
of	O
antineutrophil	O
cytoplasmic	O
antibody	O
in	O
a	O
patient	O
with	O
L	B-Drug
-	I-Drug
tryptophan	I-Drug
induced	O
eosinophilia	B-ADE
-	I-ADE
myalgia	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	2611

Peripheral	B-ADE
neuropathy	I-ADE
and	O
cerebellar	B-ADE
syndrome	I-ADE
associated	O
with	O
amiodarone	B-Drug
therapy	O
.	O

-DOCSTART-	2293

Cryptococcus	B-ADE
neoformans	I-ADE
fatal	I-ADE
sepsis	I-ADE
in	O
a	O
chronic	O
lymphocytic	O
leukemia	O
patient	O
treated	O
with	O
alemtuzumab	B-Drug
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	1369

METHODS	O
:	O
A	O
79-year	O
-	O
old	O
woman	O
being	O
treated	O
with	O
imiquimod	B-Drug
5	O
days	O
per	O
week	O
for	O
a	O
nodular	O
basal	O
cell	O
developed	O
a	O
verrucous	B-ADE
plaque	I-ADE
over	O
the	O
treatment	O
area	O
after	O
7	O
weeks	O
of	O
therapy	O
.	O

-DOCSTART-	3860

Methamphetamine	B-Drug
's	O
extensive	O
physiologic	O
effects	O
,	O
inconsistent	O
street	O
purity	O
,	O
and	O
multiple	O
routes	O
of	O
administration	O
offer	O
many	O
possibilities	O
for	O
injury	B-ADE
to	I-ADE
the	I-ADE
cornea	I-ADE
.	O

-DOCSTART-	2426

He	O
had	O
been	O
taking	O
trimethoprim	B-Drug
-	O
sulfamethoxazole	B-Drug
for	O
approximately	O
eight	O
days	O
when	O
he	O
revisited	O
his	O
family	O
physician	O
,	O
complaining	O
of	O
headaches	B-ADE
,	O
dizziness	B-ADE
,	O
difficulty	B-ADE
with	I-ADE
speech	I-ADE
,	O
weakness	B-ADE
,	O
and	O
itching	B-ADE
on	I-ADE
the	I-ADE
trunk	I-ADE
of	O
his	O
body	O
and	O
legs	O
,	O
where	O
a	O
maculopapular	B-ADE
rash	I-ADE
was	O
noted	O
.	O

-DOCSTART-	4005

Acute	B-ADE
renal	I-ADE
failure	I-ADE
in	O
a	O
patient	O
receiving	O
treatment	O
with	O
suramin	B-Drug
.	O

-DOCSTART-	1790

Pancreatitis	B-ADE
is	O
a	O
very	O
rare	O
adverse	O
effect	O
associated	O
with	O
the	O
use	O
of	O
amiodarone	B-Drug
,	O
and	O
only	O
four	O
cases	O
of	O
amiodarone	B-Drug
-	O
induced	O
pancreatitis	B-ADE
have	O
been	O
reported	O
in	O
literature	O
.	O

-DOCSTART-	61

The	O
patient	O
had	O
recurrence	O
of	O
urticaria	B-ADE
and	O
angioedema	B-ADE
a	O
year	O
and	O
a	O
half	O
later	O
,	O
at	O
which	O
point	O
the	O
NPH	B-Drug
was	O
stopped	O
and	O
she	O
was	O
desensitized	O
to	O
regular	O
insulin	B-Drug
.	O

-DOCSTART-	1301

CONCLUSIONS	O
:	O
In	O
these	O
3	O
cases	O
,	O
the	O
unique	O
positive	O
ocular	O
finding	O
was	O
corneal	B-ADE
endothelial	I-ADE
deposits	I-ADE
,	O
which	O
may	O
be	O
related	O
to	O
the	O
use	O
of	O
rifabutin	B-Drug
.	O

-DOCSTART-	2431

Exacerbation	O
of	O
anthracycline	B-Drug
-	O
induced	O
early	B-ADE
chronic	I-ADE
cardiomyopathy	I-ADE
with	O
ATRA	O
:	O
role	O
of	O
B	O
-	O
type	O
natriuretic	O
peptide	O
as	O
an	O
indicator	O
of	O
cardiac	O
dysfunction	O
.	O

-DOCSTART-	1765

Juvenile	B-ADE
absence	I-ADE
epilepsy	I-ADE
exacerbated	O
by	O
valproic	B-Drug
acid	I-Drug
.	O

-DOCSTART-	1710

Hypoxia	B-ADE
is	O
a	O
predisposing	O
factor	O
for	O
premature	B-ADE
ductal	I-ADE
closure	I-ADE
and	O
often	O
occurs	O
after	O
maternal	O
indomethacin	B-Drug
therapy	O
.	O

-DOCSTART-	1441

Nephrotic	B-ADE
syndrome	I-ADE
in	O
a	O
multiple	O
sclerosis	O
patient	O
treated	O
with	O
interferon	B-Drug
beta	I-Drug
1a	I-Drug
.	O

-DOCSTART-	297

MI	B-ADE
related	O
to	O
the	O
use	O
of	O
activated	O
and	O
non	O
-	O
activated	O
PCCs	B-Drug
predominantly	O
affects	O
young	O
patients	O
who	O
often	O
have	O
no	O
preceding	O
history	O
of	O
,	O
or	O
risk	O
factors	O
for	O
,	O
MI	O
and	O
tends	O
to	O
be	O
associated	O
with	O
large	O
cumulative	O
doses	O
of	O
concentrate	O
.	O

-DOCSTART-	2968

This	O
report	O
describes	O
the	O
first	O
case	O
of	O
insulin	B-Drug
-	O
induced	O
cardiac	B-ADE
failure	I-ADE
in	O
a	O
patient	O
without	O
underlying	O
heart	O
disease	O
.	O

-DOCSTART-	1821

Flecainide	B-Drug
overdose	O
can	O
rapidly	O
result	O
in	O
profound	O
cardiovascular	B-ADE
collapse	I-ADE
,	O
and	O
is	O
associated	O
with	O
a	O
relatively	O
high	O
mortality	O
.	O

-DOCSTART-	2068

Sexual	B-ADE
dysfunction	I-ADE
associated	O
with	O
intrathecal	O
baclofen	B-Drug
use	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

-DOCSTART-	3273

Complete	O
remission	O
of	O
the	O
nephrosis	B-ADE
occurred	O
after	O
discontinuation	O
of	O
hydroxychloroquine	B-Drug
therapy	O
.	O

-DOCSTART-	186

The	O
three	O
reported	O
cases	O
demonstrate	O
that	O
troglitazone	B-Drug
is	O
an	O
idiosyncratic	O
hepatotoxin	O
that	O
can	O
lead	O
to	O
irreversible	B-ADE
liver	I-ADE
injury	I-ADE
.	O

-DOCSTART-	1000

Amifostine	B-Drug
-	O
induced	O
fever	B-ADE
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	4032

We	O
thus	O
concluded	O
that	O
an	O
excessive	O
dose	O
of	O
AZ	B-Drug
had	O
probably	O
destroyed	B-ADE
the	I-ADE
gastric	I-ADE
mucosal	I-ADE
barrier	I-ADE
or	O
thrombocytopenia	B-ADE
due	I-ADE
to	I-ADE
bone	I-ADE
marrow	I-ADE
disorder	I-ADE
and	O
thus	O
eventually	O
led	O
to	O
the	O
development	O
of	O
hemorrhagic	B-ADE
gastritis	I-ADE
.	O

-DOCSTART-	690

Carboplatin	B-Drug
hypersensitivity	O
presenting	O
as	O
coronary	B-ADE
vasospasm	I-ADE
-	O
a	O
case	O
report	O
.	O

-DOCSTART-	4199

Elderly	O
patients	O
for	O
whom	O
nitrate	B-Drug
has	O
been	O
prescribed	O
should	O
be	O
warned	O
of	O
the	O
occurrence	O
of	O
hypotension	B-ADE
,	O
leading	O
to	O
unconsciousness	B-ADE
.	O

-DOCSTART-	1291

TREATMENT	O
/	O
OUTCOME	O
:	O
Standard	O
anti	O
-	O
tuberculosis	O
therapy	O
was	O
administered	O
but	O
was	O
complicated	O
by	O
interaction	O
with	O
cyclosporine	B-Drug
and	O
drug	O
-	O
induced	O
cholestasis	B-ADE
.	O

-DOCSTART-	2067

RESULTS	O
:	O
A	O
male	O
and	O
a	O
female	O
patient	O
with	O
spasticity	O
treated	O
with	O
intrathecal	O
baclofen	B-Drug
were	O
recognized	O
to	O
have	O
sexual	B-ADE
dysfunction	I-ADE
side	O
effects	O
from	O
treatment	O
.	O

-DOCSTART-	3730

Prolongation	B-ADE
of	I-ADE
the	I-ADE
QT	I-ADE
interval	I-ADE
observed	O
in	O
a	O
Japanese	O
patient	O
with	O
vivax	O
malaria	O
following	O
treatment	O
with	O
halofantrine	B-Drug
.	O

-DOCSTART-	756

The	O
diagnosis	O
of	O
hypothermia	B-ADE
was	O
delayed	O
until	O
it	O
was	O
apparent	O
for	O
several	O
days	O
but	O
resolved	O
with	O
the	O
discontinuation	O
of	O
risperidone	B-Drug
and	O
continuation	O
of	O
clozapine	O
.	O

-DOCSTART-	3431

A	O
42	O
year	O
old	O
man	O
,	O
treated	O
for	O
testicular	O
carcinoma	O
with	O
combination	O
chemotherapy	O
that	O
included	O
bleomycin	B-Drug
,	O
developed	O
life	O
threatening	O
interstitial	B-ADE
pneumonitis	I-ADE
.	O

-DOCSTART-	332

Quetiapine	B-Drug
and	O
obsessive	B-ADE
-	I-ADE
compulsive	I-ADE
symptoms	I-ADE
(	O
OCS	B-ADE
)	O
:	O
case	O
report	O
and	O
review	O
of	O
atypical	O
antipsychotic	O
-	O
induced	O
OCS	B-ADE
.	O

-DOCSTART-	1049

Patients	O
should	O
be	O
informed	O
about	O
the	O
risk	O
of	O
osteonecrosis	B-ADE
when	O
taking	O
dexamethasone	B-Drug
as	O
an	O
antiemetic	O
drug	O
.	O

-DOCSTART-	2922

Intravenous	O
verapamil	B-Drug
therapy	O
in	O
babies	O
may	O
cause	O
apnea	B-ADE
,	O
hypotension	B-ADE
,	O
and	O
bradycardia	B-ADE
;	O
continued	O
episodes	O
of	O
atrial	B-ADE
flutter	I-ADE
in	O
a	O
child	O
may	O
cause	O
sudden	B-ADE
death	I-ADE
;	O
quinidine	B-Drug
may	O
be	O
related	O
to	O
the	O
death	B-ADE
;	O
children	O
with	O
"	O
familial	O
seizure	O
disorders	O
"	O
may	O
in	O
fact	O
have	O
the	O
long	B-ADE
QT	I-ADE
interval	I-ADE
syndrome	I-ADE
.	O

-DOCSTART-	3867

Methotrexate	B-Drug
-	O
induced	O
liver	B-ADE
cirrhosis	I-ADE
.	O

-DOCSTART-	3873

Fatal	B-ADE
intravascular	I-ADE
autoimmune	I-ADE
hemolytic	I-ADE
anemia	I-ADE
after	O
fludarabine	B-Drug
treatment	O
for	O
chronic	O
lymphocytic	O
leukemia	O
.	O

-DOCSTART-	3639

Unintended	O
exposure	O
to	O
acyclovir	B-Drug
early	O
in	O
pregnancy	O
,	O
which	O
is	O
not	O
uncommon	O
,	O
may	O
cause	O
excessive	B-ADE
maternal	I-ADE
and	I-ADE
physician	I-ADE
anxiety	I-ADE
.	O

-DOCSTART-	3743

CONCLUSION	O
:	O
The	O
administration	O
of	O
tissue	B-Drug
plasminogen	I-Drug
activator	I-Drug
was	O
responsible	O
for	O
the	O
large	O
extent	O
of	O
hemorrhage	B-ADE
and	O
should	O
be	O
considered	O
in	O
the	O
differential	O
diagnosis	O
of	O
hemorrhagic	B-ADE
choroidal	I-ADE
detachment	I-ADE
.	O

-DOCSTART-	3199

To	O
our	O
knowledge	O
,	O
this	O
recurrence	O
of	O
amiodarone	B-Drug
pulmonary	B-ADE
toxicity	I-ADE
has	O
not	O
been	O
reported	O
previously	O
.	O

-DOCSTART-	3006

Gold	B-Drug
nephropathy	B-ADE
:	O
tissue	O
analysis	O
by	O
X	O
-	O
ray	O
fluorescent	O
spectroscopy	O
.	O

-DOCSTART-	3451

CONCLUSION	O
:	O
Squamous	B-ADE
metaplasia	I-ADE
in	O
these	O
cases	O
appears	O
to	O
be	O
a	O
consequence	O
of	O
progestin	B-Drug
therapy	O
.	O

-DOCSTART-	3667

DISCUSSION	O
:	O
Electrolyte	B-ADE
disorders	I-ADE
associated	O
with	O
foscarnet	B-Drug
are	O
reviewed	O
.	O

-DOCSTART-	2775

We	O
report	O
the	O
case	O
of	O
a	O
patient	O
with	O
the	O
acquired	O
immunodeficiency	O
syndrome	O
treated	O
with	O
rifampicin	B-Drug
who	O
had	O
a	O
'	O
normal	O
'	O
screening	O
test	O
for	O
adrenal	O
insufficiency	O
,	O
yet	O
had	O
clinical	O
evidence	O
of	O
adrenal	B-ADE
failure	I-ADE
.	O

-DOCSTART-	3179

Case	O
report	O
of	O
withdrawal	O
dyskinesia	B-ADE
associated	O
with	O
amoxapine	B-Drug
.	O

-DOCSTART-	1281

Visual	B-ADE
system	I-ADE
side	I-ADE
effects	I-ADE
caused	O
by	O
parasympathetic	B-ADE
dysfunction	I-ADE
after	O
botulinum	B-Drug
toxin	I-Drug
type	I-Drug
B	I-Drug
injections	O
.	O

-DOCSTART-	1585

Myocardial	B-ADE
ischemia	I-ADE
associated	O
with	O
high	O
-	O
dose	O
carmustine	B-Drug
infusion	O
.	O

-DOCSTART-	1747

Exacerbations	B-ADE
of	I-ADE
the	I-ADE
heart	I-ADE
failure	I-ADE
were	O
temporally	O
related	O
to	O
the	O
administration	O
of	O
the	O
antitumor	O
antibiotics	O
actinomycin	B-Drug
-	I-Drug
D	I-Drug
(	O
NSC-3053	B-Drug
)	O
and	O
mithramycin	B-Drug
(	O
NSC-24559	B-Drug
)	O
.	O

-DOCSTART-	4007

Other	O
potential	O
causes	O
of	O
renal	B-ADE
failure	I-ADE
were	O
not	O
present	O
in	O
our	O
patient	O
and	O
his	O
renal	O
function	O
gradually	O
recovered	O
with	O
the	O
cessation	O
of	O
suramin	B-Drug
treatment	O
.	O

-DOCSTART-	2106

Methylphenidate	B-Drug
-	O
associated	O
enuresis	B-ADE
in	O
attention	O
deficit	O
hyperactivity	O
disorder	O
.	O

-DOCSTART-	58

Patients	O
receiving	O
neutral	B-Drug
protamine	I-Drug
Hagedorn	I-Drug
(	I-Drug
NPH	I-Drug
)	I-Drug
insulin	I-Drug
are	O
at	O
increased	O
risk	O
for	O
the	O
development	O
of	O
protamine	B-ADE
hypersensitivity	I-ADE
.	O

-DOCSTART-	1308

We	O
report	O
a	O
case	O
of	O
a	O
women	O
in	O
whom	O
a	O
malignant	B-ADE
mixed	I-ADE
mesodermal	I-ADE
tumor	I-ADE
was	O
diagnosed	O
while	O
she	O
was	O
taking	O
raloxifene	B-Drug
,	O
which	O
is	O
also	O
a	O
selective	O
estrogen	O
receptor	O
modulator	O
.	O

-DOCSTART-	1365

Rapid	O
onset	O
of	O
quetiapine	B-Drug
-	O
induced	O
diabetic	B-ADE
ketoacidosis	I-ADE
in	O
an	O
elderly	O
patient	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3127

Pulmonary	B-ADE
gold	I-ADE
toxicity	I-ADE
.	O

-DOCSTART-	3263

Cefoxitin	B-Drug
-	O
associated	O
renal	B-ADE
failure	I-ADE
.	O

-DOCSTART-	2044

Severe	B-ADE
symptomatic	I-ADE
hyponatremia	I-ADE
during	O
sibutramine	B-Drug
therapy	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	166

The	O
development	O
of	O
erythroid	O
leukemia	O
plus	O
carcinoma	B-ADE
in	O
these	O
two	O
men	O
suggests	O
mutagenic	O
change	O
secondary	O
to	O
cyclophosphamide	B-Drug
therapy	O
.	O

-DOCSTART-	3385

Acute	B-ADE
reversible	I-ADE
ataxo	I-ADE
-	I-ADE
myoclonic	I-ADE
encephalopathy	I-ADE
with	O
flecainide	B-Drug
therapy	O
.	O

-DOCSTART-	761

After	O
reviewing	O
the	O
literature	O
we	O
suggest	O
the	O
CPM	B-ADE
was	O
a	O
complication	O
of	O
lithium	B-Drug
toxicity	O
which	O
affected	O
the	O
lateral	O
geniculate	O
nucleus	O
which	O
produced	O
blindness	B-ADE
.	O

-DOCSTART-	893

Thus	O
cabergoline	B-Drug
may	O
cause	O
similar	O
pleuropulmonary	B-ADE
abnormalities	I-ADE
to	O
bromocriptine	B-Drug
.	O

-DOCSTART-	1011

Scleromyxedema	B-ADE
in	O
a	O
patient	O
with	O
multiple	O
sclerosis	O
and	O
monoclonal	O
gammopathy	O
on	O
interferon	B-Drug
beta-1a	I-Drug
.	O

-DOCSTART-	21

We	O
describe	O
a	O
life	O
threatening	O
side	O
effect	O
of	O
acute	O
epoprostenol	B-Drug
infusion	O
(	O
pulmonary	B-ADE
edema	I-ADE
)	O
in	O
a	O
patient	O
with	O
pulmonary	O
hypertension	O
associated	O
with	O
limited	O
scleroderma	O
and	O
discuss	O
its	O
management	O
and	O
potential	O
etiology	O
.	O

-DOCSTART-	3651

OBJECTIVE	O
:	O
To	O
report	O
the	O
first	O
five	O
cases	O
of	O
amphotericin	B-Drug
B	I-Drug
overdose	O
with	O
secondary	O
cardiac	B-ADE
complications	I-ADE
in	O
a	O
pediatric	O
population	O
.	O

-DOCSTART-	3481

High	B-ADE
-	I-ADE
grade	I-ADE
atrioventricular	I-ADE
block	I-ADE
during	O
dipyridamole	B-Drug
stress	O
testing	O
.	O

-DOCSTART-	2560

Insulin	B-ADE
-	I-ADE
dependent	I-ADE
diabetes	I-ADE
mellitus	I-ADE
associated	O
with	O
danazol	B-Drug
.	O

-DOCSTART-	1096

Purple	B-ADE
glove	I-ADE
syndrome	I-ADE
,	O
named	O
for	O
its	O
distinctive	O
purple	B-ADE
discoloration	I-ADE
and	O
swelling	B-ADE
of	I-ADE
the	I-ADE
hands	I-ADE
in	O
the	O
distribution	O
of	O
a	O
glove	O
,	O
is	O
an	O
uncommon	O
complication	O
of	O
intravenous	O
phenytoin	B-Drug
administration	O
through	O
small	O
dorsal	O
veins	O
of	O
the	O
hands	O
.	O

-DOCSTART-	2187

The	O
role	O
of	O
Adriamycin	B-Drug
in	O
the	O
production	O
of	O
cardiotoxicity	B-ADE
is	O
reviewed	O
.	O

-DOCSTART-	3630

Four	O
days	O
after	O
the	O
initial	O
injection	O
of	O
3.6	O
mg	O
of	O
goserelin	B-Drug
acetate	I-Drug
,	O
severe	B-ADE
dyspnea	I-ADE
developed	O
due	O
to	O
worsening	B-ADE
pleuritis	I-ADE
carcinomatosa	I-ADE
,	O
which	O
was	O
considered	O
as	O
a	O
flare	B-ADE
-	I-ADE
up	I-ADE
.	O

-DOCSTART-	1132

In	O
this	O
paper	O
we	O
report	O
a	O
case	O
of	O
nimodipine	B-Drug
overdosage	O
resulting	O
in	O
prolonged	B-ADE
hypotension	I-ADE
and	O
hypoxemia	B-ADE
,	O
which	O
was	O
successfully	O
treated	O
with	O
calcium	O
gluconate	O
.	O

-DOCSTART-	847

Acute	B-ADE
psychosis	I-ADE
associated	O
with	O
levetiracetam	B-Drug
.	O

-DOCSTART-	2851

Metastatic	B-ADE
osteomyelitis	I-ADE
following	O
BCG	B-Drug
vaccination	O
.	O

-DOCSTART-	3706

Acute	B-ADE
dystonic	I-ADE
reaction	I-ADE
with	O
low	O
-	O
dose	O
pimozide	B-Drug
.	O

-DOCSTART-	3974

CONCLUSIONS	O
:	O
The	O
value	O
of	O
multihormonal	O
therapy	O
in	O
breast	O
carcinoma	O
is	O
not	O
established	O
,	O
and	O
the	O
addition	O
of	O
progestogens	O
to	O
tamoxifen	B-Drug
may	O
not	O
reduce	O
of	O
developing	O
endometrial	B-ADE
lesions	I-ADE
,	O
including	O
carcinoma	B-ADE
.	O

-DOCSTART-	511

This	O
case	O
report	O
describes	O
the	O
development	O
of	O
asymptomatic	O
visual	B-ADE
field	I-ADE
defects	I-ADE
(	O
VFDs	B-ADE
)	O
in	O
a	O
psychiatric	O
patient	O
with	O
bipolar	O
disorder	O
receiving	O
adjunctive	O
tiagabine	B-Drug
treatment	O
.	O

-DOCSTART-	3152

Interstitial	B-ADE
pneumopathy	I-ADE
and	O
low	O
-	O
dosage	O
amiodarone	B-Drug
.	O

-DOCSTART-	1453

Atrial	B-ADE
fibrillation	I-ADE
after	O
vardenafil	B-Drug
therapy	O
.	O

-DOCSTART-	4262

Because	O
psoralens	B-Drug
sensitize	O
skin	O
to	O
ultraviolet	O
A	O
light	O
,	O
phototoxic	B-ADE
reactions	I-ADE
are	O
the	O
most	O
frequent	O
adverse	O
effect	O
of	O
this	O
treatment	O
.	O

-DOCSTART-	3180

Occurrence	O
of	O
withdrawal	O
dyskinesia	B-ADE
indicates	O
that	O
the	O
neuroleptic	O
effects	O
of	O
amoxapine	B-Drug
may	O
be	O
clinically	O
significant	O
.	O

-DOCSTART-	3269

Amiodarone	B-Drug
was	O
the	O
third	O
drug	O
to	O
induce	O
AVT	B-ADE
in	O
this	O
patient	O
;	O
she	O
received	O
200	O
mg	O
/	O
day	O
six	O
days	O
per	O
week	O
for	O
six	O
months	O
.	O

-DOCSTART-	3144

Hyponatremia	B-ADE
in	O
patients	O
treated	O
with	O
lorcainide	B-Drug
,	O
a	O
new	O
antiarrhythmic	O
drug	O
.	O

-DOCSTART-	4052

Acute	B-ADE
renal	I-ADE
failure	I-ADE
with	O
severe	B-ADE
tubulointerstitial	I-ADE
changes	I-ADE
in	O
a	O
patient	O
with	O
minimal	O
change	O
nephrotic	O
syndrome	O
treated	O
with	O
enalapril	B-Drug
.	O

-DOCSTART-	1114

In	O
this	O
report	O
,	O
we	O
present	O
a	O
case	O
of	O
hypoglycaemic	B-ADE
coma	I-ADE
associated	O
with	O
SP	B-Drug
,	O
an	O
adverse	O
reaction	O
that	O
is	O
likely	O
to	O
be	O
underreported	O
and	O
expected	O
to	O
occur	O
with	O
greater	O
frequency	O
as	O
the	O
use	O
of	O
SP	B-Drug
increases	O
.	O

-DOCSTART-	1998

Phenytoin	B-Drug
toxicity	O
:	O
an	O
easily	O
missed	O
cause	O
of	O
cerebellar	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1103

Pulmonary	B-ADE
fibrosis	I-ADE
is	O
a	O
severe	O
complication	O
associated	O
with	O
bis	B-Drug
-	I-Drug
chloronitrosourea	I-Drug
(	O
BCNU	B-Drug
)	O
therapy	O
.	O

-DOCSTART-	2358

Three	O
days	O
after	O
receiving	O
intravitreal	O
injection	O
of	O
bevacizumab	B-Drug
(	O
1.25	O
mg	O
in	O
0.1	O
ml	O
)	O
,	O
he	O
developed	O
acute	B-ADE
vision	I-ADE
loss	I-ADE
and	O
change	B-ADE
of	I-ADE
consciousness	I-ADE
.	O

-DOCSTART-	3658

A	O
case	O
is	O
reported	O
of	O
a	O
40	O
year	O
old	O
woman	O
treated	O
with	O
intraventricular	O
IL-2	B-Drug
for	O
leptomeningeal	O
disease	O
who	O
developed	O
progressive	O
cognitive	B-ADE
dysfunction	I-ADE
.	O

-DOCSTART-	1480

Radiation	B-ADE
recall	I-ADE
from	O
gemcitabine	B-Drug
is	O
rare	O
,	O
but	O
can	O
potentially	O
arise	O
in	O
any	O
site	O
that	O
has	O
been	O
previously	O
irradiated	O
.	O

-DOCSTART-	883

The	O
cases	O
of	O
CBZ	B-Drug
-	O
induced	O
SLE	B-ADE
reported	O
in	O
the	O
literature	O
were	O
reviewed	O
.	O

-DOCSTART-	3004

Two	O
of	O
these	O
patients	O
,	O
who	O
also	O
received	O
the	O
anti	O
-	O
emetic	O
prochlorperazine	B-Drug
,	O
lost	B-ADE
consciousness	I-ADE
for	O
48	O
-	O
72	O
h	O
and	O
then	O
fully	O
recovered	O
.	O

-DOCSTART-	2829

Pharmacokinetic	O
determinants	O
of	O
6-mercaptopurine	B-Drug
myelotoxicity	B-ADE
and	O
therapeutic	O
failure	O
in	O
children	O
with	O
acute	O
lymphoblastic	O
leukemia	O
.	O

-DOCSTART-	1137

L	B-Drug
-	I-Drug
asparaginase	I-Drug
-	O
induced	O
pancreatitis	B-ADE
is	O
an	O
uncommon	O
but	O
potential	O
lethal	B-ADE
complication	I-ADE
of	O
the	O
treatment	O
of	O
leukemia	O
.	O

-DOCSTART-	2901

He	O
became	O
hyperkalemic	B-ADE
on	O
rechallenge	O
with	O
timolol	B-Drug
and	O
normokalemic	O
following	O
its	O
withdrawal	O
.	O

-DOCSTART-	2814

A	O
case	O
of	O
halothane	B-Drug
induced	O
hepatitis	B-ADE
is	O
reported	O
in	O
a	O
middle	O
aged	O
woman	O
who	O
underwent	O
gastric	O
surgery	O
for	O
morbid	O
obesity	O
.	O

-DOCSTART-	358

Serious	B-ADE
adverse	I-ADE
events	I-ADE
experienced	O
by	O
patients	O
with	O
chronic	O
heart	O
failure	O
taking	O
spironolactone	B-Drug
.	O

-DOCSTART-	3428

Extrapyramidal	B-ADE
side	I-ADE
effects	I-ADE
induced	O
by	O
some	O
selective	O
serotonin	O
reuptake	O
inhibitors	O
(	O
SSRIs	O
)	O
,	O
i.e.	O
fluoxetine	B-Drug
and	O
sertraline	B-Drug
,	O
have	O
been	O
previously	O
reported	O
in	O
patients	O
with	O
depression	O
and	O
obsessive	O
-	O
compulsive	O
disorder	O
(	O
OCD	O
)	O
.	O

-DOCSTART-	655

The	O
first	O
case	O
concerns	O
a	O
70-year	O
-	O
old	O
man	O
who	O
developed	O
severe	O
aplastic	B-ADE
anemia	I-ADE
7	O
weeks	O
after	O
treatment	O
with	O
500	O
mg	O
of	O
ticlopidine	B-Drug
daily	O
.	O

-DOCSTART-	2150

On	O
the	O
other	O
hand	O
,	O
aspirin	B-Drug
may	O
have	O
promoted	O
the	O
enlargement	B-ADE
of	I-ADE
spontaneous	I-ADE
hemorrhage	I-ADE
from	O
meningioma	O
.	O

-DOCSTART-	3880

This	O
pattern	O
is	O
suggestive	O
of	O
renal	B-ADE
toxicity	I-ADE
due	O
to	O
tobramycin	B-Drug
.	O

-DOCSTART-	1336

BACKGROUND	O
:	O
Interferon	B-Drug
(	O
IFN	B-Drug
)	O
-	O
associated	O
retinopathy	B-ADE
is	O
typically	O
characterized	O
by	O
retinal	B-ADE
hemorrhages	I-ADE
and	O
cotton	B-ADE
wool	I-ADE
spots	I-ADE
at	O
the	O
posterior	O
fundus	O
,	O
but	O
visual	O
function	O
is	O
usually	O
maintained	O
.	O

-DOCSTART-	3691

Although	O
the	O
essential	O
cause	O
of	O
PV	B-ADE
is	O
unclear	O
,	O
its	O
onset	O
has	O
occasionally	O
been	O
associated	O
with	O
drug	O
therapy	O
,	O
in	O
particular	O
penicillamine	B-Drug
.	O

-DOCSTART-	2134

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
ciprofloxacin	B-Drug
-	O
induced	O
SJS	B-ADE
and	O
acute	O
onset	O
of	O
VBDS	B-ADE
,	O
and	O
reviewed	O
the	O
related	O
literature	O
.	O

-DOCSTART-	2275

With	O
the	O
first	O
cyclosporine	B-Drug
dose	O
,	O
the	O
patient	O
complained	O
of	O
leg	B-ADE
pain	I-ADE
that	O
was	O
most	O
severe	O
during	O
the	O
cyclosporine	B-Drug
infusion	O
.	O

-DOCSTART-	3896

Infants	O
are	O
particularly	O
susceptible	O
to	O
chronic	O
nitrate	B-Drug
-	O
induced	O
methemoglobinemia	B-ADE
because	O
of	O
their	O
low	O
stomach	O
acid	O
production	O
,	O
large	O
numbers	O
of	O
nitrite	O
-	O
reducing	O
bacteria	O
,	O
and	O
the	O
relatively	O
easy	O
oxidation	O
of	O
fetal	O
hemoglobin	O
.	O

-DOCSTART-	4235

Clinicians	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
that	O
vinorelbine	B-Drug
may	O
cause	O
SIADH	B-ADE
and	O
possibly	O
hypokalemia	B-ADE
.	O

-DOCSTART-	3626

Neutropenia	B-ADE
is	O
an	O
infrequent	O
complication	O
following	O
administration	O
of	O
the	O
angiotensin	O
-	O
converting	O
enzyme	O
(	O
ACE	O
)	O
inhibitor	O
,	O
captopril	B-Drug
.	O

-DOCSTART-	1650

Morphine	B-Drug
,	O
an	O
opium	O
alkaloid	O
,	O
frequently	O
causes	O
side	O
effects	O
such	O
as	O
hyperhidrosis	B-ADE
and	O
facial	B-ADE
flushing	I-ADE
,	O
but	O
serious	O
cutaneous	O
adverse	O
drug	O
reactions	O
are	O
seldom	O
observed	O
.	O

-DOCSTART-	2206

After	O
cessation	O
of	O
amantadine	B-Drug
,	O
the	O
edema	B-ADE
resolved	O
,	O
and	O
the	O
endothelial	O
cell	O
densities	O
were	O
<	O
or=600/mm	O
.	O

-DOCSTART-	2442

CONCLUSION	O
:	O
Zidovudine	B-Drug
is	O
well	O
a	O
known	O
cause	O
of	O
anaemia	B-ADE
and	O
thus	O
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
initiation	O
of	O
antiretroviral	O
therapy	O
.	O

-DOCSTART-	2409

Colonic	B-ADE
necrosis	I-ADE
is	O
known	O
as	O
a	O
rare	O
complication	O
following	O
the	O
administration	O
of	O
Kayexalate	B-Drug
(	O
sodium	B-Drug
polystryrene	I-Drug
sulfonate	I-Drug
)	O
in	O
sorbitol	O
.	O

-DOCSTART-	849

The	O
psychotic	B-ADE
behavior	I-ADE
resolved	O
completely	O
soon	O
after	O
the	O
discontinuation	O
of	O
levetiracetam	B-Drug
.	O

-DOCSTART-	3106

The	O
5	O
patients	O
had	O
severe	O
renovascular	O
disease	O
which	O
might	O
thus	O
represent	O
a	O
significant	O
risk	O
factor	O
in	O
the	O
development	O
of	O
captopril	B-Drug
-	O
induced	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
.	O

-DOCSTART-	2195

Four	O
months	O
after	O
receiving	O
an	O
orthotopic	O
liver	O
transplant	O
,	O
a	O
51-year	O
-	O
old	O
man	O
was	O
admitted	O
for	O
progressive	B-ADE
liver	I-ADE
failure	I-ADE
and	O
severe	B-ADE
hepatocellular	I-ADE
necrosis	I-ADE
thought	O
to	O
be	O
due	O
to	O
tacrolimus	B-Drug
.	O

-DOCSTART-	380

Motor	B-ADE
fluctuations	I-ADE
appear	O
after	O
2	O
-	O
3	O
years	O
of	O
levodopa	B-Drug
treatment	O
,	O
and	O
affect	O
at	O
least	O
50	O
%	O
of	O
patients	O
after	O
five	O
years	O
.	O

-DOCSTART-	3927

Delay	B-ADE
of	I-ADE
corneal	I-ADE
wound	I-ADE
healing	I-ADE
in	O
patients	O
treated	O
with	O
colchicine	B-Drug
.	O

-DOCSTART-	1569

Physicians	O
should	O
keep	O
in	O
mind	O
that	O
taxanes	O
such	O
as	O
paclitaxel	B-Drug
have	O
the	O
potential	O
to	O
cause	O
pneumonitis	B-ADE
and	O
lung	B-ADE
fibrosis	I-ADE
.	O

-DOCSTART-	3498

INTRODUCTION	O
-	O
The	O
aim	O
of	O
this	O
case	O
report	O
is	O
to	O
present	O
a	O
15-year	O
follow	O
-	O
up	O
of	O
a	O
patient	O
with	O
phenytoin	B-Drug
(	O
PHT	B-Drug
)	O
intoxication	O
with	O
unilateral	B-ADE
gingival	I-ADE
hyperplasia	I-ADE
(	O
GH	O
)	O
.	O

-DOCSTART-	3731

The	O
pharmaceutical	O
company	O
producing	O
Halfan	B-Drug
has	O
reported	O
8	O
cardiac	B-ADE
arrests	I-ADE
,	O
leading	O
to	O
6	O
deaths	B-ADE
,	O
when	O
a	O
higher	O
dose	O
than	O
recommended	O
was	O
used	O
,	O
there	O
was	O
recent	O
or	O
concomitant	O
treatment	O
with	O
mefloquine	B-Drug
,	O
there	O
was	O
pre	O
-	O
existing	O
prolongation	O
of	O
the	O
QT	O
interval	O
or	O
the	O
patient	O
had	O
a	O
thiamine	O
deficiency	O
.	O

-DOCSTART-	643

Although	O
vasculitis	B-ADE
has	O
been	O
reported	O
in	O
the	O
course	O
of	O
hairy	O
cell	O
leukaemia	O
,	O
it	O
has	O
only	O
rarely	O
been	O
reported	O
as	O
the	O
consequence	O
of	O
cladribine	B-Drug
treatment	O
.	O

-DOCSTART-	1649

Acute	B-ADE
generalized	I-ADE
exanthematous	I-ADE
pustulosis	I-ADE
caused	O
by	O
morphine	B-Drug
,	O
confirmed	O
by	O
positive	O
patch	O
test	O
and	O
lymphocyte	O
transformation	O
test	O
.	O

-DOCSTART-	2087

Levofloxacin	B-Drug
-	O
induced	O
delirium	B-ADE
with	I-ADE
psychotic	I-ADE
features	I-ADE
.	O

-DOCSTART-	4240

Thus	O
,	O
an	O
immunological	O
mechanism	O
might	O
be	O
involved	O
in	O
the	O
mechanism	O
of	O
pirmenol	B-Drug
-	O
induced	O
QT	B-ADE
prolongation	I-ADE
and	O
T	B-ADE
wave	I-ADE
inversion	I-ADE
on	O
the	O
electrocardiogram	O
.	O

-DOCSTART-	1233

To	O
the	O
best	O
of	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
reported	O
patient	O
with	O
captopril	B-Drug
-	O
induced	O
pemphigus	B-ADE
in	O
whom	O
no	O
new	O
lesions	O
developed	O
after	O
subsequent	O
treatment	O
with	O
enalapril	O
.	O

-DOCSTART-	2521

Aminoglutethimide	B-Drug
was	O
discontinued	O
until	O
completion	O
of	O
radiotherapy	O
,	O
and	O
the	O
rash	B-ADE
resolved	O
.	O

-DOCSTART-	751

Early	O
peritoneal	O
dialysis	O
has	O
not	O
previously	O
been	O
reported	O
for	O
lisinopril	B-Drug
induced	O
multiorgan	B-ADE
failure	I-ADE
.	O

-DOCSTART-	1245

Retinoic	B-Drug
acid	I-Drug
may	O
increase	O
the	O
risk	O
of	O
bone	B-ADE
marrow	I-ADE
transplant	I-ADE
nephropathy	I-ADE
.	O

-DOCSTART-	3012

It	O
is	O
suggested	O
therefore	O
that	O
methotrexate	B-Drug
be	O
added	O
to	O
the	O
list	O
of	O
agents	O
capable	O
of	O
inducing	O
diffuse	B-ADE
interstitial	I-ADE
pulmonary	I-ADE
fibrosis	I-ADE
.	O

-DOCSTART-	2299

Rhabdomyolysis	B-ADE
following	O
clarithromycin	B-Drug
monotherapy	O
.	O

-DOCSTART-	3097

Disulfiram	B-ADE
-	I-ADE
like	I-ADE
reactions	I-ADE
with	O
newer	O
cephalosporins	O
:	O
cefmenoxime	B-Drug
.	O

-DOCSTART-	3628

Can	O
magnesium	B-Drug
sulfate	I-Drug
therapy	O
impact	O
lactogenesis	B-ADE
?	O

-DOCSTART-	1279

In	O
this	O
study	O
,	O
we	O
report	O
on	O
three	O
individual	O
patients	O
who	O
received	O
BTX	B-Drug
-	I-Drug
B	I-Drug
and	O
who	O
subsequently	O
developed	O
parasympathetic	B-ADE
dysfunction	I-ADE
of	I-ADE
the	I-ADE
visual	I-ADE
system	I-ADE
after	O
injections	O
of	O
BTX	B-Drug
-	I-Drug
B	I-Drug
at	O
remote	O
sites	O
.	O

-DOCSTART-	3071

Salicylate	B-Drug
hepato	B-ADE
toxicity	I-ADE
in	O
rheumatic	O
fever	O
.	O

-DOCSTART-	546

Polymyositis	B-ADE
is	O
a	O
rare	O
complication	O
of	O
interferon	B-Drug
alpha	I-Drug
treatment	O
as	O
a	O
result	O
of	O
immune	O
-	O
modulating	O
role	O
of	O
the	O
drug	O
itself	O
.	O

-DOCSTART-	1643

We	O
conclude	O
that	O
myocardial	B-ADE
infarction	I-ADE
may	O
develop	O
in	O
patients	O
treated	O
with	O
high	O
-	O
dose	O
glucocorticoids	B-Drug
for	O
Graves	O
'	O
ophthalmopathy	O
,	O
and	O
increased	O
blood	O
pressure	O
may	O
herald	O
this	O
complication	O
.	O

-DOCSTART-	3186

A	O
case	O
history	O
of	O
a	O
15-year	O
-	O
old	O
boy	O
who	O
developed	O
incapacitating	O
tardive	B-ADE
dyskinesia	I-ADE
that	O
resolved	O
during	O
treatment	O
with	O
deanol	B-Drug
is	O
presented	O
.	O

-DOCSTART-	960

DISCUSSION	O
:	O
Colchicine	B-Drug
,	O
the	O
most	O
important	O
drug	O
in	O
treatment	O
of	O
FMF	O
,	O
can	O
cause	O
myopathy	B-ADE
in	O
patients	O
with	O
impaired	O
renal	O
and	O
hepatic	O
function	O
.	O

-DOCSTART-	2170

Leflunomide	B-Drug
-	O
induced	O
toxic	B-ADE
epidermal	I-ADE
necrolysis	I-ADE
in	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	2627

Fluoxetine	B-Drug
-	O
induced	O
akathisia	B-ADE
:	O
clinical	O
and	O
theoretical	O
implications	O
.	O

-DOCSTART-	2272

Cyclosporine	B-Drug
-	O
induced	O
pain	B-ADE
syndrome	I-ADE
in	O
a	O
child	O
undergoing	O
hematopoietic	O
stem	O
cell	O
transplant	O
.	O

-DOCSTART-	3133

One	O
type	O
of	O
SMON	B-ADE
is	O
associated	O
with	O
acrodermatitis	B-ADE
enteropathica	I-ADE
which	O
has	O
a	O
very	O
high	O
frequency	O
of	O
occurrence	O
in	O
association	O
with	O
administration	O
of	O
clioquinol	B-Drug
.	O

-DOCSTART-	1947

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
rheumatoid	O
arthritis	O
treated	O
with	O
low	O
-	O
dose	O
methotrexate	B-Drug
(	O
15	O
mg	O
/	O
week	O
)	O
who	O
developed	O
infection	B-ADE
with	I-ADE
both	I-ADE
M.	I-ADE
tuberculosis	I-ADE
and	I-ADE
M.	I-ADE
chelonae	I-ADE
after	O
the	O
revision	O
of	O
a	O
prosthetic	O
hip	O
.	O

-DOCSTART-	1150

The	O
harlequin	B-ADE
color	I-ADE
change	I-ADE
and	O
association	O
with	O
prostaglandin	B-Drug
E1	I-Drug
.	O

-DOCSTART-	3692

Pemphigus	B-ADE
vulgaris	I-ADE
precipitated	O
by	O
glibenclamide	B-Drug
therapy	O
.	O

-DOCSTART-	4259

Treatment	O
of	O
ELP	B-ADE
in	O
children	O
is	O
generally	O
supportive	O
,	O
with	O
the	O
symptoms	O
and	O
roentgenographic	B-ADE
abnormalities	I-ADE
resolving	O
within	O
months	O
after	O
stopping	O
the	O
use	O
of	O
mineral	B-Drug
oil	I-Drug
.	O

-DOCSTART-	1939

We	O
report	O
(	O
to	O
our	O
knowledge	O
,	O
for	O
the	O
first	O
time	O
in	O
a	O
child	O
)	O
the	O
emergence	O
of	O
psychosis	B-ADE
in	O
a	O
12-year	O
old	O
white	O
girl	O
with	O
an	O
increased	O
efavirenz	B-Drug
concentration	O
and	O
heterozygous	O
gene	O
polymorphism	O
of	O
the	O
CYP2B6-G516	O
T	O
.	O

-DOCSTART-	32

Hypersensitivity	O
to	O
aspirin	B-Drug
can	O
be	O
manifested	O
as	O
acute	O
asthma	O
,	O
urticaria	B-ADE
and/or	O
angioedema	B-ADE
,	O
or	O
a	O
systemic	B-ADE
anaphylactoid	I-ADE
reaction	I-ADE
.	O

-DOCSTART-	1534

Reversible	O
sirolimus	B-Drug
-	O
associated	O
pneumonitis	B-ADE
after	O
heart	O
transplantation	O
.	O

-DOCSTART-	2694

We	O
discuss	O
a	O
variety	O
of	O
bronchopulmonary	O
complications	O
of	O
IBD	B-ADE
and	O
their	O
association	O
with	O
sulfasalazine	B-Drug
.	O

-DOCSTART-	4190

Although	O
praziquantel	B-Drug
administration	O
may	O
have	O
been	O
effective	O
in	O
killing	O
the	O
parasite	O
in	O
both	O
patients	O
,	O
we	O
are	O
concerned	O
about	O
the	O
production	O
of	O
marked	O
inflammation	B-ADE
as	O
a	O
result	O
of	O
treatment	O
.	O

-DOCSTART-	1969

Methotrexate	B-Drug
-	O
induced	O
papular	B-ADE
eruption	I-ADE
following	O
treatment	O
of	O
psoriasis	O
has	O
not	O
been	O
previously	O
reported	O
.	O

-DOCSTART-	2309

Flurbiprofen	B-Drug
-	O
associated	O
acute	B-ADE
tubulointerstitial	I-ADE
nephritis	I-ADE
.	O

-DOCSTART-	165

Acute	B-ADE
erythroid	I-ADE
leukemia	I-ADE
after	O
cyclophosphamide	B-Drug
therapy	O
for	O
multiple	O
myeloma	O
:	O
report	O
of	O
two	O
cases	O
.	O

-DOCSTART-	4096

In	O
this	O
report	O
,	O
one	O
patient	O
who	O
developed	O
gangrene	B-ADE
after	O
bleomycin	B-Drug
and	O
vincristine	B-Drug
/	O
vinblastine	B-Drug
chemotherapy	O
for	O
AIDS	O
-	O
related	O
Kaposi	O
's	O
sarcoma	O
and	O
another	O
HIV	O
-	O
infected	O
patient	O
who	O
exhibited	O
symptoms	O
of	O
severe	B-ADE
Raynaud	I-ADE
's	I-ADE
phenomenon	I-ADE
related	O
to	O
the	O
same	O
regimen	O
are	O
presented	O
.	O

-DOCSTART-	320

Though	O
physicians	O
treating	O
large	O
populations	O
of	O
patients	O
with	O
HIV	O
are	O
well	O
aware	O
of	O
this	O
complication	O
,	O
only	O
one	O
other	O
report	O
of	O
nevirapine	B-Drug
-	O
associated	O
SJS	B-ADE
has	O
been	O
documented	O
in	O
the	O
dermatology	O
literature	O
.	O

-DOCSTART-	2639

We	O
report	O
a	O
case	O
of	O
ibuprofen	B-Drug
-	O
induced	O
meningitis	B-ADE
in	O
an	O
otherwise	O
healthy	O
individual	O
.	O

-DOCSTART-	1378

One	O
patient	O
was	O
an	O
80-year	O
-	O
old	O
woman	O
who	O
was	O
admitted	O
for	O
Staphylococcus	B-ADE
aureus	I-ADE
knee	I-ADE
arthritis	I-ADE
after	O
several	O
intraarticular	O
injections	O
of	O
sodium	B-Drug
hyaluronate	I-Drug
and	O
corticosteroids	B-Drug
.	O

-DOCSTART-	113

The	O
relationship	O
between	O
infliximab	B-Drug
treatment	O
and	O
lymphoma	B-ADE
in	O
Crohn	O
's	O
disease	O
.	O

-DOCSTART-	96

Taxane	B-Drug
-	O
induced	O
glaucoma	B-ADE
.	O

-DOCSTART-	3570

Currently	O
the	O
use	O
of	O
zidovudine	B-Drug
is	O
one	O
of	O
the	O
few	O
specific	O
measures	O
available	O
,	O
and	O
as	O
a	O
potentially	O
teratogenic	B-ADE
and	O
fetotoxic	B-ADE
agent	O
,	O
any	O
decision	O
for	O
its	O
use	O
requires	O
evaluation	O
of	O
the	O
potential	O
for	O
fetal	B-ADE
damage	I-ADE
.	O

-DOCSTART-	2212

Therefore	O
,	O
amantadine	B-Drug
was	O
permanently	O
discontinued	O
and	O
the	O
cornea	B-ADE
cleared	O
again	O
.	O

-DOCSTART-	1833

Intravitreal	O
triamcinolone	B-Drug
may	O
have	O
had	O
an	O
influence	O
on	O
the	O
exacerbation	B-ADE
of	I-ADE
retinochoroiditis	I-ADE
in	O
the	O
posterior	O
pole	O
of	O
the	O
patient	O
.	O

-DOCSTART-	1593

Reactivation	B-ADE
of	I-ADE
cytomegalovirus	I-ADE
probably	O
followed	O
the	O
treatment	O
of	O
Wegener	O
's	O
granulomatosis	O
with	O
corticosteroids	O
and	O
azathioprine	B-Drug
.	O

-DOCSTART-	3228

Intrahepatic	B-ADE
cholestasis	I-ADE
and	O
cutaneous	B-ADE
bullae	I-ADE
associated	O
with	O
glibenclamide	B-Drug
therapy	O
are	O
described	O
in	O
a	O
61-year	O
-	O
old	O
diabetic	O
patient	O
who	O
presented	O
wit	O
hypoglycaemic	O
coma	O
.	O

-DOCSTART-	1397

Baclofen	B-Drug
withdrawal	O
:	O
a	O
cause	O
of	O
prolonged	O
fever	B-ADE
in	O
the	O
intensive	O
care	O
unit	O
.	O

-DOCSTART-	4036

On	O
the	O
next	O
day	O
,	O
after	O
a	O
total	O
dose	O
of	O
only	O
600	O
mg	O
of	O
danazol	B-Drug
,	O
gingival	B-ADE
bleeding	I-ADE
and	O
purpura	B-ADE
occurred	O
.	O

-DOCSTART-	695

Fluorouracil	O
for	O
allergic	B-ADE
reactions	I-ADE
to	O
capecitabine	B-Drug
.	O

-DOCSTART-	2661

Rifampin	B-Drug
-	O
associated	O
thrombocytopenia	B-ADE
secondary	O
to	O
poor	O
compliance	O
.	O

-DOCSTART-	1615

Severe	B-ADE
adenovirus	I-ADE
pneumonia	I-ADE
(	O
AVP	B-ADE
)	O
following	O
infliximab	B-Drug
infusion	O
for	O
the	O
treatment	O
of	O
Crohn	O
's	O
disease	O
.	O

-DOCSTART-	3538

Response	O
of	O
a	O
promethazine	B-Drug
-	O
induced	O
coma	B-ADE
to	O
flumazenil	O
.	O

-DOCSTART-	2235

Multifocal	O
electroretinographic	O
abnormalities	O
in	O
ethambutol	B-Drug
-	O
induced	O
visual	B-ADE
loss	I-ADE
.	O

-DOCSTART-	933

Generalised	B-ADE
cutaneous	I-ADE
rash	I-ADE
associated	O
with	O
ganciclovir	B-Drug
therapy	O
has	O
rarely	O
been	O
reported	O
in	O
literature	O
.	O

-DOCSTART-	3355

Inappropriate	B-ADE
antidiuretic	I-ADE
hormone	I-ADE
secretion	I-ADE
after	O
high	O
dose	O
vinblastine	B-Drug
.	O

-DOCSTART-	3206

The	O
incidence	O
of	O
oral	O
-	O
verapamil	B-Drug
-	O
induced	O
hypotension	B-ADE
in	O
the	O
presence	O
of	O
concomitant	O
beta	O
-	O
adrenergic	O
blockade	O
by	O
the	O
oral	O
route	O
is	O
quite	O
rare	O
.	O

-DOCSTART-	1578

Grade	B-ADE
3	I-ADE
hepatotoxicity	I-ADE
(	O
AST	O
and	O
ALT	O
>	O
5	O
to	O
20	O
upper	O
limit	O
normal	O
)	O
or	O
higher	O
has	O
been	O
observed	O
in	O
as	O
many	O
as	O
1.4	O
%	O
of	O
MS	O
patients	O
on	O
IFN	B-Drug
beta	I-Drug
.	O

-DOCSTART-	693

Capecitabine	B-Drug
was	O
discontinued	O
and	O
the	O
allergic	B-ADE
reactions	I-ADE
resolved	O
after	O
the	O
woman	O
took	O
diphenhydramine	O
for	O
1	O
week	O
.	O

-DOCSTART-	2804

A	O
patient	O
is	O
presented	O
with	O
typical	O
hyperthyroidism	B-ADE
,	O
who	O
developed	O
a	O
severe	B-ADE
proximal	I-ADE
muscle	I-ADE
weakness	I-ADE
and	O
a	O
raised	B-ADE
creatine	I-ADE
phosphokinase	I-ADE
after	O
treatment	O
for	O
hyperthyroidism	O
with	O
propylthiouracil	B-Drug
(	O
100	O
mg	O
orally	O
,	O
three	O
times	O
a	O
day	O
)	O
.	O

-DOCSTART-	3489

Multifocal	B-ADE
inflammatory	I-ADE
leukoencephalopathy	I-ADE
associated	O
with	O
levamisole	B-Drug
therapy	O
.	O

-DOCSTART-	1094

The	O
autopsy	O
findings	O
and	O
a	O
detailed	O
medical	O
history	O
supported	O
the	O
conclusion	O
that	O
clozapine	B-Drug
-	O
induced	O
hypersensitivity	B-ADE
myocarditis	I-ADE
was	O
the	O
most	O
likely	O
cause	O
of	O
death	O
.	O

-DOCSTART-	3833

Acetazolamide	B-Drug
may	O
have	O
accelerated	O
the	O
development	O
of	O
osteomalacia	B-ADE
by	O
several	O
mechanisms	O
,	O
including	O
increased	O
renal	O
calcium	O
excretion	O
.	O

-DOCSTART-	950

We	O
present	O
a	O
case	O
of	O
a	O
20-year	O
-	O
old	O
woman	O
who	O
ingested	O
900	O
mg	O
of	O
glyburide	B-Drug
causing	O
refractory	O
hypoglycemia	B-ADE
resistant	O
to	O
treatment	O
with	O
intravenous	O
dextrose	O
,	O
glucagon	O
,	O
and	O
diazoxide	O
.	O

-DOCSTART-	759

Clozapine	B-Drug
-	O
induced	O
akathisia	B-ADE
in	O
children	O
with	O
schizophrenia	O
.	O

-DOCSTART-	1893

Because	O
etoposide	B-Drug
-	O
induced	O
pulmonary	B-ADE
toxicity	I-ADE
is	O
an	O
uncommon	O
but	O
serious	O
adverse	O
event	O
,	O
clinicians	O
must	O
be	O
vigilant	O
about	O
the	O
possibility	O
of	O
it	O
,	O
so	O
that	O
the	O
optimal	O
treatment	O
can	O
start	O
as	O
soon	O
as	O
possible	O
.	O

-DOCSTART-	2439

Interferon	B-Drug
-	O
induced	O
psychosis	B-ADE
as	O
a	O
"	O
psychiatric	O
contraindication	O
"	O
to	O
hepatitis	O
C	O
treatment	O
:	O
a	O
review	O
and	O
case	O
-	O
based	O
discussion	O
.	O

-DOCSTART-	521

This	O
is	O
the	O
first	O
reported	O
case	O
of	O
hepatolithiasis	B-ADE
during	O
octreotide	B-Drug
therapy	O
.	O

-DOCSTART-	3891

However	O
,	O
given	O
the	O
clinically	O
significant	O
result	O
to	O
the	O
interaction	O
between	O
tolazoline	B-Drug
and	O
cimetidine	B-Drug
we	O
report	O
,	O
the	O
use	O
of	O
cimetidine	B-Drug
in	O
tolazoline	B-Drug
induced	O
upper	B-ADE
gastrointestinal	I-ADE
hemorrhage	I-ADE
should	O
deserve	O
more	O
attention	O
.	O

-DOCSTART-	1242

While	O
the	O
introduction	O
of	O
carmustine	B-Drug
wafers	O
(	O
Gliadel	B-Drug
wafers	O
)	O
into	O
the	O
tumor	O
resection	O
cavity	O
has	O
been	O
shown	O
to	O
be	O
a	O
beneficial	O
therapy	O
for	O
malignant	O
glioma	O
,	O
it	O
is	O
recognized	O
that	O
clinically	O
significant	O
cerebral	B-ADE
edema	I-ADE
is	O
a	O
potential	O
adverse	O
effect	O
.	O

-DOCSTART-	920

Seizure	B-ADE
with	O
hyponatremia	B-ADE
in	O
a	O
child	O
prescribed	O
desmopressin	B-Drug
for	O
nocturnal	O
enuresis	O
.	O

-DOCSTART-	2462

The	O
current	O
report	O
describes	O
a	O
man	O
who	O
was	O
prescribed	O
zonisamide	B-Drug
for	O
epilepsy	O
and	O
subsequently	O
developed	O
widespread	O
skin	B-ADE
rash	I-ADE
,	O
acute	B-ADE
kidney	I-ADE
injury	I-ADE
,	O
high	B-ADE
-	I-ADE
grade	I-ADE
fever	I-ADE
,	O
eosinophilia	B-ADE
,	O
liver	B-ADE
dysfunction	I-ADE
,	O
lymphadenopathy	B-ADE
and	O
an	B-ADE
increase	I-ADE
in	I-ADE
antihuman	I-ADE
herpesvirus-6	I-ADE
immunoglobulin	I-ADE
G	I-ADE
titer	I-ADE
.	O

-DOCSTART-	2846

Rebound	O
hyperglycemia	B-ADE
following	O
overdosing	O
of	O
insulin	B-Drug
in	O
cats	O
with	O
diabetes	O
mellitus	O
.	O

-DOCSTART-	3965

Pneumonitis	B-ADE
is	O
emerging	O
as	O
one	O
of	O
the	O
most	O
unpredictable	O
and	O
potentially	O
serious	O
,	O
adverse	O
effects	O
of	O
treatment	O
with	O
MTX	B-Drug
.	O

-DOCSTART-	3412

Acute	B-ADE
renal	I-ADE
failure	I-ADE
in	O
a	O
child	O
associated	O
with	O
acyclovir	B-Drug
.	O

-DOCSTART-	1499

Moreover	O
,	O
treatment	O
with	O
immunosuppressive	O
drugs	O
such	O
as	O
cyclosporine	B-Drug
,	O
cisplatin	B-Drug
,	O
tacrolimus	B-Drug
,	O
and	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
can	O
induce	O
a	O
condition	O
resembling	O
RPLS	B-ADE
.	O

-DOCSTART-	4091

Prothipendylhydrochloride	B-Drug
-	O
induced	O
priapism	B-ADE
:	O
case	O
report	O
.	O

-DOCSTART-	901

Although	O
an	O
association	O
between	O
exposure	O
to	O
bleomycin	B-Drug
and	O
the	O
development	O
of	O
scleroderma	B-ADE
has	O
been	O
suspected	O
,	O
few	O
cases	O
are	O
reported	O
.	O

-DOCSTART-	3333

Abnormalities	B-ADE
of	I-ADE
the	I-ADE
pupil	I-ADE
and	O
visual	O
-	O
evoked	O
potential	O
in	O
quinine	B-Drug
amblyopia	B-ADE
.	O

-DOCSTART-	1571

Infections	B-ADE
are	O
a	O
major	O
adverse	O
effect	O
during	O
the	O
treatment	O
with	O
anti	B-Drug
-	I-Drug
TNF	I-Drug
-	I-Drug
alpha	I-Drug
.	O

-DOCSTART-	3983

CASE	O
SUMMARIES	O
:	O
In	O
each	O
case	O
,	O
the	O
patients	O
were	O
treated	O
over	O
5	O
years	O
with	O
lovastatin	B-Drug
and	O
developed	O
rhabdomyolysis	B-ADE
that	O
coincided	O
with	O
the	O
completion	O
of	O
a	O
prescribed	O
regimen	O
of	O
a	O
newer	O
macrolide	O
antibiotic	O
.	O

-DOCSTART-	454

The	O
cause	O
of	O
death	O
was	O
determined	O
to	O
be	O
acute	B-ADE
intoxication	I-ADE
by	O
olanzapine	B-Drug
,	O
and	O
the	O
manner	O
of	O
death	O
was	O
accidental	O
.	O

-DOCSTART-	467

Vocal	B-ADE
cord	I-ADE
paralysis	I-ADE
as	O
a	O
consequence	O
of	O
peritonsillar	O
infiltration	O
with	O
bupivacaine	B-Drug
.	O

-DOCSTART-	3377

We	O
recommended	O
periodic	O
examination	O
of	O
the	O
serum	O
proteins	O
in	O
patients	O
receiving	O
diphenylhydantoin	B-Drug
in	O
order	O
to	O
detect	O
development	O
of	O
monoclonal	B-ADE
gammopathy	I-ADE
.	O

-DOCSTART-	1478

Gemcitabine	B-Drug
-	O
related	O
radiation	B-ADE
recall	I-ADE
in	O
a	O
patient	O
with	O
pancreatic	O
cancer	O
.	O

-DOCSTART-	586

Granulocytopenia	B-ADE
and	O
agranulocytosis	B-ADE
are	O
considered	O
among	O
the	O
most	O
dangerous	O
adverse	O
effects	O
of	O
clozapine	B-Drug
.	O

-DOCSTART-	1963

The	O
incidence	O
of	O
5-fluorouracil	B-Drug
(	O
5-FU	B-Drug
)	O
-	O
related	O
cardiotoxicity	B-ADE
seems	O
to	O
be	O
dosage	O
and	O
schedule	O
dependent	O
.	O

-DOCSTART-	1305

CASE	O
:	O
A	O
malignant	B-ADE
mixed	I-ADE
mesodermal	I-ADE
tumor	I-ADE
was	O
diagnosed	O
in	O
a	O
64-year	O
-	O
old	O
woman	O
with	O
a	O
bicornuate	O
uterus	O
while	O
she	O
was	O
taking	O
raloxifene	B-Drug
for	O
osteoporosis	O
prevention	O
.	O

-DOCSTART-	1259

Propylthiouracil	B-Drug
-	O
induced	O
sensorineural	B-ADE
hearing	I-ADE
loss	I-ADE
associated	O
with	O
antineutrophil	B-ADE
cytoplasmic	I-ADE
antibodies	I-ADE
.	O

-DOCSTART-	3046

A	O
15-kg	B-ADE
weight	I-ADE
gain	I-ADE
developed	O
in	O
a	O
patient	O
during	O
the	O
third	O
week	O
of	O
ibuprofen	B-Drug
therapy	O
.	O

-DOCSTART-	2198

We	O
report	O
the	O
first	O
case	O
of	O
a	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(	O
HIV-1	O
)	O
-	O
infected	O
individual	O
receiving	O
combination	O
antiretroviral	O
therapy	O
,	O
which	O
included	O
ritonavir	O
,	O
who	O
developed	O
Cushing	B-ADE
syndrome	I-ADE
with	O
profound	O
complications	O
after	O
epidural	O
triamcinolone	B-Drug
injections	O
.	O

-DOCSTART-	3341

Hepatotoxicity	B-ADE
associated	O
with	O
use	O
of	O
D	B-Drug
-	I-Drug
penicillamine	I-Drug
in	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	3520

In	O
our	O
patient	O
,	O
DIAN	B-ADE
possibly	O
was	O
related	O
to	O
cefuroxime	B-Drug
,	O
but	O
the	O
patient	O
did	O
not	O
experience	O
associated	O
allergic	O
symptoms	O
.	O

-DOCSTART-	1020

Warfarin	B-Drug
-	O
associated	O
thoracic	B-ADE
aortic	I-ADE
dissection	I-ADE
in	O
an	O
elderly	O
woman	O
.	O

-DOCSTART-	3439

We	O
describe	O
two	O
cases	O
that	O
illustrate	O
the	O
use	O
of	O
lithium	B-Drug
in	O
the	O
treatment	O
of	O
veterans	O
with	O
PTSD	O
who	O
complained	O
of	O
serious	O
problems	O
with	O
irritability	B-ADE
or	O
angry	B-ADE
outbursts	I-ADE
.	O

-DOCSTART-	1846

BACKGROUND	O
:	O
Headaches	B-ADE
have	O
been	O
reported	O
as	O
a	O
potential	O
side	O
effect	O
of	O
capecitabine	B-Drug
therapy	O
.	O

-DOCSTART-	3455

Furosemide	B-Drug
-	O
associated	O
fever	B-ADE
.	O

-DOCSTART-	3973

CASES	O
:	O
Two	O
postmenopausal	O
women	O
treated	O
with	O
tamoxifen	B-Drug
and	O
progestational	O
agents	O
for	O
breast	O
carcinoma	O
developed	O
uterine	B-ADE
enlargement	I-ADE
and	O
intermittent	B-ADE
spotting	I-ADE
.	O

-DOCSTART-	2308

Withdrawal	O
of	O
Depakote	B-Drug
resulted	O
in	O
resolution	O
of	O
the	O
effusion	B-ADE
.	O

-DOCSTART-	2346

A	O
case	O
of	O
acute	B-ADE
respiratory	I-ADE
failure	I-ADE
due	O
to	O
diaphragmatic	O
weakness	O
following	O
adalimumab	B-Drug
therapy	O
for	O
psoriasis	O
is	O
described	O
.	O

-DOCSTART-	442

Indinavir	B-Drug
-	O
associated	O
nephrolithiasis	B-ADE
and	O
chronic	O
interstitial	B-ADE
nephritis	I-ADE
were	O
the	O
only	O
possible	O
causes	O
identified	O
in	O
this	O
patient	O
.	O

-DOCSTART-	3582

Concurrent	B-ADE
acute	I-ADE
megaloblastic	I-ADE
anaemia	I-ADE
and	O
pneumonitis	B-ADE
:	O
a	O
severe	O
side	O
-	O
effect	O
of	O
low	O
-	O
dose	O
methotrexate	B-Drug
therapy	O
during	O
rheumatoid	O
arthritis	O
.	O

-DOCSTART-	3806

Nephrogenic	B-ADE
diabetes	I-ADE
insipidus	I-ADE
(	O
NDI	B-ADE
)	O
is	O
a	O
well	O
-	O
documented	O
complication	O
of	O
lithium	B-Drug
use	O
.	O

-DOCSTART-	494

Agranulocytosis	B-ADE
and	O
granulocytopenia	B-ADE
associated	O
with	O
quetiapine	B-Drug
.	O

-DOCSTART-	1418

Acute	B-ADE
myocardial	I-ADE
ischemia	I-ADE
following	O
accidental	O
intravenous	O
administration	O
of	O
epinephrine	B-Drug
in	O
high	O
concentration	O
.	O

-DOCSTART-	3754

Based	O
on	O
our	O
findings	O
,	O
it	O
is	O
thus	O
concluded	O
that	O
cisplatin	B-Drug
may	O
cause	O
C.	B-ADE
difficile	I-ADE
colitis	I-ADE
.	O

-DOCSTART-	2336

Transient	B-ADE
cardiac	I-ADE
arrhythmias	I-ADE
related	O
to	O
lopinavir	B-Drug
/	O
ritonavir	B-Drug
in	O
two	O
patients	O
with	O
HIV	O
infection	O
.	O

-DOCSTART-	2794

The	O
observations	O
suggest	O
that	O
testicular	B-ADE
swelling	I-ADE
and	O
pain	B-ADE
are	O
side	O
effects	O
of	O
desipramine	B-Drug
.	O

-DOCSTART-	925

In	O
a	O
single	O
practice	O
during	O
the	O
21	O
years	O
1971	O
-	O
1991	O
,	O
the	O
incidence	O
of	O
gestational	B-ADE
diabetes	I-ADE
in	O
pregnancies	O
in	O
which	O
norethisterone	B-Drug
was	O
prescribed	O
was	O
32.4	O
%	O
(	O
22	O
of	O
69	O
)	O
in	O
comparison	O
with	O
7.1	O
%	O
in	O
pregnancies	O
in	O
which	O
the	O
women	O
did	O
not	O
take	O
norethisterone	O
(	O
137	O
of	O
1,684	O
)	O
(	O
p	O
<	O
0.001	O
)	O
.	O

-DOCSTART-	1316

The	O
purpose	O
of	O
this	O
review	O
is	O
to	O
increase	O
awareness	O
among	O
physicians	O
and	O
other	O
health	O
care	O
professionals	O
that	O
DIC	B-ADE
may	O
be	O
a	O
rare	O
but	O
potentially	O
severe	O
complication	O
of	O
anti	B-Drug
-	I-Drug
D	I-Drug
IGIV	I-Drug
treatment	O
.	O

-DOCSTART-	3446

In	O
patients	O
with	O
a	O
known	O
access	O
to	O
INH	O
,	O
seizures	B-ADE
should	O
be	O
considered	O
to	O
be	O
caused	O
by	O
INH	B-Drug
toxicity	O
unless	O
proved	O
otherwise	O
.	O

-DOCSTART-	68

Hepato	B-ADE
-	I-ADE
biliary	I-ADE
abnormalities	I-ADE
secondary	O
to	O
ceftriaxone	B-Drug
use	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3900

Atenolol	B-Drug
induced	O
memory	B-ADE
impairment	I-ADE
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	729

Visual	B-ADE
hallucinations	I-ADE
associated	O
with	O
zonisamide	B-Drug
.	O

-DOCSTART-	3850

Metabolic	B-ADE
acidosis	I-ADE
induced	O
by	O
cetrimide	B-Drug
-	O
chlorhexidine	B-Drug
solution	O
in	O
hydatid	O
cyst	O
surgery	O
.	O

-DOCSTART-	3609

Meperidine	B-Drug
-	O
associated	O
central	B-ADE
nervous	I-ADE
system	I-ADE
(	I-ADE
CNS	I-ADE
)	I-ADE
excitatory	I-ADE
toxicities	I-ADE
are	O
believed	O
to	O
be	O
caused	O
by	O
accumulation	B-ADE
of	I-ADE
the	I-ADE
active	I-ADE
metabolite	I-ADE
normeperidine	I-ADE
.	O

-DOCSTART-	4174

1	O
.	O
Changes	B-ADE
in	I-ADE
the	I-ADE
plasma	I-ADE
cortisol	I-ADE
level	I-ADE
were	O
reported	O
in	O
a	O
male	O
patient	O
with	O
panic	O
disorder	O
during	O
the	O
period	O
of	O
low	O
-	O
dose	O
alprazolam	B-Drug
treatment	O
(	O
mean	O
0.62	O
+	O
/-	O
0.15	O
mg	O
/	O
day	O
)	O
compared	O
with	O
during	O
the	O
period	O
of	O
high	O
-	O
dose	O
period	O
(	O
mean	O
1.08	O
+	O
/-	O
0.28	O
mg	O
/	O
day	O
)	O
.	O

-DOCSTART-	2940

Administration	O
of	O
intravenous	O
nitroglycerin	B-Drug
in	O
a	O
patient	O
with	O
idiopathic	O
pulmonary	O
hypertension	O
resulted	O
in	O
an	O
increase	B-ADE
in	I-ADE
pulmonary	I-ADE
artery	I-ADE
pressure	I-ADE
associated	O
with	O
a	O
decrease	B-ADE
in	I-ADE
blood	I-ADE
flow	I-ADE
that	O
is	O
best	O
explained	O
by	O
an	O
increase	B-ADE
in	I-ADE
pulmonary	I-ADE
vascular	I-ADE
resistance	I-ADE
.	O

-DOCSTART-	1561

Dipyrone	B-Drug
-	O
induced	O
granulocytopenia	B-ADE
:	O
a	O
case	O
for	O
awareness	O
.	O

-DOCSTART-	3225

Gold	B-Drug
nephropathy	B-ADE
.	O

-DOCSTART-	587

The	O
female	O
patient	O
received	O
clozapine	B-Drug
in	O
a	O
daily	O
dose	O
of	O
400	O
mg	O
,	O
which	O
induced	O
agranulocytosis	B-ADE
after	O
2	O
months	O
.	O

-DOCSTART-	2075

The	O
second	O
patient	O
exhibited	O
sudden	O
PLMS	B-ADE
following	O
olanzapine	B-Drug
injection	O
.	O

-DOCSTART-	2761

Bone	B-ADE
formation	I-ADE
induced	O
in	O
an	O
infant	O
by	O
systemic	O
prostaglandin	B-Drug
-	I-Drug
E2	I-Drug
administration	O
.	O

-DOCSTART-	1651

We	O
describe	O
a	O
case	O
of	O
a	O
man	O
treated	O
with	O
an	O
EGFR	O
-	O
inhibitor	O
(	O
erlotinib	B-Drug
)	O
for	O
a	O
cell	O
lung	O
cancer	O
who	O
developed	O
skin	B-ADE
manifestations	I-ADE
localized	O
in	O
an	O
uncommon	O
area	O
and	O
with	O
an	O
atypical	O
evolution	O
.	O

-DOCSTART-	2874

Pulmonary	B-ADE
edema	I-ADE
occurred	O
24	O
hours	O
after	O
intravenous	O
ritodrine	B-Drug
therapy	O
and	O
10	O
hours	O
after	O
subcutaneous	O
terbutaline	B-Drug
therapy	O
.	O

-DOCSTART-	3622

Neurologic	B-ADE
degeneration	I-ADE
associated	O
with	O
nitrous	B-Drug
oxide	I-Drug
anesthesia	O
in	O
patients	O
with	O
vitamin	O
B12	O
deficiency	O
.	O

-DOCSTART-	1635

PURPOSE	O
:	O
Topiramate	B-Drug
-	O
induced	O
angle	B-ADE
-	I-ADE
closure	I-ADE
glaucoma	I-ADE
(	O
TiACG	O
)	O
is	O
believed	O
to	O
be	O
related	O
to	O
its	O
sulfonamide	O
moiety	O
.	O

-DOCSTART-	2450

Introduction	O
of	O
etanercept	B-Drug
was	O
also	O
clinically	O
effective	O
but	O
followed	O
by	O
development	O
of	O
severe	B-ADE
heart	I-ADE
failure	I-ADE
.	O

-DOCSTART-	2559

After	O
discontinuation	O
of	O
danazol	B-Drug
the	O
diabetes	B-ADE
completely	O
resolved	O
.	O

-DOCSTART-	969

Infliximab	B-Drug
-	O
induced	O
lupus	B-ADE
in	O
Crohn	O
's	O
disease	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	3925

BACKGROUND	O
:	O
Colchicine	B-Drug
has	O
a	O
known	O
adverse	B-ADE
effect	I-ADE
on	I-ADE
wound	I-ADE
healing	I-ADE
through	O
its	O
inhibitory	O
effect	O
on	O
tubulin	O
-	O
dependent	O
cell	O
functions	O
and	O
through	O
collagenase	B-ADE
activation	I-ADE
.	O

-DOCSTART-	1016

Methotrexate	B-Drug
pneumonitis	B-ADE
in	O
nonsurgical	O
treatment	O
of	O
ectopic	O
pregnancy	O
.	O

-DOCSTART-	1362

Pseudoephedrine	B-Drug
-	O
induced	O
hemorrhage	B-ADE
associated	O
with	O
a	O
cerebral	B-ADE
vascular	I-ADE
malformation	I-ADE
.	O

-DOCSTART-	77

The	O
association	O
of	O
venlafaxine	B-Drug
treatment	O
with	O
ischaemic	B-ADE
events	I-ADE
could	O
be	O
explained	O
by	O
its	O
unique	O
pharmacological	O
and	O
haemodynamic	O
properties	O
.	O

-DOCSTART-	2832

During	O
the	O
first	O
treatment	O
,	O
dysarthria	B-ADE
and	O
ataxia	B-ADE
were	O
seen	O
after	O
completion	O
of	O
the	O
patient	O
's	O
eighth	O
and	O
final	O
dose	O
of	O
HDARAC	B-Drug
.	O

-DOCSTART-	977

We	O
experienced	O
a	O
male	O
patient	O
with	O
psoriasis	O
and	O
hypertension	O
whose	O
conditions	O
were	O
treated	O
with	O
tacalcitol	B-Drug
ointment	O
and	O
thiazide	B-Drug
,	O
respectively	O
,	O
resulting	O
in	O
hypercalciuria	B-ADE
and	O
hypercalcemia	B-ADE
.	O

-DOCSTART-	259

Ritonavir	B-Drug
acted	O
as	O
a	O
CYP3A4	O
inhibitor	O
,	O
diminishing	B-ADE
carbamazepine	I-ADE
metabolism	I-ADE
and	O
provoking	O
an	O
increase	B-ADE
in	I-ADE
serum	I-ADE
levels	I-ADE
and	O
clinical	B-ADE
toxicity	I-ADE
.	O

-DOCSTART-	1831

Physicians	O
should	O
be	O
cognizant	O
of	O
this	O
potential	O
complication	O
in	O
patients	O
receiving	O
thalidomide	B-Drug
or	O
thalidomide	O
-	O
like	O
drugs	O
who	O
present	O
with	O
fever	B-ADE
and	O
pulmonary	B-ADE
infiltrates	I-ADE
and	O
fail	O
to	O
improve	O
despite	O
treatment	O
with	O
broad	O
-	O
spectrum	O
antibiotics	O
.	O

-DOCSTART-	1236

Thalidomide	B-Drug
neuropathy	B-ADE
in	O
childhood	O
.	O

-DOCSTART-	3098

This	O
is	O
the	O
first	O
report	O
of	O
a	O
disulfiram	B-ADE
-	I-ADE
like	I-ADE
reaction	I-ADE
with	O
cefmenoxime	B-Drug
.	O

-DOCSTART-	1601

The	O
following	O
is	O
a	O
case	O
report	O
analysis	O
intended	O
to	O
draw	O
attention	O
to	O
the	O
need	O
for	O
better	O
care	O
coordination	O
by	O
describing	O
the	O
observed	O
relationship	O
of	O
olanzapine	B-Drug
to	O
metabolic	O
changes	O
manifested	O
as	O
uncontrolled	B-ADE
diabetes	I-ADE
mellitus	I-ADE
and	O
weight	B-ADE
gain	I-ADE
.	O

-DOCSTART-	2718

Ethambutol	B-Drug
is	O
frequently	O
used	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
,	O
and	O
,	O
although	O
optic	B-ADE
neuropathies	I-ADE
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
ethambutol	O
,	O
this	O
adverse	O
side	O
effect	O
has	O
been	O
considered	O
to	O
be	O
rare	O
and	O
generally	O
reversible	O
with	O
discontinuation	O
of	O
the	O
medication	O
.	O

-DOCSTART-	1955

Amiodarone	B-Drug
is	O
well	O
recognized	O
as	O
an	O
anti	O
-	O
arrhythmic	O
drug	O
containing	O
a	O
high	O
dose	O
of	O
iodine	O
with	O
considerable	O
potential	O
to	O
cause	O
thyroid	B-ADE
dysfunction	I-ADE
.	O

-DOCSTART-	1098

Our	O
patient	O
was	O
a	O
72-year	O
-	O
old	O
man	O
with	O
advanced	O
Parkinson	O
's	O
disease	O
(	O
PD	O
)	O
who	O
received	O
levodopa	B-Drug
and	O
anti	O
-	O
cholinergic	O
drugs	O
and	O
whose	O
head	O
had	O
become	O
almost	O
completely	B-ADE
bald	I-ADE
.	O

-DOCSTART-	4201

Syncope	B-ADE
in	O
a	O
65-year	O
-	O
old	O
woman	O
after	O
nitrate	B-Drug
ingestion	O
.	O

-DOCSTART-	30

Pravastatin	B-Drug
is	O
associated	O
with	O
myotonia	B-ADE
in	O
animals	O
.	O

-DOCSTART-	2233

Although	O
his	O
renal	O
function	O
recovered	O
completely	O
with	O
high	O
-	O
dose	O
leucovorin	O
,	O
hemodialysis	O
,	O
charcoal	O
hemoperfusion	O
,	O
and	O
carboxypeptidase	O
G2	O
,	O
we	O
present	O
this	O
case	O
to	O
emphasize	O
that	O
signs	O
of	O
renal	B-ADE
toxicity	I-ADE
may	O
be	O
present	O
as	O
early	O
as	O
2	O
hours	O
after	O
the	O
completion	O
of	O
a	O
4-hour	O
MTX	B-Drug
infusion	O
,	O
and	O
to	O
suggest	O
that	O
monitoring	O
for	O
MTX	O
toxicity	O
should	O
perhaps	O
begin	O
within	O
a	O
few	O
hours	O
after	O
the	O
completion	O
of	O
4-hour	O
MTX	O
infusion	O
.	O

-DOCSTART-	1237

Thalidomide	B-Drug
neuropathy	B-ADE
is	O
often	O
associated	O
with	O
proximal	B-ADE
weakness	I-ADE
and	O
may	O
progress	O
even	O
after	O
discontinuation	O
of	O
treatment	O
,	O
in	O
the	O
phenomenon	O
of	O
'	O
coasting	O
'	O
.	O

-DOCSTART-	3067

Chlorambucil	B-Drug
-	O
induced	O
chromosome	B-ADE
damage	I-ADE
to	O
human	O
lymphocytes	O
is	O
dose	O
-	O
dependent	O
and	O
cumulative	O
.	O

-DOCSTART-	2680

The	O
authors	O
describe	O
a	O
patient	O
with	O
hemiparesis	O
who	O
developed	O
the	O
syndrome	O
of	O
irreversible	O
lithium	B-Drug
-	O
effectuated	O
neurotoxicity	B-ADE
(	O
SILENT	O
)	O
while	O
being	O
treated	O
with	O
lithium	O
for	O
a	O
manic	O
episode	O
.	O

-DOCSTART-	3274

Hepatitis	B-ADE
following	O
cimetidine	B-Drug
administration	O
.	O

-DOCSTART-	2771

A	O
case	O
report	O
of	O
the	O
hypersensitivity	B-ADE
syndrome	I-ADE
occurring	O
in	O
a	O
patient	O
being	O
treated	O
with	O
dapsone	B-Drug
for	O
a	O
brown	O
recluse	O
spider	O
bite	O
is	O
presented	O
.	O

-DOCSTART-	60

She	O
continued	O
to	O
receive	O
regular	O
insulin	B-Drug
4	O
times	O
per	O
day	O
over	O
the	O
following	O
3	O
years	O
with	O
only	O
occasional	O
hives	B-ADE
.	O

-DOCSTART-	3339

Niflumic	B-Drug
acid	I-Drug
-	O
induced	O
skeletal	B-ADE
fluorosis	I-ADE
:	O
iatrogenic	O
disease	O
or	O
therapeutic	O
perspective	O
for	O
osteoporosis	O
?	O

-DOCSTART-	2700

Physicians	O
who	O
use	O
sulfasalazine	O
to	O
treat	O
patients	O
with	O
inflammatory	O
bowel	O
disease	O
should	O
be	O
aware	O
of	O
the	O
signs	O
of	O
sulfasalazine	B-Drug
-	O
induced	O
lupus	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	1948

DIAGNOSIS	O
:	O
Sustained	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
possibly	O
owing	O
to	O
thalidomide	B-Drug
treatment	O
.	O

-DOCSTART-	3923

Mesalamine	B-Drug
may	O
cause	O
hypersensitivity	B-ADE
pneumonitis	I-ADE
in	O
patients	O
with	O
Crohn	O
's	O
disease	O
.	O

-DOCSTART-	2175

After	O
treatment	O
with	O
a	O
beta	O
-	O
sympathomimetic	O
drug	O
(	O
Partusisten	B-Drug
)	O
one	O
fetus	O
developed	O
supraventricular	B-ADE
tachycardia	I-ADE
.	O

-DOCSTART-	2729

The	O
pharmacology	O
and	O
toxicology	O
of	O
chloral	B-Drug
hydrate	I-Drug
are	O
discussed	O
with	O
particular	O
reference	O
to	O
the	O
cardiac	B-ADE
arrhythmias	I-ADE
that	O
are	O
seen	O
with	O
overdosage	O
.	O

-DOCSTART-	3328

Propranolol	B-Drug
:	O
an	O
unrecognized	O
cause	O
of	O
central	B-ADE
nervous	I-ADE
system	I-ADE
dysfunction	I-ADE
in	O
patients	O
undergoing	O
cardiopulmonary	O
bypass	O
.	O

-DOCSTART-	2986

Chlorambucil	B-Drug
central	B-ADE
nervous	I-ADE
toxicity	I-ADE
:	O
a	O
significant	O
side	O
effect	O
of	O
chlorambucil	O
therapy	O
in	O
childhood	O
nephrotic	O
syndrome	O
.	O

-DOCSTART-	3878

She	O
had	O
just	O
finished	O
a	O
3-week	O
course	O
of	O
intravenous	O
tobramycin	B-Drug
for	O
bronchiectasis	O
and	O
had	O
an	O
elevated	O
serum	O
tobramycin	O
trough	O
level	O
1	O
week	O
before	O
the	O
onset	O
of	O
tetany	B-ADE
.	O

-DOCSTART-	1744

However	O
,	O
cyclosporine	B-Drug
dependency	O
is	O
associated	O
with	O
the	O
risk	O
of	O
nephrotoxicity	B-ADE
.	O

-DOCSTART-	3025

This	O
article	O
describes	O
two	O
cases	O
of	O
aplastic	B-ADE
anemia	I-ADE
,	O
at	O
least	O
one	O
of	O
which	O
was	O
almost	O
certainly	O
induced	O
by	O
the	O
use	O
of	O
methazolamide	B-Drug
,	O
and	O
one	O
case	O
of	O
agranulocytosis	B-ADE
related	O
to	O
the	O
use	O
of	O
methazolamide	B-Drug
.	O

-DOCSTART-	3387

Bone	B-ADE
marrow	I-ADE
aplasia	I-ADE
and	O
severe	B-ADE
skin	I-ADE
rash	I-ADE
after	O
a	O
single	O
low	O
dose	O
of	O
methotrexate	B-Drug
.	O

-DOCSTART-	229

The	O
polycystic	B-ADE
changes	I-ADE
disappeared	O
from	O
the	O
ovaries	O
in	O
2	O
of	O
the	O
women	O
after	O
valproate	B-Drug
therapy	O
was	O
discontinued	O
,	O
and	O
the	O
2	O
women	O
who	O
had	O
gained	B-ADE
weight	I-ADE
and	O
developed	O
amenorrhea	B-ADE
while	O
being	O
treated	O
with	O
valproate	B-Drug
lost	O
weight	O
and	O
resumed	O
menstruating	O
after	O
the	O
change	O
in	O
medication	O
.	O

-DOCSTART-	3655

Hepatotoxic	B-ADE
effects	I-ADE
in	O
a	O
child	O
receiving	O
valproate	B-Drug
and	O
carnitine	B-Drug
.	O

-DOCSTART-	916

We	O
consider	O
asterixis	B-ADE
to	O
be	O
an	O
easily	O
overlooked	O
sign	O
of	O
neurotoxicity	B-ADE
,	O
which	O
may	O
occur	O
even	O
at	O
low	O
or	O
moderate	O
dosage	O
levels	O
,	O
if	O
certain	O
drugs	O
as	O
lithium	B-Drug
or	O
clozapine	B-Drug
are	O
used	O
in	O
combination	O
with	O
CBZ	B-Drug
.	O

-DOCSTART-	2618

Several	O
possible	O
explanations	O
of	O
the	O
mechanism	O
of	O
renal	B-ADE
failure	I-ADE
associated	O
with	O
the	O
use	O
of	O
dextran-40	B-Drug
are	O
discussed	O
.	O

-DOCSTART-	2739

Isoniazid	B-Drug
and	O
ethambutol	B-Drug
as	O
a	O
cause	O
of	O
optic	B-ADE
neuropathy	I-ADE
.	O

-DOCSTART-	149

Gliclazide	B-Drug
-	O
induced	O
acute	B-ADE
hepatitis	I-ADE
.	O

-DOCSTART-	1444

Capecitabine	B-Drug
-	O
induced	O
multifocal	B-ADE
leukoencephalopathy	I-ADE
:	O
a	O
report	O
of	O
five	O
cases	O
.	O

-DOCSTART-	890

Hemodynamic	B-ADE
collapse	I-ADE
following	O
labetalol	B-Drug
administration	O
in	O
preeclampsia	O
.	O

-DOCSTART-	1599

Severe	B-ADE
acidosis	I-ADE
in	O
patients	O
taking	O
metformin	B-Drug
--	O
rapid	O
reversal	O
and	O
survival	O
despite	O
high	O
APACHE	O
score	O
.	O

-DOCSTART-	570

Severe	O
serotonin	B-ADE
syndrome	I-ADE
induced	O
by	O
mirtazapine	B-Drug
monotherapy	O
.	O

-DOCSTART-	4237

OBJECTIVE	O
:	O
To	O
describe	O
onset	O
of	O
syndrome	B-ADE
of	I-ADE
inappropriate	I-ADE
antidiuretic	I-ADE
hormone	I-ADE
(	O
SIADH	B-ADE
)	O
associated	O
with	O
vinorelbine	B-Drug
therapy	O
for	O
advanced	O
breast	O
cancer	O
.	O

-DOCSTART-	2936

Although	O
adverse	O
reactions	O
to	O
protamine	O
are	O
reported	O
infrequently	O
and	O
are	O
usually	O
mild	O
,	O
we	O
recently	O
observed	O
the	O
first	O
fatal	O
case	O
of	O
type	B-ADE
I	I-ADE
anaphylaxis	I-ADE
resulting	O
from	O
protamine	B-Drug
.	O

-DOCSTART-	904

We	O
describe	O
the	O
development	O
of	O
cutaneous	B-ADE
scleroderma	I-ADE
in	O
3	O
patients	O
coincident	O
with	O
the	O
use	O
of	O
bleomycin	B-Drug
in	O
low	O
cumulative	O
doses	O
of	O
less	O
than	O
100	O
U	O
.	O

-DOCSTART-	3284

Delayed	B-ADE
pseudocyst	I-ADE
of	I-ADE
the	I-ADE
pancreas	I-ADE
can	O
be	O
a	O
complication	O
of	O
intramuscular	O
L	B-Drug
-	I-Drug
asparaginase	I-Drug
.	O

-DOCSTART-	3211

Drug	O
-	O
induced	O
psychosis	B-ADE
resulted	O
from	O
the	O
administration	O
of	O
quinacrine	B-Drug
hydrochloride	I-Drug
at	O
a	O
dosage	O
of	O
100	O
mg	O
twice	O
daily	O
for	O
the	O
treatment	O
of	O
discoid	O
lupus	O
.	O

-DOCSTART-	4129

We	O
postulate	O
that	O
the	O
bolus	O
of	O
sulprostone	B-Drug
resulted	O
in	O
possible	O
coronary	B-ADE
spasm	I-ADE
that	O
resulted	O
in	O
cardiac	B-ADE
arrest	I-ADE
.	O

-DOCSTART-	4110

It	O
was	O
hypothesized	O
that	O
valproic	B-Drug
acid	I-Drug
may	O
interfere	O
with	O
glucuronidation	O
of	O
lamotrigine	B-Drug
,	O
leading	O
to	O
increased	B-ADE
serum	I-ADE
lamotrigine	I-ADE
levels	I-ADE
,	O
or	O
perhaps	O
alter	O
the	O
drug	O
's	O
metabolism	O
,	O
resulting	O
in	O
accumulation	B-ADE
of	I-ADE
a	I-ADE
toxic	I-ADE
intermediate	I-ADE
metabolite	I-ADE
.	O

-DOCSTART-	3370

Barbiturate	B-Drug
-	O
induced	O
submassive	B-ADE
hepatic	I-ADE
necrosis	I-ADE
.	O

-DOCSTART-	3675

In	O
the	O
third	O
child	O
,	O
the	O
tics	B-ADE
ceased	O
after	O
CBZ	B-Drug
discontinuation	O
.	O

-DOCSTART-	3092

One	O
of	O
these	O
was	O
clofazimine	B-Drug
,	O
an	O
aniline	O
aposafranine	O
derivative	O
known	O
to	O
produce	O
a	O
ceroid	B-ADE
-	I-ADE
like	I-ADE
pigment	I-ADE
in	O
the	O
tissues	O
of	O
patients	O
treated	O
with	O
this	O
drug	O
or	O
lepromatous	O
leprosy	O
.	O

-DOCSTART-	2413

CONCLUSIONS	O
:	O
These	O
results	O
suggest	O
that	O
clozapine	B-Drug
may	O
cause	O
TD	B-ADE
;	O
however	O
,	O
the	O
prevalence	O
is	O
low	O
and	O
the	O
severity	O
is	O
relatively	O
mild	O
,	O
with	O
no	O
or	O
mild	O
self	O
-	O
reported	O
discomfort	B-ADE
.	O

-DOCSTART-	3657

We	O
report	O
on	O
a	O
child	O
with	O
fatal	B-ADE
valproate	B-Drug
-	O
related	O
hepatotoxic	B-ADE
effects	I-ADE
despite	O
this	O
supplementation	O
.	O

-DOCSTART-	3175

Amphotericin	B-Drug
B	I-Drug
nephrotoxicity	B-ADE
in	O
humans	O
decreased	O
by	O
salt	O
repletion	O
.	O

-DOCSTART-	3393

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
case	O
of	O
griseofulvin	B-Drug
-	O
exacerbated	O
lupus	B-ADE
in	O
which	O
nephrotic	B-ADE
syndrome	I-ADE
has	O
been	O
observed	O
.	O

-DOCSTART-	391

Levofloxacin	B-Drug
induced	O
polymorphic	B-ADE
ventricular	I-ADE
tachycardia	I-ADE
with	O
normal	O
QT	O
interval	O
.	O

-DOCSTART-	2057

Diagnosis	O
of	O
sclerosing	B-ADE
glomerulonephritis	I-ADE
occurred	O
in	O
this	O
patient	O
during	O
anastrozole	B-Drug
use	O
,	O
suggesting	O
a	O
newly	O
defined	O
side	O
effect	O
of	O
anastrozole	O
.	O

-DOCSTART-	1622

Gemcitabine	B-Drug
-	O
induced	O
rectus	B-ADE
abdominus	I-ADE
radiation	I-ADE
recall	I-ADE
.	O

-DOCSTART-	59

Protamine	B-ADE
allergy	I-ADE
as	O
a	O
complication	O
of	O
insulin	B-Drug
hypersensitivity	O
:	O
A	O
case	O
report	O
.	O

-DOCSTART-	1147

As	O
linezolid	B-Drug
has	O
been	O
shown	O
to	O
have	O
hematologic	B-ADE
side	I-ADE
effects	I-ADE
,	O
blood	O
count	O
monitoring	O
is	O
recommended	O
in	O
patients	O
receiving	O
this	O
drug	O
for	O
long	O
-	O
term	O
therapy	O
.	O

-DOCSTART-	4229

The	O
patient	O
was	O
initially	O
treated	O
with	O
hydration	O
and	O
furosemide	B-Drug
but	O
developed	O
congestive	B-ADE
heart	I-ADE
failure	I-ADE
.	O

-DOCSTART-	5

RESULTS	O
:	O
A	O
44-year	O
-	O
old	O
man	O
taking	O
naproxen	B-Drug
for	O
chronic	O
low	O
back	O
pain	O
and	O
a	O
20-year	O
-	O
old	O
woman	O
on	O
oxaprozin	B-Drug
for	O
rheumatoid	O
arthritis	O
presented	O
with	O
tense	B-ADE
bullae	I-ADE
and	O
cutaneous	B-ADE
fragility	I-ADE
on	O
the	O
face	O
and	O
the	O
back	O
of	O
the	O
hands	O
.	O

-DOCSTART-	3503

Propoxyphene	B-Drug
-	O
induced	O
wide	B-ADE
complex	I-ADE
dysrhythmia	I-ADE
responsive	O
to	O
sodium	O
bicarbonate	O
therapy	O
has	O
not	O
been	O
previously	O
reported	O
in	O
the	O
literature	O
.	O

-DOCSTART-	3543

There	O
are	O
now	O
reports	O
of	O
liver	B-ADE
failure	I-ADE
following	O
treatment	O
of	O
childhood	O
cancers	O
with	O
AMD	B-Drug
.	O

-DOCSTART-	434

Acute	B-ADE
lung	I-ADE
injury	I-ADE
associated	O
with	O
5-fluorouracil	B-Drug
and	O
oxaliplatinum	B-Drug
combined	O
chemotherapy	O
.	O

-DOCSTART-	917

Encephalopathy	B-ADE
and	O
seizures	B-ADE
induced	O
by	O
intravesical	O
alum	B-Drug
irrigations	O
.	O

-DOCSTART-	1157

Progressive	B-ADE
anemia	I-ADE
following	O
combination	O
therapy	O
with	O
interferon	B-Drug
-	I-Drug
alpha	I-Drug
and	O
interleukin-2	B-Drug
in	O
a	O
patient	O
with	O
metastatic	O
renal	O
cell	O
carcinoma	O
.	O

-DOCSTART-	696

It	O
was	O
postulated	O
that	O
the	O
allergic	B-ADE
reaction	I-ADE
was	O
most	O
likely	O
caused	O
by	O
capecitabine	B-Drug
or	O
the	O
intermediate	O
metabolites	O
based	O
on	O
the	O
immediate	O
reappearance	O
of	O
symptoms	O
from	O
the	O
rechallenge	O
,	O
pharmacokinetic	O
data	O
,	O
and	O
well	O
-	O
tolerance	O
of	O
fluorouracil	O
.	O

-DOCSTART-	3531

Additionally	O
,	O
danazol	B-Drug
produces	O
hepatocellular	B-ADE
damage	I-ADE
in	O
approximately	O
10	O
%	O
of	O
women	O
.	O

-DOCSTART-	4120

Risperidone	B-Drug
-	O
induced	O
tardive	B-ADE
dyskinesia	I-ADE
.	O

-DOCSTART-	2332

Can	O
ketamine	B-Drug
prescribed	O
for	O
pain	O
cause	O
damage	B-ADE
to	I-ADE
the	I-ADE
urinary	I-ADE
tract	I-ADE
?	O

-DOCSTART-	3417

The	O
interval	O
between	O
initiating	O
treatment	O
with	O
interferon	B-Drug
alfa	I-Drug
and	O
onset	O
of	O
anterior	B-ADE
ischemic	I-ADE
optic	I-ADE
neuropathy	I-ADE
was	O
similar	O
to	O
that	O
of	O
interferon	B-Drug
-	O
associated	O
vascular	B-ADE
retinopathy	I-ADE
.	O

-DOCSTART-	1359

The	O
authors	O
suggest	O
that	O
in	O
the	O
absence	O
of	O
any	O
proven	O
benefit	O
of	O
itraconazole	B-Drug
prophylaxis	O
,	O
and	O
given	O
the	O
interaction	O
of	O
this	O
drug	O
with	O
vincristine	B-Drug
leading	O
to	O
severe	O
and	O
even	O
potentially	O
fatal	B-ADE
toxicities	I-ADE
,	O
the	O
combination	O
use	O
of	O
these	O
drugs	O
should	O
be	O
avoided	O
.	O

-DOCSTART-	3679

CONCLUSIONS	O
:	O
The	O
observation	O
that	O
neurotoxicity	B-ADE
developed	O
with	O
a	O
delay	O
of	O
24	O
to	O
48	O
hours	O
after	O
acyclovir	B-Drug
peak	O
serum	O
concentrations	O
could	O
explain	O
the	O
wide	O
range	O
of	O
acyclovir	B-Drug
levels	O
reported	O
in	O
similar	O
cases	O
.	O

-DOCSTART-	2839

Hypogammaglobulinemia	B-ADE
associated	O
with	O
gold	B-Drug
therapy	O
:	O
evidence	O
for	O
a	O
partial	O
maturation	O
blockade	O
of	O
B	O
cells	O
.	O

-DOCSTART-	2612

Life	O
-	O
threatening	O
hyponatremia	B-ADE
caused	O
by	O
vinblastine	B-Drug
.	O

-DOCSTART-	941

The	O
treatment	O
for	O
acidosis	O
and	O
hyperkalaemia	O
should	O
be	O
started	O
as	O
soon	O
as	O
RTA	B-ADE
is	O
diagnosed	O
,	O
and	O
the	O
dosage	O
of	O
FK506	B-Drug
should	O
also	O
be	O
reduced	O
if	O
possible	O
.	O

-DOCSTART-	2172

Thymic	B-ADE
enlargement	I-ADE
in	O
a	O
patient	O
with	O
juvenile	O
idiopathic	O
arthritis	O
during	O
etanercept	B-Drug
therapy	O
.	O

-DOCSTART-	1887

Oxcarbazepine	B-Drug
-	O
associated	O
angioedema	B-ADE
manifested	O
by	O
swelling	O
of	O
the	O
face	O
,	O
eyes	O
,	O
lips	O
,	O
or	O
tongue	O
or	O
difficulty	O
swallowing	O
or	O
breathing	O
(	O
or	O
both	O
)	O
is	O
a	O
rare	O
but	O
potentially	O
life	O
-	O
threatening	O
reaction	O
for	O
which	O
early	O
recognition	O
and	O
management	O
are	O
vital	O
.	O

-DOCSTART-	2682

Life	O
-	O
threatening	O
cranial	B-ADE
dystonia	I-ADE
following	O
trihexyphenidyl	B-Drug
withdrawal	O
.	O

-DOCSTART-	4011

When	O
the	O
disease	O
recurred	O
conventional	O
amphotericin	B-Drug
B	I-Drug
was	O
used	O
again	O
,	O
but	O
had	O
to	O
be	O
stopped	O
because	O
of	O
severe	B-ADE
side	I-ADE
effects	I-ADE
.	O

-DOCSTART-	1613

Cutaneous	B-ADE
rashes	I-ADE
and	O
eruptions	B-ADE
can	O
be	O
caused	O
by	O
many	O
medications	O
,	O
including	O
carbamazepine	B-Drug
.	O

-DOCSTART-	2454

Common	O
adverse	O
events	O
(	O
frequency	O
10	O
%	O
)	O
of	O
lacosamide	B-Drug
doses	O
up	O
to	O
600	O
mg	O
/	O
day	O
include	O
nonspecific	O
central	O
nervous	O
system	O
effects	O
(	O
e.g.	O
,	O
dizziness	B-ADE
,	O
ataxia	B-ADE
,	O
diplopia	B-ADE
,	O
and	O
somnolence	B-ADE
)	O
.	O

-DOCSTART-	3902

A	O
potential	O
role	O
for	O
renal	O
and	O
hepatic	O
impairment	O
in	O
the	O
observed	O
protracted	O
course	O
of	O
amiodarone	B-Drug
-	O
induced	O
thyrotoxicosis	B-ADE
is	O
suggested	O
.	O

-DOCSTART-	1745

Quinapril	B-Drug
is	O
an	O
angiotensin	O
-	O
converting	O
enzyme	O
inhibitor	O
(	O
ACE	O
-	O
inhibitor	O
)	O
and	O
overdose	O
can	O
lead	O
to	O
prolonged	B-ADE
hypotension	I-ADE
and	O
,	O
less	O
frequently	O
,	O
transient	B-ADE
renal	I-ADE
impairment	I-ADE
.	O

-DOCSTART-	2065

Only	O
one	O
case	O
of	O
severe	B-ADE
symptomatic	I-ADE
hepatitis	I-ADE
occurring	O
after	O
pulse	O
therapy	O
with	O
itraconazole	B-Drug
for	O
onychomycosis	O
and	O
requiring	O
transplantation	O
has	O
been	O
reported	O
previously	O
.	O

-DOCSTART-	1584

Cardiac	B-ADE
toxicity	I-ADE
related	O
to	O
BCNU	B-Drug
has	O
not	O
been	O
described	O
well	O
.	O

-DOCSTART-	3986

Erythromycin	B-Drug
is	O
a	O
macrolide	O
antibiotic	O
that	O
may	O
increase	O
the	O
risk	O
of	O
lovastatin	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
.	O

-DOCSTART-	1579

Post	O
marketing	O
studies	O
of	O
Interferon	B-Drug
-	I-Drug
beta	I-Drug
(	O
IFN	B-Drug
beta	I-Drug
)	O
therapy	O
in	O
multiple	O
sclerosis	O
(	O
MS	O
)	O
have	O
demonstrated	O
surprisingly	O
high	O
rates	O
of	O
hepatotoxicity	B-ADE
.	O

-DOCSTART-	158

The	O
case	O
histories	O
are	O
presented	O
of	O
two	O
patients	O
who	O
developed	O
lung	B-ADE
disease	I-ADE
associated	O
with	O
the	O
use	O
of	O
nitrofurantoin	B-Drug
with	O
histological	O
features	O
of	O
bronchiolitis	B-ADE
obliterans	I-ADE
organising	I-ADE
pneumonia	I-ADE
(	O
BOOP	B-ADE
)	O
,	O
a	O
rare	O
but	O
recognised	O
form	O
of	O
drug	O
induced	O
injury	O
.	O

-DOCSTART-	702

It	O
has	O
been	O
suggested	O
that	O
PPE	B-ADE
caused	O
by	O
cytarabine	B-Drug
does	O
not	O
recur	O
with	O
subsequent	O
cytarabine	O
re	O
-	O
challenge	O
.	O

-DOCSTART-	2003

Allergic	B-ADE
contact	I-ADE
dermatitis	I-ADE
from	O
4-chloro-7-nitrobenzofurazan	B-Drug
.	O

-DOCSTART-	3281

Ulcerating	B-ADE
enteritis	I-ADE
associated	O
with	O
flucytosine	B-Drug
therapy	O
.	O

-DOCSTART-	2889

It	O
was	O
restarted	O
6	O
weeks	O
later	O
,	O
and	O
10	O
weeks	O
after	O
that	O
,	O
the	O
patient	O
presented	O
with	O
fulminant	B-ADE
hepatic	I-ADE
failure	I-ADE
,	O
which	O
resolved	O
rapidly	O
after	O
cessation	O
of	O
nicotinic	B-Drug
acid	I-Drug
therapy	O
.	O

-DOCSTART-	120

Prolonged	O
responses	O
were	O
achieved	O
with	O
low	O
doses	O
of	O
HU	B-Drug
(	O
3	O
-	O
10	O
mg	O
/	O
kg	O
/	O
day	O
)	O
and	O
higher	O
doses	O
were	O
associated	O
with	O
mild	B-ADE
reversible	I-ADE
hematologic	I-ADE
or	O
hepatic	B-ADE
toxicity	I-ADE
and	O
no	O
further	O
increases	O
in	O
Hb	O
.	O

-DOCSTART-	895

Flaccid	B-ADE
quadriparesis	I-ADE
was	O
noted	O
after	O
discontinuation	O
of	O
vecuronium	B-Drug
.	O

-DOCSTART-	2673

Treatment	O
of	O
amiodarone	B-Drug
-	O
induced	O
thyrotoxicosis	B-ADE
(	O
AIT	O
)	O
with	O
thionamide	O
,	O
lithium	O
or	O
radioactive	O
iodine	O
is	O
ineffective	O
.	O

-DOCSTART-	3234

Neurophysiological	O
mechanisms	O
which	O
aid	O
in	O
elucidating	O
the	O
role	O
of	O
disulfiram	B-Drug
in	O
the	O
etiology	O
of	O
catatonia	B-ADE
are	O
discussed	O
.	O

-DOCSTART-	3808

The	O
association	O
of	O
central	B-ADE
diabetes	I-ADE
insipidus	I-ADE
(	O
CDI	B-ADE
)	O
with	O
lithium	B-Drug
use	O
is	O
rare	O
.	O

-DOCSTART-	3304

Lithium	B-Drug
is	O
known	O
to	O
cause	O
acute	B-ADE
renal	I-ADE
failure	I-ADE
and	O
tubulo	B-ADE
-	I-ADE
interstitial	I-ADE
disease	I-ADE
,	O
but	O
the	O
recently	O
described	O
association	O
with	O
proteinuria	B-ADE
or	O
nephrotic	B-ADE
syndrome	I-ADE
is	O
little	O
recognized	O
.	O

-DOCSTART-	3276

There	O
have	O
been	O
only	O
two	O
reports	O
of	O
cimetidine	B-Drug
-	O
induced	O
hepatitis	B-ADE
.	O

-DOCSTART-	3217

The	O
mechanism	O
of	O
anaphylactoid	B-ADE
reaction	I-ADE
to	O
zomepirac	B-Drug
in	O
this	O
case	O
,	O
therefore	O
,	O
remains	O
unclear	O
.	O

-DOCSTART-	4217

The	O
pulmonary	B-ADE
toxicity	I-ADE
of	O
gold	B-Drug
salts	O
is	O
an	O
uncommon	O
cause	O
of	O
life	O
-	O
threatening	O
respiratory	B-ADE
failure	I-ADE
.	O

-DOCSTART-	3972

Although	O
its	O
side	O
effects	O
are	O
few	O
,	O
tamoxifen	B-Drug
increases	O
the	O
incidence	O
of	O
proliferative	B-ADE
lesions	I-ADE
of	I-ADE
the	I-ADE
endometrium	I-ADE
,	O
which	O
theoretically	O
should	O
be	O
preventable	O
with	O
progestational	O
agents	O
.	O

-DOCSTART-	2605

Procainamide	B-Drug
-	O
induced	O
incessant	B-ADE
supraventricular	I-ADE
tachycardia	I-ADE
in	O
the	O
Wolff	O
-	O
Parkinson	O
-	O
White	O
syndrome	O
.	O

-DOCSTART-	3480

Esophageal	B-ADE
candidiasis	I-ADE
was	O
diagnosed	O
at	O
endoscopy	O
in	O
two	O
patients	O
receiving	O
omeprazole	B-Drug
therapy	O
.	O

-DOCSTART-	2544

Antacid	O
and	O
sucralfate	B-Drug
-	O
induced	O
hypophosphatemic	B-ADE
osteomalacia	I-ADE
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	2536

Awareness	O
of	O
this	O
route	O
of	O
intoxication	O
might	O
be	O
important	O
in	O
patients	O
in	O
whom	O
neurologic	O
or	O
psychiatric	B-ADE
symptoms	I-ADE
develop	O
while	O
large	O
amounts	O
of	O
lidocaine	B-Drug
cream	O
are	O
being	O
used	O
.	O

-DOCSTART-	543

Warfarin	B-Drug
-	O
associated	O
bleeding	B-ADE
generally	O
is	O
considered	O
deleterious	O
;	O
however	O
,	O
in	O
our	O
patient	O
it	O
unmasked	O
an	O
early	O
stage	O
of	O
colon	O
cancer	O
and	O
thus	O
may	O
have	O
saved	O
the	O
patient	O
's	O
life	O
.	O

-DOCSTART-	2873

Pulmonary	B-ADE
edema	I-ADE
as	O
a	O
delayed	O
complication	O
of	O
ritodrine	B-Drug
therapy	O
.	O

-DOCSTART-	772

Toxicity	B-ADE
related	O
to	O
chloroquine	B-Drug
treatment	O
of	O
resistant	O
vivax	O
malaria	O
.	O

-DOCSTART-	132

Elevated	B-ADE
serum	I-ADE
triglycerides	I-ADE
with	O
clozapine	B-Drug
resolved	O
with	O
risperidone	O
in	O
four	O
patients	O
.	O

-DOCSTART-	1995

Exfoliative	B-ADE
dermatitis	I-ADE
secondary	O
to	O
tobramycin	B-Drug
sulfate	I-Drug
.	O

-DOCSTART-	2764

Severe	B-ADE
visual	I-ADE
loss	I-ADE
after	O
a	O
single	O
dose	O
of	O
vincristine	B-Drug
in	O
a	O
patient	O
with	O
spinal	O
cord	O
astrocytoma	O
.	O

-DOCSTART-	4024

The	O
patient	O
's	O
previous	O
rash	B-ADE
and	O
the	O
temporal	O
relation	O
of	O
this	O
event	O
and	O
the	O
ingestion	O
of	O
phenolphthalein	B-Drug
,	O
as	O
well	O
as	O
the	O
similarity	O
of	O
this	O
case	O
to	O
other	O
reports	O
,	O
point	O
to	O
phenolphthalein	B-Drug
as	O
the	O
cause	O
of	O
TEN	B-ADE
in	O
this	O
patient	O
.	O

-DOCSTART-	3184

Metabolic	O
balance	O
studies	O
and	O
rechallenge	O
with	O
hydrochlorothiazide	B-Drug
were	O
undertaken	O
to	O
investigate	O
the	O
mechanism	O
of	O
the	O
thiazide	O
-	O
induced	O
hyponatremia	B-ADE
.	O

-DOCSTART-	1686

Thus	O
any	O
case	O
of	O
severe	B-ADE
neutropenia	I-ADE
occurring	O
in	O
a	O
patient	O
receiving	O
olanzapine	B-Drug
is	O
alarming	O
to	O
clinicians	O
.	O

-DOCSTART-	99

We	O
report	O
a	O
case	O
of	O
acute	O
hyperphosphatemia	B-ADE
secondary	O
to	O
rectal	O
administration	O
of	O
sodium	B-Drug
phosphate	I-Drug
and	O
sodium	B-Drug
biphosphate	I-Drug
(	O
Fleet	O
enema	O
)	O
.	O

-DOCSTART-	1429

A	O
selective	O
association	O
between	O
fluoxetine	B-Drug
and	O
extensive	O
,	O
prominent	O
eye	B-ADE
movements	I-ADE
in	I-ADE
nonrapid	I-ADE
eye	I-ADE
movement	I-ADE
(	I-ADE
NREM	I-ADE
)	I-ADE
sleep	I-ADE
was	O
detected	O
,	O
utilizing	O
Fisher	O
's	O
exact	O
one	O
-	O
tailed	O
statistic	O
(	O
p	O
less	O
than	O
0.00001	O
for	O
each	O
comparison	O
)	O
.	O

-DOCSTART-	2366

She	O
was	O
diagnosed	O
with	O
Epstein	B-ADE
-	I-ADE
Barr	I-ADE
virus	I-ADE
-	I-ADE
associated	I-ADE
polymorphic	I-ADE
lymphoproliferative	I-ADE
disorder	I-ADE
(	O
LPD	B-ADE
)	O
due	O
to	O
immunodeficiency	B-ADE
caused	O
by	O
MTX	B-Drug
administration	O
.	O

-DOCSTART-	1225

These	O
findings	O
suggest	O
that	O
clozapine	B-Drug
-	O
induced	O
seizures	B-ADE
can	O
be	O
successfully	O
treated	O
,	O
that	O
gradual	O
dose	O
titration	O
can	O
reduce	O
the	O
likelihood	O
of	O
further	O
episodes	O
of	O
seizures	O
and	O
that	O
concomitant	O
use	O
of	O
a	O
suitable	O
mood	O
stabilizer	O
/	O
anti	O
-	O
epileptic	O
medication	O
can	O
improve	O
the	O
outcome	O
of	O
treatment	O
-	O
resistant	O
schizophrenia	O
.	O

-DOCSTART-	1403

We	O
report	O
a	O
case	O
of	O
an	O
infant	O
with	O
complex	O
congenital	O
heart	O
disease	O
who	O
was	O
placed	O
on	O
captopril	B-Drug
for	O
afterload	O
reduction	O
following	O
cardiac	O
surgery	O
and	O
subsequently	O
developed	O
pulmonary	B-ADE
infiltrates	I-ADE
with	I-ADE
eosinophilia	I-ADE
.	O

-DOCSTART-	523

However	O
,	O
in	O
the	O
mid	O
-	O
to	O
-	O
late	O
1980s	O
,	O
a	O
series	O
of	O
letters	O
to	O
the	O
editor	O
and	O
case	O
reports	O
announced	O
an	O
association	O
between	O
tamoxifen	B-Drug
therapy	O
in	O
women	O
with	O
breast	O
cancer	O
and	O
the	O
development	O
of	O
endometrial	B-ADE
carcinoma	I-ADE
.	O

-DOCSTART-	718

CONCLUSIONS	O
:	O
Clarithromycin	B-Drug
may	O
be	O
a	O
cause	O
of	O
fulminant	B-ADE
liver	I-ADE
failure	I-ADE
either	O
alone	O
or	O
by	O
inhibiting	O
the	O
metabolism	O
of	O
other	O
drugs	O
.	O

-DOCSTART-	2866

Upper	B-ADE
tract	I-ADE
urothelial	I-ADE
malignancy	I-ADE
after	O
cyclophosphamide	B-Drug
therapy	O
:	O
a	O
case	O
report	O
and	O
literature	O
review	O
.	O

-DOCSTART-	2762

A	O
case	O
of	O
severe	B-ADE
visual	I-ADE
loss	I-ADE
following	O
a	O
single	O
dose	O
of	O
vincristine	B-Drug
is	O
described	O
.	O

-DOCSTART-	524

In	O
this	O
healthy	O
population	O
,	O
the	O
relative	O
risk	O
of	O
developing	O
endometrial	B-ADE
carcinoma	I-ADE
in	O
the	O
tamoxifen	B-Drug
arm	O
was	O
2.54	O
,	O
although	O
when	O
stratified	O
by	O
age	O
,	O
in	O
women	O
over	O
50	O
,	O
the	O
risk	O
grew	O
to	O
4.01	O
.	O

-DOCSTART-	967

We	O
describe	O
a	O
patient	O
who	O
developed	O
NEH	B-ADE
on	O
three	O
separate	O
occasions	O
provoked	O
by	O
two	O
different	O
chemotherapeutic	O
agents	O
--	O
cytarabine	B-Drug
and	O
mitoxantrone	B-Drug
.	O

-DOCSTART-	4113

Six	O
of	O
13	O
outpatients	O
with	O
schizophrenia	O
who	O
participated	O
in	O
a	O
ten	O
-	O
week	O
open	O
trial	O
of	O
risperidone	B-Drug
had	O
an	O
initial	O
good	O
response	O
to	O
the	O
medication	O
followed	O
by	O
development	O
of	O
intolerable	B-ADE
affect	I-ADE
,	O
including	O
feelings	B-ADE
of	I-ADE
agitation	I-ADE
and	O
depression	B-ADE
and	O
periods	B-ADE
of	I-ADE
crying	I-ADE
and	O
insomnia	B-ADE
.	O

-DOCSTART-	1179

We	O
present	O
three	O
cases	O
from	O
the	O
Provincial	O
Toxicology	O
Center	O
of	O
British	O
Columbia	O
,	O
Canada	O
in	O
which	O
suicidal	B-ADE
overdose	I-ADE
deaths	I-ADE
were	O
associated	O
with	O
quetiapine	B-Drug
.	O

-DOCSTART-	427

Although	O
taxol	B-Drug
has	O
shown	O
significant	O
activity	O
in	O
advanced	O
ovarian	O
cancer	O
,	O
peripheral	B-ADE
neuropathy	I-ADE
is	O
likely	O
to	O
become	O
the	O
major	O
dose	O
-	O
limiting	O
toxicity	O
.	O

-DOCSTART-	617

Multiple	B-ADE
pulmonary	I-ADE
nodules	I-ADE
:	O
an	O
unusual	O
presentation	O
of	O
fludarabine	B-Drug
pulmonary	B-ADE
toxicity	I-ADE
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

-DOCSTART-	4159

It	O
was	O
concluded	O
that	O
ANCA	B-ADE
is	O
closely	O
related	O
to	O
the	O
pathogenesis	O
of	O
crescentic	O
glomerulonephritis	O
and	O
that	O
treatment	O
with	O
PTU	B-Drug
appeared	O
to	O
induce	O
ANCA	B-ADE
.	O

-DOCSTART-	2537

Nitrendipine	B-Drug
-	O
induced	O
gingival	B-ADE
hyperplasia	I-ADE
.	O

-DOCSTART-	3546

CONCLUSIONS	O
:	O
Although	O
budesonide	B-Drug
may	O
be	O
beneficial	O
because	O
of	O
its	O
anti	O
-	O
inflammatory	O
effects	O
,	O
clinicians	O
should	O
be	O
alert	O
to	O
its	O
potential	O
for	O
causing	O
contact	B-ADE
dermatitis	I-ADE
.	O

-DOCSTART-	37

Acute	B-ADE
generalized	I-ADE
exanthematous	I-ADE
pustulosis	I-ADE
induced	O
by	O
salazosulfapyridine	B-Drug
in	O
a	O
patient	O
with	O
ulcerative	O
colitis	O
.	O

-DOCSTART-	124

A	O
36-y	O
-	O
o	O
patient	O
with	O
schizophrenia	O
,	O
who	O
had	O
consumed	O
gradually	O
increasing	O
quantities	O
of	O
oolong	B-Drug
tea	I-Drug
that	O
eventually	O
reached	O
15	O
L	O
each	O
day	O
,	O
became	O
delirious	B-ADE
and	O
was	O
admitted	O
to	O
a	O
psychiatric	O
hospital	O
.	O

-DOCSTART-	2659

Long	O
lasting	O
respiratory	B-ADE
depression	I-ADE
induced	O
by	O
morphine-6-glucuronide	B-Drug
?	O

-DOCSTART-	1219

The	O
patient	O
was	O
found	O
to	O
have	O
no	B-ADE
motile	I-ADE
sperm	I-ADE
with	O
a	O
normal	O
sperm	O
count	O
,	O
while	O
taking	O
a	O
dose	O
of	O
400	O
mg	O
/	O
day	O
of	O
carbamazepine	B-Drug
.	O

-DOCSTART-	352

Symptoms	O
and	O
endoscopic	B-ADE
lesions	I-ADE
quickly	O
regressed	O
within	O
1	O
week	O
of	O
meloxicam	B-Drug
withdrawal	O
.	O

-DOCSTART-	2677

This	O
panic	B-ADE
anxiety	I-ADE
was	O
not	O
relieved	O
by	O
taking	O
etizolam	O
and	O
flunitrazepam	O
again	O
,	O
but	O
subsided	O
rapidly	O
by	O
the	O
re	O
-	O
administration	O
of	O
mianserin	B-Drug
30	O
mg	O
/	O
day	O
,	O
and	O
because	O
of	O
that	O
the	O
depressive	O
symptom	O
also	O
disappeared	O
.	O

-DOCSTART-	2585

Upon	O
discontinuation	O
of	O
MTX	B-Drug
,	O
her	O
ascites	B-ADE
resolved	O
,	O
and	O
her	O
arthritis	O
became	O
more	O
active	O
.	O

-DOCSTART-	769

There	O
are	O
no	O
previous	O
reports	O
in	O
the	O
literature	O
about	O
the	O
emergence	O
of	O
CML	B-ADE
during	O
treatment	O
with	O
hydroxyurea	B-Drug
.	O

-DOCSTART-	2215

Extrapyramidal	B-ADE
symptoms	I-ADE
are	O
well	O
-	O
documented	O
complications	O
of	O
therapy	O
with	O
haloperidol	B-Drug
,	O
even	O
when	O
small	O
doses	O
are	O
used	O
.	O

-DOCSTART-	2542

Glaucoma	B-ADE
secondary	O
to	O
epithelial	O
downgrowth	O
and	O
5-fluorouracil	B-Drug
.	O

-DOCSTART-	185

Other	O
thiazolidinediones	O
currently	O
in	O
clinical	O
trials	O
may	O
be	O
able	O
to	O
provide	O
the	O
therapeutic	O
benefits	O
of	O
troglitazone	B-Drug
without	O
significant	O
hepatotoxicity	B-ADE
.	O

-DOCSTART-	404

Adenosine	B-Drug
-	O
induced	O
ventricular	B-ADE
fibrillation	I-ADE
.	O

-DOCSTART-	539

Dermatitis	B-ADE
to	O
captopril	B-Drug
.	O

-DOCSTART-	1113

Case	O
report	O
:	O
life	B-ADE
-	I-ADE
threatening	I-ADE
hypoglycaemia	I-ADE
associated	O
with	O
sulfadoxine	B-Drug
-	I-Drug
pyrimethamine	I-Drug
,	O
a	O
commonly	O
used	O
antimalarial	O
drug	O
.	O

-DOCSTART-	1194

PVT	B-ADE
during	O
chemotherapy	O
in	O
children	O
is	O
a	O
rare	O
event	O
and	O
appears	O
to	O
be	O
closely	O
related	O
to	O
intensive	O
chemotherapy	O
containing	O
busulfan	B-Drug
and	O
to	O
be	O
associated	O
with	O
HVOD	B-ADE
.	O

-DOCSTART-	418

Possible	O
linkage	O
of	O
amprenavir	B-Drug
with	O
intracranial	B-ADE
bleeding	I-ADE
in	O
an	O
HIV	O
-	O
infected	O
hemophiliac	O
.	O

-DOCSTART-	1570

Pulmonary	B-ADE
fibrosis	I-ADE
is	O
a	O
complication	O
of	O
paclitaxel	B-Drug
therapy	O
that	O
may	O
occur	O
despite	O
treatments	O
with	O
corticosteroids	O
.	O

-DOCSTART-	2391

Ciprofloxacin	B-Drug
-	O
induced	O
hemorrhagic	B-ADE
vasculitis	I-ADE
is	O
a	O
rare	O
side	O
effect	O
.	O

-DOCSTART-	81

The	O
purpose	O
of	O
this	O
report	O
is	O
to	O
document	O
a	O
new	O
case	O
of	O
in	O
utero	O
CP	B-Drug
exposure	O
with	O
multiple	B-ADE
congenital	I-ADE
anomalies	I-ADE
and	O
to	O
establish	O
an	O
apparent	O
CP	B-Drug
embryopathy	B-ADE
phenotype	O
.	O

-DOCSTART-	423

Linear	B-ADE
immunoglobulin	I-ADE
A	I-ADE
bullous	I-ADE
dermatosis	I-ADE
induced	O
by	O
gemcitabine	B-Drug
.	O

-DOCSTART-	2924

The	O
authors	O
report	O
a	O
further	O
case	O
of	O
methimazole	B-Drug
-	O
associated	O
liver	B-ADE
damage	I-ADE
and	O
present	O
a	O
brief	O
review	O
of	O
eleven	O
previous	O
cases	O
found	O
in	O
the	O
literature	O
.	O

-DOCSTART-	993

Pigmentary	B-ADE
disorders	I-ADE
are	O
recognized	O
adverse	O
effects	O
of	O
the	O
semi	O
-	O
synthetic	O
tetracycline	O
derivative	O
antibiotic	O
,	O
minocycline	B-Drug
.	O

-DOCSTART-	3400

We	O
recommend	O
the	O
cautious	O
use	O
of	O
ketorolac	B-Drug
in	O
patients	O
with	O
underlying	O
illnesses	O
where	O
NSAID	O
-	O
induced	O
ototoxicity	B-ADE
could	O
result	O
in	O
adverse	O
otologic	O
consequences	O
.	O

-DOCSTART-	2841

Herpes	B-ADE
simplex	I-ADE
esophagitis	I-ADE
in	O
a	O
renal	O
transplant	O
patient	O
treated	O
with	O
cyclosporine	B-Drug
A	I-Drug
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	349

Renal	B-ADE
failure	I-ADE
associated	O
with	O
acetazolamide	B-Drug
therapy	O
for	O
glaucoma	O
.	O

-DOCSTART-	2151

Our	O
case	O
is	O
the	O
second	O
one	O
in	O
which	O
hemorrhage	B-ADE
from	O
a	O
meningioma	O
may	O
have	O
been	O
induced	O
by	O
aspirin	B-Drug
prophylaxis	O
.	O

-DOCSTART-	714

Anaphylaxis	B-ADE
to	O
cisplatin	B-Drug
is	O
an	O
infrequent	O
life	O
-	O
threatening	O
complication	O
which	O
may	O
occur	O
even	O
in	O
patients	O
who	O
have	O
received	O
prior	O
treatment	O
with	O
cisplatin	O
.	O

-DOCSTART-	3349

Papilloedema	B-ADE
and	O
hepatic	B-ADE
dysfunction	I-ADE
apparently	O
induced	O
by	O
perhexiline	B-Drug
maleate	I-Drug
(	O
Pexid	B-Drug
)	O
.	O

-DOCSTART-	1196

Retinal	B-ADE
abnormalities	I-ADE
,	O
including	O
retinal	B-ADE
hemorrhage	I-ADE
and	O
"	B-ADE
cotton	I-ADE
-	I-ADE
wool	I-ADE
"	I-ADE
spots	I-ADE
,	O
often	O
occur	O
within	O
the	O
first	O
8	O
weeks	O
in	O
the	O
course	O
of	O
interferon	B-Drug
therapy	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
.	O

-DOCSTART-	2303

Onset	O
of	O
male	O
gynaecomastia	B-ADE
in	O
a	O
patient	O
treated	O
with	O
sunitinib	B-Drug
for	O
metastatic	O
renal	O
cell	O
carcinoma	O
.	O

-DOCSTART-	1361

Only	O
one	O
report	O
links	O
phenylpropanolamine	B-Drug
consumption	O
to	O
an	O
intracerebral	B-ADE
hemorrhage	I-ADE
in	O
a	O
patient	O
with	O
an	O
AVM	O
.	O

-DOCSTART-	435

Diarrhoea	B-ADE
,	O
T	B-ADE
-	I-ADE
CD4	I-ADE
+	I-ADE
lymphopenia	I-ADE
and	O
bilateral	B-ADE
patchy	I-ADE
pulmonary	I-ADE
infiltrates	I-ADE
developed	O
in	O
a	O
male	O
60	O
yrs	O
of	O
age	O
,	O
who	O
was	O
treated	O
with	O
oxaliplatinum	B-Drug
and	O
5-fluorouracil	B-Drug
for	O
unresectable	O
rectum	O
carcinoma	O
.	O

-DOCSTART-	1627

Acute	O
severe	O
intoxication	O
with	O
carbamazepine	B-Drug
is	O
associated	O
with	O
seizures	B-ADE
,	O
coma	B-ADE
and	O
respiratory	B-ADE
depression	I-ADE
.	O

-DOCSTART-	292

Gangrene	B-ADE
of	O
the	O
fingertips	O
after	O
bleomycin	B-Drug
and	O
methotrexate	B-Drug
.	O

-DOCSTART-	1984

We	O
describe	O
3	O
AS	O
patients	O
treated	O
with	O
etanercept	B-Drug
for	O
active	O
AS	O
who	O
developed	O
new	O
onset	O
of	O
CD	B-ADE
while	O
AS	O
related	O
symptoms	O
responded	O
well	O
to	O
etanercept	O
.	O

-DOCSTART-	2168

Olanzapine	B-Drug
-	O
induced	O
hyperglycaemic	B-ADE
coma	I-ADE
and	O
neuroleptic	B-ADE
malignant	I-ADE
syndrome	I-ADE
:	O
case	O
report	O
and	O
review	O
of	O
literature	O
.	O

-DOCSTART-	1265

Flucloxacillin	B-Drug
-	O
induced	O
aplastic	B-ADE
anaemia	I-ADE
and	O
liver	B-ADE
failure	I-ADE
.	O

-DOCSTART-	4247

The	O
development	O
of	O
cutaneous	B-ADE
ecchymosis	I-ADE
associated	O
with	O
a	O
sudden	B-ADE
fall	I-ADE
in	I-ADE
hemoglobin	I-ADE
after	O
the	O
administration	O
of	O
alteplase	B-Drug
should	O
strongly	O
suggest	O
the	O
possibility	O
of	O
diffuse	B-ADE
subfascial	I-ADE
hematoma	I-ADE
.	O

-DOCSTART-	579

Lansoprazole	B-Drug
-	O
induced	O
thrombocytopenia	B-ADE
.	O

-DOCSTART-	806

This	O
clinical	O
course	O
suggests	O
that	O
the	O
sensorimotor	B-ADE
polyneuropathy	I-ADE
may	O
have	O
been	O
caused	O
by	O
5-ASA	B-Drug
.	O

-DOCSTART-	84

In	O
all	O
cases	O
,	O
seizures	B-ADE
were	O
controlled	O
by	O
withdrawal	O
of	O
phenytoin	B-Drug
and	O
reduction	O
of	O
drug	O
levels	O
.	O

-DOCSTART-	2133

Vanishing	B-ADE
bile	I-ADE
duct	I-ADE
and	O
Stevens	B-ADE
-	I-ADE
Johnson	I-ADE
syndrome	I-ADE
associated	O
with	O
ciprofloxacin	B-Drug
treated	O
with	O
tacrolimus	O
.	O

-DOCSTART-	3289

The	O
course	O
of	O
delirium	B-ADE
due	O
to	O
lithium	B-Drug
intoxication	O
.	O

-DOCSTART-	3093

Severe	B-ADE
neurotoxicity	I-ADE
with	O
methyl	B-Drug
G	I-Drug
:	I-Drug
CALGB	I-Drug
experience	O
.	O

-DOCSTART-	2211

RESULTS	O
:	O
A	O
52-year	O
-	O
old	O
woman	O
with	O
Parkinson	O
disease	O
who	O
had	O
taken	O
amantadine	B-Drug
for	O
6	O
years	O
had	O
bilateral	B-ADE
corneal	I-ADE
edema	I-ADE
for	O
2	O
months	O
at	O
baseline	O
.	O

-DOCSTART-	3295

The	O
case	O
history	O
confirms	O
that	O
gold	B-Drug
treatment	O
,	O
even	O
in	O
the	O
same	O
patient	O
,	O
can	O
give	O
rise	O
to	O
a	O
wide	O
range	O
of	O
skin	B-ADE
disturbances	I-ADE
,	O
which	O
in	O
many	O
cases	O
do	O
not	O
break	O
out	O
until	O
long	O
after	O
the	O
drug	O
has	O
been	O
withdrawn	O
.	O

-DOCSTART-	3640

A	O
severe	O
form	O
of	O
exophthalmos	B-ADE
resulting	O
from	O
lithium	B-Drug
therapy	O
has	O
not	O
been	O
described	O
in	O
the	O
literature	O
.	O

-DOCSTART-	3047

Edema	B-ADE
associated	O
with	O
ibuprofen	B-Drug
therapy	O
.	O

-DOCSTART-	298

Recombinant	O
VIIa	O
concentrate	O
in	O
the	O
management	O
of	O
bleeding	O
following	O
prothrombin	B-Drug
complex	I-Drug
concentrate	I-Drug
-	O
related	O
myocardial	B-ADE
infarction	I-ADE
in	O
patients	O
with	O
haemophilia	O
and	O
inhibitors	O
.	O

-DOCSTART-	3534

Acyclovir	B-Drug
neurotoxicity	B-ADE
:	O
clinical	O
experience	O
and	O
review	O
of	O
the	O
literature	O
.	O

-DOCSTART-	1058

We	O
report	O
a	O
case	O
of	O
unintentional	O
overdose	O
of	O
oral	O
pilocarpine	B-Drug
tablets	O
that	O
resulted	O
in	O
bradycardia	B-ADE
,	O
mild	B-ADE
hypotension	I-ADE
,	O
and	O
muscarinic	B-ADE
symptoms	I-ADE
in	O
a	O
patient	O
with	O
Sjogren	O
's	O
syndrome	O
.	O

-DOCSTART-	357

In	O
some	O
cases	O
this	O
seems	O
to	O
happen	O
because	O
spironolactone	B-Drug
causes	O
diarrhoea	B-ADE
.	O

-DOCSTART-	2040

The	O
authors	O
report	O
one	O
case	O
of	O
incomplete	B-ADE
posterior	I-ADE
hyaloid	I-ADE
detachment	I-ADE
(	O
PHD	O
)	O
following	O
intravitreal	O
pegaptanib	B-Drug
to	O
treat	O
DME	O
.	O

-DOCSTART-	3978

Circulating	O
anticoagulant	O
in	O
the	O
procainamide	B-Drug
-	O
induced	O
lupus	B-ADE
syndrome	I-ADE
.	O

-DOCSTART-	834

After	O
a	O
two	O
-	O
month	O
interruption	O
of	O
interferon	O
administration	O
,	O
natural	O
interferon	B-Drug
alpha	I-Drug
was	O
given	O
but	O
followed	O
by	O
another	O
episode	O
of	O
the	O
same	O
neurological	B-ADE
manifestations	I-ADE
.	O

-DOCSTART-	944

L	B-Drug
-	I-Drug
DOPA	I-Drug
-	O
induced	O
excessive	O
daytime	B-ADE
sleepiness	I-ADE
in	O
PD	O
:	O
a	O
placebo	O
-	O
controlled	O
case	O
with	O
MSLT	O
assessment	O
.	O

-DOCSTART-	16

Methemoglobinemia	B-ADE
after	O
axillary	O
block	O
with	O
bupivacaine	B-Drug
and	O
additional	O
injection	O
of	O
lidocaine	B-Drug
in	O
the	O
operative	O
field	O
.	O

-DOCSTART-	2796

Benzocaine	B-Drug
,	O
an	O
ester	O
-	O
type	O
local	O
anesthetic	O
,	O
was	O
believed	O
responsible	O
for	O
apparent	O
methemoglobinemia	B-ADE
in	O
a	O
cat	O
.	O

-DOCSTART-	1822

Managing	O
cardiovascular	B-ADE
collapse	I-ADE
in	O
severe	O
flecainide	B-Drug
overdose	O
without	O
recourse	O
to	O
extracorporeal	O
therapy	O
.	O

-DOCSTART-	727

Gabapentin	B-Drug
withdrawal	O
presenting	O
as	O
status	B-ADE
epilepticus	I-ADE
.	O

-DOCSTART-	2642

Their	O
parkinsonism	B-ADE
improved	O
on	O
discontinuation	O
of	O
metoclopramide	B-Drug
therapy	O
.	O

-DOCSTART-	682

In	O
summary	O
,	O
we	O
report	O
herein	O
the	O
first	O
case	O
of	O
SIADH	B-ADE
believed	O
to	O
be	O
an	O
adverse	O
effect	O
of	O
mizoribin	B-Drug
,	O
which	O
may	O
therefore	O
needed	O
to	O
be	O
added	O
to	O
the	O
list	O
of	O
drugs	O
which	O
can	O
induce	O
SIADH	B-ADE
.	O

-DOCSTART-	3191

Nine	O
azotemic	O
patients	O
who	O
developed	O
a	O
coagulopathy	B-ADE
associated	O
with	O
the	O
use	O
of	O
either	O
cephalosporin	B-Drug
or	O
moxalactam	B-Drug
antibiotics	O
are	O
reported	O
.	O

-DOCSTART-	2690

Two	O
patients	O
treated	O
with	O
alprazolam	B-Drug
had	O
histories	O
suggestive	O
of	O
a	O
bipolar	O
disorder	O
and	O
developed	O
lithium	O
-	O
responsive	O
manic	B-ADE
episodes	I-ADE
.	O

-DOCSTART-	335

OBJECTIVE	O
:	O
To	O
report	O
on	O
the	O
possible	O
development	O
of	O
serotonin	B-ADE
syndrome	I-ADE
in	O
a	O
patient	O
receiving	O
clomipramine	B-Drug
after	O
clozapine	B-Drug
was	O
withdrawn	O
from	O
the	O
treatment	O
regimen	O
.	O

-DOCSTART-	2648

These	O
nail	B-ADE
changes	I-ADE
gradually	O
disappeared	O
when	O
the	O
dose	O
of	O
clofazimine	B-Drug
was	O
reduced	O
.	O

-DOCSTART-	2753

Paradoxical	B-ADE
precipitation	I-ADE
of	I-ADE
tonic	I-ADE
seizures	I-ADE
by	O
lorazepam	B-Drug
in	O
a	O
child	O
with	O
atypical	O
absence	O
seizures	O
.	O

-DOCSTART-	2240

We	O
report	O
two	O
cases	O
of	O
tenofovir	B-Drug
(	O
TDF	B-Drug
)	O
-	O
associated	O
nephrotoxicity	B-ADE
in	O
perinatally	O
HIV	O
-	O
infected	O
adolescents	O
.	O

-DOCSTART-	4135

We	O
describe	O
a	O
patient	O
with	O
androgen	O
-	O
independent	O
prostate	O
cancer	O
in	O
whom	O
PSA	B-ADE
continued	I-ADE
to	I-ADE
decrease	I-ADE
for	O
a	O
period	O
of	O
15	O
months	O
after	O
flutamide	B-Drug
withdrawal	O
.	O

-DOCSTART-	133

In	O
two	O
patients	O
clozapine	B-Drug
was	O
reinstated	O
after	O
risperidone	O
was	O
discontinued	O
;	O
serum	B-ADE
triglyceride	I-ADE
levels	I-ADE
increased	I-ADE
.	O

-DOCSTART-	831

We	O
report	O
a	O
case	O
of	O
SJS	B-ADE
in	O
a	O
14-year	O
-	O
old	O
male	O
with	O
nephrotic	O
syndrome	O
,	O
who	O
was	O
treated	O
with	O
oral	O
prednisolone	B-Drug
for	O
6	O
weeks	O
.	O

-DOCSTART-	2402

Therefore	O
,	O
although	O
garenoxacin	B-Drug
reportedly	O
causes	O
fewer	O
adverse	O
reactions	O
for	O
cardiac	B-ADE
rhythms	I-ADE
than	O
third	O
-	O
generation	O
quinolone	O
antibiotics	O
,	O
one	O
must	O
be	O
cautious	O
of	O
the	O
interference	O
of	O
other	O
drugs	O
during	O
hypokalemia	B-ADE
in	O
order	O
to	O
prevent	O
TdP	O
.	O

-DOCSTART-	233

Colchicine	B-Drug
-	O
induced	O
myopathy	B-ADE
in	O
renal	O
failure	O
.	O

-DOCSTART-	1802

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
serotonin	B-ADE
syndrome	I-ADE
associated	O
with	O
interaction	O
between	O
fentanyl	B-Drug
and	O
citalopram	B-Drug
,	O
as	O
evidenced	O
by	O
medication	O
history	O
,	O
clinical	O
features	O
and	O
reversal	O
following	O
discontinuation	O
of	O
fentanyl	B-Drug
.	O

-DOCSTART-	1402

Captopril	B-Drug
-	O
induced	O
pulmonary	B-ADE
infiltrates	I-ADE
with	I-ADE
eosinophilia	I-ADE
in	O
an	O
infant	O
with	O
congenital	O
heart	O
disease	O
.	O

-DOCSTART-	2274

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
calcineurin	B-Drug
-	O
induced	O
pain	B-ADE
syndrome	I-ADE
(	O
CIPS	O
)	O
in	O
a	O
child	O
undergoing	O
his	O
second	O
hematopoietic	O
stem	O
cell	O
transplant	O
(	O
HSCT	O
)	O
.	O

-DOCSTART-	2456

Methotrexate	B-Drug
may	O
rarely	O
provoke	O
serositis	B-ADE
,	O
even	O
with	O
low	O
doses	O
and	O
after	O
just	O
a	O
few	O
weeks	O
of	O
therapy	O
.	O

-DOCSTART-	1285

Clearance	O
rates	O
of	O
cerivastatin	O
metabolites	O
in	O
a	O
patient	O
with	O
cerivastatin	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
.	O

-DOCSTART-	700

Reduction	O
of	O
methylprednisolone	B-Drug
dosage	O
rather	O
than	O
insulin	O
therapy	O
resulted	O
in	O
better	O
control	O
of	O
glycemia	B-ADE
.	O

-DOCSTART-	2724

Nifedipine	B-Drug
may	O
induce	O
,	O
or	O
aggravate	O
,	O
pre	O
-	O
existing	O
,	O
gastro	B-ADE
-	I-ADE
oesophageal	I-ADE
reflux	I-ADE
.	O

-DOCSTART-	1590

A	O
few	O
recent	O
individual	O
case	O
reports	O
have	O
suggested	O
that	O
a	O
myasthenic	B-ADE
syndrome	I-ADE
may	O
be	O
associated	O
with	O
statin	B-Drug
treatment	O
,	O
but	O
this	O
association	O
is	O
not	O
well	O
described	O
.	O

-DOCSTART-	2144

Acute	B-ADE
syphilitic	I-ADE
posterior	I-ADE
placoid	I-ADE
chorioretinitis	I-ADE
following	O
intravitreal	O
triamcinolone	B-Drug
acetonide	I-Drug
injection	O
.	O

-DOCSTART-	2524

Data	O
have	O
been	O
published	O
regarding	O
the	O
possibility	O
that	O
tamoxifen	B-Drug
may	O
be	O
responsible	O
for	O
the	O
subsequent	O
development	O
of	O
carcinoma	B-ADE
of	I-ADE
the	I-ADE
corpus	I-ADE
uteri	I-ADE
in	O
these	O
patients	O
.	O

-DOCSTART-	29

Myotonia	B-ADE
associated	O
with	O
sarcoidosis	O
:	O
marked	O
exacerbation	O
with	O
pravastatin	B-Drug
.	O

-DOCSTART-	3039

This	O
progressed	O
to	O
tracheal	B-ADE
compression	I-ADE
with	O
stridor	O
after	O
he	O
had	O
taken	O
some	O
aspirin	B-Drug
for	O
relief	O
of	O
the	O
neck	O
pain	O
.	O

-DOCSTART-	3726

In	O
this	O
report	O
,	O
two	O
cases	O
of	O
ET	O
which	O
evolved	O
into	O
AL	B-ADE
without	O
prior	O
exposure	O
to	O
radiation	O
or	O
alkylating	O
agents	O
,	O
and	O
which	O
were	O
treated	O
with	O
long	O
-	O
term	O
hydroxyurea	B-Drug
therapy	O
,	O
are	O
described	O
.	O

-DOCSTART-	985

Reflex	B-ADE
sympathetic	I-ADE
dystrophy	I-ADE
syndrome	I-ADE
in	O
renal	O
transplanted	O
patients	O
under	O
immunosuppression	O
with	O
tacrolimus	B-Drug
.	O

-DOCSTART-	3772

CONCLUSIONS	O
:	O
There	O
was	O
a	O
temporal	O
relationship	O
between	O
the	O
onset	O
of	O
nonconvulsive	B-ADE
status	I-ADE
epilepticus	I-ADE
and	O
initiation	O
of	O
ifosfamide	B-Drug
infusion	O
.	O

-DOCSTART-	4127

Suxamethonium	B-Drug
apnoea	B-ADE
terminated	O
with	O
commercial	O
serumcholinesterase	O
.	O

-DOCSTART-	1427

Linezolid	B-Drug
-	O
induced	O
dyserythropoiesis	B-ADE
:	O
chloramphenicol	O
toxicity	O
revisited	O
.	O

-DOCSTART-	1898

Rifampin	B-Drug
-	O
induced	O
hypothyroidism	B-ADE
without	O
underlying	O
thyroid	O
disease	O
.	O

-DOCSTART-	3038

Severe	B-ADE
acidosis	I-ADE
from	O
acetazolamide	B-Drug
in	O
a	O
diabetic	O
patient	O
.	O

-DOCSTART-	3226

Gold	B-Drug
-	I-Drug
salt	I-Drug
therapy	O
may	O
result	O
in	O
damage	B-ADE
to	I-ADE
proximal	I-ADE
tubules	I-ADE
that	O
leak	O
renal	O
tubular	O
antigens	O
,	O
which	O
in	O
turn	O
complex	O
with	O
autoantibody	O
and	O
produce	O
an	O
autoimmune	O
membranous	O
nephropathy	O
.	O

-DOCSTART-	2052

L	B-Drug
-	I-Drug
asparaginase	I-Drug
-	O
induced	O
posterior	B-ADE
reversible	I-ADE
encephalopathy	I-ADE
syndrome	O
during	O
acute	O
lymphoblastic	O
leukemia	O
treatment	O
in	O
children	O
.	O

-DOCSTART-	3174

A	O
major	O
limitation	O
in	O
the	O
use	O
of	O
amphotericin	B-Drug
B	I-Drug
is	O
its	O
potential	O
to	O
cause	O
nephrotoxicity	B-ADE
.	O

-DOCSTART-	1349

Tegaserod	B-Drug
-	O
associated	O
ischemic	B-ADE
colitis	I-ADE
.	O

-DOCSTART-	1045

Agranulocytosis	B-ADE
is	O
a	O
rare	O
adverse	O
effect	O
associated	O
with	O
prolonged	O
vancomycin	B-Drug
therapy	O
,	O
and	O
is	O
potentially	O
serious	O
,	O
especially	O
in	O
end	O
stage	O
renal	O
disease	O
(	O
ESRD	O
)	O
patients	O
.	O

-DOCSTART-	1535

Two	O
cases	O
of	O
sirolimus	B-Drug
-	O
associated	O
pneumonitis	B-ADE
have	O
been	O
reported	O
after	O
cardiac	O
transplantation	O
.	O

-DOCSTART-	1264

In	O
addition	O
,	O
ethambutol	B-Drug
rarely	O
causes	O
visual	B-ADE
loss	I-ADE
during	O
the	O
early	O
period	O
or	O
when	O
given	O
at	O
lower	O
doses	O
.	O

-DOCSTART-	256

When	O
the	O
acute	O
manic	O
state	O
is	O
characterized	O
by	O
marked	O
psychotic	B-ADE
symptoms	I-ADE
and	O
intense	B-ADE
anxiety	I-ADE
,	O
it	O
may	O
be	O
associated	O
with	O
increased	O
vulnerability	O
to	O
the	O
development	O
of	O
severe	O
lithium	B-Drug
neurotoxicity	B-ADE
.	O

-DOCSTART-	1597

We	O
report	O
a	O
case	O
of	O
chronic	O
use	O
of	O
HCQ	B-Drug
associated	O
with	O
torsade	B-ADE
de	I-ADE
pointes	I-ADE
.	O

-DOCSTART-	154

Cushing	B-ADE
's	I-ADE
syndrome	I-ADE
persisted	O
more	O
than	O
6	O
months	O
while	O
TCA	B-Drug
concentrations	O
remained	O
detectable	O
for	O
at	O
least	O
80	O
days	O
.	O

-DOCSTART-	3296

Secondary	B-ADE
hyperparathyroidism	I-ADE
in	O
certain	O
patients	O
with	O
lithium	B-Drug
nephrotoxicity	B-ADE
is	O
also	O
possible	O
.	O

-DOCSTART-	519

Hepatolithiasis	B-ADE
(	O
intrahepatic	O
stone	O
)	O
during	O
octreotide	B-Drug
therapy	O
for	O
acromegaly	O
:	O
a	O
case	O
report	O
.	O

-DOCSTART-	1868

Colchicine	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
.	O

-DOCSTART-	3530

Acute	B-ADE
pancreatitis	I-ADE
associated	O
with	O
danazol	B-Drug
treatment	O
for	O
endometriosis	O
.	O

-DOCSTART-	3190

Nevertheless	O
,	O
the	O
coagulopathy	B-ADE
seemed	O
to	O
be	O
most	O
closely	O
associated	O
with	O
the	O
administration	O
of	O
the	O
cephalosporin	B-Drug
.	O

-DOCSTART-	3120

Transient	B-ADE
hemiparesis	I-ADE
caused	O
by	O
phenytoin	B-Drug
toxicity	O
.	O

-DOCSTART-	1331

RESULTS	O
:	O
Both	O
patients	O
experienced	O
a	O
previously	O
unreported	O
side	O
effect	O
--	O
falling	B-ADE
backward	I-ADE
--	O
associated	O
with	O
bupropion	B-Drug
use	O
.	O

-DOCSTART-	1415

Rhabdomyolysis	B-ADE
caused	O
by	O
tocolysis	O
with	O
oral	O
ritodrine	B-Drug
hydrochloride	I-Drug
in	O
a	O
pregnant	O
patient	O
with	O
myotonic	O
dystrophy	O
.	O

-DOCSTART-	3641

Lithium	B-Drug
therapy	O
was	O
discontinued	O
because	O
of	O
poor	O
compliance	O
to	O
the	O
medication	O
and	O
intolerable	O
polyuria	B-ADE
.	O

-DOCSTART-	1007

There	O
have	O
been	O
several	O
reported	O
cases	O
of	O
omeprazole	B-Drug
-	O
induced	O
AIN	B-ADE
.	O

-DOCSTART-	1210

Vision	B-ADE
declined	I-ADE
after	O
treatment	O
with	O
methylprednisolone	B-Drug
,	O
after	O
which	O
fundus	O
examination	O
became	O
consistent	O
with	O
progressive	O
outer	O
retinal	O
necrosis	O
.	O

-DOCSTART-	2631

Horner	B-ADE
's	I-ADE
syndrome	I-ADE
and	O
demyelinating	B-ADE
peripheral	I-ADE
neuropathy	I-ADE
caused	O
by	O
high	O
-	O
dose	O
cytosine	B-Drug
arabinoside	I-Drug
.	O

-DOCSTART-	3138

Although	O
they	O
had	O
complex	O
medical	O
problems	O
,	O
the	O
high	O
serum	O
concentrations	O
of	O
ampicillin	B-Drug
at	O
the	O
time	O
of	O
seizures	O
without	O
their	O
recurrence	O
after	O
discontinuing	O
the	O
antibiotic	O
suggest	O
that	O
the	O
seizures	B-ADE
were	O
related	O
to	O
the	O
ampicillin	B-Drug
therapy	O
.	O

-DOCSTART-	3290

Life	O
-	O
threatening	O
hyperkalemia	B-ADE
induced	O
by	O
arginine	B-Drug
.	O

-DOCSTART-	852

Risperidone	B-Drug
-	O
induced	O
obsessive	B-ADE
-	I-ADE
compulsive	I-ADE
symptoms	I-ADE
in	O
two	O
children	O
.	O

-DOCSTART-	730

Doxycycline	B-Drug
-	O
induced	O
hypoglycemia	B-ADE
in	O
a	O
nondiabetic	O
young	O
man	O
.	O

-DOCSTART-	3123

Stroke	B-ADE
-	I-ADE
like	I-ADE
syndrome	I-ADE
after	O
gold	B-Drug
sodium	I-Drug
thiomalate	I-Drug
induced	O
vasomotor	B-ADE
reaction	I-ADE
.	O

-DOCSTART-	3989

To	O
our	O
knowledge	O
,	O
these	O
cases	O
are	O
the	O
first	O
published	O
reports	O
of	O
lovastatin	B-Drug
-	O
induced	O
rhabdomyolysis	B-ADE
associated	O
with	O
azithromycin	B-Drug
and	O
clarithromycin	B-Drug
.	O

-DOCSTART-	667

METHODS	O
:	O
A	O
case	O
is	O
presented	O
of	O
a	O
45-year	O
-	O
old	O
woman	O
on	O
prolonged	O
gemcitabine	B-Drug
treatment	O
for	O
ovarian	O
cancer	O
who	O
developed	O
HUS	B-ADE
and	O
recovered	O
after	O
drug	O
discontinuation	O
.	O

-DOCSTART-	3602

The	O
failure	O
of	O
therapy	O
with	O
disopyramide	O
and	O
mexiletine	O
to	O
reproduce	O
this	O
observation	O
suggests	O
either	O
a	O
previously	O
unreported	O
electrophysiologic	B-ADE
effect	I-ADE
of	O
,	O
or	O
idiosyncratic	O
response	O
to	O
,	O
procainamide	B-Drug
.	O

-DOCSTART-	167

Scleroderma	B-ADE
-	I-ADE
like	I-ADE
reaction	I-ADE
induced	O
by	O
uracil	B-Drug
-	I-Drug
tegafur	I-Drug
(	O
UFT	B-Drug
)	O
,	O
a	O
second	O
-	O
generation	O
anticancer	O
agent	O
.	O

-DOCSTART-	2871

Torsade	B-ADE
de	I-ADE
pointes	I-ADE
represents	O
a	O
potential	O
complication	O
of	O
chronic	O
amiodarone	B-Drug
therapy	O
.	O

-DOCSTART-	3879

Tetany	B-ADE
in	O
a	O
child	O
with	O
AIDS	O
receiving	O
intravenous	O
tobramycin	B-Drug
.	O

-DOCSTART-	308

In	O
2	O
of	O
the	O
3	O
cases	O
the	O
patients	O
were	O
also	O
taking	O
lithium	B-Drug
carbonate	I-Drug
and	O
beta	O
-	O
blockers	O
,	O
both	O
of	O
which	O
could	O
have	O
contributed	O
to	O
the	O
incontinence	B-ADE
.	O

-DOCSTART-	27

Calcipotriol	B-Drug
(	O
Daivonex	O
R	O
;	O
Leo	O
Pharmaceuticals	O
,	O
Zurich	O
,	O
Switzerland	O
)	O
may	O
cause	O
irritation	B-ADE
of	I-ADE
the	I-ADE
skin	I-ADE
,	O
whereas	O
allergic	B-ADE
reactions	I-ADE
are	O
less	O
common	O
.	O

-DOCSTART-	3239

A	O
case	O
of	O
SIADH	B-ADE
associated	O
with	O
desipramine	B-Drug
treatment	O
in	O
an	O
elderly	O
depressed	O
woman	O
is	O
described	O
.	O

-DOCSTART-	613

Leiomyosarcoma	B-ADE
in	O
urinary	O
bladder	O
after	O
cyclophosphamide	B-Drug
therapy	O
for	O
retinoblastoma	O
and	O
review	O
of	O
bladder	O
sarcomas	O
.	O

-DOCSTART-	55

CONCLUSION	O
:	O
Patients	O
with	O
insulin	B-Drug
allergy	O
may	O
not	O
have	O
complete	O
resolution	O
of	O
their	O
symptoms	O
after	O
standard	O
desensitization	O
,	O
particularly	O
those	O
patients	O
with	O
concomitant	O
protamine	B-ADE
allergy	I-ADE
.	O

-DOCSTART-	4138

Animals	O
treated	O
with	O
HAL	B-Drug
showed	O
a	O
highly	O
significant	B-ADE
32%-46	I-ADE
%	I-ADE
loss	I-ADE
of	I-ADE
tyrosine	I-ADE
hydroxylase	I-ADE
(	I-ADE
TH	I-ADE
)	I-ADE
immunoreactive	I-ADE
neurons	I-ADE
in	O
the	O
substantia	O
nigra	O
,	O
and	O
20	O
%	O
contraction	O
of	O
the	O
TH	O
stained	O
dendritic	O
arbour	O
.	O

-DOCSTART-	3859

Keratitis	B-ADE
in	O
methamphetamine	B-Drug
abusers	O
.	O

-DOCSTART-	1325

In	O
deciding	O
if	O
tamoxifen	B-Drug
therapy	O
is	O
warranted	O
,	O
all	O
potentially	O
life	O
-	O
threatening	O
adverse	O
events	O
associated	O
with	O
tamoxifen	B-Drug
should	O
be	O
considered	O
,	O
including	O
endometrial	B-ADE
adenocarcinoma	I-ADE
or	O
uterine	B-ADE
sarcoma	I-ADE
.	O

